[go: up one dir, main page]

AU2001296871A1 - Pyrazole compounds useful as protein kinase inhibitors - Google Patents

Pyrazole compounds useful as protein kinase inhibitors

Info

Publication number
AU2001296871A1
AU2001296871A1 AU2001296871A AU9687101A AU2001296871A1 AU 2001296871 A1 AU2001296871 A1 AU 2001296871A1 AU 2001296871 A AU2001296871 A AU 2001296871A AU 9687101 A AU9687101 A AU 9687101A AU 2001296871 A1 AU2001296871 A1 AU 2001296871A1
Authority
AU
Australia
Prior art keywords
ring
optionally substituted
aliphatic
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296871A
Inventor
David Bebbington
Jean-Damien Charrier
Robert Davies
Julian M.C. Golec
Ronald Knegtel
Pan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27398347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001296871(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2001296871A1 publication Critical patent/AU2001296871A1/en
Priority to AU2006201265A priority Critical patent/AU2006201265B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)

Description

PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to US Provisional Patent Application 60/232,795 filed September 15, 2000, US Provisional Patent Application 60/257,887 filed December 21, 2000 and US Provisional Patent Application 60/286,949 filed April 27, 2001, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION The present invention is in the field of medicinal chemistry and relates to compounds that are protein kinase inhibitors, compositions containing such compounds and methods of use. More particularly, this invention relates to compounds that are inhibitors of GSK-3 and Aurora-2 protein kinases . The invention also relates to methods of treating diseases associated with these protein kinases, such as diabetes, cancer and Alzheimer's disease.
BACKGROUND OF THE INVENTION The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of enzymes and other biomolecules associated with target diseases. One important class of enzymes that has been the subject of extensive study is the protein kinases.
Protein kinases mediate intracellular signal transduction. They do this by effecting a phosphoryl extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H202) , cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor (TNF- α) ) , and growth factors (e.g. granulocyte maσrophage- colony-stimulating factor (GM-CSF) , and fibroblast growth factor (FGF) . An extracellular stimulus may effect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of cell cycle. Many diseases are associated with abnormal cellular responses triggered by protein kinase- ediated events. These diseases include autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.
Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer,- such as colon, breast and other solid tumors. This kinase is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora- 2 protein has been found to be overexpressed. See Bischoff et al., EMBO J. , 1998, 17, 3052-3065; Schumacher et al., J. Cell Biol . , 1998, 143, 1635-1646; Kimura et al., <J. Biol . Chem. , 1997, 272, 13766-13771.
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of α and β ■ isoforms that are each encoded by distinct genes [Coghlan et al., Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinio Genetics Dev. , 10, 508-514 (2000)]. GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al., J". Cell Biol . (2000) 151, 117]. These diseases may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role. GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins . These proteins include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor β-catenin, the translation initiation factor elF2B, as well as ATP citrate lyase, axin, heat shock factor-1, α-Jun, c-Myc, c-Myb, CREB, and CEPBα. These diverse protein targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
In a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes, insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis. Along this pathway, GSK-3 is a negative regulator of the insulin-induced signal. Normally, the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase. The inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al., PNAS, 93, 8455-9 (1996); Cross et al . , Biochem. J. , 303, 21-26 (1994); Cohen, Biochem . Soc . Trans . , 21, 555-567 (1993); Massillon et al., Biochem J. 299, 123-128 (1994)]. However, in a diabetic patient where the insulin response is impaired, glycogen synthesis and glucose uptake fail to increase despite the presence of relatively high blood levels of insulin. This leads to abnormally high blood levels of glucose with acute and long term effects that may ultimately result in cardiovascular disease, renal failure and blindness. In such patients, the normal insulin-induced inhibition of GSK-3 fails to occur. It has also been reported that in patients with type II diabetes, GSK-3 is overexpressed [WO 00/38675] . Therapeutic inhibitors of GSK-3 are therefore potentially useful for treating diabetic patients suffering from an impaired response to insulin.
GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known β-amyloid peptide and the formation of intracellular neurofibrillary tangles. The neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al . , Current Biology 4, 1077-86 (1994); Brownlees et al . , Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
Another substrate of GSK-3 is β-catenin which is degradated after phosphorylation by GSK-3. Reduced levels of β-catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al., Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al . , J". Neuropathol . Exp, 56, 70-78 (1997)]. As a result of the biological importance of
GSK-3, there is current interest in therapeutically effective GSK-3 inhbitors. Small molecules that inhibit GSK-3 have recently been reported [WO 99/65897 (Chiron) and WO 00/38675 (SmithKline Beecham) ] . For many of the aforementioned diseases associated with abnormal GSK-3 activity, other protein kinases have also been targeted for treating the same diseases. However, the various protein kinases often act through different biological pathways. For example, certain quinazoline derivatives have been reported recently as inhibitors of p38 kinase (WO 00/12497 to Scios) . The compounds are reported to be useful for treating conditions characterized by enhanced p38- activity and/or enhanced TGF-β activity. While p38 activity has been implicated in a wide variety of diseases, including diabetes, p38 kinase is not reported to be a constituent of an insulin signaling pathway that regulates glycogen synthesis or glucose uptake. Therefore, unlike GSK-3, p38 inhibition would not be expected to enhance glycogen synthesis and/or glucose uptake .
There is a continued need to find new therapeutic agents to treat human diseases. The protein kinases aurora-2 and GSK-3 are especially attractive targets for the discovery of new therapeutics due to their important role in cancer, diabetes, Alzheimer's disease and other diseases. DESCRIPTION OF THE INVENTION It has now been found that compounds of this invention and pharmaceutical compositions thereof are effective as protein kinase inhibitors, particularly as inhibitors of aurora-2 and GSK-3. These compounds have the general formula I :
or a pharmaceutically acceptable derivative or prodrug thereof, wherein: Z1 to Z4 are as described below; Ring A is selected from the group consisting of :
e g and
G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2, 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyσlic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D; R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι_6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx and Ry are independently selected from T-R3, or Rx and Rγ are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3, and any substitutable nitrogen on said ring formed by Rx and Rγ is substituted by R4;
T is a valence bond or a Cι-4 alkylidene chain; R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4;
R3 is selected from -R, -halo, -OR, -C(=0)R,' -C02R, -COCOR, -COCHsCOR, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R4)2, -C0N(R7)2, -S02N(R7)2, -OC (=0) R, ' -N (R7) COR, -N(R7)C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2/. -C=NN(R4)2, -C=N-0R, -N (R7) CON (R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0)N(R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7, -C02(Cι-6 aliphatic), -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR,
-C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(Rs)CO-, -N (R6) C (O) O- , -N(R6)CON(R6)-, -N(R6)S02N(Rs)-, -N (R6)N (R6) - , . . -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-,
-C(Rs)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(Re)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)CON(R6)-;
W is -C(R6)20-, -C(RS)2S-, -C(Rs)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0)-, -C(Rs)OC(0)N(R6) -, -C (R6) 2N (Rs) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6) -, -C(R6)=N-0-, -C(R6)2N(R6)N(R6) -, -C (R6) 2N (R6) S02N (R6) - , -C(R6)2N(R6)C0N(R6)-, or -C0N(R6)-; each R6 is independently selected from- hydrogen or an optionally substituted Cχ-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted Cι-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6; and R9 is selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2/ -OC(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Cχ.6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2,
-C=N-OR, -N(R4)C0N(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2.
As used herein, the following definitions shall apply unless otherwise indicated. The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term " (un) substituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
The term "aliphatic" as used herein means straight-chain, branched or cyclic Cι-C12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation but which are not aromatic. For example, suitable aliphatic groups include substituted or- unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl. The terms "alkyl", "alkoxy", "hydroxyalkyl", "alkoxyalkyl" , and "alkoxycarbonyl" , used alone or as part of a larger moiety includes both straight and branched chains containing one to twelve carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms. The term "cycloalkyl" used alone or as part of a larger moiety shall include cyclic C3-Cι2 hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.
The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, CI, Br, or I.
The term "heteroatom" means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term "nitrogen" includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl) , NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl) .
.The terms "carbocycle" , "carbocyclyl" , "carbocyclo" , or "carbocyclic" as used herein means an aliphatic ring system having three to fourteen members. The terms "carbocycle", "carbocyclyl", "carbocyclo", or "carbocyclic" whether saturated or partially unsaturated, also refers to rings that are optionally substituted. The terms "carbocycle" , "carbocyclyl" , "carbocyclo" , or "carbocyclic" also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as in a decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
The term "aryl" used alone or as part of a larger moiety as in "aralkyl" , aralkoxy" , or "aryloxyalkyl" , refers to aromatic ring groups having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2- anthracyl . The term "aryl" also refers to rings that are optionally substituted. The term "aryl" may be used interchangeably with the term "aryl ring" . "Aryl" also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2- anthracyl. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring. The term "heterocycle" , "heterocyclyl", or
"heterocyclic" as used herein includes non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of heterocyclic rings include 3-1H- benzimidazol-2-one, (1~-substituted) -2-oxo-benzimidazol-3- yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydropyrany1, 3-1etrahydropyrany1, 4- tetrahydropyranyl , [1, 3] -dioxalanyl, [1, 3] -dithiolanyl, [1,3] -dioxanyl, 2-tetrahydrothiophenyl, 3- tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4- morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4- thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3- pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1- phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, and benzothianyl . Also included within the scope of the term "heterocyclyl" or "heterocyclic", as it is used herein, is a group in which a non-aromatic heteroato -containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment, is on the non-aromatic heteroatom-containing ring. The term "heterocycle" , "heterocyclyl" , or "heterocyclic" whether saturated or partially unsaturated, also refers to rings ' that are optionally substituted.
The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy" , refers to heteroaromatic ring groups having five to fourteen members . Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4- isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2- triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl , benzofuranyl , indolyl, quinolinyl, benzotriazolyl, benzothiazolyl , benzooxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzoisoxazolyl. Also included within the scope of the term "heteroaryl" , as it is used herein, is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [3 , 4-d] pyri idinyl . The term "heteroaryl" also refers to rings that are optionally substituted. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic" .
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen, -R°, -OR°, -SR°, 1, 2-methylene-dioxy, 1, 2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph) , substituted Ph, -O(Ph), substituted -O(Ph), -CH2(Ph), substituted -CH2(Ph) , -CH2CH2(Ph), substituted -CH2CH2(Ph), -N02, -CN, -N(R°)2, -NR°C{0)R°, -NR°C(O)N(R°) 2, -NR°C02R°, -NR°NR°C(0)R°, -NR°NR°C (O) N (R°) 2, -NR°NR0C02R0, -C(0)C(0)R°, -C(0)CH2C(0)R°, -C02R°, -C(0)R°, -C(0)N(R°)2, -OC(0)N(R°)2, -S(0)2R°, -S02N(R°)2, -S(0)R°, -NR°S02N (R°) 2, -NR°S02R°, -C(=S)N(R°)2, -C (=NH) -N (R°) 2, - (CH2)yNHC (O) R°, - (CH2)yNHC(0)CH(V-R°) (R°) ; wherein R° is hydrogen, a substituted or unsubstituted aliphatic group, an unsubstituted heteroaryl or heterocyclic ring, phenyl
(Ph) , substituted Ph, -O(Ph), substituted -O(Ph), -CH2(Ph), or substituted -CH2(Ph); y is 0-6; and V is a linker group. Examples of substituents on the aliphatic group or the phenyl ring of R° include amino, alkylamino, dialkylamino, aminocarbonyl , halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl , alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl . An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include those -listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: =0, =S, =NNHR*, =NN(R*)2, =N-, =NNHC(0)R*, =NNHC02 (alkyl) , =NNHS02 (alkyl) , or =NR*, where each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group. Examples of substituents on the aliphatic group include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminσcarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl , alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl .
Suitable substituents on the nitrogen of a non- aromatic heterocyclic ring include -R+, -N(R+)2, -C(0)R+, -C02R+, -C(0)C(0)R\ -C(0)CH2C(0)R\ -S02R+, -S02N(R+)2,
-C(=S)N(R+)2, -C(=NH) ~N(R+)2, and -NR+S02R+; wherein R+ is hydrogen, an aliphatic group, a substituted aliphatic group, phenyl (Ph) , substituted Ph, -O(Ph), substituted -O(Ph) , CH2(Ph), substituted CH2 (Ph) , or an unsubstituted heteroaryl or heterocyclic ring.
Examples of substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl , alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl .
The term "linker group" or "linker" means an organic moiety that connects two parts of a compound. Linkers are typically comprised of an atom such as oxygen or sulfur, a unit such as -NH-, -CH2-, -C(O)-, -C(0)NH-, or' a chain of atoms, such as an alkylidene chain. The molecular mass of a linker is typically in the range of about 14 to 200, preferably in the range of 14 to 96 with a length of up to about six atoms. Examples of linkers include a saturated or unsaturated Cι-6 alkylidene chain which is optionally substituted, and wherein one or two saturated carbons of the chain are optionally replaced by -C(O)-, -C(0)C(0)-, -C0NH-, -CONHNH-, -C02-, -0C(0)-, -NHC02-, -0-, -NHC0NH-, -OC(0)NH-, -NHNH- , -NHC0-, -S-, -SO-, -S02-, -NH-, -S02NH-, or -NHS02- .
The term "alkylidene chain" refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation. The optional substituents are as described above for an aliphatic group.
A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Compounds of formula I or salts thereof may be formulated into compositions. In a preferred embodiment, the composition is a pharmaceutical composition. In one embodiment, the composition comprises an amount of the protein kinase inhibitor effective to inhibit a protein kinase, particularly GSK-3, in a biological sample or in a patient. In another embodiment, compounds of this invention and pharmaceutical compositions thereof, which comprise an amount of the protein kinase inhibitor effective to treat or prevent a GSK-3-mediated condition and a pharmaceutically acceptable carrier, adjuvant, or vehicle, may be formulated for administration to a patient.
The term "GSK-3-mediated condition" or "disease", as used herein, means any disease or other deleterious condition or state in which GSK-3 is known to play a role. Such diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS- associated dementia, amyotrophic lateral sclerosis (AML) , multiple sclerosis (MS) , schizophrenia, cardiomycete hypertrophy, reperfusion/ischemia, and baldness.
One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β-catenin, which is useful for treating schizophrenia.
Another aspect of the invention relates to inhibiting GSK-3 activity in a biological sample, which method comprises contacting the biological sample with a GSK-3 inhibitor of formula I.
Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurσra-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof .
The term "Aurora-2-mediated condition" or "disease", as used herein, means any disease or other deleterious condition in which Aurora is known to play a role. The term "Aurora-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with an Aurora-2 inhibitor. Such conditions include, without limitation, cancer. The term "cancer" includes, but is not limited to the following cancers: colon and ovarian.
Another aspect of the invention relates to inhibiting Aurora-2 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 inhibitor of formula I, or a composition thereof.
Another aspect of this invention relates to a method of treating or preventing a CDK-2-mediated diseases with a CDK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. The term "CDK-2-mediated condition" or
"disease", as used herein, means any disease or other deleterious condition in which CDK-2 is known to play a role. The term "CDK-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with a CDK-2 inhibitor. Such conditions include, without limitation, cancer, Alzheimer's disease, restenosis, angiogenesis, glo erulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. See Fischer, P.M. and Lane, D.P., Current Medicinal Chemistry, 7, 1213-1245 (2000); Mani, S., Wang, C, Wu, K. , Francis, R. and Pestell, R. , Exp . Opin . Invest . Drugs, 9 , 1849 (2000); Fry, D.W. and Garrett, M.D., Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs, 2, 40-59 (2000) .
Another aspect of the invention relates to. inhibiting CDK-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
Another aspect of this invention relates to a method of treating or preventing an ERK-2-mediated diseases with an ERK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
The term "ERK-mediated condition" , as used herein means any disease state or other deleterious condition in which ERK is known to play a role. The term "ERK-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with a ERK-2 inhibitor. Such conditions include, without limitation, cancer, stroke, diabetes, hepatomegaly, cardiovascular disease including cardiomegaly, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders including asthma, inflammation, neurological disorders and hormone-related diseases. The term "cancer" includes, but is not limited to the following cancers: breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarσinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon- rectum, large intestine, rectum, brain and central nervous system, and leukemia. ERK-2 protein kinase and its implication in various diseases has been described [Bokemeyer et al . 1996, Kidney Int . 49, 1187; Anderson et al., 1990, ature 343, 651; Crews et al., 1992, Science 258, 478; Bjorbaek et al., 1995, J. Biol . Chem. 270, 18848; Rouse et al . , 1994, Cell 78, 1027; Raingeaud et al., 1996, Mol . Cell Biol . 16, 1247; Raingeaud et al . 1996; Chen et al . , 1993 Proc. Natl . Acad. Sci . USA 90, 10952; Oliver et al . , 1995, Proc. Soc. Exp . Biol . Med. 210, 162; Moodie et al . , 1993, Science 260, 1658; Frey and Mulder, 1997, Cancer Res . 57, 628; Sivaraman et al., 1997, J Clin . Invest . 99, 1478; Whelchel et al., 1997, Am. J. Respir. Cell Mol . Biol . 16, 589].
Another aspect of the invention relates to inhibiting ERK-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
Another aspect of this invention relates to a method of treating or preventing an AKT-mediated diseases with an AKT inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. The term "AKT-mediated condition", as used herein, means any disease state or other deleterious condition in which AKT is known to play a role. The term "AKT-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with a AKT inhibitor. AKT-mediated diseases or conditions include, but are not limited to, proliferative disorders, cancer, and neurodegenerative disorders. The association of AKT, also known as protein kinase B, with various diseases has been described [Khwaja, A., Nature, pp. 33-34, 1990; Zang, Q. Y., et al, Oncogene, 19 2000; Kazuhiko, N., et al, The Journal of Neuroscience, 20 2000] .
Another aspect of the invention relates to inhibiting AKT activity in a biological sample or a patient, which method comprises administering to the • patient a compound of formula I or a composition' comprising said compound.
Another aspect of this invention relates to a method of treating or preventing a Src-mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a- therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. The term "Src-mediated condition" , as used herein means any disease state or other deleterious condition in which Src is known to play a role. The term "Src-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with a Src inhibitor. Such conditions include, without limitation, hypercalcemia, osteoporosis, osteoarthritis, cancer, symptomatic treatment of bone metastasis, and Paget's disease. Src protein kinase and its implication in various diseases has been described [Soriano, Cell , 69, 551 (1992); Soriano et al . , Cell , 64 , 693 (1991);
Takayanagi, <J. Clin . Invest . , 104, 137 (1999); Boschelli, Drugs of the Future 2000, 25(7), 717, (2000); Talamonti, J. Clin . Invest . , 91, 53 (1993); Lutz, Biochem. Biophys . Res . 243, 503 (1998); Rosen, J. Biol . Chem . , 261, 13754 (1986); Bolen, Proc. Natl . Acad. Sci . USA, 84, 2251
(1987); Masaki, Hepatologry, 27, 1257 (1998); Biscardi, Adv. Cancer Res . , 76, 61 (1999); Lynch, Leukemia, 7, 1416 (1993); Wiener, Clin . Cancer Res . , 5, 2164 (1999); Staley, Cell Growth Diff. , .8, 269 (1997)]. Another aspect of the invention relates to inhibiting Src activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound. The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof .
The term "patient" includes human and veterinary subjects. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for in vitro assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
The amount effective to inhibit protein kinase, for example, GSK-3 and Aurora-2, is one that measurably inhibits the kinase activity where compared to the activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.
Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
The compositions of the present invention may be administered orally, parenterally, by i halation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non- irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols. The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs .
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers . Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are. prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified diseases or disorders.
A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species .
Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in . obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+(Cι-4 alkyl) 4 salts. This invention also envisions the quate nization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
The amount of the protein kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated and the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of the inhibitor will also depend upon the particular compound in the composition. Depending upon the particular protein kinase- mediated condition to be treated. or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention. For example, in the treatment of diabetes other anti-diabetic agents may be combined with the GSK-3 inhibitors of this invention to treat diabetes. These agents include, without limitation, insulin or insulin analogues, in injectable or inhalation form, glitazones, alpha glucosidase inhibitors, biguanides, insulin sensitizers, and sulfonyl ureas.
Other examples of agents the inhibitors of this invention may also be combined with include, without limitation, chemotherapeutic agents or other anti- proliferative agents such as adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives; anti- inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and i munosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti- convulsants, ion channel blockers, riluzole, and anti- Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
Those additional agents may be administered separately from the protein kinase inhibitor-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor of this invention in a single composition.
Compounds of this invention may exist in alternative tautomeric forms, as in tautomers 1 and 2 shown below. Unless otherwise indicated, the representation of either tautomer is meant to include the other.
1 2
Rx and Ry (at positions Z3 and Z4, respectively) may be taken together to form a fused ring, providing a bicyclic ring system containing Ring A. Preferred Rx/Ry rings include a 5-, 6-, 7-, or 8 -membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said Rx/Ry ring is optionally substituted. Examples of Ring A systems are shown below by compounds I-A through I-DD, wherein Z1 is nitrogen or C(R9) and Z2 is nitrogen or C(H) .
I-G I-H I-I
I-J I-K I-L
I-P l-Q I-R
I-S I-T I-U
I-BB I-CC I-DD
Preferred bicyclic Ring A systems include I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, and I-M, more preferably I-A, I-B, I-C, I-F, and I-H, and most preferably I-A, I-B, and I-H. In the monocyclic Ring A system, preferred Rx groups, when present, include hydrogen, alkyl- or dialkylamino, acetamido, or a Cι-4 aliphatic group such as methyl, ethyl, cyclopropyl, isopropyl or t-butyl. Preferred Ry groups, when present, include T-R3 wherein T is a valence bond or a methylene, and R3 is -R, -N(R4)2, or -OR. Examples of preferred Ry include 2-pyridyl, 4- pyridyl, piperidinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or dialkylamino, acetamido, optionally substituted phenyl such as phenyl or halo- substituted phenyl, and methoxymethyl .
In the bicyclic Ring A system, the ring formed when Rx and Ry are taken together may be substituted or unsubstituted. Suitable substituents include -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R)2, -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N(R4)C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2 , -N(R)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2, wherein R and R4 are as defined above. Preferred Rx/Ry ring substituents include -halo,' -R, -OR, -COR, -C02R, -C0N(R4)2, -CN, or -N(R4)2 wherein R is hydrogen or an optionally substituted Cι_6 aliphatic group.
R2 and R2' may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6 -membered carbocyclo ring, wherein said fused ring is optionally substituted. These are exemplified in the following formula I compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring include one or more of the following: -halo, -N(R4)2, -C .3 alkyl, -C1-3 haloalkyl, -N02, -0(Cι_3 alkyl) , -C02 (C1-3 alkyl), -CN, -S02 (C1-3 alkyl) , -S02NH2, -OC(0)NH2, - NH2S02(Cι-3 alkyl) , -NHC (0) (C1-3 alkyl) , -C(0)NH2, and -00(0!- 3 alkyl) , wherein the (Cι_3 alkyl) is most preferably methyl . When the pyrazole ring system is monocyclic, preferred R2 groups include hydrogen, Cι_4 aliphatic, alkoxycarbonyl, (un) substituted phenyl., hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl , and (N- heterocyclyl) carbonyl. Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH20H, CH20CH3, CH2CH2CH2OH, CH2CH2CH2OCH3, CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHC00C (CH3) 3,
CONHCH(CH3')2, CONHCH2CH=CH2, CONHCH2CH2OCH3, CONHCH2Ph, CONH(cyclohexyl) , C0N(Et)2, CON(CH3)CH2Ph, CONH(n-C3H7) , CON(Et)CH2CH2CH3, CONHCH2CH (CH3) 2, CON (n-C3H7) 2, CO (3- methoxymethylpyrrolidin-1-yl) , C0NH(3-tolyl) , C0NH(4- tolyl), CONHCH3, CO(morpholin-l-yl) , C0(4-methylpipera'zin- 1-yl) , CONHCH2CH2OH, C0NH2, and CO (piperidin-1-yl) . A preferred R2' group is hydrogen. An embodiment that is particularly useful for treating GSK3 -mediated diseases relates to compounds of formula II :
II or a pharmaceutically acceptable derivative or prodrug thereof, wherein; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2, 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8; R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι_6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι_6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3, and any substitutable nitrogen on said ring formed by Rx and Ry is substituted by R4;
T is a valence bond or a Cχ_4 alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together .with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4;
R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R4)2, -CON(R7)2, -S02N(R7)2/-OC(=0)R, -N(R7)C0R, -N(R7) C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R7) CON (R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0)N(R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cx-6 aliphatic, C6-ι0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cχ.6 aliphatic) , -CON(R7)2/ or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cχ-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0) N (R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (0) 0- , -N(R6)C0N(R6) -, -N(R6)S02N(R6) -, -N (R6)N(R6) -, -C(0)N(R6)-, -0C(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N(R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6) -, -C (R6) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)CON(R6) -; W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-,
-C(R6)OC(0) -, -C(R6)OC(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, '-C(R6)=NN(R6) -, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)CON(R6)-, or -CON(R6)-; each R6 is independently selected from hydrogen, an. optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted C .6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and each R8 is independently selected from an optionally substituted Cι_4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6. When the Rx and Ry groups of formula II are taken together to form a fused ring, preferred Rx/Ry rings include a 5-, 6-, 1- , or 8-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said Rx/Ry ring is optionally substituted. This provides a bicyclic ring system containing a pyrimidine ring.. Examples of preferred pyrimidine ring systems of formula II are the mono- and bicyclic systems shown below.
II-A II-B II-C
II-D II-E II-F
II-G II-H II-I
II-M II-N II-O
More preferred pyrimidine ring systems of formula II include II-A, II-B, II-C, II-F, and II-H, most preferably II-A, II-B, and II-H.
In the monocyclic pyrimidine ring system of formula II, preferred Rx groups include hydrogen, alkyl- or dialkylamino, acetamido, or a Cχ_4 aliphatic group such as methyl, ethyl, cyclopropyl, isopropyl or t-butyl. Preferred Ry groups include T-R3 wherein T is a valence bond or a methylene, and R3 is -R, -N(R4)2, or -OR. When R3 is -R or -OR, a preferred R is an optionally substituted group selected from Cι_6 aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. Examples of preferred Ry include 2-pyridyl, 4-pyridyl, piperidinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or dialkylamino, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl, and methoxymethyl .
In the bicyclic pyrimidine ring system of formula II, the ring formed when Rx and Ry are taken together may be substituted or unsubstituted. Suitable substituents include -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted d-e aliphatic) , -N(R4)N(R4)2, " -C=NN(R4)2, -C=N-0R, -N(R4)C0N(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2, wherein R and R are as defined above. Preferred Rx/Ry ring substituents include -halo, -R, -OR, -COR, -C02R, -CON(R4)2, -CN, or -N(R)2 wherein R is an optionally substituted Cι-6 aliphatic group. The R2 and R2' groups of formula II may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula II compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring of formula II include one or more of the following: -halo, -N(R4)2, -Ci-4 alkyl, -Cι_4 haloalkyl, -N02, -0(d-4 alkyl), -C02 (Cι-4 alkyl) , -CN, -S02 (Cι_4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02(Cι-4 alkyl) , -NHC(O) (Cι-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Cι-4 alkyl) group is methyl.
When the pyrazole ring system of formula II is monocyclic, preferred R2 groups include hydrogen, a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cχ-6 aliphatic group. Examples of such preferred R2 groups include methyl, t-butyl, -CH2OCH3, cyclopropyl, furanyl, thienyl, and phenyl. A preferred R2' group is hydrogen.
More preferred ring systems of formula II are the following, which may be substituted as described above, wherein R2 and R2' are taken together with the pyrazole ring to form an indazole ring; and Rx and Ry are each methyl, or Rx and Ry are taken together with the pyrimidine ring to form a quinazoline or. tetrahydroquinazoline ring:
II -Aa II-Ba II-Ha
Particularly preferred are those compounds of formula II-Aa, II-Ba, or II-Ha wherein ring C is a phenyl ring and R1 is halo, methyl, or trifluoromethyl. Preferred formula II Ring C groups are phenyl and pyridinyl. When two adjacent substituents on Ring C are taken together to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl, quinolinyl and. isoquinolinyl.
An important feature of the formula II compounds is the R1 ortho substituent on Ring C. An ortho position on Ring C or Ring D is defined relative to the position where Ring A is attached. Preferred R1 groups include -halo, an optionally substituted Cι_6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6. When R1 is an optionally substituted Cι_6 aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3/ -CI, -F, -CN, -C0CH3, -OCH3, -OH, -CH2CH3, -OCH2CH3, -CH3, -CF2CH3, cyclohexyl, t- butyl, isopropyl, cyclopropyl, -C≡CH, -C≡C-CH3, -S02CH3, -S02NH2, -N(CH3)2, -C02CH3, -CONH2/ -NHC0CH3, -OC(0)NH2, -NHS02CH3, and -OCF3.
On Ring C of formula II, preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2, optionally substituted Cι-6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R4)2, and -N(R4)S02R. More preferred R5 substituents include -CI, -F, -CN, -CF3, -NH2, -NH(Cι.4 aliphatic), -N(Cι_4 aliphatic)2, -0(Cχ:4 aliphatic), Cι_4 aliphatic, and -C02 (Ci.4 aliphatic). Examples of such preferred R5 substituents include -CI, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, ethyl, cyclopropyl, isopropyl-, t- butyl, and -C02Et.
Preferred formula II compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring; .
(b) Rx is hydrogen or Cι-4 aliphatic and Ry is T-R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 0-2 ring nitrogens;
(c) R1 is -halo, an optionally substituted Cι_6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(RS)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6; and
(d) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C .6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6 -membered carbocyclo ring.
More preferred compounds of formula II have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring; (b) Rx is hydrogen or methyl and Ry is -R,
N(R4)2, or -OR, or Rx and Ry are taken together with their intervening atoms to form a 5-7 membered unsaturated or partially unsaturated carbocyclo ring optionally substituted with -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2,
-S02N(R4)2, -OC(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N(R4)CON(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2; (c) R1 is -halo, a Cι_6 haloaliphatic. group, a Cι-6 aliphatic group, phenyl, or -CN;
(d) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Cι-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring; and
(e) each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cι_6
■aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R4)2, or -N(R)S02R.
Even more preferred compounds of formula II have one or more, and more preferably all, of the features selected from the group consisting of: (a) Ring C is a phenyl ring optionally substituted by -R5;
• (b) Rx is hydrogen or methyl and Ry is methyl, methoxymethyl , ethyl , cyclopropyl , isopropyl, t-butyl, alkyl- or an optionally substituted group selected from
2-pyridyl, 4-pyridyl, piperidinyl, or phenyl, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted benzo ring or partially unsaturated 6-membered carbocyclo ring; (c) R1 is -halo, a d-4 aliphatic group optionally substituted with halogen, or -CN;
(d) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -C1. alkyl,
-Cι- haloalkyl, -N02, -0(d-4 alkyl) , -C02 (C^ alkyl) , -CN, -S02(Cι_4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (Cx-4 alkyl) , -NHC(O) (Cι-4 alkyl) , -C(0)NH2, or -CO (Cι-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group; and
(e) each R5 is independently selected from -CI, -F, -CN,' -CF3, -NH2, -NH(C1_4 aliphatic), -N(Cχ,4 aliphatic)2, -0(Cι-4 aliphatic), Cχ-4 aliphatic, and -C02(Cχ-4 aliphatic).
Representative compounds of formula II are shown below in Table 1.
Table 1.
II-l II-2 II-3
II-4 II-5 II-6
II-7 II-8 II-9
11-10 11-11 11-12
11-19 11-20 11-21
11-22 11-23 11-24
11-25 11-26 11-27
11-28 11-29 11-30
11-31 11-32 11-33
.
11-34 11-35 11-36
11-37 11-38 11-39
11-43 11-44 11-45
11-46 11-47 11-48
11-49 11-50 11-51
-61 11-62 11-63
11-64 11-65 11-66
11-67 ■11-68 11-69
11-70 11-71 11-72
11-73 1-74 11-75
11-79 11-80 11-81
11-82 11-83 11-84
11-85 11-86 11-87
11-88 11-89 11-90
11-91 11-92 11-93
11-94 11-95 11-96
11-100 11-101 11-102
11-103 11-104 11-105
11-106 11-107 11-108
11-109 11-110 11-111
11-112 11-113 11-114
11-115 11-116 11-117
11-121 11-122 11-123
11-124 11-125 11-126
11-127 11-128 11-129
11-130 11-131 11-132
11-133 11-134 11-135
11-136 11-137 11-138
11-139 11-140 11-141
11-142 11-143 11-144
11-145 11-146 11-147
11-148 11-149 11-150
11-151 11-152 11-153
11-154 11-155 11-156
11-157 11-158 11-159
11-160 11-161 11-162
11-163 11-164 11-165
11-166 11-167 11-168
11-169 11-170 11-171
11-172 11-173 11-174
11-175 11-176 11-177
11-178 11-179 11-180
11-181 11-182 11-183
11-184 11-185 11-186
11-187 11-188 11-189
11-190 11-191 11-192
11-193 11-194 11-195
11-196 11-197 11-198
11-199 11-200 11-201
11-202 11-203 11-204
11-205 11-206 11-207
11-208 11-209 11-210
11-211 11-212 11-213
11-214 11-215 11-216
11-217 11-218 11-219
11-220 11-221 11-222
11-223 11-224 11-225
11-226 11-227 11-228
11-229 11-230 11-231
11-232 11-233 11-234
11-235 11-236 11-237
11-238 11-239 11-240
11-244 11-245 11-246
11-247 11-248 11-249
11-250 11-251
In another embodiment, this invention provides a composition comprising a compound of formula II and a pharmaceutically acceptable carrier.
One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula II.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula II. Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula II. This method is especially useful for diabetic patients.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula II. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin. in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula II. This method is especially useful for treating schizophrenia. One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula II. Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula II. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula II.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula II. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. Another method relates to inhibiting GSK-3,
Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula II, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2.
Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula II, as described above.
Another embodiment of this invention relates to compounds of formula III :
III or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
Rx and Ry are taken together with their intervening atoms to form a fused, benzo ring or a 5-8 membered carbocyclo ring, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3;
T is a valence bond or a C1.4 alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4; R3 is selected from -R, -halo, =0, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=O)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι-.6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N (R4) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cτ.ζ aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι-6 aliphatic) , -C0N(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R )2, -OC(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι-6 aliphatic), -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R )2, -N(R4)S02R, or -OC (=0)N (R4) 2; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (O) O- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-,
-C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(Rs)=N-0-, -C(R6)2N(RS)N(R6)-, -C (R6) 2N (R6) S02N(R6) - , or -C(R6)2N(R6)CON(R6)-; W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0) -, -C(R6)OC(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6)-, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, -C (R6) 2N (R6) CON (R6) - , or . -CON (Rs) - ; each R6 is independently selected from hydrogen or an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and each R7 is independently selected from hydrogen or an optionally substituted Cι-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring .
Preferred formula III Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula III Ring D bicyclic rings include 1,2,3,4- tetrahydroisoquinolinyl, 1, 2, 3, 4-tetrahydroquinolinyl, 2,3-dihydro-lH-isoindolyl, 2, 3-dihydro-lH-indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred bicyclic Ring D systems include naphthyl and isoquinolinyl.
Preferred R5 substituents on Ring D of formula III include halo, oxo, CN, -N02, -N(R )2 -C02R, -C0NH(R4), -N(R4)C0R, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6.10 aryl, or C±.6 aliphatic. More preferred R5 substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, Cβ-io aryl, or Ci-6 aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH2OH, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
Preferred rings formed when the Rx and Ry groups of formula III are taken together to form a fused ring include a 5-, 6-, or 7-membered unsaturated or partially unsaturated carbocyclo ring, wherein any substitutable carbon on said fused ring is substituted by oxo or T-R3. Examples of preferred bicyclic ring systems are shown below.
III-A III -B III -C
Preferred substituents on the Rx/Ry fused ring of formula III include -R, oxo, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R)2, -OC(=0)R, -N(R4)C0R, -N (R4) C02 (optionally substituted Ci.6 aliphatic) , -N(R)N(R4)2, -C=NN(R4)2,
-C=N-OR, -N(R4)CON(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4) 2, wherein R and R4 are as defined above. More preferred substituents on the Rx/Ry fused ring include halo, CN, oxo, Cι-6 alkyl, Cχ-6 alkoxy, (Cι-6 alkyl) carbonyl, (Cχ-5 alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl. Examples of such preferred substituents include methoxy, methyl, isopropyl, methylsulfonyl, cyano, chloro, pyrrolyl, methoxy, ethoxy, ethylamino, acetyl, and acetamido.
Preferred R2 substituents of formula III include hydrogen, Cι_4 aliphatic, alkoxycarbonyl, (un) substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl,. mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl , phenylaminocarbonyl , and (N- heterocyclyl) carbonyl . Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH2OH, CH2OCH3, CH2CH2CH2OH, CH2CH2CH20CH3, CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHCOOC (CH3) 3,
CONHCH(CH3)2, CONHCH2CH=CH2, CONHCH2CH2OCH3, CONHCH2Ph, CONH(cyclohexyl) , CON(Et)2, CON(CH3) CH2Ph, CONH(n-C3H7) , CON(Et)CH2CH2CH3, C0NHCH2CH (CH3) 2, CON (n-C3H7) 2, CO (3- methoxymethylpyrrolidin-1-yl) , CONH(3-tolyl) , C0NH(4- tolyl), CONHCH3, CO(morpholin-l-yl) , CO (4-methylpiperazin- 1-yl) , CONHCH2CH2OH, C0NH2/ and CO (piperidin-1-yl) .
When the R2 and R2' groups of formula III are taken together to form a ring, preferred R2/R2' ring systems containing the pyrazole ring include benzo, pyrido, pyrimido, 3-oxo-2iT-pyridazino, and a partially unsaturated 6-membered carbocyclo ring. Examples of such preferred R2/R2' ring systems containing the pyrazole ring include the following:
Preferred substituents on the R2/R2' fused ring of formula III include one or more of the following: -halo, -N(R4)2, -Ci-4 alkyl, -Cι_4 haloalkyl, -N02, -0(Cι-4 alkyl), -C02 (Cι-4 alkyl) , -CN, -S02 (Cι- alkyl) , -S02NH2, -OC(0)NH2, -NH2S02(C1.4 alkyl) , -NHC(O) (Cι-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (Cα-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Ci-4 alkyl) group is methyl.
Preferred formula III compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1, 2, 3,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2,3-dihydro-liϊ-isoindolyl, 2,3- dihydro-lH- indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Rx and Ry are taken together with their intervening atoms to form an optionally substituted benzo ring or a 5-7 membered carbocyclo ring; and
(c) R2' is hydrogen or methyl and R2 is T-W-R6 or R, wherein W is -C(R6)20-, -C(R6)2N(R6) -, -CO-, -C02-, -C(R6)0C(0)-, -C(R6)2N(R6)CO-, -C (R6) 2N (R6) C (0) 0- , or -CON(R6)-, and R is an optionally substituted group' selected from Cι-6 aliphatic or phenyl, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstitutedbenzo, pyrido, pyrimido, or partially unsaturated 6-membered carbocyclo ring. More preferred compounds of formula III have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3 , 4-tetrahydroquinolinyl, 2,3-dihydro-lH-isoindolyl, 2, 3 -dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl;
(b) Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 5-7 membered carbocyclo ring optionally substituted with -R, oxo, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R )2, -OC(=0)R, -N(R4)C0R, -N(R)C02 (optionally substituted Cχ.β aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2 , -N(R4)S02N(R4)2, -N(R)S02R, or -OC (=0) N (R4) 2; and
(c) each R5 is independently selected from halo, OXO, CN, N02, -N(R4)2, -C02R, -CONH(R4), -N(R)C0R, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cι-6 aliphatic.
Even more preferred compounds of formula III have one or more, and more preferably all, of the features selected from the group consisting of: (a) Rx and Ry are taken together with their intervening atoms to form a benzo or 6-membered partially unsaturated carbocyclo ring optionally substituted with halo, CN, oxo, Ci-e alkyl, Cχ.6 alkoxy, (Cι-6 alkyl) carbonyl, (Ci-6 alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl;
(b) each R5 is independently selected from -halo, -CN, -oxo, -SR, -OR, -N(R)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6rιo aryl, or Cι_6 aliphatic; and
(c) R2' is hydrogen and R2 is selected from R2' is hydrogen or methyl and R2 is T-W-R6 or R, wherein W is -C(R6)20-, -C(R6)2N(R6)-, -CO-, -C02-, -C (R6) OC (O) - , -C(R6)2N(R6)C0-, or -CON(R6)-, and R is an optionally substituted group selected from Cι-6 aliphatic or phenyl, or R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cι_4 alkyl, -d_4 haloalkyl, -N02, -0(Cx-4 alkyl), -C02 (Cι-4 alkyl) , -CN, -S02 (d-4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02(Cx-4 alkyl) , -NHC(O) (Cι-- alkyl) , -C(0)NH2, or -CO ( -4 alkyl) , wherein the (Cι_4 alkyl) is a straight, branched, or cyclic alkyl group. Representative compounds of formula III are set forth in Table 2 below.
Table 2
III-l III-2 III -3
III-4 III-5 III-6
III-7 III-8 111-9
III-IO III-ll 111-12
111-13 111-14 111-15
111-16 111-17 111-18
111-19 111-20 111-21
111-22 111-23 111-24
111-25 111-26 111-27
111-28 111-29 111-30
111-31 111-32 111-33
111-34 111-35 111-36
111-40 111-41 111-42
111-43 111-44 111-45
111-46 111-47 111-48
111-49 111-50 111-51
111-52 111-53 111-54
111-55 111-56 111-57
111-58 111-59 111-60
111-61 111-62 111-63
111-64 . . - ILI-65 111-66
3 c
111-67 111-68 111-69
111-70 111-71 111-72
111-73 111-7 111-75
111-76 111-77 111-78
111-79 111-80 111-81
111-82 111-83 111-84
.111-85 111-86 111-87
111-88 111-89 111-90
111-91 111-92 111-93
111-94 111-95 111-96
111-97 111-98 111-99 '
III-100 III-101 III-102
III-103 III-104 III-105
III-106 III-107 III-108
III-109 III-llO III-lll
III-112 III-113 III-114
III-115 III-116 III-117.
III-118 III-119 III-120
III-121 III-122 III-123
III-124 III-125 III-126
III-127 III-128 III-129
111-130 III-131 III-132
III-133 III-134 III-135
III-136 III-137 III-138
III-139 III-140 III-141
III- 142 III-143 III-144
In another embodiment, this invention provides a composition comprising a compound of formula III and a pharmaceutically acceptable carrier. One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula III. Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula III.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful for diabetic patients.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula III.
Another aspect relates, to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula III . Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis.
One aspect of this invention relates to a method of inhibiting Src activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula III.
Another aspect relates to a method of treating a disease that is alleviated, by treatment with a Src inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula III. This method is especially useful for treating hypercalcemia, osteoporosis, osteoarthritis, cancer, symptomatic treatment of bone metastasis, and Paget's disease.
Another method relates to inhibiting GSK-3, Aurora, CDK-2, or Src activity in a biological sample, which method comprises contacting the biological sample with the GSK-3, Aurora, CDK-2, or Src inhibitor of formula III, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora, CDK-2, or Src.
Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora, CDK-2, or Src, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula III, as described above.
Compounds of formula III, wherein R2' is hydrogen and Rx and Ry are taken together with the pyrimidine ring to form an optionally substituted quinazoline ring system, are also inhibitors of ERK-2 and AKT protein kinases.
Accordingly, another method of this invention relates to a method of inhibiting ERK-2 or AKT activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula III, wherein R2' is hydrogen and Rx and Ry are taken together with the pyrimidine ring to form an optionally substituted quinazoline ring system.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a ERK-2 or AKT inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula III, wherein R2' is hydrogen and Rx and Ry are taken together with the pyrimidine ring to form an optionally substituted quinazoline ring system. This method is especially useful for treating cancer, stroke, hepatomegaly, cardiovascular disease,. Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, restenosis, psoriasis, allergic disorders including asthma, inflammation, and neurological disorders.
Another embodiment of this invention relates to compounds of formula IV:
IV or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring is optionally and independently substituted by T-R3, and any substitutable nitrogen on said' ring is substituted by R4;
T is a valence bond or a Ci-4 alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring containing 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein said fused ring is optionally substituted by up to three groups independently selected from halo, oxo, -CN, -N02, -R7, or -V-R6;
R3 is selected from -R, -halo, =0, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02, -CN, -S(0)R, -S(0)2R, -SR, . -N(R4)2, -CON(R)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cχ-6 aliphatic, C6.ι0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; each R4 is independently selected from -R7, -COR7, -C02 (optionally substituted Cι-6 aliphatic) , -C0N(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R)2, -OC(=0)R, -N(R4)C0R, -N(R4)C02 (optionally substituted Ci-s aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)C0-, -N (R6) C (0) 0- , -N(R6)C0N(R6) -, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -0C(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0) -, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - .
-C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)CON(R6)-; W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0)-, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6)-, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, ,-C(R6)2N(R6)CON.(R6)-, or -CON(R6)-; each R6. is independently selected from hydrogen or an optionally substituted -4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and each R7 is independently selected from hydrogen or an optionally substituted d-6 aliphatic group, or two R7 on. the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl ring or heteroaryl .
Preferred formula IV Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. Preferred formula IV Ring D bicyclic rings include 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3, 4-tetrahydroquinolinyl, 2, 3-dihydro-liT-isoindolyl, 2, 3-dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred Ring D bicyclic rings include naphthyl and isoquinolinyl.
Preferred substituents on Ring D of formula IV include halo, oxo, CN, -N02, -N(R4)2, -C02R, -CONH(R4) , -N(R4)C0R, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cι-6 aliphatic. More preferred R5 substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6_ι0 aryl, or Ci-e aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CHOH, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
When the Rx and Ry groups of formula IV are taken together to form a fused ring, preferred Rx/Ry rings include a 5-, 6-, 7-, or 8-membered unsaturated or partially unsaturated ring having 1-2 heteroatoms. This provides a bicyclic ring system containing the pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IV are the mono- and bicyclic systems shown below.
IV-D IV-E IV-G
IV-H itf-σ IV-K
IV- L IV-M IV-N
IV-AA IV-BB IV-CC
IV -DD
More preferred pyrimidine ring systems of formula IV include V-E, IV-G, IV-H, IV-J, IV-K, IV-L, IV-M, IV-T, and V-U.
In the monocyclic pyrimidine ring system of formula IV, preferred Rx groups include hydrogen, amino, nitro, alkyl- or dialkylamino, acetamido, or a Cι_4 aliphatic group such as methyl, ethyl, cyclopropyl, isopropyl or t-butyl. Preferred Ry groups include T-R3 wherein T is a valence bond or a methylene, and R3 is -R, -N(R4)2, or -OR. When R3 is -R or -OR, a preferred R is an optionally substituted group selected from C -β aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. Examples of preferred Ry groups include 2-pyridyl, 4-pyridyl, piperidinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or dialkylamino, acetamido, optionally substituted phenyl such as phenyl, methoxyphenyl, trimethoxyphenyl, or halo-substituted phenyl , and methoxymethyl .
In the bicyclic pyrimidine ring system of formula IV, the ring formed when Rx and Ry are taken together may be substituted or unsubstituted. Suitable substituents include -R, halo, -OR, -C(=0)R, -C02R,
-COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)C0R, -N (R4) C02 (optionally substituted Ci-e aliphatic) , -N(R )N(R )2, -C=NN(R4)2, -C=N-0R, -N(R )C0N(R4)2, -N (R4) S02N (R4) 2, -N(R )S02R, or -OC(=0)N(R4) 2, wherein R and R4 are as defined above for compounds of formula IV. Preferred Rx/Ry ring substituents include -halo, -R, -OR, -COR, -C02R, -CON(R4)2, -CN, or -N(R4)2 wherein R is a substituted or unsubstituted Ci-β aliphatic group.
The R2 and R2' groups of formula IV may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IV compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring of formula IV include one or more of the following:
-halo, -N(R4)2, -Ci-4 alkyl, -Ci-4 haloalkyl, -N02, -0(d-4 alkyl), -C02 (d_4 alkyl) , -CN, -S02 (d-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (d-4 alkyl) , -NHC (O) (Ci-4 alkyl) , -C(0)NH2, and -CO (Cχ-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Cι_4 alkyl) group is methyl.
When the pyrazole ring system of formula IV is monocyclic, preferred R2 groups include hydrogen, a substituted or unsubstituted group selected from aryl, heteroaryl, or a Ci-e aliphatic group. Examples of such preferred R2 groups include methyl, t-butyl, -CH2OCH3, cyclopropyl, furanyl, thienyl, and phenyl. A preferred R2' group is hydrogen. Preferred formula IV compounds have one or more, and more preferably all, of the features selected from the group consisting of :
(a) Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1, 2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3-dihydro-lff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Rx is hydrogen or Ci-4 aliphatic and Ry is T- R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 1-2 ring heteroatoms ; and
(c) R2' is hydrogen or methyl and R2 is T-W-R6 or R, wherein W is -C(R6)20-, -C(R6)2N(R6) -, -CO-, -C02-, -C(R6)OC(0)-, -C(R6)2N(R6)C0-, -C (R6) 2N (R6) C (0) O- , or -C0N(R6)-, and R is an optionally substituted group selected from d-6 aliphatic or phenyl, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido, or partially unsaturated 6-membered carbocyclo ring.
More preferred compounds of formula IV have one or more, and more preferably all, of the features selected from the group consisting of :
(a) Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2, 3, 4 -tetrahydroquinolinyl, 2, 3-dihydro-lff-isoindolyl, 2, 3 -dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, .or naphthyl;
(b) Rx is hydrogen or methyl and Ry is -R, N(R)2, or -OR, or Rx and Ry are taken together with their intervening atoms to form a 5-7 membered unsaturated or partially unsaturated ring having 1-2 ring nitrogens, wherein said ring is optionally substituted with -R, halo, oxo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R)2, -OC(=0)R,
-N(R)COR, -N(R)C02 (optionally substituted Cχ.6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R)S02R, or -OC (=0) N (R4) 2; and
(c) each R5 is independently selected from halo, OXO, CN, N02, -N(R4)2, -C02R, -C0NH(R4), -N(R4)COR,
-S02N(R4)2/ -N(R4)S02R,. -SR, -OR, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cχ-6 aliphatic.
Even more preferred compounds of formula IV have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Rx and Ry are taken together with their intervening atoms to form a 6 -membered unsaturated or partially unsaturated ring having 1-2 ring nitrogens, optionally substituted with halo, CN, oxo, Cχ.& alkyl, Ci-e alkoxy, (Cι-6 alkyl) carbonyl, (d_.6 alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl;
(b) each R5 is independently selected from -halo, -CN, -oxo, -SR, -OR, -N(R)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-IQ aryl, or Cι_6 aliphatic; and
(c) R2' is hydrogen and R2 is T-W-R6 or R, wherein W is -C(R6)20-, -C(R6)2N(R6) -, -CO-, -C02-, -C(R6)OC(0) -, -C(R6)2N(R6)CO-, or -C0N(R6)-, and R is an optionally substituted group selected from Cχ.6 aliphatic or phenyl, or R2 and R2' are. taken together with their intervening atoms to form a benzo, pyrido, or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, oxo, -N(R4)2, -d_4 alkyl, -C1-4 haloalkyl, -N02, -0 (d-4 alkyl) , -C02(Cι-4 alkyl) , -CN, -S02 ( -4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (C1-4 alkyl) , -NHC(O) (C1-4 alkyl) , -C(0)NH2, or -CO (C1-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group.
Representative compounds of formula IV are set forth in Table 3 below.
Table 3.
IV- 1 IV-2 IV-3
IV-4 IV-5 IV- 6
IV-7 IV- 8 ' IV- 9
IV-10 IV-11 IV-12
IV- 13 IV- 14 IV- 15
IV-16 IV-17 IV-18
IV-19 IV- 20 IV-21
IV-22 IV- 23 IV-24
IV-25 IV-26 IV-27
IV-28 IV-29 IV-30
to N to N to
IV-31 IV-32 IV-33
In another embodiment, this invention provides a composition comprising a compound of formula IV and a . pharmaceutically acceptable carrier.
One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula IV.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula IV.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IV.. This method is especially useful for diabetic patients-.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IV.. This method is especially useful in halting or slowing the progression of Alzheimer's disease.
Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IV. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering, to the patient a therapeutically effective amount of a composition comprising a compound of formula IV. Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula IV. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula IV.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula IV. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. Another method relates to inhibiting GSK-3,
Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula IV, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2.
Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IV, as described above.
Another embodiment of this invention relates to compounds of formula V:
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Z1 is N, CRa, or CH and Z2 is N or CH, provided that one of Z1 and Z2 is nitrogen;
G is Ring C or Ring D;
Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D' is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D; R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cχ.6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι_6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3, and any substitutable nitrogen on said ring, formed by Rx and Ry is substituted by R4; T is a valence bond or a d-4 alkylidene chain; R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4; R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R)2, -CON(R7)2, -S02N(R7)2, -OC(=0)R, -N(R7)C0R, -N(R7) C02 (optionally substituted d_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R7) CON (R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0)N (R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cχ.6 aliphatic, C6-ιo aryl, a' heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cχ.6 aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2/ -C=NN(R4)2, -C=N-OR, -N(R4) CON(R4) 2,
-N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N (R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)C0-, -N (R6) C (0) O- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N(R6)N(R6) -, -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6)2N(R6) - , -C(R6)2N(R6)C(0) -, -C(R6)2N(R6)C(0)0-, -C (Rδ) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N(R6) S02N(R6) - , or -C (R6) 2N (R6) CON (R6) - ;
W is -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0)-, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6) -, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, -C(R6)2N(R6)CON(R6)-, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted d-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted Cι_4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -C0N(R6)2, or -C02R6; and Ra is selected from halo, -OR, -C(=0)R, -C02R, -COCOR, -NOa, -CN, -S(0)R, -S02R, -SR, -N(R)2, -CON(R4)2,
-S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N (R4) C02 (optionally substituted d-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R)CON(R4)2, -N (R4) S02N(R4) 2, -N(R)S02R, -OC(=0)N(R4)2, or an optionally substituted group selected from Ci-e aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
Compounds of formula V may be represented by specifying Z1 and Z2 as shown below:
Va Vb Vc
When the Rx and Ry groups of formula V are taken together to form a fused ring, preferred Rx/Ry rings include a 5-, 6-, 7-, or 8-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said Rx/Ry ring is optionally substituted. This provides a bicyclic ring system containing a pyridine ring. Examples of preferred bicyclic ring systems of formula V are shown below.
Va-C Vb-C Vc-C
Va-E Vb-E Vc-E
Va-P Vb-P . Vc-P
More preferred bicyclic ring systems of formula V include Va-A, Vb-A, Vc-A, Va-B, Vb-B, Vc-B, Va-D, Vb-D, Vc-D, Va-E, Vb-E, Vc-E, Va-J, Vb-J, Vc-J, Va-K, Vb-K, Vc-K, Va-L, Vb-L, Vc-L, Va-M, Vb-M, and Vc-M, most preferably Va-A, Vb-A, Vc-A, Va-B, Vb-B, and Vσ-B. In the monocyclic pyridine ring system of formula V, preferred Rx groups include hydrogen, alkyl- or dialkylamino, acetamido, or a C1-4 aliphatic group such as methyl, ethyl, cyclopropyl, isopropyl or t-butyl. Preferred Ry groups include T-R3 wherein T is a valence bond or a methylene, and R3 is -R, -N(R4)2, or -OR. When R3 is -R or -OR, a preferred R is an optionally substituted group selected from Ci-e aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. Examples of preferred Ry include 2-pyridyl, 4-pyridyl, . piperidinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or dialkylamino, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl, and methoxymethyl .
In the bicyclic ring system of formula V, the ring formed when Rx and Ry are taken together may be substituted or unsubstituted. Suitable substituents include -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N(R4)C02 (optionally substituted Cχ.6 aliphatic), -N(R4)N(R)2, -C=NN(R4)2, -C=N-0R, -N(R4)CON(R)2, -N(R4)S02N(R4)2, -N(R)S02R, or
-0C(=0)N(R4)2, wherein R and R4 are as defined above.
■Ill- Preferred Rx/Ry ring substituents include -halo, -R, -OR, -COR, -C02R, -CON(R4)2, -CN, or -N(R4)2 wherein R is an optionally substituted Cχ.6 aliphatic group.
The R2 and R2' groups of formula V may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula V compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring of formula V include one or more of the following: -halo, -N(R4)2, -Cx-4 alkyl, -d-4 haloalkyl, -N02, -0(d-4 alkyl) , -C02 (d-4 alkyl) , -CN, -S02 (Ci-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02(Cι-4 alkyl) , -NHC(O) (d-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Cι-4 alkyl) group is methyl.
When the pyrazole ring system is monocyclic, preferred R2 groups include hydrogen, Cι_4 aliphatic, alkoxycarbonyl, (un) substituted phenyl , hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl, and (N- heterocyclyl) carbonyl. Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH20H, CH2OCH3, CH2CH2CH2OH, CH2CH2CH2OCH3, CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHC0OC (CH3) 3, C0NHCH(CH3)2, CONHCH2CH=CH2, CONHCH2CH2OCH3, CONHCH2Ph, CONH(cyclohexyl) , CON(Et)2, CON(CH3) CH2Ph, CONH(n-C3H7) , . CON(Et)CH2CH2CH3, CONHCH2CH (CH3) 2, CON (n-C3H7) 2, CO (3- methoxymethylpyrrolidin-1-yl) , CONH(3-tolyl) , CONH(4- tolyl) , CONHCH3, CO (morpholin-1-yl) , CO (4-methylpiperazin- l-yl) , CONHCH2CH2OH, CONH2, and CO (piperidin-1-yl) . A preferred R2' group is hydrogen.
More preferred ring systems of formula V are the following, which may be substituted as described above, wherein R2 and R2' are taken together with the pyrazole ring to form an optionally substituted indazole ring; and Rx and Ry are each methyl, or Rx and Ry are taken together with the pyridine ring to form an optionally substituted quinoline, isoquinoline, tetrahydroquinoline or tetrahydroisoquinoline ring:
V-Aa V-Ba V-Ha
When G is Ring C, preferred formula V Ring C groups are phenyl and pyridinyl. When two adjacent substituents on Ring C are taken together to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl and isoquinolinyl. Preferred R1 groups include -halo, an optionally substituted d-e aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR6, -OC(0)NH2, or -NHS02R6. When R1 is an optionally substituted Ci-β aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3, -Cl, -F, -CN, -COCH3, -0CH3, -OH, -CH2CH3, -0CH2CH3, -CH3, -CF2CH3, cyclohexyl, t-butyl, isopropyl, cyclopropyl, -C≡CH, -C≡C-CH3, -S02CH3, -SO2NH2, -N(CH3)2, -C02CH3, -CONH2, -NHCOCH3, -OC(0)NH2, -NHS02CH3, and -OCF3.
On Ring C preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2, optionally substituted d-6 aliphatic group, -OR, -C(0)R, -C02R, -C0NH(R4) , -N(R4)COR, -S02N(R4)2, and -N(R4)S02R. More preferred R5 substituents include -Cl, -F, -CN, -CF3,
-NH2, -NH(Ci-4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι- aliphatic), d-4 aliphatic, and -C02(Cι-4 aliphatic). Examples of such preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, .ethyl, cyclopropyl, isopropyl, t-butyl, and -C02Et.'
When G is Ring D, preferred formula V Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula V Ring D bicyclic rings include 1, 2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2,3-dihydro-lff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred bicyclic Ring D systems include naphthyl and isoquinolinyl .
Preferred substituents on Ring D of formula V include one or more of the following: halo, oxo, CN, -N02, -N(R4)2, -C02R, -CONH(R4), -N(R4)COR, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cι_6 aliphatic. More preferred Ring D substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-10 aryl, or Cχ.β aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH2OH, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
Preferred formula V compounds have one or more, and more preferably all, of the features selected from the group consisting of: (a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Cχ-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -0C(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3 , 4-tetrahydroquinolinyl, 2,3-dihydro-lff-isoindolyl, 2,3-dihydro-lff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Rx is hydrogen or d-4 aliphatic and Ry is T- R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 0-2 ring nitrogens ; and (c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a d_6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
More preferred compounds of formula V have one or more, and more preferably all, of the features selected from the group consisting of: (a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cχ.6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2 , 3-dihydro-lff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Rx is hydrogen or methyl and Ry is -R, N(R4)2, or -OR, or Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 5-7 membered partially unsaturated carbocyclo ring, said benzo or carbocyclo ring optionally substituted with -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)C0R, -N(R4) C02 (optionally substituted d-e aliphatic), -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0) N (R4) 2;
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a d_6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cι,6 aliphatic group, -OR, -C(0)R, ~C02R, -C0NH(R4), -N(R4)COR, -S02N(R4)2, or -N(R4)S02R.
Even more preferred compounds of formula V have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -Rs, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι-4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Rx is hydrogen or methyl and Ry is methyl, methoxymethyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or an optionally substituted group selected from
2-pyridyl, 4-pyridyl, piperidinyl, or phenyl, or Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 6-membered partially unsaturated carbocyclo ring optionally substituted with halo, CN, oxo, Ci-e alkyl, d-6 alkoxy, (Ci-e alkyl) carbonyl, (Cι-e alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl; (c) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -d-4 alkyl, -Ci-4 haloalkyl, -N02/ -0{d_4 alkyl) , -C02 (d_4 alkyl) , -CN, -S02 (d-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (Cι_4 alkyl) , -NHC(O) (Ci-4 alkyl) , -C(0)NH2, or -CO (Cχ-4 alkyl) , wherein the (Cι_4 alkyl) is a straight, branched, or cyclic alkyl group; and
(d) Ring D is substituted by oxo or Rs, wherein each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(d_4 aliphatic), -N(Cι_4 aliphatic)2, -0(d- aliphatic), d-4 aliphatic, and -C02(Cι-4 aliphatic).
Representative compounds of formula V are set forth in Table 4 below.
Table 4.
V-l V-2 V-3
V-4 V-5 V-6
V-7 V-8 V-9
V-58 V-59 V-60
V-64 V-65 V-66
In another embodiment, this invention provides a composition comprising a compound of formula V and a pharmaceutically acceptable carrier.
One aspect of this. invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula V.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula V.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula V. This method is especially useful for diabetic patients. Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula V. This method is especially useful in halting or slowing the progression of Alzheimer's disease.
Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula V. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula V.
Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula V. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula V.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula V. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis.
Another method relates to inhibiting GSK-3, Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula V, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2. Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula V, as described above. Another embodiment of this invention relates to compounds of formula VI :
R2 to NH HN' *"N'
N^N
RΪΛN
VI
or a pharmaceutically acceptable derivative or prodrug thereof, wherein: G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2, 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or C .6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted hγ up to three groups independently selected from halo, oxo, or -R8, said Ci-e aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; Ry is T-R3'; T is a valence bond or a C1-4 alkylidene chain; R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4; R3' is an optionally substituted group selected from Ci-e aliphatic, C3-ι0 carbocyclyl, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10. ring atoms; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι-6 aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R)2 -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (0) 0- , -N(R6)C0N(R6) -, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(Rs)2SO-, -C(R6) 2SO2- , -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6) -, -C (R6) 2N (R6) S02N(R6) - , or -C(R6)2N(R6)CON(R6)-; W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO- , -C02-, -C(R6)OC(0)-, -C(R6)OC.(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(RS)=NN(R6)-, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)CON(R6)-, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted C1-4 aliphatic group, or two Rδ groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Ci-e aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and each R8 is independently selected from an optionally substituted C1-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6.
Preferred Ry groups of formula VI include T-R3' wherein T is a valence bond or a methylene, and R3' is an optionally substituted group selected from Cχ.6 aliphatic, C3-10 carbocyclyl, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms. A preferred R3' group is an optionally substituted group selected from C3.6 carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. Examples of preferred Ry include 2-pyridyl, 4-pyridyl, piperidinyl, morpholinyl, cyclopropyl, cyclohexyl, and optionally substituted phenyl such as phenyl or halo-substituted phenyl .
The R2 and R2' groups of formula VI may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula VI compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring include one or more of the following: -halo, -N(R4)2, -Cι-4 alkyl, - - haloalkyl, -N02, -0(Cι-4 alkyl) , -C02 (Cι_4 alkyl), -CN, -S02 (d-4 alkyl) , -S02NH2, -OC(0)NH2,
-NH2S02(d-4 alkyl) , -NHC(O) (d-4 alkyl) , -C(0)NH2, and -CO (Cχ-4 alkyl) , wherein the (d_4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Cι-4 alkyl) group is methyl. When the pyrazole ring system is monocyclic, preferred R2 groups of formula VI include hydrogen, Cι-4 aliphatic, alkoxycarbonyl, (un) substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl , and (N- heterocyclyl) carbonyl . Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH20H, CH20CH3, CH2CH2CH2OH, CH2CH2CH2OCH3, CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHCOOC (CH3) 3,
CONHCH(CH3)2, CONHCH2CH=CH2, CONHCH2CH2OCH3, CONHCH2Ph, CONH (cyclohexyl) , CON (Et) 2, CON(CH3) CH2Ph, CONH (n-C3H7) , CON(Et)CH2CH2CH3, CONHCH2CH(CH3) 2, CON(n-C3H7) 2/ CO(3- methoxymethylpyrrolidin-1-yl) , CONH (3-tolyl) , CONH(4- tolyl), CONHCH3, CO(morpholin-l-yl) , CO(4-methylpiperazin- 1-yl) , CONHCH2CH2OH, CONH2, and CO (piperidin-1-yl) . A preferred R2' group is hydrogen.
When G is Ring C, preferred formula VI Ring C groups are phenyl and pyridinyl . When two adjacent substituents on Ring C are taken together • to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl and isoquinolinyl. Preferred R1 groups include -halo, an optionally substituted d-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -0C(0)NH2, or -NHS02R6. When R1 is an optionally substituted Ci-β aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3, -Cl, -F, -CN, -COCH3, -OCH3, -OH, -CH2CH3, -OCH2CH3, -CH3, -CF2CH3, cyclohexyl, t-butyl, isopropyl, cyclopropyl, -C≡CH, -C≡C-CH3, -S02CH3, -S02NH2, -N(CH3)2, -C02CH3, -CONH2, .
-NHCOCH3, -OC(0)NH2, -NHS02CH3, and -OCF3.
On Ring C preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2, optionally substituted d-e aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R)2, and -N(R4)S02R. More preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NH(Cι-4 aliphatic) , -N(d-4 aliphatic)2, -0(Cχ-4 aliphatic), Cι_4 aliphatic, and -C02(Cχ.4 aliphatic). Examples of such preferred R5 substituents. include -Cl, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, and -C02Et.
When G is Ring D, preferred formula VI Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula VI Ring D bicyclic rings include 1,2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2,3-dihydro-lff-isoindo.lyl, 2,3- dihydro-Iff- indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred bicyclic Ring D systems include naphthyl and isoquinolinyl. Preferred substituents on formula VI Ring D include one or more of the following: halo, oxo, CN, -N02, -N(R4)2, -C02R, -CONH(R4), -N(R4)C0R, -S02N(R )2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6.10 aryl, or d-6 aliphatic. More preferred Ring D substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Ci-β aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH2OH, pyrrolidinyl, OPh, CF3, C≡CH, Cl,
Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
Preferred formula VI compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is selected from a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Ci-e aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR5, -OC(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, • pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl , 1,2,3, 4 -tetrahydroquinolinyl , 2 , 3-dihydro- Iff-isoindolyl , 2,3-dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Ry is T-R3' , wherein T is a valence bond or a methylene; and
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a d-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
More preferred compounds of formula VI have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cχ,6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl; 1, 2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3-dihydro-Iff- isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Ry is T-R3' , wherein T is a valence bond or a methylene and R3' is an optionally substituted group selected from Cχ.6 aliphatic, C3.6 carbocyclyl, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; (c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Ci-e aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo, ring; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cχ.6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R)2, or -N(R4)S02R.
Even more preferred compounds of formula VI have one or more, and more preferably all, of the features selected from the group consisting of: (a) Ry is T-R3', wherein T is a valence bond or a methylene and R3' is an optionally substituted group selected from Cι_ aliphatic, C3-<; carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(b) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a d-4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ; (c) R2 and R2' are taken together with their intervening, atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cx-4 alkyl, -Ci-4 haloalkyl, -N02, -0(Cι-4 alkyl) , -C02 (Cι-4 alkyl) , -CN, -S02(Cι-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (Cι-4 alkyl) , -NHC(O) (d-4 alkyl) , -C(0)NH2, or -CO (Ci-4 alkyl) , wherein the (d_4 alkyl) is a straight, branched, or cyclic alkyl group; and (d) Ring D is substituted by oxo or R5, wherein each Rs is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Ci-4 aliphatic), -N(Cχ-4 aliphatic)2, -0(d-4 aliphatic), d-4 aliphatic, and -C02(d-4 aliphatic).
Another embodiment of this invention relates to compounds of formula Via:
or a pharmaceutically acceptable derivative or prodrug thereof, wherein: G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8; Ring D is a 5-7 membered monocyclic ring or 8-10 membered ■ bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι-6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; T is a valence bond or a Cι_4 alkylidene chain; R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N0 , -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4; each R is independently selected from hydrogen or an optionally substituted group selected from C .ζ aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a . heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι-6 aliphatic) , -C0N(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2,
-N(R4)S02N(R4)2, -N(R)S02R, or -OC (=0)N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02- , -N(R6)C0-, -N (R6) C (0) O- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N(R6) N(R6) - , -C(0)N(R6)-, -OC(0)N(R6) -, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , . -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(O)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N(R6) - , or -C(R6)2N(R6)CON(R6) -;
W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0)-, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(R6).2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι_ aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together wit the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and each R8 is independently selected from an optionally substituted Cα-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6,. -N(R6)2, -N(R6)N(Rδ)2, -CN, -N02, -CON(R6)2, or
Preferred rings formed by the R2 and groups of formula Via include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula Via compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the R2/R2' fused ring include one or more of the following: -halo, -N(R)2, -Cι_4 alkyl, -d-4 haloalkyl, -N02, -0(d-4 alkyl) , -C02(Cι-4 alkyl), -CN, -S02 (Cχ-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (Cι-4 alkyl) , -NHC (0) (C1-4 alkyl) , -C(0)NH2, and -CO (C1-4 alkyl) , wherein the (Cι_4 alkyl) is a straight; branched, or cyclic alkyl group. Preferably, the (Cι_4 alkyl) group is methyl .
When G is Ring C, preferred formula Via Ring C groups are phenyl and pyridinyl . When two adj acent substituents on Ring C are taken together to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl and isoquinolinyl. Preferred R1 groups include -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6. When R1 is an optionally substituted Cι_6 aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3, -Cl, -F, -CN, -COCH3, -OCH3, -OH, -CH2CH3, -0CH2CH3, -CH3, -CF2CH3, cyclohexyl, t-butyl, isopropyl, cyclopropyl, -C≡CH,
-C≡C-CH3, -S02CH3, -S02NH2, -N(CH3)2, -C02CH3, -CONH2, -NHC0CH3/ -0C(0)NH2, -NHS02CH3, and -0CF3.
On Ring C preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2, optionally substituted Cι-6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)C0R, -S02N(R4)2, and -N(R4)S02R. More preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NH(Cχ-4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι-4 aliphatic), Cι_4 aliphatic, and -C02(Cι-4 aliphatic). Examples of such preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, and -C02Et.
When G is Ring D, preferred formula Via Ring D monocyclic rings include substituted and unsubstituted phenyl * pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula Via Ring D bicyclic rings include 1, 2, 3 ,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred bicyclic Ring D systems include naphthyl and isoquinolinyl. Preferred substituents on the formula Via Ring D include one or more of the following: halo, oxo, CN, -N02, -N(R4)2, -C02R, -C0NH(R4), -N(R4)COR, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Ci-e aliphatic. More preferred Ring D substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cχ-6 aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH2OH, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy. Preferred formula Via compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR6, -0C(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl , 1,2,3, 4-tetrahydroquinolinyl , 2, 3 -dihydro-Iff-isoindolyl, 2, 3-dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring; and
(b) R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6- membered carbocyclo ring. More preferred compounds of formula Via have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι-6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2,3,4-tetrahydroisoquinoliny1 , 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl;
(b) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cι-4 alkyl, -d-4 haloalkyl, -N02, -0 (Cι-4 alkyl) , -C02 (d-4 alkyl) , -CN, -S02(Cι-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (d-4 alkyl) , -NHC(O) (Ci-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (Cι-4 alkyl) is a straight, branched, or cyclic alkyl group; and (c) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cι-6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R)COR, -S02N(R4)2, or -N(R4)S02R. Even more preferred compounds of formula Via have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι- aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl; (b) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R)2/ -Cι-4 alkyl, -Cι-4 haloalkyl, -N02, -0(Cι-4 alkyl) , -C02 (Cι-4 alkyl) , -CN, -S02 (d-4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (Cι_4 alkyl) ,
-NHC(O) (Ci-4 alkyl) , -C(0)NH2, or -CO (C1-4 alkyl) , wherein the (C1-4 alkyl) is a straight, branched, or cyclic alkyl group,- and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Cι-4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι_4 aliphatic), Cι_4 aliphatic, and -C02(Cι-4 aliphatic).
Representative compounds of formula VI and IVa are set forth in Table 5 below.
Table 5 ,
VI - 1 VI -2 VI -3
VI-4 VI-5 VI -6
VI-7 VI-8 VI-9
-10 VI-11 VI-12
I -13 VI-14 VI-15
to Fto3C toto Cl' VI-16 VI-17 VI-18
VI-19 VI-20 VI-21
-22 VI-23 VI-24
VI-25 VI-26 VI-27 VI-28 VI-29 VI-30
Cl' HN^ Cl*
VI-31 VI-32 VI-33
VI-34 VI-35 VI-36
VI-37 VI-38 VI-39
VI-40 VI-41 VI-42
VI-43 VI-44 VI-45
VIa-1 VIa-2 VIa-3
to
VIa-4 VIa-5 VIa-6
Via- 7 Via- 8 Via- 9
Via-10 VIa-11 VIa-12
In another embodiment, this invention provides a composition comprising a compound of formula VI or Via and a pharmaceutically acceptable carrier. One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via. Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 -inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VI or Via.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via. This method is especially useful for diabetic patients.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in. a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via. This method- is .especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via.
Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VI or Via. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer. One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VI or Via. Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VI or Via. This method is' especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis-.
Another method relates to inhibiting GSK-3, Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula VI or Via, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2.
Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula VI or Via, as described above.
Another embodiment of this invention relates to compounds of formula VII:
VII or a pharmaceutically acceptable derivative or prodrug thereof, wherein: G is Ring C or Ring D;
Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2, 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a si -membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D; R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι_6 aliphatic group optionally . substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; Ry is hydrogen or T-R3";
T is a valence bond, hydrogen, or a Cι-4 alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4;
R3" is selected from an optionally substituted group selected from C3-10 carbocyclyl, C6_ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι-6 aliphatic) , -CON(R7)2, or -S02R7/ or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR,
-C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) C0N(R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0) N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (0) 0- , -N(R6)C0N(R6)-, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - ,
-C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (Rδ) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N (R6) - , or -C (R6) 2N (R6) CON (R6) - ; W is -C(R6)20-, -C(Rδ)2S-, -C(Rδ)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-,
-C(Rδ)OC(0) -, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(Rδ)2N(R6)C(0)0-, -C(R6)=NN(R6)-, -C(R6)=N-0-, -C (R6) 2N (R6) N (R6) - , -C (Rδ) 2N (Rδ) S02N (R6) - , -C(Rδ)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted d_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_.6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted Cι-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -C0N(R6)2, or -C02R6; and R9 is selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2,
-S02N(R4)2, -0C(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Ci-e aliphatic) , -N(R4)N(R4)2, -C=NN(R)2, -C=N-0R, -N(R4)C0N(R4)2, -N(R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2. Preferred Ry groups of formula .VII include T-R3" wherein T is a valence bond or a methylene. Preferred R3" groups include an optionally substituted group selected from C3.6 carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. Examples of preferred Ry include 2-pyridyl, 4-pyridyl, piperidinyl, cyclopropyl, and an optionally substituted phenyl such as phenyl or halo-substituted phenyl.
The R2 and R2' groups of formula VII may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula VII compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on- the R2/R2' fused ring include one or more of the following: -halo, -N(R4)2, -C1-4 alkyl, -d-4 haloalkyl, -N02, -0 (Cι_ alkyl) , -C02 (C1-4 alkyl), -CN, -S02 (Cι-4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02(Cι-4 alkyl) , -NHC(O) (Cι-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (d_4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Cι-4 alkyl) group is methyl.
When the pyrazole ring system of formula VII is monocyclic, preferred R2 groups include hydrogen, Cι_4 aliphatic, alkoxycarbonyl, (un) substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarboήyl , and (N- heterocyclyl) carbonyl. Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH20H, CH20CH3, CH2CH2CH20H, CH2CH2CH2OCH3 , CH2CH2CH2OCH2Ph, CH2CH2CH2NH2 , CH2CH2CH2NHCOOC (CH3) 3, CONHCH(CH3)2, CONHCH2CH=CH2 , C0NHCH2CH20CH3 , CONHCH2Ph,
CONH(cyclohexyl) , CON(Et)2, CON(CH3) CH2Ph, CONH (n-C3H7) , CON(Et)CH2CH2CH3, CONHCH2CH (CH3) 2, CON (n-C3H7) 2, C0(3- methoxymethylpyrrolidin-1-yl) , CONH (3 -tolyl) , C0NH(4- tolyl) , CONHCH3, CO(morpholin-l-yl) , CO(4-methylpiperazin- 1-yl) , CONHCH2CH2OH, CONH2, and CO (piperidin-1-yl) . A preferred R2' group is hydrogen.
When G is Ring C, preferred formula VII Ring C groups are phenyl and pyridinyl . When two adj acent substituents on Ring C are taken together to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl and isoquinolinyl . Preferred R1 groups include -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR6, -OC(0)NH2, or -NHS02Rδ. When R1 is an optionally substituted Cι-6 aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3, -Cl, -F,
-CN, -COCH3, -OCH3, -OH, -CH2CH3, -0CH2CH3, -CH3, -CF2CH3, cyclohexyl, t-butyl, isopropyl, cyclopropyl, -C≡CH, -CSC-CH3, -S02CH3, -S02NH2, -N(CH3)2, -C02CH3, -CONH2, -NHCOCH3, -OC(0)NH2, -NHSO2CH3, and -OCF3. On Ring C preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2, optionally substituted d-5 aliphatic group, -OR, -C(0)R, -C02R, -C0NH(R4), -N(R4)COR, -S02N(R4)2, and -N(R4)S02R. More preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NH(Cι_4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι-4 aliphatic), d-4 aliphatic, and -C02(Cι-4 aliphatic). Examples of such preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, and -C02Et.
When G is Ring D, preferred formula VII Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two. adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula VII Ring D bicyclic rings include 1,2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3-dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, and naphthyl. Examples of more preferred bicyclic Ring D systems include naphthyl and isoquinolinyl.
Preferred substituents on Ring D include one or more of the following: halo, oxo, CN, -N02, -N(R4)2, -C02R, -C0NH(R4), -N(R4)C0R, -S02N(R4)2, -N(R)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ι0 aryl, or Cι-6 aliphatic. More preferred Ring D substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ι0 aryl, or Ci-g aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH20H, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
Preferred formula VII compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHC0R6, -OC(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3, 4 -tetrahydroquinolinyl, 2 , 3 -dihydro-Iff-isoindolyl , 2,3 -dihydro-Iff-indolyl , isoquinolinyl, quinolinyl, or naphthyl ring; (b) Ry is T-R3", wherein T is a valence bond or a methylene; and
(c) R2' is hydrogen and R2 is hydrogen or a ' substituted or unsubstituted group selected from aryl, heteroaryl, or a Ci-e aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
More preferred compounds of formula VII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Ci-g haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2,3 ,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from C3.6 carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Ci-e aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02,
-N(R4)2, optionally substituted Cι-6 aliphatic group, -OR, -C(0)R, -C02R> -C0NH(R4) , -N(R4)C0R, -S02N(R4)2, or -N(R4)S02R.
Even more preferred compounds of formula VII have one or more, . and more preferably all, of the features selected from the group consisting of :
(a) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(b) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a C1-.4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ;
(c) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cι_4 alkyl, -d-4 haloalkyl, -N02, -0(d-4 alkyl) , -C02 (Ci-4 alkyl) , -CN, -S02(d-4 alkyl) , -S02NH2, -0C(0)NH2/ -NH2S02 (Cι-4 alkyl) , -NHC(O) (Ci-4 alkyl) , -C(0)NH2, or -CO (Cι-4 alkyl) , wherein the (Cι_4 alkyl) is a straight, branched, or cyclic alkyl group ; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Cι-4 aliphatic), -N(Cι-4 aliphatic)2, -0(C!-4 aliphatic), C1- aliphatic, and -C02(Cι-4 aliphatic).
Representative compounds of formula VII are set forth in Table 6 below.
Table 6.
VII-4 VII-5 VII-6
-7 VII-8 -9
to
VII-10 VII-11 VII-12
VII-13 VII-14 VII-15
VII-16 VII-17 VII-18
VII-22 VII-23 VII-24
VII-25 VII-26 VII-27
VII - 28 VII -29 VII - 30
VII-31 VII-32 VII -33
VII-34 VII-35 VII-36
In another embodiment, this invention provides a composition comprising a compound of formula VII and a pharmaceutically acceptable carrier.
One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VII.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VII.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition' comprising a compound of formula VII. This method is especially useful for diabetic patients. Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VII. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VII. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VII.
Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VII. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity. in a patient, comprising administering to the patient a therapeutically effective amount of .a composition comprising a compound of formula VII.
Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VII. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. Another method relates to inhibiting GSK-3, Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula VII, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2. Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of. formula VII, as described above. Another embodiment of this invention relates to compounds of formula VIII:
VIII
or a pharmaceutically acceptable derivative or prodrug thereof, wherein: Z1 is N or CR9, Z2 is N or CH, and Z3 is N or CRX, provided that one of Zα and Z3 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2, 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by halo, oxo, or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι_6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι_6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx is T-R3;
T is a valence bond or a Cι- alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4;
R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02/ -CN, -S(0)R, -S(0)2R, -SR, -N(R)2, -C0N(R7)2, -S02N(R7)2, -OC(=0)R, -N(R7)COR, -N(R7)C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R7) CON(R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0) N (R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Ci-e- aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι_6 aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each RΞ is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N (R4) CON (R4) 2,
-N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N (R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (Rδ) C (0) O- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N (R6)N (R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(Rδ)C(0)0-, -C (Rδ) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N (R6) - , or -C (R6) 2N(Rδ) CON (R6) - ; W is -C(Rδ)20-, -C(R6)2S-, -C(R6)2SO-, -C(Rδ)2S02-, -C(R6)2S02N(R6) -, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)0C(0)-, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C (R6).=N-0- , -C(R6)2N(Rδ)N(R6) -, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)C0N(R6)-, or -C0N(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted d-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6; and
R9 is selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R)2, -CON(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Ci-e aliphatic) , -N(R)N(R4) 2, -C=NN(R4)2, -C=N-OR, -N(R4)CON(R4)2, -N(R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2.
Accordingly, the present invention relates to compounds of formula Villa, Vlllb, VIIIc and Vllld as shown below:
Villa VIIlb VIIIc Vllld
Preferred Rx groups of formula VIII include T-R wherein T is a valence bond or a methylene and R3 is CN, -R, or -OR. When R3 is -R, preferred R3 groups include an optionally substituted group selected from Cι-6 aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. When R3 is -OR, preferred R groups include an optionally substituted group d-β aliphatic group such as alkyl- or dialkylaminoalkyl and aminoalkyl. Examples of preferred Rx include acetamido, CN, piperidinyl, piperazinyl, phenyl, pyridinyl, imidazol-1-yl, imidazol- 2-yl, cyclohexyl, cyclopropyl, methyl, ethyl, isopropyl, t-butyl, NH2CH2CH2NH, and NH2CH2CH20.
Preferred R9 groups of formula VIII, when present, include R, OR, and N(R4)2. . Examples of preferred R9 include methyl, ethyl, NH2, NH2CH2CH2NH, N(CH3)2CH2CH2NH, N(CH3)2CH2CH20, (piperidin-l-yl)CH2CH20, and NH2CH2CH20.
The R2 and R2' groups of formula VIII may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula VIII compounds having a pyrazole-containing bicyclic ring system:
Preferred substituents on the formula VIII
R2/R2' fused ring include one or more of the following: -halo, -N(R4)2, -Ci-4 alkyl, -d-4 haloalkyl, -N02, -0(Cι-4 alkyl), -C02 (Cι-4 alkyl) , -CN, -S02(d_4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02(d-4 alkyl) , -NHC(O) (d-4 alkyl) , -C(0)NH2, and -CO (Cι-4 alkyl) , wherein the (Cι-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (Ci-4 alkyl) group is methyl.
When the pyrazole ring system of formula VIII is monocyclic, preferred R2 groups include hydrogen, Cι-4 aliphatic, alkoxycarbonyl, (un) substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl , dialkylaminoalkyl , phenylaminocarbonyl , and (N- heterocyclyl ) carbonyl . Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH2OH, CH2OCH3, CH2CH2CH2OH, CH2CH2CH2OCH3 , CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHCOOC (CH3) 3, CONHCH(CH3)2, CONHCH2CH=CH2 , CONHCH2CH2OCH3 , CONHCH2Ph,
CONH(cyclohexyl) , CON(Et)2, CON(CH3) CH2Ph, CONH(n-C3H7) , CON(Et)CH2CH2CH3, CONHCH2CH (CH3) 2, CON (n-C3H7) 2, CO (3- methoxymethylpyrrolidin-1-yl) , CONH (3 -tolyl) , C0NH(4- tolyl) , CONHCH3, CO (morpholin-1-yl) , CO(4-methylpiperazin- 1-yl) , CONHCH2CH2OH, C0NH2, and CO (piperidin-1-yl) . A preferred R2' group is hydrogen.
When G is Ring C, preferred formula VIII Ring C groups are phenyl and pyridinyl. When two adjacent substituents oh Ring C are taken together to form a fused ring, Ring C is contained in a bicyclic ring system. Preferred fused rings include a benzo or pyrido ring. Such rings preferably are fused at ortho and meta positions of Ring C. Examples of preferred bicyclic Ring C systems include naphthyl and isoquinolinyl. Preferred R1 groups include -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6. When R1 is an optionally substituted Cι_6 aliphatic group, the most preferred optional substituents are halogen. Examples of preferred R1 groups include -CF3, -Cl, -F,
-CN, -COCH3, -OCH3, -OH, -CH2CH3, -OCH2CH3 -CH3, -CF2CH3, cyclohexyl, t-butyl, isopropyl, cyclopropyl, -C≡CH, -C≡C-CHs/ -S02CH3, -S02NH2, -N(CH3)2, -C02CH3, -CONH2, -NHC0CH3/ -OC(0)NH2, -NHS02CH3, and -OCF3. On Ring C preferred R5 substituents, when present, include -halo, -CN, -N02, -N(R4)2/ optionally substituted Cι_6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R4)2, and -N(R4)S02R. More preferred R5 substituents include -Cl, -F, -CN, -CF3, -NH2, -NH(Ci_4 aliphatic) , -N(Cι_4 aliphatic) 2, -0(Cι-4 aliphatic), Cι_4 aliphatic, and -C02(Cι_ aliphatic). Examples of such preferred Rs substituents include -Cl, -F, -CN, -CF3, -NH2, -NHMe, -NMe2, -OEt, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, and -C02Et.
When G is Ring D, preferred formula VIII Ring D monocyclic rings include substituted and unsubstituted phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, and morpholinyl rings. When two adjacent substituents on Ring D are taken together to form a fused ring, the Ring D system is bicyclic. Preferred formula VIII Ring D bicyclic rings include 1, 2, 3, -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2,3-dihydro-lff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, and naphthyl . Examples of more pre erred bicyclic Ring D systems include naphthyl and isoquinolinyl.
Preferred RΞ substituents on Ring D of formula VIII. include halo, oxo, CN, -N02, -N(R4)2, -C02R,- -CONH(R4) , -N(R4)C0R, -S02N(R)2, -N(R4)S02R, -SR, -OR, -C(0)R, or substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or Cι-6 aliphatic. More preferred RΞ substituents include -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ι0 aryl, or Cι-6 aliphatic. Examples of Ring D substituents include -OH, phenyl, methyl, CH2OH, CH2CH20H, pyrrolidinyl, OPh, CF3, C≡CH, Cl, Br, F, I, NH2, C(0)CH3, i-propyl, tert-butyl, SEt, OMe, N(Me)2, methylene dioxy, and ethylene dioxy.
Preferred formula VIII compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a. phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Cα-<s aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3", 4- tetrahydroisoquinolinyl, 1,2,3, 4-tetrahydroquinolinyl, 2, 3-dihydro-Iff-isoindolyl, 2, 3-dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring; (b) Rx is T-R3 wherein T is a valence bond or a methylene; and
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cι-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
More preferred compounds of formula VIII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι-6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3-dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Rx is T-R3 wherein T is a valence bond or a methylene and R3 is CN, -R or -OR;
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Cι_6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring; and
(d) each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Ci-e aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)COR, -S02N(R4)2, or -N(R)S02R.
Even more preferred compounds of formula VIII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Rx is T-R3 wherein T is a valence bond or a methylene and R3 is -R or -OR wherein R is an optionally substituted group selected from Cι-6 aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(b) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι_4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ; (c) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -d-4 alkyl, -Ci- haloalkyl, -N02, -0(Cι- alkyl) , -C02 (d- . alkyl) , -CN, -S02(Cι_4 alkyl) , -S02NH2, -OC(0)NH2, -NH2S02 (C1-4 alkyl) ,
-NHC(O) (C1-4 alkyl) , -C(0)NH2, or -CO (C1-4 alkyl) , wherein the (C1- alkyl) is a straight, branched, or cyclic alkyl group;
(d) each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Cι-4 aliphatic), -N(C1.4 aliphatic)2, -0(Cι-4 aliphatic), Cι-4 aliphatic, and -C02(Cι_4 aliphatic); and
(e) R9 is R, OR, or N(R4)2. Representative compounds of formula VIII are set forth in Table 7 below.
Table 7.
VIII-4 VIII-5 VIII-6
VIII-7 VIII-8 VIII-9
VIII-10 VIII-11 VIII-12
VIII-13 VIII-14 VIII-15
VIII-16 VIII-17 VIII-18
VIII-19 VIII-20 VIII-21
VIII-22 VIII-23 VIII-24
VIII-25 VIII-26 VIII-27
VIII-28 VIII-29 VIII-30
VIII-31 VIII-32 VIII-33
VIII-34 VIII-35 VIII-36
VIII-37 VIII-38 VIII-39
VIII-40 VIII-41 VIII-42
VIII-43 VIII-44 VIII-45
VIII-46 VIII-47 VIII-48
VIII-49 VIII-50 VIII-51
VIII -52 VIII -53 VIII -54
In another embodiment, this invention provides a composition comprising a compound of formula VIII and a pharmaceutically acceptable carrier. One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VIII. Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VIII.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VIII. This method is especially useful for diabetic patients.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VIII. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula VIII. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VIII.
Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula VIII. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
One aspect of this invention relates to a method of inhibiting CDK-2 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula VIII. Another aspect relates to a method of treating a disease that is alleviated by treatment with a CDK-2 inhibitor, said method comprising the step of ■ administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising. a compound of formula VIII. This method is especially useful for treating cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis .
Another method relates to inhibiting GSK-3/ Aurora, or CDK-2 activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula VIII, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3, Aurora or CDK-2.
Each of the aforementioned methods directed to the inhibition of GSK-3, Aurora or CDK-2, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula VIII, as described above.
The above formula I compounds contain a pyrazole ring bearing the R2 and R2' substituents. In their search for further inhibitors of the protein kinases GSK and Aurora, applicants sought to replace the pyrazole moiety of formula I with other heteroaromatic rings. . One of the more effective pyrazole ring replacements was found to be a triazole ring. Inhibitors having this triazole ring are otherwise structurally similar to the formula I compounds and are represented by the general formula IX: R*
N A-
HN Λ. NH
N
ΪZ R RXtoXz,X-
IX
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D;
Ring C is selected from a phenyl, pyridinyl, pyrimidmyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring .nitrogen by -R4, provided that when Ring D is a six-me bered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl,- 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι-S aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3, and any substitutable nitrogen on said ring formed by Rx and Ry is substituted by R4;
T is a valence bond or a C1-4 alkylidene chain;
R2 is -R or -T-W-R6;
R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -C0CH2C0R, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R)2. -CON(R7)2, -S02N(R7)2, -OC(=0)R, -N(R7)C0R, -N(R7)C02 (optionally substituted Cι-S aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R7) CON(R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC(=0) N(R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from d_6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι-6 aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to for a 5-8 membered heterocyclyl or , heteroaryl ring; each. R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N(R4) C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2,
-N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring, fused to Ring C;
V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (O) 0- , -N(R6)C0N(R6)-, -N(R6)S02N(R6)-, -N(R6) N(R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(Rδ)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (Rδ) 2N (R6) S02N(R6) - , or
-C(Rδ)2N(R6)CON(R6) -; W is -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)~, -CO-, -C02-, -C(R6)0C(0)-, -C(R6)OC(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C (R6) =NN (Rs) - , -C(R6)=N-0-, -C (R6) 2N (R6) N (R6) - , -C (R6) 2N (R6) S02N (R6) - , -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted d-4 aliphatic group, -OR6, -SR6, -COR6,
-S02R6, -N.(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6; and R9 is selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Ci-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R)CON(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -0C(=0)N(R4)2.
Compounds of formula IX may exist in alternative tautomeric forms, as in tautomers 1-3 shown below. Unless otherwise indicated, the representation of any of these tautomers is meant to include the other two..
The Rx and Ry groups of formula IX may be taken together to form a fused ring, providing a bicyclic ring system containing Ring A. Preferred Rx/Ry rings include a 5-, 6-, 7-, or 8-meτnbered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said Rx/Ry ring is optionally substituted. Examples of Ring A systems are shown below by compounds IX- through IX-DD, wherein Z1 is nitrogen or C(R9) and Z2 is nitrogen or C(H).
IX-D IX-E IX-F
IX-G -H IX- 1
IX-J IX-K IX-L
IX-BB IX-CC IX-DD
Preferred bicyclic Ring A systems of formula IX include IX-A, IX-B, IX-C, IX-D, IX-E, IX-F, IX-G, IX-H, IX-I, IX-J, IX-K, IX-L, and IX-M, more preferably IX-A, IX-B, IX-C, IX-F, and IX-H, and most preferably IX-A, IX- B, and IX-H.
In the monocyclic Ring A system of formula IX, preferred Rx groups include hydrogen, alkyl- or 5 dialkylamino, acetamido, or a Cι-4 aliphatic group such as methyl, ethyl, cyclopropyl, isopropyl or t-butyl. Preferred Ry groups, when present, include T-R3 wherein T is a valence bond or a methylene, and R3 is -R, -N(R)2, or -OR. Examples of preferred Ry include 2-pyridyl, 4-
10 pyridyl, piperidinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or dialkylamino, acetamido, optionally substituted phenyl such as phenyl or halo- substituted phenyl, and methoxymethyl .
In the bicyclic Ring A system of formula IX,
15 the ring formed by Rx and Ry taken together may be substituted or unsubstituted. Suitable substituents include -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted d-6
2.0 aliphatic), -N(R4)N(R4) 2, -C=NN(R4)2, -C=N-OR, -N(R4)CON(R4)2, -N(R)S02N(R4)2, -N(R4)S02R, or -0C(=0)N(R4)2, wherein R and R4 are as defined above. Preferred Rx/Ry ring substituents include -halo, -R, -OR, -COR, -C02R, -CON(R4)2, -CN, or -N(R4)2 wherein R is an
25 optionally substituted Cι-6 aliphatic group.
Preferred R2 groups of formula IX include hydrogen, Cι-4 aliphatic, alkoxycarbonyl, (un) substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl ,
30 dialkylaminoalkyl, phenylaminocarbonyl , and (N- heterocyclyl ) carbonyl . Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, C02H, C02CH3, CH2OH, CH2OCH3, CH2CH2CH2OH, CH2CH2CH2OCH3 , CH2CH2CH2OCH2Ph , CH2CH2CH2NH2 , CH2CH2CH2NHC00C ( CH3 ) 3 # CONHCH (CH3) 2 , CONHCH2CH=CH2 , CONHCH2CH2OCH3 , CONHCH2Ph , CONH (cyclohexyl ) , CON (Et) 2 , CON (CH3) CH2Ph, CONH (n-C3H7) , CON (Et) CH2CH2CH3 , CONHCH2CH (CH3) 2 , CON (n-C3H7) 2 , CO (3 - methoxymethylpyrrolidin-1-yl) , CONH (3 -tolyl ) , C0NH (4 - tolyl) , CONHCH3 , CO (morpholin-l-yl) , CO (4-methylpiperazin- 1-yl) , CONHCH2CH2OH, CONH2 , and CO (piperidin-1-yl) . A more preferred R2 group for formula IX compounds is hydrogen . An embodiment that is particularly useful for treating GSK3 -mediated diseases relates to compounds of formula X wherein ring A is a pyrimidine ring :
X
or a pharmaceutically acceptable derivative or prodrug thereof, wherein; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2, 4-triazinyl ring, . wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
R1 is selected from -halo, -CN, -N02, T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings ..each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι-6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx and Ry are independently selected from T-R3, or.Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo-or T-R3, and any substitutable nitrogen on said ring formed by Rx and Ry is substituted by R4;
T is a valence bond or a Ci-4 alkylidene chain;
R2 is -R or -T-W-R6;
R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -C0CH2C0R, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R)2, -CON(R7)2, -S02N(R7)2,-0C(=0)R, -N(R7)COR, -N(R7)C02 (optionally substituted Cι-S aliphatic) , -N(R )N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R7) CON (R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0) N (R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι_6 aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2,
-N(R4)S02N(R)2, -N(R4)S02R, or -OC (=0) N (R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)C0-, -N (R6) C (0) 0- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N (R6) N(R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)CON(R6)-; W is -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)'-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)0C(0)-, -C(R6)0C(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6) -, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι- aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Ci-e aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and each R8 is independently selected from an optionally substituted Cι_ aliphatic group, -OR6, -SR6, -COR6,
-S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6.
Compounds of formula X are structurally similar to compounds of formula II except for the replacement of the pyrazole ring moiety by the triazole ring moiety.
Preferred R2, Rx, Ry and Ring C groups of formula X are as described above for the formula II compounds . Preferred formula X compounds have one or more, and more preferably all, of the features selected from' the group consisting of: .
(a) Ring C is a phenyl or pyridinyl ring,, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring;
(b) Rx is hydrogen or Cι_4 aliphatic and Ry is T- R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 0-2 ring nitrogens;
(c) R1 is -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR6, -OC(0)NH2, or -NHS02R6; and (d) R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cι_6 aliphatic group. More preferred compounds of formula X have one or more, and more preferably all, of the features selected from the group consisting of :
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring;
(b) Rx is hydrogen or methyl and Ry is -R, N(R4)2, or -OR, or Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 5-7 membered carbocyclo ring, wherein said ring formed by Rx and Ry is optionally substituted with -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02 :, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N (R4) C02 (optionally substituted Ci-6 aliphatic) , -N(R )N(R4) 2, -C=NN(R4)2,
-C=N-0R, -N(R4)CON(R4)2, -N(R4) S02N(R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2;
(c) R1 is -halo, a Cι-6 haloaliphatic group, a d- 6 aliphatic group, phenyl, or -CN; (d) R2 is hydrogen or a substituted or unsubstituted group selected from aryl or a Cχ-6 aliphatic group ; . and
(e) each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cι_6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4) , -N(R4)COR, -S02N(R4)2, or -N(R4)S02R.
Even more preferred compounds of formula X have one or more, and more preferably all, of the features selected rom the group consisting of : (a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring; (b) Rx is hydrogen or methyl and Ry is methyl, methoxymethyl , ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or an optionally substituted group selected from 2-pyridyl, 4-pyridyl, piperidinyl, or phenyl, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted benzo ring or a 6-membered carbocyclo ring;
(c) R1 is -halo, a Cι-4 aliphatic group optionally substituted with halogen, or -CN; (d) R2 is hydrogen or a Cι-6 aliphatic group; and
(e) each R5 is independently selected from -Cl,
-F, -CN,. -CF3, -NH2, -NH (d-4 aliphatic) , -N(Cι-4 aliphatic)2, -0(Cι-4 aliphatic), Cι-4 aliphatic, and
-C02(Cι-4 aliphatic). Another embodiment of this invention relates to compounds of formula XI :
XI
or a pharmaceutically acceptable derivative or prodrug thereof , wherein: Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4,. provided that when Ring D is a si -membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
Rx and Ry are taken together with their intervening atoms to form a fused benzo ring or 5-8 membered carbocyclo ring, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3;
T is a valence bond or a d_.4 alkylidene chain;
R2 is -R or -T-W-R6; R3 is selected from -R, -halo, =0, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R)2, -OC(=0)R, -N(R4)COR, -N(R4)C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring • atoms; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cι_6 aliphatic) , -C0N(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each RΞ is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Ci-e aliphatic) , -N(R4)N(R )2, -C=NN(R)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2;
V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)C0-, -N (R6) C (0) 0- , -N(R6)CON(R6) -, -N(R6)S02N(R6)-, -N(R6)N(R6) -, -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R5)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6) -, -C (R6) 2N (R6) S02N (R6) - , or 5 -C(R6)2N(R6)C0N.(R6)-;
W is -C(R6)20-, -C(R6)2S-, -C(R6)2S0-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02-, -C(R6)OC(0) -, -C(R6)OC(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6)-, -C(R6)=N-0-, 10. -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen or an optionally substituted Cι.4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together 15 with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and each R7 is independently selected from hydrogen or an optionally substituted d-6 aliphatic group, or two R7 on the same nitrogen are taken together with the 20 nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring .
Compounds of formula XI are structurally similar to compounds of formula III except for the replacement of the pyrazole ring moiety by the triazole 5 ring moiety. Preferred R2, Rx, Ry, and Ring D groups of formula XI are as described above for the formula III compounds. Preferred formula XI compounds have one or more, and more preferably all, of the features selected from the group consisting of: 0 (a) Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff- indolyl, isoquinolinyl, quinolinyl, or . naphthyl ring;
(b) Rx and Ry are taken together with their intervening atoms to form an optionally substituted benzo ring or 5-7 membered carbocyclo ring; and
(c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Ci-e aliphatic group.
More preferred compounds of formula XI have one or more, and more preferably all, of the features selected from the- group consisting of :
(a) Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1, 2, 3 , 4-tetrahydroquinolinyl, 2 , 3 -dihydro-Iff-isoindolyl , 2,3 -dihydro-Iff- indolyl , isoquinolinyl, quinolinyl, or naphthyl;
(b) Rx and Ry are taken together with their intervening atoms to form a benzo ring or 5-7 membered carbocyclo ring, wherein said ring formed by Rx and Ry is optionally substituted with -R, oxo, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-0R, -N(R4) C0N(R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0) N (R4) 2;
(c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl or a Cι-6 aliphatic group ; and (d) each R5 is independently selected from halo, oxo, CN, N02, -N(R)2, -C02R, -C0NH(R4), -N(R4)C0R, -S02N(R4)2, -N(R4)S02R, -SR, -OR, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or d_6 aliphatic. Even more preferred compounds of formula XI have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Rx and Ry are taken together with their intervening atoms to form a benzo ring or 6-membered carbocyclo ring, wherein said ring formed by Rx and Ry is optionally substituted with halo, CN, oxo, Cι_6 alkyl, Cι-6 alkoxy, (Cι-6 alkyl) carbonyl, (Cι-6 alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl;
(b) each R5 is independently selected from -halo, -CN, -oxo, -SR, -OR, -N(R4)2/ -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ι0 aryl, or Cι_6 aliphatic; and (c) R2 is hydrogen or a Cι_6 aliphatic group.
Another embodiment of this invention relates to compounds of formula XII :
XII
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring is optionally and independently substituted by T-R3, and any substitutable nitrogen on said ring is substituted by
R4;
T is a valence bond or a Cι-4 alkylidene chain; R2 is -R or -T-W-R6;
R3 is selected from -R, -halo, =0, -OR, -C(=0)R, -C02R, -COCOR, -C0CH2C0R, -N02, -CN, -S(0)R, -S(0)2R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -0C(=0)R, -N(R)COR, ' -N(R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N (R4) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, C6-ι0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Ci-e aliphatic) , -CON(R)2. or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R)2, -S02N(R4)2, -OC(=0)R, -N(R)C0R, -N(R4)C02 (optionally substituted Ci-e aliphatic) , -N(R4)N(R4)a, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2f -N(R4)S02N(R4)2, -N(R)S02R, or -OC (=0)N (R4) 2; V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (0) 0- , -N(R6)CON(R6) -, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -OC(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0) -, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (Rδ) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C (R6) 2N (R6) S02N(R6) - , or -C(R6)2N(R6)CON(R6) -; W is -C(R6)20-, -C(R)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02- , -C(R6)OC(0)-, -C(R6)OC(0)N(R6)-, -C (R6) 2N (R6) CO- , -C(Rδ)2N(R6)C(0)0-, -C(R6)=NN(R6)-, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen or an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and each R7 is independently selected from hydrogen or an optionally substituted Cx-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl ring or heteroaryl .
Compounds of formula XII are structurally similar to compounds of formula IV except for the replacement of the pyrazole ring moiety by the triazole ring moiety. Preferred R2, Rx, Ry, and Ring D groups of formula XII are as described above for the formula IV compounds. Preferred formula XII compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring; (b) Rx is hydrogen or Cι-4 aliphatic and Ry is T-
R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 1-2 ring heteroatoms ; and (c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a
Cι-6 aliphatic group.
More preferred compounds of formula XII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2, 3, 4-tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2, 3-dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl;
(b) Rx is hydrogen or methyl and Ry is -R, N(R)2, or -OR, or Rx and Ry are taken together with their intervening atoms to < form a 5-7 membered unsaturated or partially unsaturated ring having 1-2 ring nitrogens, wherein said ring is optionally substituted with -R, halo, oxo, -OR, -C(=0)R, -C02R, -COCOR, ,-N02, -CN, -S(0)R, . -S02R, -SR, -N(R)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R)COR, -N(R4)C02 (optionally substituted Cι-6 aliphatic) , -N (R4 ) N (R4) 2 , -C=NN (R4 ) 2 , -C=N-OR , -N (R4 ) CON (R4) 2 , -N (R4 ) S02N (R4 ) 2 , -N (R ) S02R, or -OC ( =0) N (R4 ) 2 ;
(c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl or a Cx,6 aliphatic group; and
. (d) each R5.is independently selected from halo, OXO, CN, N02, -N(R4)2, -C02R, -C0NH(R4), -N(R)COR, -S02N(R4)2, -N(R)S02R, -SR, -OR, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ιo aryl, or C ~6 aliphatic.
Even more preferred compounds of formula XII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Rx and Ry are taken together with their intervening atoms to form a 6-membered unsaturated or partially unsaturated ring having 1-2 ring nitrogens, optionally substituted with halo, CN, oxo, Cι_6 alkyl, Cι-6 alkoxy, (Cι-6 alkyl) carbonyl, (Cι-S alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl;
(b) each R5 is independently selected from -halo, -CN, -oxo, -SR, -OR, -N(R4)2, -C(0)R, or a substituted or unsubstituted group selected from 5-6 membered heterocyclyl, C6-ι0 aryl, or Cι-6 aliphatic; and (c) R2 is hydrogen or a Cι-6 aliphatic group.
Another embodiment of this invention relates to compounds of formula XIII:
XIII
or a pharmaceutically acceptable derivative or prodrug thereof, wherei :
Z1 is nitrogen, CRa, or CH, and Z2 is nitrogen or CH; provided that one of Z1 and Z2 is nitrogen;'
G is Ring C or Ring D;
Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any substitutable non- ortho carbon position on Ring C is independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N02/ T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι-6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι-6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein any substitutable carbon on said fused ring formed by Rx and Ry is substituted by oxo or T-R3, and any substitutable nitrogen on said ring formed by Rx and Ry is substituted by R4;
T is a valence bond or a Cι_4 alkylidene chain;
R3 is selected from -R, -halo, -OR, -C(=0)R, -C02R, -COCOR, -COCH2COR, -N02f -CN, ~S(0)R, -S(0)2R, -SR, -N.(R4)2, -CON(R7)2, -S02N(R7)2, -0C(=0)R, -N(R7)C0R, -N(R7) C02 (optionally substituted Ci-e aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R7) CON (R7) 2, -N(R7)S02N(R7)2, -N(R4)S02R, or -OC (=0)N (R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from Cι-6 aliphatic, Cs_ι0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Ci-e aliphatic) , -CON(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R )2, -0C(=0)R, -N(R4)C0R, -N(R4) C02 (optionally substituted d-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2,
-N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0)N(R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C; V is -0-, -S-, -SO-, -S02-, -N(R6)S0 -, -S02N(R6)-, -N(R6)-, -CO-, -C02-, -N(R6)CO-, -N (R6) C (0) 0- , -N(R6)CON(R6)-, -N(R6)S02N(R6)-, -N (R6) N (R6) - , -C(0)N(R6)-, -0C(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(Rδ)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0)-, -C(R6)2N(R6)C(0)0-, -C (R6) =NN(R6) - , -C(R6)=N-0-, -C(Rδ)2N(R6)N(R6) -, -C (Rδ) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)CON(R6)-; W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C(R6)2N(R6)-, -CO-, -C02- , -C(R6)0C(0)-, -C(R6)OC(0)N(R6) -, -C (Rδ) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6)-, -C(R6)2N(R6)CON(R6)-, or -C0N(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen ' atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Ci-e aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted d-4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(Rδ)2, or -C02R6; and
Ra is selected from halo, -OR, -C(=0)R, -C02R, -COCOR, -N02/ -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N (R4) C02 (optionally substituted Ci-6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R)C0N(R4)2, -N (R4).S02N(R4) 2, -N(R4)S02R, -OC(=0)N(R4)2, or an optionally substituted group selected from Ci-e aliphatic, C6-ι0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
Compounds of formula XIII may be represented by specifying Z1 and Z2 as shown below:
XHIa XIIlb
Compounds of formula XIII are structurally similar to compounds of formula V except for the replacement of the pyrazole ring moiety by the triazole ring moiety. Preferred R2, Rx, Ry, Ra, and Ring G groups of formula XIII are as described above for the formula V compounds.. Preferred formula XIII compounds have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Ci-β aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02Rδ; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3, 4-tetrahydroquinolinyl , 2, 3-dihydro-Iff-isoindolyl, 2, 3 -dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Rx is hydrogen or .Cι_4 aliphatic and Ry is T- R3, or Rx and Ry are taken together with their intervening atoms to form an optionally substituted 5-7 membered unsaturated or partially unsaturated ring having 0-2 ring nitrogens; and
(c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cι_6 aliphatic group. More preferred compounds of formula XIII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι_6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3, 4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Rx is hydrogen or methyl and Ry is -R, N(R4) , or -OR, or Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 5-7 membered carbocyclo ring, wherein said ring formed by Rx and Ry is optionally substituted with -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R)2, -CON(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)C0R, -N (R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4) 2, -C=NN(R4)2, -C=N-OR, -N(R)C0N(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2;
(c) R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Cι-6 aliphatic group; and
(d) each R5 is independently selected from -halo, -CN, -N02, -N(R)2, optionally substituted Cι-6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4) , -N(R4)C0R, -S02N(R4) , or -N(R)S02R, and, when Ring G is Ring D, Ring D is substituted by oxo or R5.
Even more preferred compounds of formula XIII have one or more, and more preferably all, of the features selected from the group consisting of:
(a) Rx is hydrogen or methyl and Ry is methyl, methoxy ethyl , ethyl, cyclopropyl, isopropyl, t-butyl, alkyl- or an optionally substituted group selected from 2-pyridyl, 4-pyridyl, piperidinyl, or phenyl, or Rx and Ry are taken together with their intervening atoms to form a benzo ring or a 6-membered carbocyclo ring wherein said ring formed by Rx and Ry is optionally substituted with halo, CN, oxo, Ci-e alkyl, Cι-6 alkoxy, (d-6 alkyl) carbonyl, (Cι-6 alkyl) sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl;
(b) Ring C is a phenyl or pyridinyl ring, optionally substituted by -R5, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι_4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2, 3 ,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ; (c) R2 is hydrogen or a Cι-6 aliphatic group; and
(d) each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Ci_4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι-.4 aliphatic), Cι- aliphatic, and -C02 (Ci-4 aliphatic) , and when Ring G is Ring D, Ring D is substituted by oxo or R5.
Representative compounds of formula IX are shown below in Table 8.
Table 8
IX- 1 IX-2 IX-3
^ to ^ to to
IX-4 . IX-5 IX-6
5 IX- 7 IX- 8 IX- 9
IX-10 IX-11 IX-12
IX-13 IX-14 IX-15
IX-19 IX-20 IX-21
IX-22 IX-23 IX-24
IX-25 IX-26 IX-27
IX-31 ' IX-32 IX-33
34 IX-35 IX-36
IX-37 IX- 38 IX-39
IX-40 IX-41 IX-42
IX-44 IX-45
IX-46 IX-47 IX-48
IX-49 IX-50 IX-51
IX-52 IX-53 IX-54
IX-55 IX-56 IX-57
IX-58 IX-59 IX-60
IX-61 IX-62 IX-63
IX-64 IX-65 IX-66
IX-67 IX-68 IX-69
IX-79 IX- 80 IX-81
IX-82 IX-83 IX-84
IX-85 IX-86 IX-87
IX-88 IX-89 IX-90
IX-91 IX-92 IX-93
IX-94 IX-95 IX-96
IX-97 IX-98 IX-99
,
IX-103 IX-104 IX-105
IX-106 IX-107 IX-108
IX-109 IX-110 IX-111
IX-112 IX-113 I -114
IX-115 IX-116 IX- •117
IX-118 IX-119 IX-120
IX-121 IX-122 IX-123
IX-124 IX-125 IX-126
to to
IX-127 IX- 128 IX-129
IX-130 IX-131 IX-132
IX-133 IX-134 IX-135
IX-139 IX-140 IX-141
IX-142 IX-143 IX-144
IX-145 IX-146 IX-147 toπH oto to
IX-148 IX-149 IX-150
IX-151 IX-152 IX-153
IX-154 IX-155 IX-156
IX-173 IX-174
In another embodiment, this invention provides a composition comprising a compound of formula IX and a pharmaceutically acceptable carrier. One aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula IX. Another aspect relates to a method of treating a disease that is alleviated by treatment with a GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula IX.
Another aspect relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IX. This method is especially useful for diabetic patients.
Another aspect relates to a method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IX. This method is especially useful in halting or slowing the progression of Alzheimer's disease. Another aspect relates to a method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound of formula IX. This method is especially useful for treating schizophrenia.
One aspect of this invention relates to a method of inhibiting Aurora activity in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of formula IX.
Another aspect relates to a method of treating a disease that is alleviated by treatment with an Aurora inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a composition comprising a compound of formula IX. This method is especially useful for treating cancer, such as colon, ovarian, and breast cancer.
Another method relates to inhibiting GSK-3 or Aurora activity in a biological sample, which method comprises contacting the biological sample with the GSK-3 or Aurora inhibitor of formula IX, or a pharmaceutical composition thereof, in an amount effective to inhibit GSK-3 or Aurora.
Each of the aforementioned compositions and methods directed to the inhibition of GSK-3 or Aurora, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IX, as described above.
The compounds of this invention may be prepared as illustrated by the Synthetic Methods below, by the Synthetic Examples, described herein and by general methods known to those skilled in the art.
General Synthetic Methods
The general, synthetic methods below provide a series of general reaction routes that were used to prepare compounds of this invention. Methods A-F below are particularly useful for preparing formula II compounds. In most cases, Ring C is drawn as a phenyl ring bearing an ortho R1 substituent. However, it will be apparent to one skilled in the art that compounds having other Ring C groups may be obtained in a similar manner. Methods analogous to methods A-F are also useful for preparing other compounds of this invention. Methods F-I below are particulary useful for preparing compounds of formula III or IV.
Method A
Method A is a general route for the preparation of compounds wherein ring C is an aryl or heteroaryl ring. Preparation of the starting dichloropyrimidine 1 may be achieved in a manner similar to that described in Chem . Pharm . Bull . , 30, 9, 1982, 3121-3124. The chlorine in position 4 of intermediate 1 may be replaced by an a inopyrazole or aminoindazole to provide intermediate 2 in a manner similar to that described in J. Med . Chem. , 38, 3547-3557 (1995) . Ring C is then introduced using a boronic ester under palladium catalysis (see Tetrahedron, 48, 37, 1992, 8117-8126) . This method is illustrated by the following procedure.
A suspension of lff-quinazoline-2,4-dione (10.0 g, 61.7 mmol) in P0Cl3 (60 mL, 644 mmol) and N,N- dimethylaniline (8mL, 63.1 mmol) is heated under reflux for 2 h. Excess POCl3 is evaporated under vacuum, the residue is poured into ice, and the precipitate is collected by filtration. The crude solid 2,4- dichloroquinazoline product may be used without further purification.
To a. solution of 2,4-dichloro-quinazoline (3.3 g, 16.6 mmol) in anhydrous ethanol (150 mL) is added 5- methyl-lff-pyrazol-3-yl amine (3.2 g, 32.9 mmol). The mixture is stirred at room temperature for 4 h, and the resulting precipitate is collected by filtration, washed with ethanol, and dried under vacuum to afford (2-chloro- quinazolin-4-yl) - (5-methyl-lff-pyrazol-3-yl) -amine.
To a solution of (2-chloro-quinazolin-4-yl) -(5- methyl-lff-pyrazol-3-yl) -amine (50 mg, 0.19 mmol) in DMF (1.0 mL) is added the desired arylboronic acid (0.38 mmol), 2M Na2C03 (0.96 mmol), and tri-t-butylphosphine (0.19 mmol). Under nitrogen, PdCl2 (dppf) (0.011 mmol) is added in one portion. The reaction mixture is then heated at 80°C for 5 to 10 hours, cooled to room temperature, and poured into water (2 mL) . The resulting precipitate is collected by filtration, washed with water, and purified by HPLC.
Method B
(i)
(iii)
Methods B through F describe routes where the pyrazole ring system is introduced after Ring C and the pyrimidine ring portion are first constructed. A versatile intermediate is the 4-chloropyrimidine 4, which is readily obtained from pyrimidinone 3 as shown in Method B(i). This reaction sequence is generally applicable for a variety of Ring C groups including aliphatic, aryl, heteroaryl, or heterocyclyl. See J. Med. Chem. , 38, 3547-3557 (1995).
For quinazoline ring systems (where Rx and Ry are taken together to form a benzo ring) , the useful intermediate 6 may be obtained by condensing an anthranilic acid or its derivative with a benzamidine as shown in Method B(ii) or by condensing a benzoylchloride with an anthranilamide as shown in Method B(iii). Many substituted anthranilic acid, anthranilamide, benzamidine and benzoylchloride starting materials may be obtained by known methods. See Aust . J. Chem. , 38, 467-474 and J". Med. Chem. , 38, 3547-3557 (1995). Method B(iii) is illustrated by the following procedure.
To a solution of anthranilamide (33 mmol) in THF and CH2C12 (1:1, 70 mL) is added the desired benzoylchloride (33 mmol) , and triethylamine (99 mmol) at room temperature. The mixture is stirred for about 14 hours. The resulting precipitate is collected by filtration, washed with CH2C12 and water, and dried under vacuum. The crude 2-benzoylaminobenzamide may be used directly for the next step without further purification. To a solution of the above crude product (13 mmol) in ethanol (50 mL) is added NaOEt (26 mmol) at room temperature. The mixture is heated under reflux for 48 to 96 h. The solvent is evaporated and the residue is neutralized using concentrated HCl to pH 7. The product is then collected by filtration and dried under vacuum to provide 2 -phenyl-3H-quinazolin-4-one that may be used without further purification.
To a suspension of the above product (12 mmol) in P0C13 (120 mmol) is added tri-ή-propylamine (24 mmol) . The mixture is heated under reflux for lh. After removal of the excess P0C13 by evaporation, the residue is dissolved in ethyl acetate, and washed with IN NaOH (twice) and water (twice) . The organic layer is dried over MgS04, the solvent is evaporated under vacuum, and the crude product is purified by flash chromatography (eluting with 10% of ethyl actetate in hexanes) to give 4-chloro-2-aryl quinazoline.
To a solution of 4-chloro-2-aryl quinazoline (0.16 mmol) in DMF (or THF, ethanol) (1 mL) is added the desired aminopyrazole or aminoindazole (0.32 mmol). The mixture is heated in DMF (or THF under reflux) at 100 to 110°C for 16 h (or in ethanol at 130-160°C for 16 hours) and then poured into water (2 mL) . The precipitate is collected by filtration and purified by HPLC.
Method C
Method D(i)
10 11
Methods C and D(i) above employ β-ketoesters 8 and 10, respectively, as pyrimidinone precursors. The substitution pattern of the Rx and Ry groups on the pyrimidinone ring will be reversed if a chlorocrotonate 11 (Synth. Comm, (1986) , 997-1002) , instead of the corresponding β-ketoester 10, is condensed with the desired benzamidine. These methods are illustrated by the following general procedure.
To a solution of a β-ketoester (5.2 mmol) and amidinium chloride (5.7 mmol) in ethanol (5 mL) is added sodium ethoxide (7.8 mmol). The mixture is heated under reflux for 7-14 hours. After evaporation the resulting residue is dissolved in water, acidified with concentrated HCl to pH 6, and then filtered to obtain a solid product 2-aryl-3ff-pyrimidin-4-one (yield 75-87%) , which may be purified by flash column chromatography if needed. To this pyrimidinone (3.7 mmol) is added P0C13 (4 mL) and n-Pr3N (1.4 mL) . The mixture is heated under reflux for 1 hour. After evaporation of the excess P0C13, the residue is dissolved in ethyl acetate, washed with IN NaOH solution (three times) and NaHC03 (once) , and dried over MgS04. The solvent is removed under vacuum and the residue is purified by flash column chromatography eluting with 10% of ethyl acetate in hexanes to give 2- aryl-4-chloro-pyrimidine as a pale yellow syrup. This crude product may be treated with a 3-aminopyrazole or 3- aminoindazole as described above. Method D (ii)
Method D(ii) above shows a general route for the preparation of the present compounds, such as compound 40, wherein Ry is N(R4)2. See II Farmaco; 52(1) 61-65 (1997) . Displacement of the 6-chloro group is exemplified here using morpholine. This method is illustrated by the following procedure.
To a solution of 2-methylmalonic acid diethyl ester (5 mmol) and sodium ethoxide (15 mmol) is added the appropriate amidine salt (5 mmol) in ethanol (10 mL) and the reaction heated at reflux for 2-24 hours. The residue is dissolved in water and acidified with 2N HCl. The resulting precipitate is filtered off and further purified by flash chromatography (yield 5-35%) to afford the pyrimidinedione 37. To 37 (1.6 mmol) is added POC13 (32 mmol) and tri-n-propylamine (6.4 mmol) and the reaction refluxed is for lh. After evaporation of excess POCI3, the residue is dissolved in ethyl acetate, basified with IN NaOH, separated and the aqueous phase twice more extracted with ethyl acetate. The combined organics are dried (sodium sulfate) and evaporated. Purification by flash chromatography provides the dichloropyrimidine (38) as a yellow oil in 23% yield.
A solution of 38 (0.33 mmol) in methanol (5 mL) is treated with an amine, exemplified here using morpholine (0.64 mmol) and refluxed 1 hour. After evaporation of solvent, the residue is purified by flash chromatography to provide the mono-chloropyrimidine 39 as a colorless oil in 75% yield.
The mono-chloropyrimidine, 39, (0.19 mmol) may be treated with a 3-aminopyrazole or 3-aminoindazσle compound in a manner substantially similar those described above in Methods A and B.
Method E
As shown by Method E, an acyl isocyanate 12 may be condensed with an enamine to provide pyrimidinone 9 (J. Org. Chem (1993), 58, 414-418; J.Med. Chem. , (1992), 35, 1515-1520; J. Org. Chem., 91967, 32, 313-214). This method is illustrated by the following general procedure.
The enamine is prepared according to W. White, et al, J. Org Chem. (1967), 32, 213-214. The acyl isocyanate is prepared according to G Bradley, et al, J Med. Chem. (1992), 35, 1515-1520. The coupling reaction then follows the procedure of S Kawamura, et al, J. Org. Chem, (1993), 58, 414-418. To the enamine (10 mmol) in tetrahydrofuran (30 mL) at 0°C under nitrogen is added dropwise over 5 min a solution of acyl isocyanate (10 mmol) in tetrahydrofuran (5 mL) . After stirring for 0.5 h, acetic acid (30 mL) is added, followed by ammonium acetate (50 mmol) . The mixture is refluxed for 2 h with continuous removal of tetrahydrofuran. The reaction is cooled to room temperature and is poured into water (100 mL) . The precipitate is filtered, washed with water and ether and dried to provide the 2 -aryl-3H-pyrimidin-4-one.
Method F
Method F shows a general route for the preparation of the present compounds wherein Rx and Ry are taken together to form a 5-8 membered partially unsaturated saturated or unsaturated ring having 1-3 heteroatoms. The condensation of a 2-amino-carboxylic acid, such as 2-amino-nicotinic acid 13, and an acid chloride 7 provides an oxazinone 14. Treatment of 14 with ammonium hydroxide will furnish the benzamide 15 which may be cyclized to a 2- (substituted) -pyrido [2, 3- d] [l,3]pyrimidin-4-one 16. This method id illustrated by the following procedure.
2- (Trifluoromethyl)benzoyl chloride (4.2 ml, 29.2 mmol) is added dropwise to a solution of 2- aminonicotinic acid (2.04g, 14.76 mmol) in 20 ml of pyridine. The reaction mixture is heated at 158 C for 30 min then cooled to room temperature. The reaction is poured into 200 ml of water and an oil forms which solidifies upon stirring. The solid is collected by vacuum filtration and washed with water and diethyl ether. The product is dried to give 2- (2- trifluoromethyl-phenyl) -pyrido [2, 3-d] [l,3]oxazin-4-one (2.56 g, 60% yield) which may be used in the next step without further purification.
2- (2-Trifluoromethyl-phenyl) -pyrido [2,3- d] [1,3] oxazin-4-one (2.51g) is stirred in 30% ammonium hydroxide (25 ml) at room temperature overnight. The resulting precipitate is filtered and rinsed with water and diethyl ether. The precipitate is dried under vacuum at 50 C overnight to give 2- (2-trifluoromethyl- benzoylamino) -nicotinamide (850 mg, 33% yield) 2- (2-Trifluoromethyl-benzoylamino) -nicotinamide
(800mg, 2.6mmol) is dissolved in 10ml of ethanol. Potassium ethoxide (435mg, 5.2mmol) is added to the solution which is heated to reflux for 16 h. The reaction mixture is evaporated in vacuo to afford a gummy residue that is dissolved in water and acidified with 10% sodium hydrogen sulfate to pH 7. The resulting precipitate is filtered and dried under vacuum at 50 C to give 2- (2-trifluoromethyl-phenyl) -3ff-pyrido [2, 3- d] pyrimidin-4-one .
Method G
Method G is analogous to Method B(i) above. This method is illustrated by the following general procedure . 2- (3,4-Dichloro-phenyl) -3ff-quinazolin-4-one
(lg, 3.43 mmol) is suspended in phosphorus oxychloride (4 mL) and the reaction mixture was stirred at 110°C for 3 hours. The solvents are then evaporated and the residue is treated carefully with an ice cold aqueous saturated solution of NaHC03. The solid is collected by filtration and washed with ether to give 4-chloro-2- (3, 5-dichloro- phenyl) -quinazoline as a white solid (993 mg, 93%).
To 4-chloro-2- (3,5-dichloro-phenyl) -quinazoline (400mg, 1.29 mmol) in THF (30 mL) is added 3-amino-5- methyl pyrazole (396 mg, 2.58 mmol) and the reaction mixture is heated at 65°C overnight. The solvents are then evaporated and the residue triturated with ethyl acetate, filtered and washed with a minimum amount of ethanol to give [2- (3,4-dichlorophenyl) -quinazolin-4-yl] -
(5-methyl-2ff-pyrazol-3-yl) -amine as a white solid (311 mg 65%): mp 274°C; αH NMR (DMSO) δ 2.34 (3H, s) , 6 . 69 (1H, s) , 7.60 (1H, m) , 7.84 (1H, d) , 7.96 (2H, d) , 8.39 (1H, dd) , 8.60 (1H, d) , 8.65 (1H, d) , 10.51 (1H, s) , 12.30
(1H, s) ; IR (solid) 1619, 1600, 1559, 1528, 1476, 1449, 1376, 1352, 797, 764, 738; MS 370.5 (M+H) + .
The THF solvent used in the previous step may be replaced by other organic solvents such as ethanol, N,N-dimethylformamide, or dioxane.
Method H
(i) 17 18
( ii ) 17 19
Method H shows routes in which a Ring D aryl group bearing a halogen (X is Br or I) may be converted to other formula III compounds. Method H(i) shows a phenylboronic acid coupling to Ring D to provide compound 18 and Method H(ii) shows an acetylene coupling to provide compound 19. Substituent X in compound 17 may be bromine or iodine. These methods are illustrated by the following procedures .
Method H(i) . To a mixture of [2-(4-bromo- phenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (196 mg, 0.51 mmol) and phenylboronic acid (75 mg, 0.62 mmol) in THF/water (l/l, 4 mL) is added Na2C03 (219 mg, 2.06 mmol), triphenylphosphine (9mg, 1/15 mol%) and palladium acetate (1 mg, 1/135 mol%) . The mixture is heated at 80°C overnight, the solvents are evaporated and the residue is purified by flash chromatography (gradient of CH2Cl2/MeOH) to give (2-biphenyl-4-yl-quinazolin-4-yl) - (5-methyl-2ff-pyrazol-3-yl) -amine as a yellow solid (99 mg, 51%) ^H NMR (DMSO) δ 2.37 (3H, s) , 6.82 (1H, s) , 7.39- 7.57 (4H, m) , 7.73-7.87 (6H, m) , 8.57 (2H, d) , 8.67 (1H, d) , 10.42 (1H, s) , 12.27 (1H, s) ; MS 378.2 (M+H) +
Method H(ii) . To a mixture of [2- (4-bromo- phenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (114 mg, 0.3 mmol), and trimethylsilylacetylene (147 mg, 1.5 mmoDin DMF (2 mL) is added Cul (1.1 mg, 1/50 mol%) , Pd(PPh3)2Cl2 (4.2 mg, 1/50 mol%) and triethylamine (121 mg, 0.36 mmol). The mixture is heated at 120°C overnight and the solvent is evaporated. The residue is triturated in ethyl acetate and the precipitate is collected by filtration. To the above precipitate suspended in THF (3 mL) is added tetrabutylammonium fluoride (1M in THF, l.leq). The reaction mixture is stirred at room temperature for two hours and the solvent is evaporated. The residue is purified by flash chromatography (gradient of CH2Cl2/MeOH) to give [2- (4-ethynylphenyl) -quinazolin-4- yl] - (5-methyl-2ff-pyrazol-3-yl) -amine as a white solid (68 mg, 70%): XE NMR (DMSO) δ 2.34 (3H, s) , 4.36 (1H, s) , 6.74 (1H, s) , 7.55 (1H, m) , 7.65 (2H, d) , 7.84 (2H, m) , 8.47 (2H, d) , 8.65 (IB, d) , 10.43 (1H, s) , 12.24 (1H, s) ; MS 326.1 (M+H)+
Method I
Method I above shows a general route for the preparation of the present compounds wherein ring D is a heteroaryl or heterocyclyl ring directly attached to the pyrimidine 2 -position via a nitrogen atom. Displacement of the 2-chloro group, exemplified here using piperidine, may be carried out in a manner similar to that described in J. Med. Chem., 38, 2763-2773 (1995) and J. Chem. Soc, 1166-1111 (1948) . This method is illustrated by the following procedure.
To a solution of (2-chloro-quinazolin-4-yl) - (lff-indazol-3-yl) -amine (1 equivalent, 0.1-0.2 mmol) in N, N-dimethylacetamide (1 ml) is added the desired amine (3 equivalents) . The resulting mixture is maintained at 100°C for 6 h and then purified by reverse-phase HPLC.
Method J
21 22
23 24
Method J above shows the preparation of compounds of formula V via the displacement of a chloro group from an appropriately substituted pyridyl ring. Method J(i) is a route for preparing compounds of formula Va (see Indian J. Chem . Sect . B, 35, 8, 1996, 871-873) . Method J(ii) is a route for preparing compounds of formula Vb (see Bioorg. Med. Chem. , 6 , 12, 1998, 2449- 2458) . For convenience, the chloropyridines 21 and 23 are shown with a phenyl substituent corresponding to Ring D of formula V. It would be apparent to one skilled in the art that Method J is also useful for preparing compounds of formula V wherein Ring D is heteroaryl, heterocyclyl, carbocyclyl or other aryl rings. Method J is illustrated by the following procedures.
Method J(i) . (5-Methyl-2ff-pyrazol-3-yl)- (2- phenyl-quinolin-4-yl) -amine. To 4-chloro-2- phenylquinoline (J. Het. Chem., 20, 1983, 121-128) (0.53g, 2.21 mmol) in diphenylether (5 mL) was added 3-amino-5- ethylpyrazole (0.43g, 4.42 mmol) and the mixture was heated at 200°C overnight with stirring. To the cooled mixture was added petroleum ether (20 mL) and the resulting crude precipitate was filtered and further washed with petroleum ether. The crude solid was purified by flash chromatography (Si02, gradient DCM-MeOH) to give the title compound as a white solid: p 242-244°C; XH NMR (DMSO) δ 2.27(3H, s) , 6.02(1H, a ) , 7.47(2H, d) , 7.53- 7.40(2H, br m) , 7.67(1H, m) , 7.92 (1H, m) , 8.09(2H, d) , 8.48 (2H, m)-, 9.20 (1H, s) , 12.17 (1H, br s) ; IR (solid) 1584, 1559, 1554, 1483, 1447, 1430, 1389; MS 301.2 (M+H) +
Method J(ii). (5-Methyl-2ff-pyrazol-3-yl) - (3- phenyl-isoquinoli -1-yl) -amine. To l-chloro-3- phenylisoquinoline (J. Het. Chem., 20, 1983, 121-
128)(0.33g, 1.37 mmol) in dry DMF (5 mL) was added 3- amino-5-methylpyrazole (0.27g, 2.74 mmol) and potassium carbonate (0.57g, 4.13 mmol) and the mixture was heated under reflux for 6 hours . The mixture was cooled and the bulk of DMF was evaporated. The residue was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried (MgS04) , filtered and concentrated. The crude was purified by flash chromatography (Si02, gradient DCM-MeOH) to give the title compound as a colourless oil; XH NMR (MeOD) δ 2.23 (3H, s) , 5.61 (1H, s) , 7.41 (1H, m) , 7.52(2H, m) , 7.62(1H, m) , 7.81(lH, m), 8.07(1H, d) , 8.19(211, m) , 8.29(1H, s) , 8.54 (1H, d) ; MS 301.2 (M+H) +
Method K
25 26 27
Method K shows a route for the preparation of compounds of formula VI. A versatile starting material is 2,4, 6-trichloro- [1,3,5] triazine 25 in which the chlorine substituents may be sequentially displaced. The displacement of one of the chlorines by an aryl Grignard reagent or an aryl boronic acid is described in PCT patent application WO 01/25220 and ffelv. Chim. Acta, 33, 1365 (1950) . The displacement of one of the chlorines by a heteroaryl ring is described in WO 01/25220; J. Het . Chem. , 11, 417 (1974); and Tetrahedron 31, 1879 (1975). These reactions provide a 2,4-dichloro- (6- substituted) [1, 3,5] triazine 26 that is a useful intermediate for the preparation of compounds of formula VI. Alternatively, intermediate 26 may be obtained by constructing the triazine. ring by known methods. See US patent 2,832,779; and US patent 2,691020 together with J. Am. Chem. Soc. 60, 1656 (1938) . In turn, one of the chlorines of 26 may be displaced as described above to provide 2-chloro- (4, 6-disubstituted) [1,3, 5] triazine 27. The treatment of 27 with an appropriate aminopyrazole provides the desired compound of formula VI.
Method L
28 29 30
31
Method L shows a route for preparing compounds of formula VII. For illustration purposes the trifluoromethylchalcone 28 is used as a starting material; however, it would be apparent to one skilled in the art that other rings may be used in place of the trifluoromethylphenyl and phenyl rings of compound 28. Substituted chalcones may be prepared by known methods, for example as described in the Indian J. Chemistry, 32B, 449 (1993) . Condensation of a chalcone with urea provides the pyrimidinone 29, which may be treated with P0C13 to give the chloropyrimidine 30. See J. Chem. Eng. Data, 30(4) 512 (1985) and Egypt . J. Chem. , 37(3), 283 (1994) . In an alternative approach to compound 30, one of the aryl rings attached to the pyrimidine is introduced by displacement of of the 4-chloro group of 2, -dichloro- (6-aryl) -pyrimidine by an aryl boronic acid using a palladium catalyst such as (Ph3P)4Pd in the presence of a base such as sodium carbonate as described in Bioorg. Med. Lett . , 9(7), 1057 (1999). Displacement of the chlorine of compound 30 by an appropriate aminopyrazole provides compounds of this invention, such as 31. The last step of this method is illustrated by the following procedure.
[4- (4-Methylpiperidin-l-yl) -pyrimidin-2-yl] - (5- methyl-2ff-pyrazol-3 -yl) -amine. To a solution of 2- chloro-4- (4-methylpiperidin-l-yl) -pyrimidine (prepared using a procedure similar to the one reported in Eur. J. Med. Chem. , 26(7) 729 (1991) ) (222 g, 1.05 mmol) in BuOH (5 mL) was added 3-amino-5-methyl-2ff-pyrazole (305mg, 3.15 mmol) and the reaction mixture was then heated under reflux overnight. The solvent was evaporated and the residue dissolved in a mixture ethanol/water (1/3, 4 mL) . Potassium carbonate (57mg, 0.41 mmol) was added and the mixture was stirred at room temperature for 2 hours . The resulting suspension was filtered, washed with water twice and rinsed with ether twice to give the title compound as a white solid (143mg, 50%) : p 193-195°C; XH NMR (DMSO) δ 0.91 (3H, d) , 1.04 (2H, m) , 1.67 (3H, m) , 2.16 (3H, s) , 2.83 (2H, t) , 4.31 (2H, m) , 6.19 (2H, m) , 7.87 (IH, d) , 8.80 (IH, br s) , 11.71 (IH, s) ; IR (solid) 1627, 1579, 1541, 1498, 1417, 1388, 1322, 1246; MS 273.3 (M+H)+.
Method M
Villa
32
VIIlb
33
VIIIc
34
Vllld
35
Method M provides routes for obtaining compounds of formula VIII. A general procedure for displacing the chlorine of a 4-chloro-6-substituted- pyridazine, 32, with an appropriately substituted pyrazole to provide Villa is described in J. Het . Chem. , 20, 1473 (1983) . Analogous reactions may be carried out as follows: (a) with 3-chloro-5-substituted-pyridazine, 33, to provide Vlllb is described in J. Med. Chem., 41(3), 311 (1998); (b) with 5-chloro-3-substituted- [1, 2, 4] triazine, 34, to provide VIIIc is described in Heterocycles, 26(12), 3259 (1987); and (c) with 3-chloro- 5-substituted- [1, 2,4] triazine, 35, to provide Vllld is described in Pol . J. Chem. , 57, 7, (1983); Indian J. Chem . Sect . B, 26, 496 (1987); and Agric. Biol . Chem. , 54(12), 3367 (1990). An alternative procedure to compounds of formula VIIIc is. described in Indian J. Chem. Sect . B, 29(5), 435 (1990).
Compounds of formula IX are prepared by methods substantially similar to those described above for the pyrazole-containing compounds of formula I. Methods A-J may be used to prepare the triazole-containing compounds of formula IX by replacing the amino-pyrazole compound with an amino-triazole compound. Such methods are specifically exemplified by Synthetic Examples 415-422 set forth below. The amino-triazole intermediate may be obtained by methods described in J. Org. Chem. USSR, 27, 952-957 (1991) .
Certain synthetic intermediates that are useful for preparing the protein kinase inhibitors of this invention are new. Accordingly, another aspect of this invention relates to a 3-aminoindazole compound of formula A:
A where R10 is one to three substituents that are each independently selected from fluoro, bro o, Cι_6 haloalkyl, nitro, or 1-pyrrolyl . Examples of such compounds include the following :
Al A2 A3 A4
A5 A6 A7 A8
A9 A10
Another aspect of this invention relates to a 4 -chloropyrimidine compound of formula B :
B wherein Rx and Ry are as defined above; R1 is selected from Cl, F, CF3, CN, or N02; and is one to three substituents that are each independently selected from H, Cl, F, CF3, N02, or CN; provided that R1 and R5 are not simultaneously Cl . Examples of compounds of formula B are shown below:
Bl B2 B3
B4 B5 B6
B7 B8 B9
BIO Bll B12
'N Cl N Cl N CF3 to to to to to
B13 B14 B15
B19 B20 Another aspect of this invention relates to compounds of formula C:
R2
R2' HN fr
N
Rytotoι c wherein Rx, Ry, R2, and R2' are as defined above. Examples of compounds of formula C are shown below:
Hgctoto to N' C1 to Cl ci C2 C3
C4 C5 C6
C7 C8 C9
CIO Cll C12
C13 C14 C15
Yet another aspect of this invention relates to compounds of formula D:
O
Yj NHCF3
Ry^N to "5
where R5, Rx and Rγ are as defined above. Examples of formula D compounds and other useful pyrimidinone intermediates are shown below:
Dl D2 D3
D4 D5 D6
D7 D8 D9
NH CI NH Cl NH Br to
"to to
CF3 D10 Dll D12
D13 D14 D15
NH CF3 to to
D20
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner. SYNTHETIC EXAMPLES The following HPLC methods were used in the analysis of the compounds as. specified in the Synthetic Examples set forth below. As used herein, the term "Rt" refers to the retention time observed for the compound using the HPLC method specified.
HPLC-Method A: Column: C18, 3, urn, 2.1 X 50 mm, "Lighting" by Jones Chromatography.
Gradient: 100% water (containing 1% acetonitrile, 0.1%- TFA) to 100% acetonitrile (containing 0.1% TFA) over 4.0 min, hold at 100% acetonitrile for 1.4 min and return to initial conditions. Total run time 7.0 min. Flow rate: 0.8 mL/min.
HPLC-Method.B:
Column: C18, 5 urn, 4.6 X 150 mm "Dynamax" by Rainin Gradient: 100% water (containing 1% acetonitrile,
0.1% TFA) to 100% acetonitrile (containing 0.1% TFA) over 20 min, hold at 100% acetonitrile for 7.0 min and return to initial conditions. Total run time 31.5 min. Flow rate: 1.0 mL/min.
HPLC-Method C:
Column: Cyano, 5 urn, 4.6 X 150 mm "Microsorb" by
Varian.
Gradient: 99% water (0.1% TFA), 1% acetonitrile (containing 0.1% TFA) to 50% water (0.1% TFA), 50% acetonitrile (containing 0.1% TFA) over 20 min, hold for 8.0 min and return to initial conditions. Total run time 30 min. Flow rate: 1.0 mL/min. HPLC -Method D :
Column: Waters (YMC) ODS-AQ 2.0x50mm, S5, 120A. Gradient: 90% water (0.2% Formic acid), 10% acetonitrile (containing 0.1% Formic acid) to 10% water (0.1% formic acid), 90% acetonitrile
(containing 0.1% formic acid) over 5.0 min, hold for 0.8 min and return to initial conditions. Total run time 7.0 min. Flow rate: 1.0 mL/min.
HPLC-Method E:
Column: 50x2.0mm Hypersil C18 BDS;5 μm Gradient: elution 100% water (0.1% TFA), to 5% water (0.1% TFA), 95% acetonitrile (containing 0.1% TFA) over 2.1 min, returning to initial conditions after 2.3 min. Flow rate: 1 mL/min.
Example 1 [2- (2-Clorophenyl) -5, 6-dimethylpyrimidin-4-yl] - (5-Methyl-2ff-pyrazol-3-yl) -amine (II-l) : XHNMR (500 MHz, DMS0-d6) δl0.4 (s, br, IH) , 7.74 (m, 2H) , 7.68 (m, IH) , 7.60 (m, IH) , 6.39 (s, IH) , 2.52 (s, 3H) , 2.30 (s, 3H) , 2.22 (S, 3H) ; MS 314.1 (M+H).
Example 2 [2- (2-Chloro-phenyl) -6,7, 8, 9-tetrahydro-5__T- cycloheptapyrimidin-4-yl] - (lJT-indazol-3-yl) -amine (II-2) :
Prepared in 30% yield. XHNMR (500MHz, DMS0-d6) δ 1.72 (m, 4H) , 1.91 (m, 2H) , 3.02 (m, 4H) , 7.05 (t, IH) , 7.33 (t, IH) , 7.39 (m, IH) , 7.47 (d, IH) , 7.55 (m, 3H) , 7.59 (d, IH) , 10.4 (m, IH) , 13.11 (br. s, IH) ; EI-MS 390.2 (M+H); HPLC-Method A, Rt 2.99 min.
Example 3 (5-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5, 6,7, 8-tetrahydro-pyrido[3,4- d]pyrimidin-4-yl] -amine (II-3) : Compound 11-18 (90 mg,
0.17 mmol) was treated with an equal weight of Pd/C (10%) in 4.4% formic acid in MeOH at room temperature for 14 h. The mixture was filtered through celite, the filtrate was evaporated, and crude product was purified by HPLC to provide 18 mg (24%) of the desired product as pale yellow solid. ^-HNMR (500 MHz, DMSO-d6) δ 12.9 (s, IH) , 9.51 (s, IH) , 9.26 (s, 2H) , 7.72 (d, IH) , 7.63 (t, IH) , 7.58 (t, IH) , 7.49 (m, 2H) , 7.21 (td, IH) , 7.15 (dd, IH) , 4.24 (s, 2H) , 3.56 (m, 2H) , 2.95 (m, 2H) ppm. MS (ES+) : m/e= 429.22 (M+H); HPLC-Method A, Rt 2.88 min.
Example 4 [2- (2-Chloro-phenyl) -6,7, 8, 9- etrahydro-5H- cycloheptapyrimidin-4-yl] - (7-fluoro-l__T-indazol-3-yl) - amine (II-4) : Prepared in 52% yield to afford a white solid. 1HNMR (500MHz, DMSO-d6) δ 1.72 (m, 4H) , 1.92 (m, 2H) , 3.00 ( , 4H) , 7.02 (td, IH) , 7.20 (dd, IH) , 7.40 (m, IH) , 7.42 (d, IH) , 7.52 (m, 3H) , 10.5 (m, IH) , 13.50 (br. S, IH) ; EI-MS 408.2 (M+H); HPLC-Method A, Rt 3.00 min.
Example 5 [2- (2-Chloro-phenyl) -6,7, 8, θ-tetrahydro-SIT- cycloheptapyrimidin^-yl] - (5-fluoro-lff-indazol-3-yl) - amine (II-5) : Prepared in 51% yield. ^ΗNMR (500MHz, DMSO- d6) δ 1.71 ( , 4H) , 1.91 (m, 2H) , 3.01 (m, 4H) , 7.24 (td, IH) , 7.41 (m, 2H) , 7.54 (m, 4H) , 10.5 (m, IH) , 13.1 (br. S, IH) ; EI-MS 408.2 (M+H) ; HPLC-Method A, Rt 3.05 min.
Example 6 [2- (2-Chloro-phenyl) -6,7, 8, 9-tetrahydro-5Jϊ- cycloheptapyrimidin-4-yl] - (5,7-difluoro-lff-indazol-3-yl) - amine (II-6) : Prepared according to Method C in 72% yield. XHNMR (500MHz, DMSO-d6) δ 1.72 (m, 4H) , 1.91 (m, 2H) , 3.01 (m, 4H) , 7.31 (m, 2H) , 7.41 (m, IH) , 7.54 (m, 3H) , 10.5 (m, IH) , 13.6 (br. S, IH) ; EI-MS 426.2 (M+H); HPLC-Method A, Rt 3.21 min. Example 7 (7-Fluoro-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5, 6,7, 8-tetrahydroquinazolin-4- . yl] -amine (II-7) : Prepared in 62% yield. 1HNMR (500 MHz, DMSO-d6) δl3.5 (s, br, 'IH) , 10.1 (s, br, IH) , 7.75 (m,
4H) , 7.33 (d, IH), 7.17 (dd, IH) , 7.00 (td, IH) , 2.80 (m, 2H) , 2.71 (m, 2H) , 1.89 (br, 4H) ppm; LC-MS (ES+) 428.44 (M+H), (ES-) 426.43 (M-H); HPLC-Method A, Rt 3.02 min.
Example 8 (5-Fluoro-l__T-indazol-3-yl) - [2- (2- trifluoromethy1-phenyl) -5,6,7, 8-tetrahydroquinazolin- - yl] -amine (II-8) : Prepared in 53% yield. '^HNMR (500 MHz, DMSO-d6.) δl3.1 (s, IH) , 10.2 (s, br, IH) , 7.75 (m, 4H) , 7.50 (dd, IH) , 7.27 (dd, IH) , 7.21 (td, IH) , 2.80 (m, 2H) , 2.72 (m, 2H) , 1.88 (m, 4H) ppm; MS (ES+) 428.43
(M+H), (ES-) 426.43 (M-H); HPLC-Method A, Rt 3.01 min.
Example 9 (5,7-Difluoro-lH-indazol-3-yl) - [2- (2- trifluorome hyl-phenyl) -5,6,7,8-tetrahydroquinazolin-4- yl] -amine (II-9) : Prepared in 37% yield. ^ΗN R (500 MHz, DMSO-d6) δl3.7 (s, IH) , 10.2 (s, br, IH) , 7.80 (d, IH) , 7.76 (t, IH) , 7.69 (m, 2H) , 7.31 (t, IH) , 7.18 (d, IH) , 2.81 (t, br, 2H) , 2.72 (t, br, 2H) , 1.90 (m, 4H) ppm; MS (ES+) 446.42 (M+H), (ES-) 444.37 (M-H); HPLC-Method A, Rt 3.09 min.
Example 10 (5-Trifluoromethyl-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5, 6,7, 8- tetrahydroquinazolin-4 - yl] -amine (11-10) : Prepared by Method C in ethanol in 35% yield. 1HNMR (500 MHz, DMSO-d6) δl3.2 (s, IH) , 10.1 (s, br, IH) , 8.01 (s, IH) , 7.76 (d, IH) , 7.66 (m, 4H) , 7.57 (d, IH) , 2.79 (m, 2H) , 2.73 (m, 2H) , 1.89 (m, 4H) ppm. MS (ES+) 478.45 (M+H), (ES-) 476.42 (M-H) ; HPLC- Method A, Rt 3.21 min. Example 11 (5,7-difluoro-l.ff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl)-6,7,8,9-tetrahydro- 5H- cycloheptapyrimidin-4-yl] -amine (11-11) : Prepared in 60% yield. White solid. XHNMR ' (500MHz, DMSO-d6) δ 1.72 (m, 4H) , .1.91 (m, 2H) , 3.01 (m, 4H) , 7.15 (dd, IH) , 7.30 (td, IH) , 7.66 (m, 2H) , 7.72 (t, IH) , 7.78 (d, IH) , 10.2 (m, IH) , 13.5 (br. s, IH) ; EI-MS 460.2 (M+H); HPLC-Method A, Rt 3.13 min.
Example 12 (6-Benzyl-2- (2-trifluoromethyl-phenyl) - 5,6,7,8-tetrahydro-pyrido [4,3-d]pyriπ_idin-4-yl) - (5- fluoro-lff-indazol-3-yl) -amine (11-12): Prepared in 49% yield. 1HNMR (500 MHz, DMSO-d6) δ 12.8 (s, IH) , 9.11 (s, IH) , 7.68 (d, IH) , 7.58 (t, IH) , 7.53 (t, IH) , 7.44 (m, 4H) , .7.37 (t, 2H) , 7.29 (t, IH) , 7.19 (m, 2H) , 3.78 (s, 2H) , 3.61 (S, 2H) , 2.81 (s, br, 4H) ppm; LC-MS (ES+) 519.24 (M+H); HPLC-Method A, Rt 3.11 min.
Example 13 (Iff-Indazol-3-yl) - [2- (2-trifluoromethyl- phenyl) -6,7, 8,9-tetrahydro-5ff-cycloheptapyrimidin-4-yl] - amine (11-13) :_Prepared in 40% yield. 1HNMR (500MHz, DMSO-d6) δ 1.70 (m, 4H) , 1.90 (m, 2H) , 3.00 (m, 4H) , 7.01 (t, IH) , 7.30 (td, IH) , 7.44 (d, IH) , 7.49 (d, IH) , 7.68 (m, 3H) , 7.77 (d, IH) , 10.01 (m, IH) , 12.83 (s, IH) ; EI- MS 424.2 (M+H); HPLC-Method A, Rt 3.17 min.
Example 14 (7-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl)-6,7,8,9-tetrahydro- 5H- cycloheptapyrimidin-4-yl] -amine (11-14): Prepared in 78% yield. ^ΗNMR (500MHz, DMSO-d6) δ 1.71 (m, 4H) , 1.91 ( , 2H) , 3.00 (m, 4H) , 6.98 (td, IH) , 7.16 (dd, IH) , 7.31 (d, IH) , 7.68 (m, 3H) , 7.77 (d, IH) , 10.25 (m, IH) , 13.40 (br. s, IH) ; EI-MS 442.2 (M+H); HPLC-Method A, Rt 3.12 mm.
Example 15 (5-Fluoro-l_ST-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -6, 7,8,9-tetrahydro-5H- cycloheptapyrimidin-4-yl] -amine (11-15) : Prepared in 63% yield. XHNMR (500MHz, DMSO-d6) δ 1.71 (m, 4H) , 1.91 ( , 2H) , 3.00 (m, 4H) , 7.20 (td, IH) , 7.25 (dd, IH) , 7.49 (dd, IH) , 7.69 (br. t, 2H) , 7.74 (m, IH) , 7.79 (d, IH) , 10.35 (m, IH) , 13.00 (br. S, IH) ; EI-MS 442.2 (M+H); HPLC-Method A, Rt 3.21 min.
Example 16 (5-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5,6,7,8- etrahydro-pyrido [4,3- d]pyrimidin-4-yl] -amine (11-16): A solution of compound 11-12 (45mg, 0.087 mmol) in methanol (4.4% HCOOH) was treated with an equal weight of Pd/C (10%) at room temperature for 14 h. The mixture was filtered through celite, the filtrate evaporated, and the crude product was purified by preparative HPLC to provide 15 mg (41%) of the desired product as yellow solid. 1HNMR (500 MHz, DMSO-d6) δl2.9 (s, IH) , 9.52 (s, IH) , 9.32 (s, 2H, TFA- OH) , 7.72 (d, IH) , 7.59 (m, 2H) , 7.49 (m, 2H) , 7.21 (m, IH) , 7.15 (m, IH) , 4.31 (s, 2H) , 3.55 (s, 2H) , 3.00 (m, 2H) ppm; LC-MS (ES+) 429.20 (M+H); HPLC-Method A, Rt 2.79 min.
Example 17 (l__T-indazol-3-yl) - [2- (2-trif luorome thyl - phenyl) -5,6,7,8-tetrahydroquinazolin-4-yl] -amine (11-17) :
Prepared in 58% yield. XHNMR (500 MHz, DMSO-d6) δ 13.0 (s, IH) , 10.3 (s, br, IH) , 7.74 (m, 4H) , 7.51 (d, IH) , 7.47 (d, IH) , 7.32 (t, IH) , 7.03 (t, IH) , 2.82 (m, 2H) , 2.73 (m, 2H) , 1.90 (m, 4H) ppm; LC-MS (ES+) 410.21 (M+H) ; HPLC-Method A, Rt 2.99 min. Example 18 (7-Benzyl-2- (2-trifluoromethyl-phenyl) - 5, 6,7, 8-tetrahydrσ-pyrido [4, 3 -d] pyrimidin-4-yl) - (5- fluoro-lff-indazol-3-yl) -amine (11-18): Prepared from compound Bll in 92% yield. 1HNMR (500 MHz, DMSO-d6) δl2.9 (S, IH) , 10.5- (s, br, IH) , 9.58 (s, IH,. TFA-OH) , 7.71 (d, IH) , 7.52 (m, 9H) , 7.19 (mi, 2H) , 4.57 (s, 2H) , 4.20 (m, 2H) , 3.70 (m, 2H) , 3.00 (m, 2H) ppm; LC-MS (ES+) 519.23 (M+H); HPLC-Method A, Rt 3.23 min.
Example 19 (lff-Indazol-3-yl) - [6-methyl-2- (2- trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (11-19) :
Prepared in 42% yield. Melting point 235-237°C; XHNMR (500 MHz, DMSO) δ 2.44 (3H, s) , 7.09 (IH, J=7.5 Hz, t) , 7.40 (IH, J=7.1 Hz, t) , 7.49 (IH, J=8.3 Hz, d) , 7.70 (3H, m) , 7.79 (IH, J=7.3 Hz, t) , 7.87 (IH, J=8.3 Hz, d) , 8.03 (IH, J=7.7 Hz, d) , 10.3 (IH, s), 12.6 (IH, s) ppm; HPLC- Method A, Rt 2.958 min; MS (FIA) 370.2 (M+H)+.
Example 20 (lff-Indazol-3-yl) - [6-phenyl-2- (2- trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (11-20) :
Prepared in 32% yield. αHNMR (500 MHz, DMSO) δ 6.94 (IH, J=7.4 Hz, t), 7.24 (IH, J=7.4 Hz, t) , 7.33 (IH, J=8.4 Hz, d) , 7.42 (3H, m) , 7.57 (IH, J=7.3 Hz, t) , 7.68 (2H, m) , 7.75 (IH, J=7.9 Hz, d) , 7.93 (3H, m) , 8.18 (IH, br s) ,
10.45 (IH, br s) , 12.5 (IH, br s) ppm; HPLC-Method A, R 4.0 min; MS (FIA) 432.2 (M+H)+.
Example 21 (lff-Indazol-3-yl) - [6- (pyridin-4-yl) -2- (2- trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (11-21):
Prepared in 12% yield. XHNMR (500 MHz, DMSO) δ 7.16 (IH, J=7.4 Hz, t), 7.46 (IH, J=7.6 Hz, t), 7.56 (IH, J=8.3 Hz, d) , 7.80 (IH, J=7.2 Hz, t) , 7.90 (2H, m) , 7.97 (IH, J=7.8 Hz, d) , 8.09 (IH, br) , 8.22 (2H, J=4.9 Hz, d) , 8.45 (IH, br s) , 8.93 (2H, J=4.8 Hz, d) , 10.9 (IH, br s) , 12.8 (IH, br s) ppm; HPLC-Method A, Rt 3.307 min; MS (FIA) 433.2 (M+H) +
Example 22 (lff-Indazol-3-yl) - [6- (pyridin-2-yl) -2- (2- trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (11-22) : Prepared in 42% yield. 1HNMR (500 MHz, DMSO) δ 7.07 (IH, J=7.4 Hz, t), 7.36 (IH, J=7.4 Hz, t) , 7.46 (IH, J=7.4 Hz, d) , 7.53 (IH, J=5.0 Hz, t) , 7.70 (IH, J=7.4 Hz, t) , 7.79 (IH, J=7.1 Hz, t) , 7.83 (IH, J=7.4 Hz, d) , 7.88 (IH, J=7.8 Hz, d) , 7.97 (IH, J=7.7 Hz, t) , 8.02 (IH, J=5.5 Hz, br d) , 8.36 (IH, J=7.8 Hz, d) , 8.75 (2H, J=4.1 Hz, d), 10.5 (IH, br s) , 12.7 (IH, br s) ppm; HPLC-Method A, Rt 3.677 min; MS (FIA) 433.2 (M+H)+.
Example 23 [6- (2-Chlorophenyl) -2- (2-trifluoromethyl- phenyl) -pyrimidin-4-yl] - (liϊ-indazol-3-yl) -amine (11-23) :
Prepared in 44% yield; 1HNMR (500 MHz, DMSO) δ 7.08 (IH, J=7.5 Hz, t) , 7.37 (IH, J=7.5 Hz, t) , 7.45 (IH, J=8.4 Hz, d) , 7.51 (2H, m) , 7.61 (IH, J=7.4, 1.9 Hz, dd) , 7.69 (2H, m) , 7.79 (2H, J=4.0 Hz, d) , 7.86 (3H, J=7.8 Hz, d) , 8.04 (2H, J=6.2 Hz, br d) , 10.7 (IH, br s) , 12.6 (IH, br s) ppm; HPLC-Method A, Rt 3.552 min; MS (FIA) 466.2 (M+H) + .
Example 24 [5, 6-Dimethyl-2- (2-trifluoro ethyl-phenyl) - pyrimidin-4-yl] - (Iff-indazol-3-yl) -amine (11-24): Prepared in 35% yield; mp 183-186°C; XHNMR (500 MHz, DMSO) δ 2.14 (3H, S) , 2.27 (3H, s) , 6.85 (IH, J=7.5 Hz, t) , 7.15 (IH, J=7.6 Hz, t) , 7.32 (3H, m) , 7.38 (IH, J=7.5 Hz , t) , 7.42 (IH, J=7.4 Hz, t) , 7.53 (IH, J=7.6 Hz, d) , 8.88 (IH, s) , 12.5 (IH, s) ppm; HPLC-Method A, Rt 2.889 min.; MS (FIA) 384.2 (M+H)'. Example 25 [5, 6 -Dimethyl-2- (2-trifluoromethyl-phenyl) - pyrimidin-4-yl] - (5-fluoro-lff-indazol-3-yl) -amine (11-25) :
Prepared in 44% yield. Melting point 160-163°C; 1HNMR (500 MHz, DMSO) δ 2.27 (3H, s) , 2.40 (3H, s) , 7.16 (2H, m) , 7.44 (2H, m) , 7.52 (IH, J=7.4 Hz, t) , 7.57 (IH, J=7.4 Hz, t) , 7.67 (IH, J=7.8 Hz, d) , 9.03 (IH, a) , 12 . 15 lH, s) ppm; HPLC-Method A, Rt 2.790 min; MS (FIA) 402.2 (M+H)+.
Example 26 [2- (2-Chlorophenyl) -5, 6 -dimethyl-pyrimidin-4- yl] - (lff-indazol-3-yl) -amine (11-26): Prepared in 30% yield. 1HNMR (500 MHz, DMSO) δ 2.14 (3H, s) , 2.33 (3H, S) , 6.84 (IH, J=7.4 Hz, t) , 7.13 (IH, J=7.4 Hz, t) , 7.19 (IH, J=6.9 Hz, br t) , 7.27 (IH, J=7.4 Hz, d) , 7.32 (3H, br m) , 7.37 (IH, J=7.1 Hz, d) , 10.0 (IH, br) , 12.8 (IH, br s) ppm; δ 2.919 min; MS (FIA) 350.1 (M+H)+.
Example 27 [5, 6-Dimethyl-2- (2-trifluoromethyl-phenyl) - pyrimidin-4-yl] - (7-fluoro-lff-indazol-3-yl) -amine (11-27):
Prepared in 92% yield. XHNMR (500 MHz, DMSO) δ 2.33 (3H, s) , 2.50 (3H, s) , 6.97 (IH, ) , 7.15 (IH, m) , 7.30 (IH, J=8.1 Hz, d) , 7.65 (3H, m) , 7.76 (IH, J=7.5 Hz, d) , 10.0 (IH, s) , 13.4 (IH, s) ppm; HPLC-Method A, Rt 3.053 min; MS (FIA) 402.2 (M+H)+.
Example 28 (5,7-Difluoro-lff-indazol-3-yl) - [5, 6-Dimethyl- 2- (2-trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (II- 28): Prepared in 50% yield. XHNMR (500 MHz, DMSO) δ 2.42 (3H, S) , 2.63 (3H, s) , 7.22 (IH, J=7.6 Hz, d) , 7.38 (IH, J=9.3, 1.7 Hz, dt) , 7.71 (IH, m) , 7.75 (IH, J=7.0 Hz, d) , 7.79 (IH, J=6.7 Hz, d) , 7.86 (IH, J=8.0 Hz, d) , 10.0 (IH, s) , 13.2 (IH, s) ppm; HPLC-Method A, Rt 3.111 min; MS (FIA) 420.2 (M+H)+.
Example 29 [2- (2-Chlorophenyl) -5, 6-dimethyl-pyrimidin-4- yl] - (5,7-difluoro-lff-indazol-3-yl) -amine (11-29):
Prepared in 58% yield. XHNMR (500 MHz, DMSO) δ 2.47 (3H, s) , 2.66 (3H, s) , 7.44 (2H, m) , 7.53 (IH, m) , 7.64 (3H, m) , 10.4 (IH, br) , 13.8 (lH, br s) ppm; HPLC-Method A, Rt 2.921 min; MS (FIA) 386.1 (M+H)+.
Example 30 [2- (2-Chlorophenyl) -5, 6-dimethyl-pyrimidin-4- yl] - (7-fiuoro-lff-indazol-3-yl) -amine (11-30): Prepared in 70% yield. XHNMR (500 MHz, DMSO) δ 2.35 (3H, s) , 2.51 (3H, s) , 7.03 (IH, J=7.8, 4.4 Hz, dt) , 7.22 (IH, ) , 7.33 (IH, J=7.4 Hz, t) , 7.42 (IH, m) , 9.19 (IH, s) , 13.3 (IH, s) ppm; HPLC-Method A, Rt 2.859 min; MS (FIA) 368,2 (M+H) + .
Example 31 [2- (2-Chlorophenyl) -5, 6-dimethyl-pyrimidin-4- yl] - (5-fluoro-lff-indazol-3-yl) -amine (11-31): Prepared in 86% yield. ^ΗNMR (500 MHz, DMSO) δ 2.49 (3H, s) , 2.68 (3H, s) , 7.38 (IH, J=9.0 Hz, t) , 7.54 (2H, m) , 7.67 (4H, m) , 10.5 (IH, br) , 13.2 (IH, br s) ppm; HPLC-Method A, Rt 2.850 min; MS (FIA) 368.1 (M+H)+.
Example 32 [2- (2 , 4-Dichlorophenyl) -5, 6-dimethyl- pyrimidin-4-yl] - (Iff-indazol-3-yl) -amine (11-32): Prepared in 52% yield. XHNMR (500 MHz, DMSO) δ 2.46 (3H, s) , 2.64 (3H, s) , 7.16 (IH, J=7.5 Hz, t) , 7.46 (IH, J=7.6 Hz, t) , 7.61 (2H, m) , 7.68 (2H, J=8.2 Hz, d) , 7.82 (IH, m) , 10.2 (IH, br) , 13.0 (IH, br s) ppm; HPLC-Method A, Rt 2.983 min; MS (FIA) 384.1 (M+H). Example 33 (5-Methyl-2ff-pyrazol-3-yl) - [2- (2- methylphenyl) -quinazolin-4-yl] -amine (11-33): ^-HNMR (DMSO) δ 1.21 (3H,S), 2.25 (3H, s) , 6.53 (IH, s) , 7.38 (4H, m) , 7.62 (IH, d) , 7.73 (IH, d), 7.81 (IH, d) , 7.89 (IH, t) , 8.70 (IH, s), 12.20 (IH, s) ; MS 316.3 (M+H)+.
Example 34 [2- (2, -Difluorophenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (11-34): ^ΗNMR (500 MHz, DMSO-d6) δl2.4 (br S, IH) , 10.8 (br s, IH) , 8.58 (d, IH). , 7.97 (m, IH) , 8.36 (m, IH) , 7.85 (m, IH) , 7.60 (m, IH) , 6.62 (s, IH) , 2.30 (s, 3H) ; MS 338.07 (M+H).
Example 35 [2- (2, 5-Dimethoxyphenyl) -quinazolin-4-yl] - (5- methyl-2JΪ-pyrazol-3-yl) -amine (11-35): XHNMR (500 MHz, DMSO-d6) δl2.5 (br s, IH) , 8.68 (br, IH) , 7.92 (t, J = 7.5 Hz, IH) , 7.86 (d, J = 8.2 Hz, IH) , 7.65 (t, J = 7.5 Hz, IH) , 7.45 (S, IH) , 7.14 (m, 2H) , 6.51 (s, IH) , 3.79 (S, 3H) , 3.67 (S, 3H) , 2.14 (s, 3H) ; MS 362.2 (M+H).
Example 36 [2- (2-Chlorophenyl) -quinazolin-4-yl] - (5- ethyl-2ff-pyrazol-3-yl) -amine (11-36): ^ΗNMR (500 MHz, DMSO-d6) δll.8 (br, IH) , 8.80 (d, J = 8.3 Hz, IH) , 8.00 (t, J = 7.6 Hz, IH) , 7.82 (d, J = 8.3 Hz, IH) , 7.78 ( , 2H) , 7.67 (d, J = 7.8 Hz, IH) , 7.61 (t, J = 7.0 Hz, IH) , 7.55 (t, J = 7.4 Hz, IH) , 6.56 (s, IH) , 2.18 (s, 3H) ; MS 336.1 (M+H) .
Example 37 [2- (2 -Methoxyphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl)-amine (11-37): 1HNMR (500 MHz, DMSO-d6) δ8.78 (s, br, IH) , 8.00 (t, J.= 7.4 Hz, IH) , 7.90 (m, 2H) , 7.74 (t, J = 7.5 Hz, IH) , 7.63 (t, J = 7.3 Hz, IH) , 7.30 (d, J = 8.4 Hz, IH) , 7.18 (t, J = 7.5 Hz, IH) , 6.58 (s, br, IH) , 3.90 (s. 3H) , 2.21 (s, 3H) ; MS 332.1 (M+H) .
Example 38 [2- (2, 6-Dimethylphenyl) -quinazolin-4 -yl] - (5- methyl-21ϊ-pyrazol-3-yl) -amine (11-38) : XHNMR (500 MHz, DMSO-d6) δl2.2 (s, br, 2H) , 8.88 (d, J = 7.7 Hz, IH) , 8.05 (t, J = 7.7 Hz, IH) , 7.80 (m, 2H) , 7.37 (t, J = 7.6 Hz, IH) , 7.21 (d, J = 7.7 Hz, 2H) , 6.36 (s, IH) , 2.16 (s, 3H) , 2.15 (s, 6H) ; MS 330.1 (M+H) .
Example 39 [2- (2-Acetylphenyl) -quinazolin-4 -yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (11-39) : XHNMR (500 MHz, DMSO-d6) δl2.35 (s, br, IH) , 8.93 (d, J = 8.4 Hz, IH) , 8.37 (d, J = 8.6 Hz, IH) , 8.20 (d, J = 7.6 Hz, IH) , 8.11 (t, J = 8.0 Hz, 2H) , 7.89 (m, 2H) , 7.77 (m, 2H) , 6.93 (s, IH) , 2.33 (s, 3H) , 2.04 (s, 3H) MS 344.1 (M+H) .
Example 40 [2- (2,3-Dimethylphenyl) -quinazolin-4-yl] - (5- me thyl -2ff-pyrazol- 3 -yl) -amine (11-40) : 1HNMR (500 MHz, DMSO-d6) δl2.6 (s, br, IH) , 12.1 (s, br, IH) , 8.91 (d, J = 7.7 Hz, IH) , 8.14 (t, J = 7.2 Hz, IH) , 7.95 (d, J = 8.4 Hz, IH) , 7.89 (t, J = 7.7 Hz, IH) , 7.58 (d, J = 7.6 Hz, IH) , 7.53 (d, J = 7.0 Hz, IH) , 7.42 (t, J = 7.6 Hz, IH) , 6.60 (S, IH) , 2.43 (s, 3H) , 2.35 (s, 3H) , 2.32 (s, 3H) ; MS 330.1 (M+H) .
Example 41 (5-Methyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-41) :
XHNMR (500 MHz, DMSO-d6) δl2.3 (s, IH) , 10.5 (s, IH) , 8.77 (d, J = 8.2 Hz, IH) , 7.92 (m, 2H) , 7.85 (m, 3H) ,
7.56 (t, J = 8.1 Hz, IH) , 7.67 (t, J = 7.4 Hz, IH) , 6.63 (s, IH) , 2.27 (s, 3H) ; MS 370.1 (M+H). Example 42 [2- (2-Ethylphenyl) -quinazolin-4 -yl] - (5-Methyl- 2ff-pyrazol-3-yl) -amine (11-42): 1HNMR (500 MHz, DMSO-d6) δ8.80 (m, IH) , 8.02 (s, br, IH) , 7.82 (d, J = 8.4 Hz, IH) , 7.77 (m, IH) , 7.62 (d, J = 7.6 Hz, IH) , 7.54 (m, IH) , 7.41 (m, 2H-) , 6.40 (s, IH) , 2.75 (q, J = 7.1 Hz, 2H) , 2.17 (s, 3H) , 0.99 (t, J = 7.5 Hz, 3H) ; MS 330.1 (M+H) .
Example 43 (2 -Biphenyl-2 -yl-quinazolin-4-yl) - (5-methyl- 2ff-pyrazol-3-yl) -amine (11-43): XHNMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 7.6 Hz, IH) , 8.04 (m, IH) , 7.75 (m, 6H) , 7.30 (m, 5H) , 5.34 (s, IH) , 2.14 (s, 3H) ; MS 378.2 (M+H).
Example 44 [2- (2-Hydroxyphenyl) -quinazolin-4-yl] - (5- Methyl-2ff-pyrazol-3-yl) -amine (11-44): XHNMR (500 MHz, DMSO-d6) δlθ.9 (s, br, IH) , 8.62 (d, J = 8.2 Hz, IH) , 8.28 (d, J = 7.9 Hz, IH) , 7.87 .(m, 2H) , 7.60 (t, J = 7.9 Hz, IH) , 7.37 (t, J = 7.8 Hz, IH) , 6.92 ( , 2H) , 6.45 (s, IH) , 2.27 (s, 3H) ; MS 318.1 (M+H).
Example 45 [2- (2-Ethoxyphenyl) -quinazolin-4-yl] - (5- Methyl-2ff-pyrazol-3-yl) -amine (11-45) : ^ΗNMR (500 MHz, DMSO-d6) δl2.1 (s, br, IH) , 8.75 (d, J « 8.3 Hz, IH) , 7.97 (t, J = 7.8 Hz, IH) , 7.82 (d, J = 8.3 Hz, IH) , 7.78 (d, J = 7.5 Hz, IH) , 7.70 (t, J = 7.8 Hz, IH) , 7.56 (t, J = 7.8 Hz, IH) , 7.22 (d, J = 8.4 Hz, IH) , 7.12 (t, J = 7.6 Hz, IH) , 6.55 (s, IH) , 4.11 (q, J = 6.9 Hz, 2H) , 2.16 (s, 3H) , 1.22 (t, J = 6.9 Hz, 3H) ; MS 346.1 (M+H) .
Example 46 [5- (Thiophen-2-yl) -2ff-pyrazol-3-yl] - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-46) :
XHNMR (500 MHz, DMSO-d6) δ 8.04 (d, J = 8.3 Hz, IH) , 8.05 (dd, J = 7.3, 8.2 Hz, IH) , 7.93 (d, J = 6.5 Hz, IH) , 7.81 (m, 5H) , 7.34 (d, J = 5.0 Hz, IH) , 7.25 (m, IH) , 7.00 (m, IH) , 6.87 (s, IH) ; MS 438.1 (M+H) .
Example 47 [4- (Thiophen-2-yl) -2ff-pyrazol-3-yl] - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-47) :
Prepared according to Method B. 1HNMR (500MHz, DMSO-d6) δ 6.97 (m, IH) , 7.08 (m, IH) , 7.27 ( , IH) , 7.36 (m, IH) , 7.66 (m, 2H) , 7.77 (m, 3H) , 7.83 (m, IH) , 8.00 (m, IH) , ' 8.18 (s, IH) , 8.62 (d, J = 8.2 Hz, IH) , 10.7 (br. s, IH) ; EI-MS 438.1 (M+H); HPLC-Method A, Rt 2.97 min.
Example 48 (4-Phenyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-48) : Prepared according to Method B. '^HNMR (500MHz, DMSO-d6) δ 7.05 (br. s, IH) , 7.14 (t, J = 7.8 Hz, IH) , 7.25 (m, 3H) , 7.43 (m, 2H) , 7.60 (m, 2H) , 7.73 (m, 2H) , 7.80 (d, IH) , 7.95 (m, IH) , 8.12 (br. s, IH) , 8.60 (m, IH) , 10.6 (br. s, IH) ; EI-MS 432.2 (M+H); HPLC-Method A, Rt 3.04 min.
Example 49 (5- fcert-Butyl-2ff-pyrazol-3-yl) - [2- (2- tri luoromethyl-phenyl) -quinazolin-4-yl] -amine (11-49) : ^NMR (500 MHz, DMS0-d6) δ 8.76 (d, J = 8.3 Hz, IH) , 7.94 (m, 2H) , 7.79 (m, 4H) , 7.70 (t, J = 7.6 Hz, IH) , 6.51 (s, IH) , 1.16 (s, 9H) ; MS 412.2 (M+H).
Example 50 (5-Phenyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-50) :
XHNMR (500MHZ, DMS0-d6) δ 7.09 (s, IH) , 7.36 (td, J = 7.8, 1.1 Hz, IH) , 7.46 (t, J = 7.8 Hz, 2H) , 7.65 (br. d, J =
8.1 Hz, 2H) , 7.78 (m, 2H) , 7.90 (m, 4H), 7.95 (d, J = 7.7 Hz, IH) , 8.00 (t, J = 7.8 Hz, IH) , 8.81 (d, J = 8.6 Hz, IH) , 11.29 (br. s, IH) ; EI-MS 432.1 (M+H) ; HPLC-Method A, Rt 3.24 min. Example 51 (4,5-Diphenyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-51) :
1HNMR (500MHz, DMS0-d6) δ 7.13 (m, IH) , 7.18 (m, 5H) , 7.36 (m, 5H) , 7.62 (m, 3H) , 7.73 (m, 2H) , 7.85 (m, IH) , 8.48 (d, J = 8.7 Hz, IH) , 10.02 (s, IH) , 13.19 (s, IH) ; EI-MS 508.2 (M+H); HPLC-Method A, Rt 3.39 min.
Example 52 (4-Carbamoyl-2_sr-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-52):
Prepared in 40% yield. XHNMR (500MHz, DMS0-d6) : δ 12.85 (s, IH) , 12.77 (S, IH) , 11.80 (s, IH) , 10.80 (s, IH) ,
8.35-7.42 (m, 9H) ; MS 399.13 (M+H) HPLC-Method A, Rt
2.782 min.
Example 53 (2ff-Pyrazol-3-yl) - [2- (2- trifluorome hylphenyl) -quinazolin- -yl] -amine (11-53) :
Prepared in 38% yield. 1HNMR (500 MHz, DMSO-d6) δ 12.52 (s, IH) , 10.65 (s, IH) , 8.75 (d, IH) , 7.91-7.68 (m, 8H) , 6.87 (s, IH) . MS: (M+H) 356.17. HPLC-Method A, Rt 2.798 min.
Example 54 (5-Hydroxy-2ff-pyrazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (11-54) : Prepared in 36% yield; αHNMR (500 MHz, DMSO-d6) δ 10.61 (s, IH) , 8.75 (s, IH) , 8.03-7.75 (m, 9H) , 5.97 (s, IH) ; MS 372.18 (M+H); HPLC-Method A, Rt 2.766 min.
Example 55 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-55):
Prepared in 30% yield. XHNMR (500 MHz, DMS0-d6) δ 12.21 (s, IH) , 10.45 (S, IH) , 8.68 (s, IH) , 7.89-7.45 (m, 8H) , 6.48 (s, IH) , 0.89 (m, 2H) , 0.62 (s, 2H) . MS 396.18 (M+H); HPLC-Method A, Rt 3.069 min.
Example 56 (5-Methoxymethyl-2ff-pyrazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-56):
Prepared in 33% yield; XHNMR (500 MHz, DMSO-d6) δ 12.51 (S, IH) , 10.48 (s, IH) , 8.60 (s, IH) , 7.81-7.55 (m, 7H) , 6.71 (s, IH) , 4.28 (s, 2H) , 3.18 (s, 3H) . MS 400.19 (M+H): HPLC-Method A, Rt 2.881 min.
Example 57 (lff-indazol-3-yl) - [2 - (2-trifluoromethyl- phenyl) -quinazolin-4-yl] -amine (11-57): Prepared to afford 51 mg (78% yield) as pale yellow solid. 1HNMR (500 MHz, DMS0-d6) δl2.7 (s, IH) , 10.4 (s, IH) , 8.55 (d, IH) , 7.81 (t, IH) , 7.71 (d, IH) , 7.61 (d, IH) , 7.58 (t, IH) , 7.46 (m, 4H) , 7.36 (d, IH) , 7.22 (t, IH) , 6.91 (t, IH) ppm; LC-MS (ES+) 406.16 (M+H), (ES-) 404.19 (M-H); HPLC- Method A, Rt 3.00 min.
Example 58 (4-Chloro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-58) :
Prepared in DMF (70% yield) as pale yellow solid. 1HNMR (500 MHz, DMS0-d6) δ 13.3 (s,.br, IH) , 10.9 (s, br, IH) , 8.60 (d, IH) , 7.97 (t, IH) , 7.81 (d, IH) , 7.75 (t, IH) , 7.67 (d, IH) , 7.63 (dd, IH) , 7.57 (m, 2H) , 7.43 (d, IH) , 7.28 (dd, IH) , 7.08 (d, IH) ppm; LC-MS (ΞS+) 440.10 (M+H), (ES-) 438.12 (M-H); HPLC-Method A, Rt 3.08 min.
Example 59 (5-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-59):
Prepared in DMF (34% yield) as pale yellow solid. XHNMR (500 MHz, DMS0-d6) δ 13.0 (s, IH) , 10.6 (s, IH) , 8.72 (d, IH) , 7.99 (t, IH) , 7.89 (d, IH) , 7.79 (d, IH) , 7.75 (t, IH) , 7.68 (m, 3H) , 7.56 (dd, IH) , 7.39 (d, IH) , 7.28 (t, IH) ppm; LC-MS (ES+) 424.12 (M+H), (ES-) m/e= 422.13 (M- H) ; HPLC-Method A, Rt 3.05 min.
Example 60 (7-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-60):
Prepared in DMF (.51% yield) as yellow solid. ^Η R (500 MHz, DMSO-d6) δl3.4 (s, IH) , 10.6 (s, IH) , 8.68 (d, IH) , 7.95 (t, IH) , 7.85 (d, IH) , 7.72 (m, 2H) , 7.63 (m, 2H) , 7.58 (m, IH) , 7.43 (d, IH) , 7.18 (dd, IH) , 7.00 (m, IH) ppm; LC-MS (ES+) 424.11 (M+H), (ES-) 422.15 (M-H); HPLC- Method A, Rt 3.06 min.
Example 61 (5-Methyl-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-61) : Prepared in DMF (81% yield) as yellow solid. 1HNMR (500 MHz,. DMSO-d6) δ 13.0 (s, br, IH) , 8.79 (br, IH) , 8.11 (br, IH) , 7.96 (d, IH) , 7.82 ( , 5H) , 7.46 (s, IH) , 7.41 (d, IH) , 7.20 (d, IH) , 2.33 (s, 3H) ppm; MS (ES+) 420.15 (M+H), (ES-) 418.17 (M-H); HPLC-Method A, Rt 3.07 min.
Example 62 [2- (2, 6-Dichloro-phenyl) -quinazolin-4-yl] - (5- fluoro-lff-indazol-3-yl) -amine (11-62): Prepared in DMF (37% yield) as yellow solid. XHNMR (500 MHz, DMS0-d6) δl3.0 (s, IH) , 10.8 (s, IH) , 8.72 (d, IH) , 7.97 (t, IH) , 7.90 (d, IH) , 7.75 (t, IH) , 7.53 (m, 3H) , 7.43 (t, IH) , 7.35 (d, IH) , 7.23 (t, IH) ppm; LCMS (ES+) 424.08 (M+H) > (ES-) 422.10 (M-H); HPLC-Method A, Rt 3.06 min.
Example 63 [2- (2-Chloro-phenyl) -quinazolin-4-yl] - (lff- indazol-3-yl) -amine (11-63): Prepared in 91% yield. 1HNMR
(500MHz, DMS0-d6) δ 7.06 (t, IH) , 7.36 (t, IH) , 7.39 (t, IH) , 7.52 (m, 3H) , 7.62 (d, IH) , 7.72 (d, IH) , 7.82 (m, IH) , 7.90 (d, IH) , 8.05 (m, IH) , 8.76 (d, IH) , 11.5 (m, IH) , 13.02 (S, IH) ; EI-MS 372.1 (M+l) ; HPLC-Method A, Rt • 2.93 min.
Example 64 (5-Trifluorome hyl-Iff-indazol-3 -yl) - [2- (2- t ifluorometh l-phenyl) -quinazolin-4-yl] -amine (11-64) : Prepared in DMF (57% yield) as yellow solid. 1HNMR (500 MHz, DMSO-d6) δl3.4 (s, br, IH) , 11.4 (br, IH) , 8.72 (d, IH) , 8.12 (s, IH) , 7.98 (t, IH) , 7.83 (d, IH) , 7.76 (d, IH) , 7.73 (dd, IH) , 7.60 (m, 4H) , 7.52 (d, IH) ppm; LC-MS (ES+) 474.12 (M+H), (ES-) 472.17 (M-H); HPLC-Method A, Rt 3.25 min.
Example 65 (4 -Trifluoromethyl-Iff-indazol-3 -yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin.-4-yl] -amine (11-65) :
Prepared in DMF (8% yield) as yellow solid. XHNMR (500 MHz, DMSO-d6) δl3.7 (s, br, IH) , 11.2 (br, IH) , 8.70 (d, IH) , 8.05 (s, IH) , 7.85 (m, 3H) , 7.65 (m, 4H) , 7.51 (m, 2H) ppm; LC-MS (ES+) 474.13 (M+H), (ES-) 472.17 (M-H); HPLC-Method A, Rt 3.15 min.
Example 66 [2- (2, 6-Dichloro-phenyl) -quinazolin-4-yl] - (lff- indazol-3-yl) -amine (11-66): Prepared in DMF (30% yield) as yellow solid. XHNMR (500 MHz, -DMSO-d6) δ 12.9 (s, IH) , 11.1 (s, IH) , 8.69 (d, IH) , 7.95 (t, IH) , 7.82 (d, IH) , 7.73 (t, IH) , 7.56 (d, IH) , 7.47 (s, IH) , 7.45 (s, IH) , 7.39 (m, 2H) , 7.26 (t, IH) , 6.92 (t, IH) ppm; LC-MS (ES+) 406.11 (M+H), (ES-) 404.12 (M-H); HPLC-Method A, Rt 3.00 min.
Example 67 (Iff-indazol-3 -yl) - [2- (2-methyl-phenyl) - quinazolin-4-yl] -amine (11-67): Prepared in 55% yield.
XHNMR (500MHz, DMSO-d6) δ 2.15 (s, 3H) , 7.09 (t, IH) , 7.26 (d, IH) , 7.31 (t, IH) , 7.39 (t, IH) , 7.42 (m, IH) , 7.55 (d IH) , 7.64 (d, IH) , 7.74 (d, IH) , 7.89 (m, IH) , 7.96 (d, IH) , 8.10 (m, IH) , 8.81 (d, IH) , 12.0 ( , IH) , 13.18 (s, IH) ; EI-MS 352.2 (M+l) ; HPLC-Method A, Rt 2.93 min.
Example 68 (7-Tri luoromethyl-Iff-indazol-3 -yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4 -yl] -amine (11-68):
Prepared in DMF (75% yield) as yellow solid. 1HNMR (500 MHz, DMS0-d6) δl3.5 (s, br, IH) , 11.2 (s, br, IH) , 8.68 (d, IH) , 7.97 (t, IH) , 7.92 (d, IH) , 7.82 (d, IH) , 7.74 (t, IH) , 7.70 (d, IH) , 7.68 (d, IH) , 7.64 (m, 2H) , 7.57 (m, IH) , 7.14 (t, IH) ppm; LC-MS (ES+) 474.11 (M+H), (ES-) 472.14 (M-H); HPLC-Method A,' Rt 3.24 min.
Example 69 (6-Tri luoromethyl-Iff-indazol-3 -yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4 -yl] -amine (11-69) : Prepared by Method B in DMF (78% yield) as yellow solid. XHNMR (500 MHz, DMSO-d6) δ l3.4 (s, br, IH) , 11.1 (s, br, IH) , 8.67 (d, IH) , 7.95 (t, IH) , 7.82 (m, 3H) , 7.72 (m, 2H) , 7.63 (m, 2H) , 7.57 (t, IH) , 7.23 (d, IH) ppm; LC-MS (ES+) 474.12 (M+H), (ES-) 472.15 (M-H); HPLC-Method A, Rt 3.28 min.
Example 70 (5-Nitro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-70) :
Prepared in DMF (82% yield) as yellow solid. ^ΗNMR (500 MHz, DMSO-d6) δl3.6 (s, br, IH) , 11.4 (s, br, IH) , 8.75 (s, IH) , 8.72 (d, IH) , 8.09 (dd, IH) , 7.98 (t, IH) , 7.83 (d, IH) , 7.75 (t, IH) , 7.70 (m, 2H) , 7.61 (m, 3H) ppm;
LC-MS (ES+) 451.14 (M+H), (ES-) 449.12 (M-H); HPLC-Method
A, Rt 3.02 min.
Example 71 (5,7-Difluoro-Iff-indazol-3 -yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-71) :
Prepared in DMF (60% yield) as yellow solid. 1HNMR (500 MHz, DMS0-d6) δl3.7 (s, br, IH) , 11.2 (s, br, IH) , 8.73 (d, IH) , 8.03 (t, IH) , 7.88 (d, IH) , 7.80 (m, 2H) , 7.70 (m, 3H) , 7.32 (m, 2H) ppm; LC-MS (ES+) 442.14 (M+H), (ES- ) 440.14 (M-H); HPLC-Method A, Rt 3.11 min.
Example 72 (4-Pyrrol-l-yl-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin- -yl] -amine (11-72) :
Prepared in DMF (33% yield) as yellow solid. XHNMR (500
MHz, DMSO-d6) δl3.4 (s, br, IH) , 11.0 (s, br, IH) , 8.53
(d, IH) , 7.98 (t, IH) , 7.75 (m, 4H) , 7.62 (m, 2H) , 7.52 (d, IH) , 7.43 (t, IH) , 7.05 (d, IH) , 6.80 (s, 2H) , 5.61
(s, 2H) ppm; LC-MS (ES+) 471.18 (M+H), (ES-) 469.18 (M-
H) ; HPLC-Method A, Rt 3.12 min.
Example 73 (5-Amino-Iff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-73): A solution of compound 11-70 (70 mg, 0.16 mmol) in MeOH (2 mL) was treated with Raney Ni until solution was colorless (about 1.5 g Raney Ni was added) . After stirring at room temperature for 40 min, the mixture was filtered through celite, the resulting celite was washed with MeOH (5 times) , and the solvent was evaporated in vacuo to provide a crude product that was then purified by HPLC to give the title compound as a yellow solid (10 mg, 15%) . m.p. 221-223°C; ^ΗNMR (500 MHz, DMSO-d6) δl3.2 (s, br, IH) , 10.7 (s, br, IH) , 9.80 (br, 2H) , 8.68 (d, IH) , 7.97 (t, IH) , 7.87 (d, IH) , 7.75 (m, 2H) , 7.65 ( , 5H) , 7.30 (d, IH) ppm; MS (ES+) 421.16 (M+H), (ES-) 419.17 (M-H); HPLC-Method A, Rt 2.41 min.
Example 74 [2- (2-Chloro-phenyl) -quinazolin-4-yl] - (7- fluoro-Iff-indazol-3 -yl) -amine (11-74): Prepared in DMF (35% yield) as yellow solid. XHNMR (500 MHz, DMS0-d6) δl3.7 (s, IH) , 11.7 (s, br, IH) , 8.80 (d, IH) , 8.15 (t, IH) , 7.99 (d, IH) , 7.88 (t, IH) , 7.68 (d, IH) , 7.60 (m, 2H) , 7.53 (t, IH) , 7.46 (t, IH) , 7.25 (dd, IH) , 7.04 (m, IH) ppm; LC-MS (ES+) 390.16 (M+H); HPLC-Method A, Rt 3.00 min.
Example 75 [2- (2-Chloro-phenyl) -quinazolin-4-yl] - (5- fluoro-lH-indazol-3 -yl) -amine (11-75) : Prepared in DMF. aHNMR (500 MHz, DMSO-d6) δl3.2 (s, IH) , 11.7 (s, br, IH) , 8.80 (d, IH) , 8.10 (t, IH) , 7.91 (m, 2H) , 7.70 (d, IH) , 7.58. (m, 4H) , 7.50 (t, IH) , 7.29 (t, IH) ppm; LC-MS (ES+) 390.17 (M+H); HPLC-Method A, Rt 3.00 min.
Example 76 [2- (2-Chloro-phenyl) -quinazolin-4-yl] - (5,7- difluoro-lff-indazol-3-yl) -amine (11-76): Prepared in DMF (55% yield) as yellow solid. XHNMR (500 MHz, DMS0-d6) δl3.8 (s, IH) , 11.5 (s, br, IH) , 8.76 (d, IH) , 8.08 (t, IH) , 7.93 (d, IH) , 7.84 (t, IH) , 7.64 (d, IH) , 7.55 (d, IH) , 7.50 (t, IH), 7.44 (m, 2H) , 7.36 (t, IH) ppm; LC-MS (ES+) 408.15 (M+H), (ES-) 406.17 (M-H); HPLC-Method A, Rt 3.08 min.
Example 77 [2- (2-Chloro-phenyl) -quinazolin-4-yl] - (5- trifluoromethyl-Iff-indazol-3-yl) -amine (11-77): Prepared in DMF ( 66% yield) as yellow solid. 1HNMR (500 MHz, DMSO- d6) δl3.5 (S, IH) , 11.4 (s, br, IH) , 8.79 (d, IH) , 8.29 (S, IH) , 8.07 (t, IH) , 7.93 (d, IH) , 7.84 (t, IH) , 7.72 (d, IH) , 7.63 (d, 2H) , 7.53 (d, IH) , 7.48 (t, IH) , 7.36 (t, IH) ppm; LC-MS (ES+) : m/e= 440.16 (M+H); (ES-): m/e= 438.18 (M-H); HPLC-Method A, Rt 3.22 min.
Example 78 [2- (2 -cyano-phenyl) -quinazolin-4-yl] - (lff- indazol-3-yl) -amine (11-78): Prepared in 13% yield. 1H- NMR ('500 MHZ, DMSO) δ 12.9 (br, IH) , 10.8 (br, IH) , 8.73 (br s, IH) , 7.97 (m, 4H) , 7.74 (m, IH) , 7.5 (m, 4H) , 7.42 (m, IH) , 7.08 (m, IH) ppm; MS (FIA) 363.2 (M+H); HPLC- Method A, R 2.971 min.
Example 79 (5-Bromo-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-79):
Prepared in DMF (64% yield) as yellow solid. 1HNMR (500 MHz, DMS0-d6) δl3.4 (s, IH) , 11.6 (s, br, 1H), .8.93 (d, IH) , 8.21 (t, IH) , 8.14 (s, IH) , 8.05 (d, IH) , 7.95 (m, 4H) , 7.86 (t, IH) , 7.65 (d, IH) , 7.59 (d, IH) ppm; MS (ES+) 486.10 (M+H), (ES-) 484.09 (M-H); HPLC-Method A, Rt 3.22 min.
Example 80 (6-Chloro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-80) : Prepared in DMF (94% yield) as yellow solid. αHNMR (500 MHz, DMS0-d6) δl3.1 (s, IH) , 11.2 (s, br, IH) , 8.73 (d, IH) , 8.03 (t, IH) , 7.87 (d, IH) , 1 . 19 (m, 2H) , 7.73 ( , 2H) , 7.67 (m, 2H) , 7.58 (s, IH) , 7.04 (dd, IH) ppm. LC-MS (ES+) 440.14 (M+H),' (ES-) 438.16 (M-H); HPLC-Method A, Rt 3.25 min.
Example 81 (7-Fluoro-6-trifluoromethyl-lff-indazol-3-yl) - [2- (2 -trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (II-
81) : Prepared in DMF (30% yield) as yellow solid. ΗNMR (500 MHz, DMS0-d6) δ 13.9 (s, IH) , 11.0 (s, br, IH) , 8.64 (d, IH) , 7.94 (t, IH) , 7.81 (d, IH) , 7.71 (m, 2H) , 7.60 (m, 4H) , 7.20 (dd, IH) ppm. LC-MS (ES+) 492.18 (M+H), (ES-) 490.18 (M-H); HPLC-Method A, Rt 3.44 min.
Example 82 (6-Bromo-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-82) :
Prepared in DMF (40% yield) as yellow solid. ^ΗNMR (500 MHz, DMSO-d6) δl3.1 (s, IH) , 11.2 (s, br, IH) , 8.73 (d, IH) , 8.03 (t, IH) , 7.87 (d, IH) , 7.80 (m, 2H) , 7.73 (m, 3H) , 7.67 (m, IH) , 7.61 (d, IH) , 7.15 (dd, IH) ppm; MS (ES+) 486.07 (M+H); HPLC-Method A, Rt 3.28 min.
Example 83 [2- (2, 4-Bis-trifluoromethyl-phenyl) - quinazolin-4 -yl] - (5,7-difluoro-lff-indazol-3-yl) -amine
(11-83) : Prepared in DMF in 28% yield. XHNMR (500MHz,
MeOH-d4) δ 8.81 (d, J=8.4Hz, IH) , 8.35-8.20 (m, 3H) , 8.19-7.96 (m, 3H) , 7.40-7.34 (m, IH) , 7.29-7.14 (m, IH) ; LC-MS (ES+) 510.14 (M+H); HPLC-Method C, Rt 8.29 min.
Example 84 (5,7-Difluoro-lff-indazol-3-yl) - [2- (4-fluoro-2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-84) :
Prepared in 48% yield. ^ΗNMR (500MHz, MeOH-d4) δ8.74- 8.63 (m, IH) , 8.23-8.10 (m, IH) , 7.99-7.90 (m, 2H) , 7.89- 7.80 (m, IH) , 7.71-7.61 (m, IH) , 7.61-7.50 (m, IH) , 7.24- 7.15 (m, IH) , 7.14-7.02 (m, IH) ; LC-MS (ES+) 460.14 (M+H); HPLC-Method C, Rt 7.59 min.
Example 85 [2- (2-Bro o-phenyl) -quinazolin-4-yl] - (5,7- difluoro-lff-indazol-3-yl) -amine (11-85): Prepared in THF (21% yield). XHNMR (500MHz, MeOH-d4) δ8.81 (d, J=8.4Hz, IH) , 8.35-8.20 (m, 3H) , 8.19-7.96 (m, 3H) , 7.40-7.34 (m, IH) , 7.29-7.14 (m, IH) ; LC-MS (ES+) 510.14 (M+H); HPLC- Method C, Rt 8.29 min.
Example 86 (5, 7-Difluoro-lff-indazol-3-yl) - [2- (5-fluoro-2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-86) : Prepared in THF (26% yield) . XHNMR (500MHz, MeOH-d4) δ8.62 (d, J=8.4Hz, IH) , 8.16-8.02 (m, IH) ,, 7. 6-7.73 (m, 3H) , 7.59-7.48 (m, IH) , 7.48-7.35 (m, IH) , 7.21-7.09 (m, IH) , 7.09-6.89 (m, IH) ; LC-MS (ES+) 460.16 (M+H); HPLC- Method C, Rt 7.28 min. Example 87 [2- (2,4-Dichloro-phenyl) -quinazolin-4-yl] - (5,7-Difluoro-lff-indazol-3-yl) -amine (11-87): Prepared in THF (16% yield). 1HNMR (500MHz, MeOH-d4) δ 8.81 (d, J=8.4Hz, IH) , 8.35-8.20 (m, 3H) , 8.19-7.96 (m, 3H) , 7.40- 7.34 (m, IH) , 7.29-7.14 (m, IH) ; LC-MS (ES+) 510.14 (M+H); HPLC-Method C, Rt 8.29 min.
Example 88 [2- (2-Chloro-5-trifluoromethyl-phenyl) - quinazolin-4 -yl] - (5,7-Difluoro-lH-indazol-3-yl) -amine (11-88): Prepared in THF (33% yield). αHNMR (500MHz,
DMSO-d6) δ 10.76 (s, IH) , 8.66 (d, J=8.3Hz, IH) , 8.06- 7.84 (m, 3H) , 7.81-7.63 (m, 3H) , 7.48-7.16 (m, 2H) ; LC-MS (ES+) 476.16 (M+H); HPLC-Method C, Rt 19.28 min.
Example 89 (4-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-89) :
Prepared in NMP (79% yield) as yellow solid. 1HNMR (500 MHz, DMS0-d6) δl3.2 (s, IH) , 10.8 (s, br, IH) , 8.63 (d, IH) , 7.97 (t, IH) , 7.85 (d, IH) , 7.74 (m, 2H) , 7.64 (t, IH) , 7.57 ( , 2H) , 7.32 (m, 2H) , 6.82 (m, IH) ppm; LC-MS (ES+) 424.17 (M+H); HPLC-Method A, Rt 3.14 min.
Example 90 (Iff-Indazol-3 -yl) - [8-methoxy-2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-90) : Prepared using THF as solvent to afford the title compound as a TFA salt (23% yield). HPLC-Method A, Rt 2.97 min (95%); XHNMR (DMS0-d6, 500 MHz) δ 12.9 (IH, bs) , 11.0 - 10.7(1H, bs) , 8.25 (IH, m) , 7.75-7.50 (8H, s) , 7.30 (IH, m) , 6.90 (IH, m) , 4.0 (3H, s) ; MS (m/z) 436.2 (M+H).
Example 91 (5-Fluoro-lff-indazol-3-yl) - [8-methoxy-2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-91)
Prepared using TFA as solvent to afford the title compound as a TFA salt (23% yield) . HPLC-Method A, Rt 3.10 min. (99%) ; 1HNMR (DMSO-d6, 500 MHz) : 13.0 (IH, bs) , 11.0 - 10.7(1H, bs) , 8.25 (IH, m) , 7.75-7.50 (7H, m) , 7.35 (IH, m) , 7.25 (IH, m) , 4.0 (3H, s) ; MS (m/z) 454.2
(M+H) .
Example 92 (7-Fluoro-lff-indazol-3-yl) - [8-methoxy-2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (ΪI-92) : Prepared using THF as solvent to afford the title compound as a TFA salt (98 mg, 58% yield) . HPLC-Method ' A, Rt 3.20 min (92%); XHNMR (DMSO-d6, 500 MHz) δ 13.45
(IH, bs) , 11.0 - 10.7(1H, bs) , 8.25 (IH, m) , 7.75-7.60
(5H, m) , 7.50 (IH, m) , 7.40 (IH, m) , 7.15 (IH, m) , 6.95
(IH, ) 4.0 (3H, s) ; MS (m/z) 454.2 (M+H).
Example 93 (5,7-Difluoro-lff-indazol-3-yl) - [8-methoxy-2- (2 -trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (II-
93) : Prepared using THF as solvent to afford the title compound as a TFA salt (36% yield) . HPLC-Method A, Rt 3.27 min. (95%); 1HNMR (DMSO-d6, 500 MHz): 13.65 (IH, bs) , 11.0 - 10.7(1H, bs) , 8.22 (IH, m) , 7.75-7.60 (5H, m) ,
7.40 (IH, m) , 7.35 (IH, m) , 7.19 (IH, m) , 4.0 (3H, s); MS (m/z) 472.-2 (M+H) .
Example 94 [2- (2-Chloro-pyridin-3-yl) -quinazolin-4-yl] - (5,7-Difluoro-lff-indazol-3-yl) -amine (11-94): Prepared in DMF. 1HNMR (500MHz, DMS0-d6) δ 13.62 (br S, IH, 11.06- 10.71 (m, IH) , 8.16-7.70 (m, 4H) , 7.60-7.09 (m, 3H) ; LC- MS (ES+) 409.14 (M+H); HPLC-Method A, Rt 2.89 min.
Example 95 [2- (2-Chloro-4-nitro-phenyl) -quinazolin-4 -yl] - (5,7-difluoro-lff-indazol-3-yl) -amine (11-95): Prepared in THF. XHNMR (500MHZ, DMS0-d6) δ 13.35 (s, IH) , 10.74 (s, IH) , 8.67 (d, J=8.4HZ, IH) , 8.29 (d, J=2.05HZ, IH) , 8.18- 8.08 (m, IH) , 8.07-7.60 (m, 4H) , 7.53-7.10 (m, 2H) . LC- MS (ES+) 453.15 (M+H); HPLC-Method D, Rt 3.63 min.
Example 96 [2- (4-Amino-2-chloro-phenyl) -quinazolin-4-yl] - (5,7-Difluoro-lff-indazol-3-yl) -amine (11-96):
A solution of compound 11-95 (8mg, 0.018mmol) and tin chloride dihydrate (22mg, O.lmmol) in ethanol (2mL) was heated at 100°C for 24h. The reaction was diluted with EtOAc (lOmL) , washed with IN NaOH solution (2xl0mL) , brine, and dried over anhydrous sodium sulfate to afford the crude product. Purification was achieved by flash chromatography on silica gel (eluting with 1-3% MeOH in CH2C12.) The title compound was isolated as pale yellow solid (1.2mg, 16% yield). LC-MS (ES+) 423.12 (M+H), HPLC-Method C, Rt 13.78 min.
Example 97 (4,5, 6,7-Tetrahydro-lff-indazol-3-yl) - [2- (2-trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-97) : Prepared in 34% yield. 1HNMR (500MHz, DMS0-d6) δ 1.58 (m, 2H) , 1.66 (m, 2H) , 2.24 (m, 2H) , 2.54 (m 2H) , 7.63 (m, 3H) , 7.71 (t, IH) , 7.75 (d, IH) , 7.78 (d, IH) , 7.85 (t, IH) , 8.53 (d, IH) , 9.99 (s, IH) , 12.09 (s, IH) ; EI-MS 410.2 (M+l) ; HPLC-Method A, Rt 3.05 min.
Example 98 (lff-Pyrazolo [4,3-b]pyridin-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-98) :
Prepared in DMF (37% yield) as yellow solid. 1HNMR (500 MHz, DMSO-d6) δ l3 .1 (s, br, IH) , 11.2 (s , br, IH) , 8 . 73 (d, IH) , 8 . 54 (dd, IH) , 8 . 12 (d, IH) , 8 . 06 (t , IH) , 7. 90 (d, IH) , 7 . 84 (t , IH) , 7 . 75 (d, IH) , 7 . 69 (m, 2H) , 7 .65 (t , IH) , 7 .47 (dd, IH) ppm; LC-MS (ES+) 407. 18 (M+H) ; HPLC-Method A, Rt 2 .77 min . Example 99 (lff-Pyrazolo[3,4-b]pyridin-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (11-99) :
Prepared in DMF (45% yield) . 1H MR (500 MHz, DMSO-d6) δl3.5 (s, br, IH) , 11.3 (s, br, IH) , 8.78 (d, IH) , 8.49 (d, IH), 8.17 (d, IH) , 8.03 (t, IH) , 7.89 (d, IH) , 7.80 (m, 2H) , 7.74 (m, 2H) , 7.68 (m, IH) , 7.08 (dd, IH) ppm. MS (ES+) 407.16 (M+H), (ES-) 405.16 (M-H); HPLC-Method A, Rt 2.80 min.
Example 100 (6-Methyl-lff-pyrazolo[3,4-b]pyridin-3-yl) - [2- (2-trifluoromethyl-phenyl) -quinazolin-4-yl] -amine (II- 100) : Prepared in DMF (11% yield) . 1ΕDMR (500 MHz, DMSO- d6) δl3.2 (s, br, IH) , 10.8 (s, br, IH) , 8.57 (d, IH) , 7.95 (t, IH) , 7.82 (d, IH) , 7.72 (t, IH) , 7.65 (m, 2H) , 7.58 ( , 2H) , 2.44 (s, 3H, buried by DMSO) , 2.20 (s, 3H) ppm. LC-MS (ES+) 435.22 (M+H), (ES-) 433.25 (M-H); HPLC- Method A, Rt 2.94 min.
Example 101 (6-Oxo-5-phenyl-5, 6-dihydro-lH-pyrazolo [4,3- c]pyridazin-3-yl) - [2- (2 -trifluoromethyl-phenyl) - quinazolin-4-yl] -amine 11-101: Prepared in DMF (6% yield). 1HNMR (500 MHz, DMSO-d6) δl2.6 (s, IH) , 11.0 (s, br, IH) , 8.60 (d, IH) , 7.95 (t, IH) , 7.88 (d, IH) , 7.80 (d, IH) , 7.68 (m, 4H) , 7.40 (s, 3H) , 7.22 (s, 2H) , 6.61 (s, IH) ppm. LC-MS (ES+) 500.21 (M+H), (ES-) 498.16 (M- H) ; HPLC-Method A, Rt 3.00 min.
Example 103 [6-Methyl-2- (2-trifluoromethoxy-phenyl) - pyrimidin-4-yl] - (5-phenyl-2H-pyrazol-3-yl) -amine (II- 103): MS 412.13 (M+H); HPLC-Method E Rt 1.248 min.
Example 104 (5-Furan-2-yl-2H-pyrazol-3-yl) - [6-methyl-2- (2-trifluoromethoxy-phenyl) -pyrimidin-4-yl] -amine (II- 104); MS 402.12 (M+H); HPLC-Method E, Rt 1.188 min. Example 105 [6-Ethyl-2- (2-trifluoromethoxy-phenyl) - pyrimidin-4-yl] - (5-methyl-2H-pyrazol-3-yl) -amine (II- 105): MS 364.14 (M+H); HPLC-Method E, Rt 1.112 min.
Example 106 [2- (2-Chloro-phenyl) -pyrido [2, 3-d] pyrimidin- 4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (11-106) : XHNMR (500 MHz, DMSO) δl2.23 (s, IH) , 10.78 (s, IH) , 7.73-7.47 (m, 7H) , 6.72 (S, IH) , 2.21 (s, 3H) . MS: (M+H) 337.02. HPLC-Method A, Rt 2.783 min.
Example 107 (5-Fluoro-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -6, 7 -dihydro-5H- cyclopentapyrimidin-4-yl] -amine (11-107) : Prepared in 68% yield. XHNMR (500MHz, DMSO-d6) δ 2.16 (t, 2H) , 2.88 (m, 2H) , 2.98 (t, 2H) , 7.21 (td, IH) , 7.29 (dd, IH) , 7.50 (dd, IH) , 7.65 (t, IH) , 7.67 (t, IH) , 7.73 (t, IH) , 7.79 (d, IH) , 10.22 (br. s, IH) , 12.99 (br. s, IH) ; EI-MS 414.2 (M+H) ; HPLC-Method A, Rt 2.92 min.
Example 108 (lff-Indazol-3-yl) - [2- (2-trifluoromethyl- phenyl) -pyrido [2, 3-d] yrimidin-4-yl] -amine (11-108) : HPLC-Method A, Rt 2.78 min. (95%); 1HNMR (DMSO-d6, 500 MHz): 12.95 (IH, bs) , 11.45 δ 11.15(1H, bs) , 9.20 (2H, m) , 7.85-7.70 -(2H, m) , 7.70-7.55 (4H, m) , 7.50 (IH, m) , 7.35 (IH, m) , 7.05 (IH, m) ; MS (m/z) 407.03 (M+H).
Example 109 (5,7-Difluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -pyrido [2, 3-d] yrimidin-4-yl] - amine (11-109) : Yellow, di-TFA salt (25% yield) . HPLC (Method A) 3.10 min. (95%); 2HNMR (DMSO-d6, 500 MHz): 13.8-13.6 (IH, bs) , 11.4 - 11.2 (IH, bs) , 9.15 (2H, m) , 7.85-7.75 (2H, m) , 7.75-7.62 (3H, m) , 7.32 (2H, m) ; MS (m/z) 442.98 (M+H) . Example 110 [2- (2-Chloro-phenyl) -pyrido [2, 3-d] pyrimidin- 4-yl] - (Iff-indazol-3-yl) -amine (11-110): Prepared from 2- aminonicotinic acid and 2-chlorobenzoyl chloride afforded the title compound as a di-TFA salt (28% yield) . HPLC- Method A, Rt 2.85 min. (95%); XHNMR (DMSO-d6, 500 MHz): 12.90 (IH, S) , 11.10 - 10.90 (IH, bs) , 9.05 (2H, m) , 7.75-7.60 (2H, m) , 7.51 (IH, m) , 7.45-7.25 (5H, m) , 6.95 (IH, m) ; MS (m/z) .372.99 (M+H) .
10
Example 111 (5-Fluoro-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5, 6,7, 8, 9, 10-hexahydro- cyclooctapyrimidin-4-yl] -amine (11-111). Prepared in 43% yield. XHNMR (500MHz, DMSO-d6) δ 1.46 (m, 2H) , 1.53 (m, 15. 2H) , 1.77 (m, 4H) , 2.95 (m, 2H) , 3.04 (m, 2H) , 7.22 (m, . 2H) , 7.50 (dd, IH) , 7.72 (m, 3H) , 7.80 (d, IH) , 10.5 (m, IH) , 13.05 (br s, IH) ; EI-MS 456.2 (M+H); HPLC-Method C, Rt 11.93 min.
20 Example 112 [2- (2-Chloro-phenyl) -6, 7-dihydro-5ff- cyclopentapyrimidin-4-yl] - (5-fluoro-lff-indazol-3-yl) - amine (11-112): Prepared in 67% yield. XHNMR (500MHz, . DMSO-d6) δ2.18 (m, 2H) , 2.89 (m, 2H) , 3.02 (t, 2H) , 7.24 (td, IH) , 7.42 (m, 2H) , 7.49 (td, IH) , 7.52 (dd, IH) ,
25 7.54 (d, IH) , 7.57 (dd, IH) , 10.50 (br. s, IH) , 13.06 (br. s, IH) ; EI-MS 380.1 (M+l) ; HPLC-Method C, Rt 9.68 min.
Example 113 (IH-Indazol-3 -yl) - [2- (2-trifluoromethyl- 0 phenyl) -6,7-dihydro-5H-cyclopentapyrimidin-4-yl] -amine
(11-113) : Prepared in 37% yield. XHNMR (500MHz, DMS0-d6) δ 2.65 (m, 2H) , 2.85 (m, 2H) , 2.99 (t, 2H) , 7.02 (t, IH) , 7.32 (t, IH) , 7.47 (d, IH) , 7.55 (d, IH) , 7.68 (t, IH) , 7.74 (t, IH) , 7.80 (d, IH) , 10.37 (br. s, IH) , 12.91 (br. s, IH) ; EI-MS 396.1 (M+H); HPLC-Method B, Rt 9.88 min.
Example 114 (7-Fluoro-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -6, 7-dihydro-5ff- cyσlopentapyrimidin-4-yl] -amine (11-114): Prepared in 40% yield. 1HNMR (500MHz, DMS0-d6) δ 2.15 (m, 2H) , 2.87 (m, 2H) , 2.97 (t, 2H) , 6.99 (td, IH) , 7.17 (dd, IH) , 7.38 (d, IH) , 7.65 (m, 2H) , 7.71 (t,.lH), 7.78 (d, IH) , 10.21 (br. S, IH) , 13.40 (br. s, IH) ; EI-MS 414.1 (M+H); HPLC-Method C, Rt 9.99 min.
Example 115 (5,7-Difluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -6, 7-dihydro-5ff- cyclopentapyrimidin-4-yl] -amine (11-115) : Prepared according to Method C in 52% yield. XHNMR (500MHz, DMSO- d6) δ 2.16 (m, 2H) , 2.89 ( , 2H) , 2.97 (t, 2H) , 7.19 (dd, IH) , 7.29 (td, IH) , 7.63 (t, IH) , 7.66 (d, IH) , 7.71 (t, IH) , 7.78 (d, IH) , 10.16 (br. s, IH) , 13.55 (br. s, IH) ; EI-MS' 432.1 (M+H); HPLC-Method C, Rt 10.09 min.
Example 116 [2- (2-Chloro-phenyl) -6, 7-dihydro-5ff- cyclopentapyrimidin-4-yl] - (lff-indazol-3-yl) -amine (II- 116) : Prepared in 56% yield. 1HNMR (500MHz, DMS0-d6) δ 2.16 (m, 2H) , 2.85 (m, 2H) , 3.01 (t, 2H) , 7.06 (t, IH) , 7.34 (t, IH) , 7.40 (t, IH) , 7.48 (m, 2H) , 7.53 (d, IH) , 7.56 (d, IH) , 7.63 (d, IH) , 10.39 (br. s, IH) , 12.91 (s, IH) ; EI-MS 362.1 (M+H); HPLC-Method A, Rt 3.09 min.
Example 117 [2- (2-Chloro-phenyl) -6, 7-dihydro-5ff- cyclopentapyrimidin-4-yl] - (7-fluoro-lff-indazol-3-yl) - amine (11-117) : Prepared in 63% yield. XHNMR (500MHz, DMS0-d6) δ 2.15 (m, 2H) , 2.87 (m, 2H) , 3.00 (t, 2H) , 7.01 (td, IH) , 7.19 (dd, IH) , 7.39 (t, IH) , 7.45 (m, 2H) , 7.51 (d, IH) , 7.55 (d, IH) , 10.35 (br. S, IH) , 13.45 (br. S, IH) ; EI-MS 380.1 (M+H); HPLC-Method A, Rt Rt 3.15 min.
Example 118 [2- (2-Chloro-phenyl) -6, 7 -dihydro-5ff- σyclopentapyrimidin-4-yl] - (5,7-difluoro-Iff-indazol-3 -yl) - amine (11-118) : Prepared in 60% yield. 1HNMR (500MHz, DMSO-d6) δ2.18 (m, 2H) , 2.91 (m, 2H) , 3.01 (t, 2H) , 7.32 (t, IH) , 7.33 (td, IH) , 7.41 (t, IH) , 7.48 (t, IH) , .7.53 (d, IH) , 7.55 (dd, IH) , 10.35 (br. s, IH) , 13.45 (br. s, IH) ; EI-MS 398.1 (M+H); HPLC-Method A, Rt Rt 3.24 min.
Example 119 (Iff-Indazol-3 -yl) - [2- (2 -trifluoromethyl- phenyl) -5,6,7,8,9,10-hexahydro-cyclooctapyrimidin-4-yl] - amine (11-119) : Prepared in 36% yield. XHNMR (500MHz, DMSO-d6) δ 1.47 ( , 2H) , 1.53 (m, 2H) , 1.78 (m, 4H) , 2.96 (m, 2H) , 3.06 (t, 2H) , 7.03 (t, IH) , 7.47 (t, IH) , 7.72 (d, IH) , 7.73 (d, IH) , 7.72 (m 3H) , 7.81 (d, IH) , 10.52 (m, IH) , 12.97 (br. s, IH) ; EI-MS 438.2 (M+l) ; HPLC-
Method A, Rt 3.37 min.
Example 120 (7-Fluoro-lH-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5,6,7,8, 9, 10-hexahydro- cyclooctapyrimidin-4-yl] -amine (11-120): Prepared in 40% yield. XHNMR (500MHz, .DMSO-d6) δ 1.46 (m, 2H) , 1.52 (m, 2H) , 1.77 ( , 4H) , 2.94 (m, 2H) , 3.04 (m, 2H) , 7.00 (td, IH) , 7.17 (dd, IH) , 7.30 (d, IH) , 7.70 (m, 3H) , 7.79 (d, IH) , 10.5 (m, IH) , 13.49 (br s, IH) ; EI-MS 456.1 (M+H); HPLC-Method A, Rt 3.43 min.
Example 121 (5, 7-Difluoro-Iff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -5,6,7, 8, 9,10-hexahydro- cyclooctapyrimidin-4-yl] -amine (11-121): Prepared in 48% yield. XHNMR (500MHz, DMSO-d6) 6 1.46 (m, 2H) , 1.52 (m, 2H) , 1.77 (m, 4H) , 2.95 (m, 2H) , 3.03 (m, 2H) , 7.14 (d, IH) , 7.30 (t, IH) , 7.73 ( , 3H) , 7.80 (d, IH) , 10.5 (m, IH) , 13.62 (br. s, IH) ; EI-MS 475.1 (M+l) ; HPLC-Method A, Rt 3.52 min.
Example 122 [6-Cyclohexyl-2- (2-trifluoromethyl-phenyl) - pyrimidin-4-yl] - (Iff-indazol-3 -yl) -amine (11-122):
Prepared in 45% yield. XHNMR (500 MHz, CDC13) δ 1.30 (2H, m) , 1.46 (2H, m) , 1.65 (2H, m) , 1.76 (2H, m) , 1.91 (2H, m) , 2.61 (IH, br m) , 7.08 (IH, t, J=7.4 Hz), 7.27 (IH, d, J=8.0 Hz), 7.35 (IH, t, J= 7.1 Hz), 7.50 (IH, t, J=7.0 Hz), 7.58 (IH, t, J=7.4 Hz), 7.66 (3H, m) , 7.72 (IH, d, J=7.8 Hz), 8.0 (IH, br) , 9.87 (IH, br) ppm; HPLC-Method D, Rt 3.57 min; LC-MS 438.17 (M+H)+
Example 123 [6- (2-Fluoro-phenyl) -2- (2-trifluoromethyl- phenyl) -pyrimidin-4-yl] - (lH-indazol-3-yl) -amine (11-123) :
Prepared in 8% yield. XHNMR (500 MHz, CDC13) δ 7.18 (3H, m) , 7.37 (IH, m) , 7.43 (IH, t, J=7.9 Hz), 7.51 (IH, d, J=7.9 Hz), 7.55 (IH, t, J=7.6 Hz), 7.65 (IH, t, J=7.4 Hz), 7.79 (IH, d, J=7.9 Hz) , 7.85 (IH, d, J= 7.6 Hz),
8.19 (2H, m) , 8.70 (IH, d, J= 8.5 Hz) ppm; HPLC-Method D, Rt 4.93 min; LC-MS 450.13 (M+H)+
Example 124 (6-Fluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinazolin-4-yl] -amine ( I-124) .
Prepared in DMF (87% yield) as yellow solid. 1HNMR (500 MHz, DMSO-d6) δl3.0 (s,.lH), 11.1 (s, br, IH) , 8.66 (d, IH) , 7.95 (t, IH) , 7.80 (d, IH) , 7.72 (m, 2H) , 7.62 (m, 4H) , 7.21 (dd, IH) , 6.84 (td, IH) ppm. LC-MS (ES+) 424.15 (M+H); HPLC-Method A, Rt 3.05 min.
Example 125 3- [2- (2 -Trifluoromethyl-phenyl) -quinazolin-4 - ylamino] -Iff-indazole-5-carboxylic acid methyl ester (II- 125): To a solution of compound 11-79 (100 mg 0.21 mmol) in DMF (2 mL) was added MeOH (1 mL) , DIEA (54 UL, 0.31 mmol) and PdCl2(dppf) (4 mg, 0.005 mmol). The flask was flushed with CO three times and then charged with a CO balloon. The reaction mixture was heated at 80°C for 14 h then poured into water. The resulting precipitate was collected and washed with water. The crude product was then purified first by flash column (silica gel, 50% •ethyl acetate in hexanes) then by preparative HPLC to to afford 11-125 (32%) as yellow solid. XHNMR (500 MHz, DMS0-d6) δl3.3 (s, IH) , 11.3 (s, br, IH) , 8.70 (d, IH) , 8.36 (s, IH) , 7.97 (t, IH) , 7.82 (m, 2H) , 7.71 (m, 3H) , 7.58 (m, 2H) , 7.51 (d, IH) , 3.75 (s, 3H) ppm; LC-MS (ES+) 464.13 (M+H); HPLC-Method A, Rt 3.12 min.
Example 208 (5-Methyl-2ff-pyrazol-3-yl) - [2- (2-naphthyl-1- yl) -quinazolin-4 -yl] -amine (11-208): aHNMR (500 MHz, DMSO- d6) δ8.92 (s, IH) , 8.73 (m, IH) , 8.39 ( , IH) , 8.09 (m, 2H) , 7.95 (m, 3H) , 7.62 (m, 3H) , 6.78 (s, IH) , 2.32 (s, 3H) ; MS 352.2 (M+H) .
Example 209 [2- (2-Chloro-phenyl) r-pyrido [2, 3-d] yrimidin- 4-yl] - (7-fluoro-lff-indazol-3-yl) -amine (11-214): Prepared from 4-Chloro-2- (2-chloro-phenyl) -pyrido [2, 3-d] pyrimidine (100 mg, 0.36mmol) and 7-Fluoro-lff-indazol-3-ylamine (108mg, 0.72mmol). Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (93 mg, 46% yield). HPLC-Method A, Rt 3.04 min; XH NMR (DMSO, 500 MHz): δ 13.67 (IH, s) , 11.40-11.25 (IH, bs) , 9.35- 9.25 (2H, m) , 7.95 (IH, m) , 7.80-7.47 (5H, m) , 7.35(1H, m) , 7.15 (IH, m) ; MS (m/z), MH+ 391.1.
Example 210 [2 - (2 -Chloro-phenyl) -pyrido [2 , 3 - d] pyrimidin - 4-yl] - (5- fluoro-lff-indazol- 3-yl) -amine (11-215) : Prepared from 4 -Chloro- 2 - (2-chloro-phenyl) -pyrido [2 , 3 -d] pyrimidine (100 mg, 0.36mmol) and 5-Fluoro-Iff-indazol-3- ylamine (108mg, 0.72mmol). Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (45 mg, 22% yield). HPLC-Method A, Rt 3.00 min; XH NMR (DMSO, 500 MHz): δ 13.0 (IH, s) , 10.90(1H, bs) , 9.15-9.05 (2H, m) , 7.70 (IH, m) , 7.60-7.30 (6H, m) , 7.20 (IH, m) ; MS (m/z) , MH+ 391.1.
Example 211 [2- (2-Chloro-phenyl) -pyrido [2, 3-d] yrimidin- 4-yl] - (5, 7-difluoro-lff-indazol-3-yl) -amine (11-216):
Prepared from 4-Chloro-2- (2 -chloro-phenyl) -pyrido [2, 3- d] pyrimidine (100 mg, 0.36mmol) and 7-Difluoro-lff- indazol-3-ylamine (112mg, 0.66mmol). Purification by preparative HPLC afforded. the title compound as a yellow, di-TFA salt (130 mg, 62% yield). HPLC-Method A, Rt 3.12 min; XH NMR (DMSO, 500 MHz): 13.80-13.60 (IH, bs) , 11.30- 11.10 (IH, bs) , 9.20-9.10 (2H, m) , 7.80 (IH, m) , 7.60- 7.30 (6H, m) ; MS (m/z), MH+ 409.1.
Example 212 [2- (2-Chloro-phenyl) -pyrido [3, 4-d]pyrimidin- 4-yl] - (Iff-indazol-3-yl) -amine (11-217): Prepared from 4- Chloro-2- (2-chloro-phenyl) -pyrido [3,4-d] pyrimidine (100 mg, 0.36mmol) and Iff-indazol-3 -ylamine (88mg, 0.66mmol) . Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (72 mg, 33% yield) . HPLC-Method A, Rt 3.21 min; XH NMR (DMSO, 500 MHz): δ 12.95 (IH, s) , 10.90 (IH, bs) , 9.25 (IH, s) , 8.75 (IH, m) , 8.55 (IH, m) , 7.65 (IH, m) , 7.55 (IH, m) , 7.50-7.30 (5H, m) , 7.00 (IH, m) ; MS (m/z), MH+ 373.1.
Example 213 [2- (2-Chloro-phenyl) -pyrido [3, 4-d] yrimidin- 4-yl] - (7-fluoro-lff-indazol-3-yl) -amine (11-218): Prepared from 4-Chloro-2- (.2-chloro-phenyl) -pyrido [3,4- ] pyrimidine (100 mg, 0.36mmol) and 7-Fluoro-lff-indazol-3 -ylamine (108mg, 0.72mmol) . Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (48.7 mg, 22% yield) . HPLC-Method A, Rt 3.35 min; XH NMR (DMSO, 500 MHz): δ 12.95 (IH, s) , 10.90 (IH, bs) , 9.25 (IH, S) , 8.75 (IH, m) , 8.55 (IH, m) , 7.70-7.35 (5H, ra) , 7.25 (IH, m) , 6.95 (IH, m) , ; MS (m/z), MH+ 391.08.
Example 214 [2- (2-Chloro-phenyl) -pyrido [3, 4-d] pyrimidin- 4-yl] - (5-fluoro-lff-indazol-3-yl) -amine (11-219): Prepared from 4-chloro-2- (2-chloro-5-fluoro-Iff-indazol-3-ylamine (108mg, 0.72mmol) . Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (57.2 mg, 26% yield) . HPLC-Method A, Rt 3.27 min; XH NMR (DMSO, 500 MHz): δ 13.05 (IH, s) , 10.95 (IH, s) , 9.25 (IH, S) , 8.75 (IH, m) , 8.55 (IH, m) , 7.60 (IH, m) , 7.55 (IH, m) , 7.50-7.30 (5H, m) , 7.25 (IH, m) ; MS (m/z), MH+ 391.1.
Example 215 [2- (2-Chloro-phenyl) -pyrido [3, 4-d] pyrimidin- 4-yl] - (5, 7-difluoro-lff-indazol-3-yl) -amine (11-220):
Prepared from 4-chloro-2- (2-chloro-7-difluoro-lff-indazol- 3-ylamine (112mg, 0.66mmol). Purification by preparative HPLC afforded the title compound as a yellow, di-TFA salt (57.2 mg, 26% yield) . HPLC-Method A, Rt 3.45 min; XH NMR (DMSO, 500 MHz): δ 13.65 (IH, a) , 11.0 (IH, s) , 9.25 (IH, S) , 8.80 (IH, m) , 8.50 (IH, m) , 7.60 (IH, m) , 7.55 (IH, m) , 7.50-7.30 (5H, m) ; MS (m/z), MH+ 409.1.
Example 216 6-Fluoro-Iff-indazol-3 -ylamine (Al) : 1HNMR (500 MHz, DMS0-d6) δll.4 (s, IH) , 7.68 (dd, IH) , 6.95 (dd, IH) , 6.75 (td, IH) , 5.45 (s, 2H) ppm; LC-MS (ES+) 152.03 (M+H); HPLC-Method A, Rt 2.00 min. Example 217 5-Fluoro-lff-indazol-3-ylamine (A2) : XHNMR (500 MHz, DMSO-d6) δ 11.3 (s, IH) , 7.43 (d, IH) , 7.22 (m, IH) , 7.08 (m, IH) , 5.29 (s, 2H) ppm; LC-MS (ES+) 152.01 (M+H); HPLC-Method A, Rt 1.93 min.
Example 218 5,7-Difluoro-IH-indazol-3 -yl-amine (A3): XHNMR
(500 MHz, CD3OD) δ7.22 (dd, J=2.0,. 8.45Hz, IH) , 7.04-6.87 (m, IH) ; LC-MS (ES+) 169.95 (M+H); HPLC-Method C, Rt 2.94 min
Example 219 7 -Fluoro-Iff-indazol-3 -ylamine (A4) : ^Η MR (500 MHz, DMSO-d6) δll.8 (s, IH) , 7.42 (d, IH) , 6.97 (m, IH) , 6.78 (m, IH) , 5.40 (s, 2H) ppm; LCMS (ES+) 152.01 (M+H); HPLC-Method A, Rt 2.00 min.
Example 220 7-Fluoro- 6-trifluoromethyl-Iff- indazol-3- yla ine (A5) : XH-NMR (500 MHz, DMSO) δ 12.5 (s, IH) , 7.75
(d, IH) , 7.25 (m, IH) , 5.85 ( , IH) ppm; MS (FIA) 220.0
(M+H); HPLC-Method A, Rt 2.899 min.
Example 221 6-Bromo-lff-indazol-3-ylamine (A6) : ^Η-NMR (500 MHz, DMSO) δ 11.5 (s, IH) , 7.65 (d, IH) , 7.40 (s, IH) , 7.00 (d, IH) , 5.45 (br S, IH) ppm; MS (FIA) 213.8 (M+H); HPLC-Method A, Rt 2.441 min.
Example 222 4-Fluoro-Iff-indazol-3 -ylamine (A7) : XH-NMR (500 MHz, DMSO) δ 11.7 (s, IH) , 7.17 (m, IH) , 7.05 (d,
IH) , 6.7 (br, IH) , 6.60 (dd, IH) , 5.20 (br s, 2H) ppm; MS (FIA) 152.0 (M+H); Method A, Rt 2.256 min.
Example 223 5-Bromo-Iff-indazol-3 -ylamine (A8) : XH-NMR (500 MHz, DMSO) δ 11.55 (br S, IH) , 7.95 (s, IH) , 7.30 (d, IH) , 7.20 (d, IH) , 5.45 (br S, 2H) ppm; MS (FIA) 213.8 (M+H); Method A, Rt 2.451 min.
Example 224 5-Nitro-lff-indazol-3-ylamine (A9) : XH-NMR (500 MHz, DMSO-d6) δ 9.00 (s, IH) , 8.20 (d, IH) , 7.45 (d, IH) , 6.15 (br s, IH) ppm-; Method A, R 2.184 min
Example 225 4-Pyrrol-1-yl-Iff-indazol-3-ylamine (A10) : XH-
NMR (500 MHz, DMSO) δ 7.20 (s, 2H) , 7.00 (s, 2H) , 6.75 ( , IH) , 6.25 (s, 2H) , 4.30 (d, IH) ppm; Method A, Rt 2.625 min.
Example 226 4-Chloro-5, 6-dimethyl-2- (2-trifluoromethyl- phenyl) -pyrimidine (Bl) : Prepared to afford a colorless oil in 75% yield. XH-NMR (500 MHz, CDC13) δ 7.70 (d,
J=7.8 Hz, IH) , 7.64 (d, J=7.6 Hz, IH) , 7.55 (t, J=7.6 Hz, IH) , 7.48 (t, J=7.5 Hz, IH) , 2.54 (s, 3H) , 2.36 (s, 3H) ppm; MS (FIA) 287.0 (M+H); HPLC-Method A, Rt 3.891 min.
Example 227 4-Chlσro-2- (2-chloro-phenyl) -5, 6-dimethyl- pyri idine (B2) : Prepared to afford a yellow-orange oil in 71% yield. XH-NMR (500 MHz, CDC13) δ 7.73 (m, IH) , 7.52 (m, IH) , 7.39 (m, 2H) , 2.66 (s, 3H) , 2.45 (s, 3H) ppm; MS (FIA) 253.0 (M+H); HPLC-Method A, Rt Rt 4.156 min.
Example 228 4-Chloro-6-methyl-2- (2-trifluoromethyl- phenyl) -pyrimidine (B3) : Prepared to afford a pale yellow oil in 68% yield. XH-NMR (500 MHz, CDC13) δ 7.72 (d, J=7.8 Hz, IH) , 7.65 (d, J=7.9 Hz, IH) , 7.57 (t, J=7.5 Hz, IH) , 7.52 (t, J=7.8 Hz, IH) , 7.16 (s, IH) , 2.54 (s, 3H) ppm; MS (FIA) 273.0 (M+H); HPLC-Method A, Rt 3.746 min. Example 229 4-Chloro-6-cyclohexyl-2- (2 -trifluoromethyl- phenyl) -pyrimidine (B4) : Prepared to afford a yellow oil in 22% yield. XH-NMR (500 MHz, CDC13 ) δ 7.70 (m, 2H) , 7.57 (t, J=7.5 Hz, IH) , 7.50 (t, J=7.5 Hz, IH) , 7.19 .(s, IH) , 2.65 (m, IH) , 1.9 (m, 2H) , 1.8 (m, 2H) , 1.5 (m, 2H) , 1.3 (m, 2H) , 1.2 (m, -2H) ppm; MS (FIA) 341.0 (M+H).
Example 230 4-Chloro-6-phenyl-2- (2-trifluoromethyl- phenyl) -pyrimidine (B5) : Prepared to afford a yellow oil in 53% yield. XH-NMR (500 MHz, CDC13) δ 8.08 (dd, J=7.9, 1.6 HZ, 2H) , 7.80 (d, J=7.6 Hz, IH) , 7.77 (d, J=7.8 Hz, IH) , 7.67 (S,- IH) , 7.61 (t, J=7.5 Hz, IH) , 7.54 (t, J=7.6 Hz, IH) , 7.47 (m, 3H) ppm; MS (FIA) 335.0 (M+H); HPLC- Method A, R 4.393 min.
Example 231 4-Chloro-2- (2, 4-dichloro-phenyl) -5, 6- di e h l-pyrimidine (B6) : Prepared to afford a white solid in 91% yield. XH-NMR (500 MHz, CDC13) δ 7.62 (d, J=8.3 Hz, IH) , 7.43 (d, J=7.0 Hz, IH) , 7.27 (dd, J=8.3, 2.0 HZ, IH) , 2.55 (s, 3H) , 2.35 (s, 3H) ppm; MS (FIA) 287, 289 (M+H); HPLC-Method A, Rt 4.140 min.
Example 232 4-Chloro-6- (2-chlorσ-phenyl) -2- (2- trifluoromethyl-phenyl) -pyrimidine (B7) : Prepared to affod a yellow oil in 52% yield. XH-NMR (500 MHz, CDC13) δ 7.75 (m, 3H) , 7.65 ( , 2H) , 7.53 (m, IH) , 7.44 (m, IH) , 7.36 (m, 2H) ppm; MS (FIA) 369.1 (M+H); HPLC-Method A, Rt 4.426 min.
Example 233 4-Chlσro-6- (2-fluoro-phenyl) -2- (2- trifluoromethyl-phenyl) -pyrimidine (B8) : Prepared to afford a yellow oil in 95% yield. XH-NMR (500 MHz, CDC13) δ 8.24 (t, J=7.9 Hz, IH) , 7.84 (s, IH) , 7.78 (d, J=7.7 Hz, IH) , 7.76 (d, J=8.0 Hz, IH) , 7.60 (t, J=7.5 Hz, IH) , 7.53 (t, J=7.6 Hz, IH) , 7.43 (m, IH) , 7.23 (t, J=7.6 Hz, IH) , 7.13 (m, IH) ppm; MS (FIA) 353.0 (M+H) .
Example 234 4-Chloro-6-pyridin-2-yl-2- (2-trifluoromethyl- phenyl) -pyrimidine (B9) : Prepared to afford a pale yellow solid in 50% yield. XH-NMR (500 MHz, CDC13) δ 8.68 (m, IH) , 8.48 (dd, J=7.9, 0.8 Hz, IH) , 8.38 (d, J=2.3 Hz, IH) , 7.84 (m, 3H) , 7.62 (t, J=7.6 Hz, IH) , 7.55 (t, J=7.6 Hz, IH) , 7.38 (m, IH) ppm; MS (FIA) 336.0 (M+H); HPLC- Method A, Rt 4.575 min.
Example 235 6-Benzyl-4-chloro-2- (2-trifluoromethyl- phenyl) -5, 6,7, 8-tetrahydro-pyrido [4, 3-d] pyrimidine (B10) : XHNMR (500 MHz, CDCl3) δ7.70 (d, IH) , 7.62 (d, IH) ," 7.55 (t, IH) , 7.48 (t, IH) , 7.32 (m, 4H) , 7.25 (m, IH) , 3.74 (s, 2H) , 3.66 (s, 2H) , 2.99 (t, 2H) , 2.80 (t, 2H) ppm; LCMS (ES+) 404.17 (M+H); HPLC-Method A, Rt 3.18 min.
Example 236 7-Benzyl-4-chloro-2- (2-trifluoromethyl- phenyl) -5, 6, 7, 8-tetrahydro-pyrido [3, 4-d] pyrimidine (Bll) :
XHNMR (500 MHz, CDC13) δ7.69 (d, IH) , 7.60 (d, IH) , 7.54 (t, IH) , 7.47 (t, IH) , 7.28 (m, 4H) , 7.20 (m, IH) , 3.68 (S, 2H) , 3.67 (s, 2H) , 2.86 (t, 2H) , 2.79 (t, 2H) ppm. MS (ES+) 404.18 (M+H); HPLC-Method A, Rt 3.12 min.
Example 237 4-Chloro-2- (4-fluoro-2-trifluoromethyl- phenyl) -quinazoline (B12) : XHNMR (500MHz, CD3OD) δ 8.43 (d, J=8.1Hz, IH) , 8.20-8.05 (m, 2H) , 8.05-7.82 (m, 2H) , 7.71-7.51 (m, 2H) . LC-MS (ES+) 327.09 (M+H). HPLC-Method D, Rt 4.56 min. Example 238 4-Chloro-2- (2-chloro-5-trifluoromethyl- phenyl) -quinazoline (B13) : LC-MS (ES+) 342.97 (M+H). HPLC-Method D, Rt 4.91 min.
Example 239 4-Chloro-2- (2-chloro-4-nitro-phenyl) - quinazoline (B14) : LC-MS (ES+) 319.98 (M+H). HPLC-Method D, Rt 4.45 min.
Example 240 4-Chloro-2- (2-trifluoromethyl-phenyl) - quinazoline (B15) : Prepared in 57% yield. White solid.
XHNMR (500MHz, DMSO-d6) δ 7.79 (t, IH) , 7.86 (t,. IH) , 7.94 (m, 3H) , 8.15 (dd, IH) , 8.20 (td, IH) , 8.37 (m, IH) ; EI- MS 308.9 (M) .
Example 241 4-Chlσro-2- (2-trif luoromethyl-phenyl) -6, 7- dihydro -5ff-cyclopentapyrimi dine (B16) : Prepared in 22% yield. XHNMR (500MHz, DMSO-d6) δ 2.19 (m, H) , 3.01 (t, 2H) , 3.08 (t, 2H) , 7.49 (t, IH) , 7.55 (t, IH) , 7.62 (d, IH) , 7.71 (d, IH) . EI-MS 299.0 (M+H)-.
Example 242 4-Chloro-2- (2 -chloro-phenyl) -6,7,8,9- tetrahydro-5ff-cycloheptapyrimidine (B17) : Prepared according to Method C in 82% yield to afford a white solid. XHNMR (500MHz, CDC13) δ 1.67 (m 4H) , 1.87 (m 2H) , 3.02 (m 4H) , 7.28 (m, 2H) , 7.40 (m,. lH), 7.65 (m, IH) ; EI-MS 293.0 (M+l) .
Example 243 4-Chloro-2- (2-trifluoromethyl-phenyl) - 5, 6,7, 8,9,10-hexahydro-cyclooctapyrimidine (B18) : Prepared in 38% yield to afford a brown oil. XHNMR
(500MHz, CDC13) δ 1.35 (m 2H) , 1.41 (m 2H) , 1.76 (m 4H) , 2.96 (m, 4H) , 7.48 (t, IH) , 7.56 (t, IH) , 7.66 (d, IH) , 7.70 (d, IH) ; EI-MS 341.0 (M+l). Example 244 4-Chloro-8-methoxy-2- (2-trifluoromethyl- phenyl) -quinazoline (B19) : Prepared from 8-methoxy-2- (2- trifluoromethyl-phenyl) -3ff-quinazolin-4-one (l.Og, 3.12mmol), triethylamine hydrochloride (472mg, 3.43mmol), and P0C13. Purification by flash chromatography afforded a white solid (89% yield) . HPLC-Method A, Rt 4.10 min, (98%), MS (m/z) 258.08 (M+H).
Example 245 2- (4-Chloro-quinazolin-2-yl) -benzonitrile (B20) : Prepared to afford a yellow solid in 1.5% yield.
XH-NMR (500 MHz, CDC13) δ 8.47 (d, IH) , 8.24 (d, IH) , 8.16 (d, IH) , 8.07 (impurity), 7.94 (t,. IH) , 7.92 (impurity), 7.86 (d, IH) , 7.68 (m, 2H) , 7.65. (impurity) , 7.54 (impurity), 7.49 (t, IH) , 4.2 (impurity), 1.05 (impurity) ppm; MS (LC/MS) 266.05 (M+H); HPLC-Method A, Rt 3.88 min.
Example 246 6-Methyl-2- (2-trifluoromethyl-phenyl) -3ff- pyrimidin-4-one (D3) : Prepared to afford a yellow solid in 50% yield. XH-NMR (500 MHz, DMS0-d6) δ 12.7 (br s, IH) , 7.9 (m, IH) , 7.8 (m, 2H) , 7.7 (m, IH) , 6.3 (s, IH) , 2.21 (s, 3H) ppm; MS (FIA) 255.0 (M+H); HPLC-Method A, Rt 2.578 min.
Example 247 6-Cyclohexyl-2- (2-trifluoromethyl-phenyl) -3ff- pyrimidin-4-one (D4) : Prepared to afford an off-white solid in 54% yield. XH-NMR (500 MHz, DMSO-d6) δ 12.9 (br S, IH) , 7.9 (m, 4H) , 6.3 (s, IH) , 2.5 (m, IH) , 1.9 (m, 5H) , 1.4 (m, 5H) ppm; MS (FIA) 323.1 (M+H); HPLC-Method A, Rt 3.842 min.
Example 248 2- (2-Chloro-5-trifluoromethyl-phenyl) -3H- quinazoli-4-one (D10) : XHNMR (500MHz, CD30D) δ 8.32-8.25 (m, IH) , 8.01 (s, IH) , 7.91-7.72 (m, IH) , 7.66-7.55 (m, IH) . LC-MS (ES+) 325.01 (M+H). HPLC-Method D, Rt 3.29 min.
Example 249 2- (4-Fluoro-2-trifluoromethyl-phenyl) -3H- quinazolin-4 -one (D14) : XHNMR (500MHz, CD30D) δ 8.28 (d, 8.0Hz, IH) , 7.94-7.84 (m, IH) , 7.84-7.77 (m, IH) , 7.76- 7.67 (m, 2H) , 7.65-7.53 (m, 2H) . LC-MS (ES+) 309.06 (M+H). HPLC-Method D, Rt 2.88 min.
Example 250 2- (4-Nitro-2-chloro-phenyl) -3H-quinazolin-4- one (D15) : LC-MS (ES+) 302.03 (M+H). HPLC-Method D, Rt 2.81 min.
Example 251 2- (5-Fluoro-2- rifluoromethyl-phenyl) -3ff- quinazolin-4-one (D17) : XHNMR (500MHz, CD30D) δ 8.28 (d, Rt J=8.05Hz, IH) , 7.96 (dd, J=5.05, 8.55Hz, IH) , 7.89 (t, J=7.9Hz, IH) , 7.78-7.69 (m,lH), 7.66-7.46 (m, 3H) . LC-MS (ES+) 309.14 (M+H). HPLC-Method D, Rt 2.90 min.
Example 252 (Iff-Indazol-3 -yl) - (2-phenyl-quinazolin-4-yl) - amine (III-1) : Prepared by Method A in DMF to afford 70 mg (50% yield) as pale yellow solid. XH NMR (500 MHz, DMSO-d6) δl3.1 (s, br, IH) , 8.48 (d, IH) , 7.91 (d, 2H) , 7.76 (br, 2H) , 7.45 (m, 2H) , 7.36 (d, IH) , 7.20 (m, 4H) , 6.86 (t, IH) ppm. MS (ES+) 338.07 (M+H); (ES-) 336.11 (M- H) ; HPLC-Method A, Rt 2.88 min.
Example 253 (5-Methyl-2ff-pyrazol-3-yl) - (2-phenyl-5, 6, 7, 8- tetrahydroquinazolin-4-yl) -amine (III-7) : Prepared according to Method A. XH NMR (500 MHz, DMS0-d6) δl2.1 (s, br, IH) , 8.70 (s, br, IH) , 8.37 (d, J = 6.7 Hz, 2H) , 7.54 (m, 3H) , 6.67 (s, IH) , 2.82 (m, 2H) , 2.68 (m, 2H) , 2.37 (S, 3H) , 1.90 (s, br, 4H) ; MS 306.1 (M+H). Example 254 (5-Methyl-2ff-pyrazol-3-yl) - (2-phenyl-6,7,8,9- tetrahydro-5ff-cycloheptapyrimidin-4-yl) -amine (III-8) : MS
320.48 (M+H); HPLC-Method E, Rt 1.124 min.
Example 255 (5-Methyl-2ff-pyrazol-3-yl) - ^-pyridin^-yl- quinazolin^ryD.-amine (III-9) : Yellow solid, mp 286- 289°C, XH NMR (DMSO) δ 2.35 (3H, s) , 6.76 (IH, s) , 7.61 (IH, m) , 7.89 (2H, m) , 8.32 (2H, d) , 8.70 (IH, d) , 8.78 (2H, d) , 10.56 (IH, br s) , 12.30 (IH, br s) ; IR (solid) 1620, 1598, 1571, 1554, 1483, 1413, 1370, 1328; MS 303.2 (M+H)+
Example 256 (7-Chloro-2~pyridin-4-yl-quinazolin-4-yl) - (5- methyl-2ff-pyrazol-3-yl) -amine (111-28) : XH NMR (DMSO-d6) δ 2.35 (3H,S), 6.75 (IH, s) , 7.65 (IH, d) , 7.93 (IH, s) ,
8.30 (2H, d) , 8.73 (IH, d) , 8.79 (2H, d) , 10.69 (IH, s) , 12.33 (IH, s) ; MS m/z 337.2 (M+H)+.
Example 257 (6-Chloro-2-pyridin-4-yl-quinazolin-4-yl) - (5- methyl-2ff-pyrazol-3-yl) -amine (111-29) : XH NMR (DMSO-d6) δ
2.31 (3H, s) , 6.74 (lH,s), 7.89 (IH, s) , 8.30 (2H, d) , 8.80 (2H, d) , 8.91 (IH, s) , 10.63 (IH, s) , 12.29 (IH, s) ; MS 337.2 (M+H)+.
Example 258 (2-Cyclohexyl-quinazolin-4-yl) - (5-methyl-2ff- pyrazol-3-yl)-amine (111-30) : XH NMR (DMSO) δ 2.35 (3H, S) , 1.70 (3H, m) , 1.87 (2H, d) , 1.99 (2H, d) , 2.95 (IH, t) , 6.72 (IH, s) , 7.75 (IH, ' d) , 7.88 (IH, s) , 7.96 (IH, S) , 8.83 (IH, s) , 11.95 (IH, s) , 12.70 (IH, s) ; MS 308.4 (M+H) + .
Example 259 (5-Methyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-31) : mp 246°C; XH NMR (400MHz) δ 2.35 (3H, s) , 6.70 (IH, br s) , 7.51-7.57 (4H, m) , 7.83- 7.84 (2H, d) , 8.47-8.50 (2H, d) , 8.65 (IH, d) , 10.4 (IH, s) , 12.2 (IH, bs) ; IR (solid) 3696, 3680, 2972, 2922, 2865; MS 302.1 (M+H)+.
Example 260 [2- (4-Iodophenyl) -quinazolin-4 -yl] - (5-methyl-
2ff-pyrazol-3-yl) -amine (111-32) : XH NMR (DMSO-d6) δ 2.34
(3H, s) , 6.72 (IH, s) , 7.56 (IH, d) , 7.84 (2H, d) , 7.93
(2H, d) , 8.23 (2H, d) , 8.65 (IH, s) , 10.44 (IH, s) , 12.24 (IH, s) ; MS 428.5 (M+H)+.
Example 261 [2- (3,4-Dichlorophenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-33) : A suspension of 2- (3,4-dichloro-phenyl) -3ff-quinazolin-4-one (lg, 3.43 mmol) in phosphorus oxychloride (4 mL) was stirred at
110°C for 3 hours. The solvent was removed by evaporation and the residue is treated carefully with cold aqueous, saturated NaHC03. The resulting solid was collected by filtration and washed with ether to afford 4-chloro-2- (3, 5-dichloro-phenyl) -quinazoline as a white solid (993 mg, 93%). To the above compound- (400mg, 1.29 mmol) in THF (30 mL) was added 3 -amino-5-methyl pyrazole (396 mg, 2.58 mmol) and the resulting mixture heated at 65°C overnight. The solvents were evaporated and the residue triturated with ethyl acetate, filtered, and washed with the minimum amount of ethanol to afford compound 111-33 as a white solid (311 mg 65%) : mp 274°C; XH NMR (DMSO) δ 2.34 (3H, s) , 6.69 (IH, s) , 7.60 (IH, m) , 7.84 (IH, d) , 7.96 (2H, d) , 8.39 (IH, dd) , 8.60 (IH, d) , 8.65 (IH, d) , 10.51 (IH, s) , 12.30 (IH, s) ; IR (solid) 1619, 1600, 1559, 1528, 1476, 1449, 1376, 1352, 797, 764, 738; MS 370.5 (M+H)+. Example 262 [2- (4-Bromophenyl) -quinazolin-4-yl] - (5- methyl-2H-pyrazol-3-yl) -amine (111-34) : mp 262-265°C; XH NMR (DMSO) δ 2.34 (3S, s) , 6.73 (IH, s) , 7.55 (IH, m) , 7.74 (2H, d) , 7.83 (2H, m) , 8.40 (2H, d) , 8.65 (IH, d) , 10.44 (IH, s) , 12.25 (IH, s) ; IR (solid) 1603, 1579, 1546, 1484, 1408, 1365; MS 380.1/382.1 (M+H)+.
Example 263 [2- (4-Chlorophenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-35) : mp >300°C; XH NMR (DMSO) δ 2.34 (3H, s) , 6.74 (IH, s) , 7.53-7.62 (3H, m) , . 7.84 (2H, d) , 8.47 (2H, d) , 8.65 (IH, d) , 10.44 (IH, s) , 12.26 (IH, s) ; IR (solid) 1628, 1608, 1584, 1546, 1489, 1408, 1369, 1169; MS 336.2 (M+H)+.
Example 264 [2- (3,5-Dichlorophenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-36) : mp 228°C; XH NMR (DMSO) δ 2.34 (3H, s) , 6.69 (IH, s) , 7.96 (IH, d) , 8.21 (3H, m) , 8.56 (IH, d) , 8.60 (2H, d) , 10.51 (IH, s) , 12.30 (IH, s) ; IR (solid) 1546, 1331, 802, 763, 729, 658, 652;. MS 370.5 (M+H)+.
Example 265 [2- (4-Cyanophenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-37) : mp 263°C; XH NMR (DMSO) δ 2.34 (3H, s) , 6.72 (IH, s) , 7.61 (IH, d) , 7.88 (2H, s) , 8.04 (2H, d) , 8.63 (2H, d) , 8.67 (IH, s) , 10.52 (IH, s) , 12.27 (IH, s) ; IR (solid) 1739, 1436, 1366, 1229, 1217; MS 327.2 (M+H)+.
Example 266 [2- (3-Iodophenyl) -quinazolin-4-yl] - (5-methyl- 2ff-pyrazol-3-yl)-amine (111-38) : mp 234-235°C; XH NMR
(DMSO) δ 2.35 (3H, s) , 6.73 (IH, s) , 7.35 (IH, m) , 7.56 (IH, m) , 7.85 (3H, m) , 8.47 (IH, m) , 8.65 (IH, m) , 8.86 (IH, S) , 10.49 (IH, s) , 12.28 (IH, br s) ; IR (solid) ' 1560, 1541, 1469, 1360; MS 428.1 (M+H)+.
Example 267 [2- (4-Ethylsulfanylphenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3 -yl) -amine (111-39) : mp ,229-231°C; XH NMR (DMSO) δ 1.29 (3H, t) , 2.35 (3H, s) , 3.07 (2H, q) , 6.76 (IH, s) , 7.43 (2H, d) , 7.51 (IH, m) , 7.81 (2H, m) , 8.41 (2H, d) , 8.64 (IH, d) , 10.38 (IH, s) , 12.24 (IH, br S) ; IR (solid) 1587, 1574, 1555, 1531, 1484, 1412, 1369; MS 362.1 (M+H)+.
Example 268 (5-Cyclopropyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-40) : mp 218-219°C; XH NMR (DMSO-d6) δ 0.70-0.80(2H, m) , 0.90-1.00 (2H, m) , 6.70 (IH, s) , 7.45-7.55 (4H, m) , 7.80-7.85 (2H, m) , 8.45-8.55 (2H, m) , 8.65 (IH, d) , 10.40 (IH, s) , 12.27 (IH, s) ; IR (solid) 1624, 1605, 1591, 1572, 1561, 1533, 1479, 1439, 1419, 1361, 1327, 997, 828, 803, 780, 762, 710; MS 328.2 (M+H) + .
Example 269 [2- (4- tert-Butylphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-41) : mp >300°C; XH NMR
(DMSO-d6) δ 1.35 (9H, s) , 2.34 (3H, s) , 6.79 (IH, s) , 7.55 (3H, d) , 7.85 (2H, d) , 8.39 (2H, d) , 8.62 (IH, d) , 10.35 (IH, S) , 12.22 (IH, s) ; IR (solid) 1603, 1599,
1577, 1561, 1535, 1481, 1409, 1371, 1359, 998, 841, 825, 766, 757; MS 358.3 (M+H)+.
Example 270 [2- (4-Chlorophenyl) -quinazolin-4-yl] - (5- cyclopropyl-2ff-pyrazol-3 -yl) -amine (111-42) : XH NMR (DMSO- d6) δ 0.77 (4H, br m) ,2.05 (IH, m) , 6.59 (IH, s) , 7.60 (IH, d) , 7.85 (2H, d) , 7.91 (2H, d) , 8.22 (2H, d) , 8.65 (IH, s) , 10.51 (1H,S), 12.33 (lH,s); MS 362.1 (M+H)+. Example 271 (2-Benzo [1,3] dioxol-5-yl-quinazolin-4-yl) - (5- methyl-2ff-pyrazol-3-yl) -amine (111-43) : XH NMR (DMSO) δ 2.33 (3H, s) , 6.13 (2H, s) , 6.78 (lH,s), 7.11 (IH, d) , 7.80 (IH, t) , 7.94 (IH, s) , 8.09 (3H, m) , 8.25 (IH, d) , 10.34 (IH, S) , 12.21 (IH, s) ; MS 346.5 (M+H)+.
Example 272 [2- (4-Dimethylaminophenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (111-44) : XH NMR (DMSO- d6) δ 2.02 (6H, s) , 2.39 (3H, s) , 6.83 (IH, s) , 7.71 (IH, d) , 7.98 (2H, s) , 8.04 (2H, d) , 8.33 (2H, d) , 8.67 (IH, S) , 11.82 (IH, S) , 12.72 (IH, s) ; MS 345.3 (M+H) + .
Example 273 [2- (3 -Methoxyphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-45) : mp 226°C; XH NMR (DMSO) δ 2.34 (3H,s), 3.92 (3H, s) , 6.72 (IH, s) , 7.21 (IH, d) , 7.57 (IH, t) , 7.79 (IH, t) , 8.02 (3H, m) , 8.14 (IH, s) , 8.79 (IH, d) , 10.39 (lH,s), 12.22 (IH, s) ; IR (solid) 1599, 1572, 1538, 1478, 1427, 1359, 833, 761, 661; MS 332.2 (M+H)+.
Example 275 (5-Cyclopropyl-2ff-pyrazol-3 -yl) - [2- (3,4- dichlorophenyl) -quinazolin-4-yl] -amine (111-46) : XH NMR
(DMSO-d6) δ 0.86 (2H, d) , 1.02 (2H, d) , 1.69 (IH, m) , 6.56 (IH, s) , 7.57 (IH, d) , 7.84 (4H, m) , 8.40 (IH, d) , 8.58 (IH, S) , 8.64 (IH, s) , 10.53 (IH, s) , 12.36 (IH, s) ; MS 396.0 (M+H)+.
Example 276 (2-Biphenyl-4-yl-quinazolin-4-yl) - (5-methyl- 2ff-pyrazol-3-yl) -amine (111-47) : To a mixture of [2- (4- bromo-phenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3- yl) -amine (111-34) (196 g,. 0.51 mmol) and phenylboronic acid (75 mg, 0.62 mmol) in THF:water (1:1, 4 mL) was added Na2C03 (219 mg, 2.06 mmol), triphenylphosphine (9mg, 1/15 mol%) and palladium acetate (1 mg, 1:135 mol%) . The resulting mixture was heated at 80°C overnight, the solvents were evaporated and the residue purified by flash chromatography (gradient of dichloromethane:MeOH) to afford 111-21 as a yellow solid (99 mg, 51%) : XH NMR (DMSO) δ 2.37 (3H, s) , 6.82 (IH, s) , 7.39-7.57 (4H, m) , ■ 7.73-7.87 (6H, m) , 8.57 (2H, d), 8.67 (IH, d) , 10.42 (IH, s) , 12.27 (IH, S) ; MS 378.2 (M+H)+.
Example 277 [2- (4-Ethynylphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-48) : To a mixture of [2- (4 -bromo-phenyl) -quinazolin-4 -yl] - (5-methyl-2ff- pyrazol-3-yl) -amine (111-34) (114 mg, 0.3 mmol), and trimethylsilylacetylene (147 mg, 1.5 mmol) in DMF (2 L) was added Cul (1.1 mg, 1:50 mol%) , Pd(PPh3)2Cl2 (4.2 mg, 1:50 mol%) and triethylamine (121 mg, 0.36 mmol). The resulting mixture was heated at 120°C overnight and the solvent evaporated. The residue was triturated in ethyl acetate and the resulting precipitate collected by filtration. The collected solid was suspended in THF (3 mL) and TBAF (IM in THF, l.leq) was added. The reaction mixture was stirred at room temperature for 2 hours and the solvent evaporated. The residue was purified by flash chromatography (silica gel, gradient of DCM:MeOH) to afford 111-48 as a white solid (68 mg, 70%) : XH NMR (DMSO) δ 2.34 (3H, s) , 4.36 (IH, s) , 6.74 (IH, s) , 7.55 (IH, m) , 7.65 (2H, d) , 7.84 (2H, m) , 8.47 (2H, d) , 8.65 (IH, d) , 10.43 (IH, S) , 12.24 (IH, s) ; MS 326.1 (M+H)X
Example 278 [2- (3-Ethynylphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl)-amine (111-49) : mp 204-207°C; XH NMR (DMSO) δ 2.34 (3H, s) , 4.28 (IH, s) , 6.74 (IH, s) , 7.55-7.63 (3H, m) , 7.83-7.87 (2H, m) , 8.49 (IH, d) , 8.57 (IH, s) , 8.65 (IH, d) , 10.46 (IH, s) , 12.27 (IH, s) ; IR (solid) 1598, 1574, 1541, 1489, 1474, 1422, 1365; MS 326.1 (M+H)+..
Example 279 [2- (3-Methylphenyl) -quinazolin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (111-50) : A suspension of lff-quinazoline-2., 4-dione (10.0 g, 61.7 mmol) in POCl3 (60 mL, 644 mmol) and N,N-dimethylaniline (8mL, 63.1 mmol) was heated under reflux for 2 h. The excess P0C13 was removed in vacuo, the residue poured into ice, and the resulting precipitate collected by filtration. The crude solid product 2,4-dichloro-quinazoline (6.5 g, 53% yield) was washed with water and dried under vacuum for next step use without further purification. To a solution of the 2,4-dichloro-quinazoline (3.3 g, 16.6 mmol) in anhydrous ethanol (150 mL) was added 5-methyl-Iff-pyrazol- 3-yl amine (3.2 g, 32.9 mmol) and the resulting mixture was stirred at room temperature for 4 hours. The resulting precipitate was collected by filtration, washed with ethanol, and dried under vacuum to afford 4.0 g (93% yield) of (2-chloro-quinazolin-4-yl) - (5-methyl-lff- pyrazol-3-yl) -amine which was used in the next step without further purification. To a solution of the (2- chloro-quinazolin-4-yl) - (5-methyl-Iff-pyrazol-3-yl) -amine (50 mg, 0.19 mmol) in DMF (1.0 mL) was added m-tolyl boronic acid (0.38 mmol), 2M Na2C03 (0.96 mmol), and tri- t-butylphosphine (0.19 mmol). The flask was flushed with nitrogen and the catalyst PdCl2(dppf) (0.011 mmol) added in one portion. The reaction mixture was then heated at 80°C for 10 hours, cooled to room temperature, and poured into water (2 mL) . The resulting precipitate was collected by filtration, washed with water, and purified by HPLC to afford 111-50 as a pale yellow solid (61mg, 75%): XH NMR (500 MHz, DMS0-d6) δl2.3 (br s, IH) , 10.4 (br S, IH) , 8.75 (d, IH) , 8.30 (s, IH) , 8.25 (d, IH) , 7.78 (s, 2H) , 7.55 (m, IH) , 7.45 (m, IH) , 7.35 (m, IH) , 6.80 (s, IH) , 2.47 (s, 3H) , 2.30 (s, 3H) ; MS 316.1 (M+H) .
Example 280 [2- (3, 5-Difluorophenyl) -quinazolin- -yl] -(5- methyl-2ff-pyrazol-3-yl) -amine (111-51) : XH NMR (500 MHz,
DMSO-d6) δl2.3 (br s, IH) , 10.8 (br S, IH) , 8.63 (d, IH) , 7.95 (d, 2H) , 7.85 ( , 2H) , 7.58 (t, IH) , 7.41 (t, IH) , 6.59 (s, IH) , 2.27 (s, 3H) ; MS 338.1 (M+H).
Example 281 [2- (3-Chloro-4-f luorophenyl) -quinazolin-4- yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (111-52) : XH NMR (500 MHz, DMSO-d6) δl2.4 (br s, IH) , 10.8 (br s, IH) , 8.65 (d, IH) , 8.50 (d, IH) , 8.36 (m, IH) , 7.85 (m, IH) , 7.60 (m, IH) , 6.62 (s, IH) , 2.30 (s, 3H) ; MS 354.1 (M+H) .
Example 282 ( 5 -Methyl -2ff- pyrazol- 3-yl) - [2- (3- trif luorome thy lphenyl) -quinazolin-4 -yl] -amine (111-53) : XH
NMR (500 MHz, DMSO-d6) δl2.2 (br, IH) , 10.45 (br, IH) , 7.53 (s, IH) , 7.43 (d, J = 7.2 Hz, IH) , 7.06 (d, J = 8.2 Hz, IH) , 6.65 (d, J = 8.3 Hz, IH) , 6.57 (t, J = 7.6 Hz, IH) , 6.51 (d, J = 7.8 Hz, IH) , 6.43 (t, J = 7.8 Hz, IH) , 6.32 (t, J = 7.6 Hz, IH) , 5.51 (s, IH) , 2.03 (s, 3H) ; MS 370.2 (M+H) .
Example 283 [2- (3-Cyanophenyl) -quinazolin-4-yl] - (5- me thyl -2ff- yrazol- 3-yl) -amine (111-54) : XH NMR (500 MHz, DMSO-d6) δ9.01 (s, IH) , 8.96 (m, 2H) , 8.28 (d, J = 7.3 Hz, IH) , 8.16 (s, br, 2H) , 8.06 (t, J = 7.8 Hz, IH) , 7.88 (m, IH) , 6.96 (S, IH) , 2.58 (s, 3H) ;" MS 327.1 (M+H) .
Example 284 [2- (3-Isopropylphenyl) -quinazolin-4 -yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (III-55) : XH NMR (500 MHz,
DMSO-d6) δ8.89 (d, J = 7.5 Hz, IH) , 8.37 (s, IH) , 8.26 (s, IH) , 8.08 (m, 2H) , 7.81 (t, br, IH) , 7.67 (m, 2H) , 6.88 (S, IH) , 3.12 (m, IH) , 2.40 (s, 3H) , 1.38 (d, J = 6.9 Hz, 6H) ; MS 344.2 (M+H) .
Example 285 (5-Methyl-2ff-pyrazol-3-yl) - (2-ρyridin-3-yl- quinazolin-4-yl) -amine (111-56) : XH NMR (500 MHz, DMSO-d6) δ9.50 (s, IH) , 8.84 (d, J = 7.3 Hz, IH) , 8.80 (d, J = 4.4 Hz, IH) , 8.66 (d, J = 8.2 Hz, IH) , 7.87 ( , 2H) , 7.77 (m, IH) , 7.60 (t, J = 7.2 Hz, IH) , 6.67 (s, IH) , 2.28 (s, 3H) ; MS 303.1 (M+H) .
Example 286 [2- (3 -Acety lphenyl) -quinazolin-4 -yl] - (5- me thy l-2ff- yrazol -3-yl) -amine (111-57) : XH NMR (500 MHz, DMSO-d6) δ8.80 (s, 1H),.8.55 (d, J = 7.7 Hz, IH) , 8.42 (d, J = 7.6 Hz, IH) , 8.00 (d, J = 7.0 Hz, IH) , 7.76 (m,
2H) , 7.58 (t, J = 7.7 Hz, IH) , 7.48 (s, br, IH) , 6.60 (s, IH) , 2.49 (s, 3H) , 2.03 (s, 3H) ; MS 344.1 (M+H) .
Example 287 [2- (3, 5-Ditrifluoromethylphenyl) -quinazolin- 4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (111-58) : H NMR (500 MHz, DMSO-d6) δlθ.7 (s, br, IH) , 8.95 (s, 2H) , 8.63 (d, J = 8.2 Hz, IH) , 8.25 (s, IH) , 7.86 (m, 2H) , 7.58 (t, J = 6.9 Hz, IH) , 6.62 (s, IH) , 2.26 (s, 3H) ; MS 438.1 (M+H) .
Example 288 [2- (3 -Hydroxymethylphenyl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (111-59) : XH NMR (500 MHz, DMSO-d6) δ 8.74 (d, J = 7.9 Hz, IH) , 8.33 (s, IH) , 8.17 (s, br, IH) , 7.95 (s, br, IH) , 7.89 (s, br, IH) , 7.62 (m, 3H) , 6.72 (s, IH) , 5.53 (s, IH) , 4.60 (s, 2H) , 2.28 (s, 3H) ; MS 332.1 (M+H).
Example 289 (5-Methyl-2ff-pyrazol-3-yl) - [2- (3- phenoxyphenyl) -quinazolin-4 -yl] -amine (111-60) : mp 231- 232°C; XH NMR (DMSO-d6) δ 2.21 (3H, s) , 6.59 (IH, s) , 7.10-7.22 (4H, m) , 7.41-7.45 (2H, m) , 7.54-7.59 (2H, m) , 7.81 (2H, S-) , 8.09 (IH, s) , 8.27 (IH, m) , 8.64 (IH, m) , 10.40 (IH, S) , 12.20 (IH, s) ; IR (solid); IR (solid) 1589, 1560, 1541, 1536, 1484, 1360, 1227; MS 394.7 (M+H)+.
Example 290 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (3- phenoxypheny1) -quinazolin-4 -yl] -amine (111-61) : mp 193- 195°C; XH NMR (DMSO-d6) δ 0.67 (2H, m) , 0.93 (2H, m),1.87 (lH,m), 6.56 (IH, s) , 7.06-7.20 (4H, m) , 7.40-7.43 (2H, m) , 7.55-7.59 (2H, m) , 7.81 (2H, s) , 8.11 (IH, s) , 8.27 (IH, ) , 8.63 (IH, m) , 10.43 (IH, s) , 12.26 (IH, s) ; IR (solid); IR (solid) 1589, 1574, 1527, 1483, 1369, 1226; MS 420.7 (M+H)+.
Example 291 (5-Methyl-2ff-pyrazol-3-yl) - (2-thiophen-3-yl- quinazolin-4-yl) -amine (111-62) : XH NMR (500 MHz, DMS0-d6) δll.78 (s, br, IH) , 8.75 (d, J = 8.1 Hz, IH) , 8.68 (s, IH) , 7.98 (dd, J = 7.9, 7.5 Hz, IH) , 7.89 ( , 2H) , 7.81 (m, IH) , 7.68 (t, J = 7.5 Η.Z, IH) , 6.69 (s, IH) , 2.30 (s, 3H) ; MS 308.1 (M+H) .
Example 292 (2-Phenyl-quinazolin-4-yl) - (2ff-pyrazol-3-yl) - amine (111-63) : mp 247-249°C; XH NMR (DMSO) δ 6.99 (IH, br s) , 7.49-7.58 (5H, m) , 7.81 (IH, br s) , 7.83 (2H, ) , 8.47-8.49 (2H, m) , 8.66 (IH, d) , 10.54 (IH, s) , 12.59
(IH, s) ; IR (solid) 3145, 2922, 1622, 1597; MS 288.2
(M+H) + .
Example 293 (2ff-Pyrazol-3-yl) - (2-pyridin-4-yl-quinazolin- 4-yl)-amine (111-64) : mp 285-286°C; XH NMR (DMSO) δ 6.99 (IH, br s) , 7.65 (IH, m) , 7.81-7.94 (3H, m) , 8.3-8.35 (2H, m) , 8.73 (IH, d) , 8.84-8.90' (2H, m) , 10.76 (IH, s) , 12.6 (IH, S) ; IR (solid) 3180, 2972, 1600, 1574; MS 289.2 (M+H)+.
Example 294 5-Ethyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-65) : mp 221-222°C; XH NMR
(DMSO) δ 1.31 (3H, t) , 2.68 (2H, d) , 6.80 (IH, s) , 7.50- 7.60 (4H, m) , 8.45-8.55 (2H, m) , 8.65-8.75 (IH, m) , 10.44 (1H,S), 12.27 (1H,S); IR (solid) 3190, 1622, 1595, 1575, 1533, 1482, 1441, 1420, 1403, 1361, 758, 711; MS 316.2 (M+H)+.
Example 295 ( -Phenyl-quinazolin-4-yl) - (5-propyl-2ff- pyrazol-3-yl) -amine (111-66) : mp 204-205°C; XH NMR (DMSO- d6) δ 1.02 (3H, t) , 1.66-1.75 (2H, m) , 2.69 (2H, t) , 6.80 (IH, s) , 7.45-7.60 (4H,m) , 7.80-7.88 (2H, m) , 8.45-8.50 (2H, m) , 8.65 (IH, d) , 10.39 (IH, s) , 12.25 (IH, s) ; IR (solid) 1621, 1560, 1572, 1533, 1479, 1441, 1421, 1363, 1328, 999, 827, 808, 763, 709, 697; MS 330.2 (M+H)+.
Example 296 (5-Isopropyl-2ff-pyrazol-3 -yl) - (2 -phenyl- quinazolin-4 -yl) -amine (111-67) : mp 218-219°C; XH NMR (DMSO-d6) δ 1.36 (6H, d) , 3.05 (IH, m) , 6.86 (IH, s) , 7.48-7.59 (4H, m) , 7.80-7.88 (2H, ) , 8.49-8.58 (2H, m) , 8.66 (IH, d) , 10.47 (IH, s) , 12.30 (IH, s) ; IR (solid) 3173, 2968, 1619, 1593, 1573, 1533, 1478, 1438, 1413,
1398, 1363, 1329, 995, 822, 798, 761, 707, 666, 659; MS 330.2 (M+H)+.
Example 297 (5- tert-Butyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-68) : mp 136-137°C; XH NMR
(DMS0-d6) δ 1.38 (9H, s) , 6.87 (IH, br S) , 7.51-7.57 (4H, m) , 7.84-7.85 (2H, m) , 8.49-8.51 (2H, m) , 8.65 (IH, d) , 10.43 (IH, S) , 12.21 (IH, br s) ; IR (solid) 3162, 2963, 1621, 1590, 1572; MS 344.2 (M+H)+. Example 298 (5- ert-Butyl-2ff-pyrazol-3-yl) - (2-pyridin-4- yl-quinazolin-4-yl) -amine (111-69) : mp >300°C; XH NMR (DMSO) δ 1.38 (9H, s) , 6.82 (IH, br s) , 7.63 (IH, m) , 7.86-7.91 (2H, m) , 8.32-8.33 (2H, d) , 8.69 (IH, d) ,
8.75-8.76 (2H, d) , 10,60 (IH, s) , 12.31 (IH, br s) ;• IR (solid) 3683, 3149, 2963, 1621; MS 345.2 (M+H)+.
Example 299 (5-Cyclopentyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-70) : mp 240-241°C; XH NMR
(DMSO-d6) δ 1.68-1.89 (6H, m) , 2.03-2.17 (2H, m) , 3.14- 3.22 (IH, m) , 6.80 (IH, s) , 7.50-7.60 (4H, m) , 7.80-7.89 (2H, m) , 8.45-8.52 (2H, m) , 8.67 (IH, d) , 10.52 (IH, s) , 12.26 (IH, s) ; IR (solid) 2957, 1621, 1591, 1571, 1531, 1476, 1438, 1405, 1370, 1325, 999, 951, 801, 775, 761, 747, 710695, 668, 654; MS 356.2 (M+H) + .
Example 300 (5-Phenyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-71) : mp 207-209°C; XH NMR (DMSO) δ 7.38-7.40 (IH, m) , 7.50-7.58 (6H, m) , 7.82-7.88 (4H, m) , 8.51 (2H, m) , 8.67 (IH, s) , 10.58 (IH, s) , 13.11 (IH, br s) ; IR (solid) 3345, 3108, 1627, 1612; MS 364.2 (M+H) + .
Example 301 (5-Carboxy-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-72) : (5-Methoxycarbonyl-2ff- pyrazol-3-yl) - (2-phenyl-quinazolin-4-yl) -amine (111-73) (345mg, 1 mmole in THF, 6 mL) was treated with NaOH (IM, 4.0 mL) , stirred at 50°C for 5 hours, cooled to room temperature, and neutralised with IM HCl. The mixture was concentrated in vacuo to remove THF then diluted with water and the resulting precipitate filtered. The residual solid was dried at 80°C under vacuum to afford 111-72 as an off-white solid (312 mg, 94%) : mp 289-291°C (dec); XH NMR (DMSO) δ 7.45 (IH, br s) , 7.50-7.60 (5H, m) , 7.80-7.88 (2H, m) , 7.40-7-50 (2H, m) , 8.60-8.70 (IH, d) , 10.70 (IH, s) , 13.00-13.80 (2H, br s) ; IR (solid) 1699, 1624, 1607, 1570,1539, 1506, 1486, 1398, 1333, 1256, 1177, 1004, 827, 764, 705; MS 332.3 (M+H)+.
Example 302 (5-Methoxyσarbonyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-73) : mp 271-273°C; XH NMR (DMSO) δ 3.95 (3H, s) , 7.50-7.65 (5H, m) , 7.80-7.98 (2H, m) , 8.40-8.50 (2H, m) , 8.65-8.73 (IH, m) , 10.80 (IH, s), 13.80 (IH, s) ; IR. (solid) 3359, 1720, 1624, 1597, 1561, 1538, 1500, 1475, 1435, 1410, 1358, 1329, 1283, 1261, 1146, 1125, 1018, 1010, 944, 827, 806, 780, 763, 703, 690, 670; MS 346.3 (M+H)+.
Example 303 (5-Hydroxymethyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-74) : A solution of (5- Methoxycarbonyl-2ff-pyrazol-3-yl) - (2-phenyl-quinazolin-4- yl) -amine (111-73) (345mg, lmmol) in anhydrous THF (lOmL) was treated with lithium borohydride (125mg, 5.75 mmol) at 65°C for 5 hours. The mixture was cooled to room temperature then combined with 2M HCl and ethyl acetate. Solid sodium hydrogen carbonate was added to achieve pH 8 and the resulting mixture extracted with ethyl acetate. The extracts were dried over magnesium sulphate and concentrated. Purification by flash chromatography (Si02, methanol-dichloromethane gradient) afforded 111-74 (95 mg, 30%) as an off-white solid: mp 238-239°C; XH NMR (DMSO) δ 4.58 (2H, d, CH2), 5.35 (IH, s, OH), 6.94 (IH, s) , 7.50-7.60 (4H, m) , 7.85-7.90 (2H, m) , 8.48-8.54 (2H, m) , 8.69 (IH, IH) , 10.40 (IH, s) , 12.48 (IH, s) ; IR (solid) 1652, 1621, 1603, 1575, 1558, 1539, 1532, 1480, 1373, 1320, 1276, 1175, 1057, 1037, 1007, 951, 865, 843, 793, 780, 7124; MS 318.2 (M+H)+. Example 304 (5-Methoxymethyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (111-75) : mp 190-191°C; XH NMR (DMSO) δ 3.34 (3H, s) , 4.45 (2H, s) , 7.00 (IH, s) , 7.50- 7.62 (4H, m) , 7.82-7.90 (2H, tϊl) , 8.45-8.52 (2H, m) , 8.65 (IH, br S) , 10.50 (IH, s) , 12.30 (IH, s) ; IR (solid) 3177, 1606, 1589, 1530, 1479, 1441, 1406, 1374, 1363, 1329, 1152, 1099, 999, 954, 834, 813, 766, 707, 691; MS 332.3 (M+H)+.
Example 305 [5- (3-Hydroxyprop-l-yl) -2ff-pyrazol-3-yl] - (2- phenyl-quinazolin-4-yl) -amine (111-76) : A solution of (5- benzyloxypropyl-2H-pyrazol-3-yl) - (2-phenyl-quinazolin-4- yl) -amine (111-78) (200mg, 0.46mmol) in toluene (4mL) and acetonitrile (8mL) was stirred with trimethylsilyl iodide (0.64ml, 4.6mmol) at 55°C for 3 hours to afford an amber coloured solution. This mixture was diluted with ethyl acetate and aqueous sodium hydrogen carbonate. The resulting layers were separated, the organic layer was dried over magnesium sulphate and concentrated in vacuo. Purification by flash chromatography (Si02, methanol- dichloromethane gradient) affords a yellow oil (115mg) . Trituration with dichloro ethane affords 111-76 as an off-white solid dried at 75°C under vacuum (83mg, 52%) : mp 164-165°C; XH NMR (DMSO) δ 1.80-1.90 (2H, m) , 2.70-2.80 (2H, m) , 3.50-3.60 (2H, m) , 4.59 (IH, s) , 6.80 (IH, s) , 7.50-7.60 (4H, m) , 7.82-7.90 (2H, m) , 8.48-8.53 (2H, m) , 8.63 (IH, s) , 10.40 (IH, s) , 12.25 (IH, s) ; IR (solid) 1622, 1587, 1574, 1562, 1528, 1480, 1440, 1421, 1368, 1329, 1173, 1052, 1030, 1006, 952, 833, 762, 734, 706, 690, 671, 665; MS 346.0(M+H)+.
Example 306 [5- (3-Methoxyprop-l-yl) -2ff-pyrazol-3-yl] - (2- phenyl-quinazolin-4-yl) -amine (111-77) : mp 169-170°C; XH
■3.02- NMR (DMSO-d6) δ 1.86-1.97 (2H, m) , 2.75 (2H, t) , 3.30 (3H, S) , 3.45 (2H, t) , 6.80 (IH, s) , 7.50-7.60 (4H, m) , 7.80- 7.90 (2H, m) , 8.45-8.55 (2H, ) , 8.67 (IH, d) , 10.30 (IH, s) , 12.25 (IH, s) ; IR (solid) 1620, 1591, 1572, 1532, 1476, 1425, 1408, 1373, 1326, 1117, 1003, 831, 764, 714, 695; MS '360.3 (M+H)+.
Example 307 [5- (3-Benzyloxyprop-l-yl) -2ff-pyrazol-3-yl] - (2-phenyl-quinazolin-4-yl) -aminei (111-78) : mp 177-178°C; XH NMR (DMSO) δ 1.92-2.03 (2H, m) , 3.76-3.85 (2H, m) ,
3.52-3.62 (2H, m) , 4.51 (2H, s) , 6.82 (IH, s) , ■ 7.28-7.40 (5H, m) , 7.46-7.58 (4H, m) , 7.80-7.85 (2H, m) , 8.47-8.52 (2H, m) , 8.66 (IH, d) , 10.4.5 (IH, s) ; IR (solid) 1621, 1591, 1562, 1532, 1479, 1454, 1426, 1408, 1374, 1101, 1006, 835, 766, 738, 712, 696; MS 436.3 (M+H)+.
Example 308 [5- (3-Aminoprop-l-yl) -2IT-pyrazol-3-yl] - (2- phenyl-quinazolin-4-yl) -amine (111-79) : A solution of [5- (3-tert-butoxycarbonylaminoprop-l-yl) -2ff-pyrazol-3-yl] - (2 -phenyl-quinazolin-4-yl) -amine (111-80) (250mg,
0.56mmol), in dichloromethahe (3mL) at 0°C was treated with TFA (2mL) . The mixture was warmed to room temperature then concentrated in vacuo. The residue was triturated - and concentrated from dichloromethane (3x5mL) and ether, then triturated with dichloromethane to crystallize the TFA salt. The resulting solid was collected by filtration and dissolved in a mixture of ethanol (3mL) and water (3mL) . Potassium carbonate was added in portions to achieve pH 8 then the mixture allowed to crystallize. The product was collected by filtration and dried at 80°C under vacuum to afford 111-79 as an off-white powder (122mg, 63%) : mp 205-207°C; XH NMR (DMSO) δ 1.68-1.83 (2H, m) , 2.65-2.80( 4H, m) , 6.80 (IH, S) , 7.50-7.60 (4H, m) , 7.80-7.90 (2H, m) , 8.45-8.53 (2H, m) , 8.65 (IH, d) , 10.45 (IH, br s) ; IR (solid) 1621, 1598, 1568, 1533, 1484, 1414, 1364, 1327, 1169, 1030, 951, 830, 776, 764, 705, 677; MS 345.3 (M+H)+.
5 Example 309 [5- (3-tert-Butoxycarbonylaminoprop-l-yl) -2ff- pyrazol-3-yl] - (2-phenyl-quinazolin-4-yl) -amine (111-80) : mp 199-200°C; XH NMR (DMSO) δ 1.37 (9H, s) , 1.71-1.82 (2H,m) , 2.67 (2H, t) , 3.00-3.11 (2H, m) , 7.81 (IH, s) , 7.99 (IH, s) , 7.50-7.60 (4H, m) , 7.80-7.85 (2H, m) , 8.48-
10 8.52 (2H, m) , 8.63 (IH, d) , 10.40 (IH, s) , 12.26 (IH, m) ; IR (solid) 2953, 1687, 1622, 1594, 1573, 1535, 1481, . 1441, 1419, 1364, 1327, 1281, 1252, 1166, 1070, 1028, 998, 951, 848, 807, 768, 740, 728, 710,693; MS 445.3 (M+H)+.
15.
Example 310 5-Isopropylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-81) : XH NMR (500MHz, DMSO-d6) δ 1.20 (d, J = 6.6 Hz, 6H) , 4.13 (m, IH) , 7.42 (br. s, IH) , 7.61 (dd, J = 7.0, 7.7 Hz, 2H) , 7.66 (t, J =
20 7.1 Hz, IH) , 7.71 (m, IH) , 7.99 (m, 2H) , 8.39 (m, IH) ,
8.42 (d, J = 7.1 Hz, 2H) , 8.74 (d, J = 8.2 Hz, IH) , 11.41 (br. s, IH) ; EI-MS 373.2 (M+H); HPLC-Method C, Rt 14.09 min.
25 Example 311 (5-Allylcarbamoyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4 -yl) -amine (111-82) : XH NMR (500MHz, DMSO-d6) δ 4.02 ( , 2H) , 5.15 (m, IH) , 5.23 (m, IH) , 5.94 (m, IH) , 7.45 (br. s, IH) , 7.60 (t, J = 6.9 Hz, 2H) , 7.64 (m, IH) , 7.72 (m, IH) , 7.98 (m, 2H) , 8.43 (m 2H) , 8.72 (d, J = 8.2 0 Hz, IH) , 8.84 (br. s, IH) , 11.34 (br. s, IH) ; EI-MS 371.2 (M+H); HPLC-Method C, Rt 13.67 min.
Example 312 [5- (2-Methoxyethylcarbamoyl) -2ff-pyrazol-3- yl] - (2-phenyl-quinazolin-4-yl) -amine (111-83) : XH NMR (500MHz, DMSO-d6) δ 3.32 (s, 3H) , 3.48 (m, 4H) , 7.36 (br. S, IH) , 7.62 (m, 2H) , 7.63 (m, IH) , 7.71 (m, IH) , 7.98 .(m, 2H) , 8.41 (dd, J = 1.4, 7.0, 2H) , 8.70 (m, 2H) , 11.30 (br. s, IH) ; EI-MS 389.2 (M+H); HPLC-Method C, Rt 12.37 5 min.
Example 313 (5-Benzylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-84) : XH NMR (500MHz, DMSO-d6) δ 4.52 (d, J = 6.0 Hz, 2H) , 7.29 (m, IH) , 7.38
10 (d, J = 4.2 Hz, 4H) , 7.58 (t, J = 7.5 Hz, 2H) , 7.63 (m, IH) , 7.72 (m, IH) , 7.98 (m, 2H) , 8.43 (d, J = 7.7 Hz, 2H) , 8.72 (d, J = 7.5 Hz, IH) , 9.23 (br. s, 2H) , 11.34 (br. s, IH) ; EI-MS 421.2 (M+H) ; HPLC-Method C, R 16.76 min.
15
Example 314 (5-Cyclohexylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-85) : XH NMR (500MHz, DMSO-d6) δ 1.16 (m, IH) , 1.34 (m, 4H), 1.62 (d, J = 2.6 Hz, IH) , 1.76 (m, 2H) , 1.85 (m, 2H) , 3.79 ( , IH) , 7.43
20 (m, IH) , 7.60 (t, J = 7.2 Hz, 2H) , 7.65 (t, J = 7.1 Hz, IH) , 7.71 (ddd, J = 2.2, 5.4, 8.2 Hz, IH) , 7.98 (m, 2H) , 8.35 (m, IH) , 8.43 (dd, J = 1.4, 7.2 Hz, 2H) , 8.72 (d, J = 8.2 Hz, IH) , 11.34 (br. s, IH) ; EI-MS 413.5 (M+H) ; HPLC-Method C,„ Rt 17.18 min.
25
Example 315 (5-Diethylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-86) : XH NMR (500MHz, DMSO-d6) δ 1.18 (br. s, 3H) , 1.25 (br. s, 3H) , 3.49 (br. S, 2H) , 3.69 (b. s, 2H) , 7.21 (s, IH) , 7.59 (t, J = 6.9
30. Hz, 2H) , 7.62 (m, IH) , 7.70 (m, IH) , 7.96 (m, 2H) , 8.39
(d, J = 7.1 Hz, 2H) , 8.74 (d, J = 8.4 Hz, IH) , 11.37 (br. S, IH) ; EI-MS 387.2 (M+H); HPLC-Method C, Rt 14.50 min. Example 316 [5- (Benzyl-methyl-carbamoyl) -2ff-pyrazol-3- yl] - (2-phenyl-quinazolin-4-yl) -amine (111-87) : XH NMR
(500MHz, DMSO-d6) δ 3.33 (s, 3H) , 4.75 (s, 2H) , 7.26 (m, IH) , 7.31 (m, IH) , 7.38 (m, 4H) , 7.58 (m, 2H) , 7.70 (m, IH) , 7.95 (m, 3H) , 8.26 (m, IH) , 8.40 (d, J = 7.8 Hz, 2H) , 8.75 (m, IH) , 11.2 (br. s, IH) ; EI-MS 435.2 (M+H); HPLC-Method C, Rt 16.77 min.
Example 317 (2-Phenyl-quinazolin-4-yl). ÷ (5- propylσarbamoyl-2ff-pyrazol-3-yl) -amine (111-88) : XH NMR
(500MHz, DMSO-d6) δ 0.94 (t, J = 7.3 Hz, 3H) , 1.57 (m, 2H) , 3.24 (q, J = 6.5 Hz, 2H) , 7.39 (br. s, IH) , 7.60 (t, J = 7.3 Hz, 2H) , 7.64 (m, IH) , 7.71 (br. t, J = 6.5 Hz, IH) , 7.98 (m, 2H) , 8.42 (d, J = 7.2 Hz, 2H) , 8.61 (br. s, IH) , 8.72 (d, J = 8.5 Hz, IH) , 11.34 (br. S, IH) ; EI-MS 373.3 (M+H); HPLC-Method C, Rt 13.51 min.
Example 318 [5- (Ethyl-isopropyl-carbamoyl) -2ff-pyrazol-3- yl] - (2-phenyl-quinazolin-4-yl) -amine (111-89) : XH NMR (500MHz, DMSO-d6) δ 0.92 (t, J = 7.4 Hz, 6H) , 1.52 (m, 2H) , 1.59 (m, IH) , 3.79 (m, 2H) , 7.53 (br. s, IH) , 7.57 (t, J = 7.5 Hz, 2H) , 7.65 (t, J = 7.2 Hz, IH) , 7.71 (m, IH) , 7.99 (m, 2H) , 8.23 (br. d, J = 8.8 Hz, IH) , 8.46 (d, J = 7.5 Hz, 2H) , 8.74 (d, J = 8.4 Hz, IH) , 11.34 (br. s, IH) ; EI-MS 401.2 (M+H); HPLC-Method C, Rt 15.51 min.
Example 319 (5-Cyclopropylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-90) : XH NMR (500MHz, DMS0-d6) δ 0.60 (m, 2H) , 0.74 (m, 2H) , 2.86 (m, IH) , 7.34 (br. s, IH) , 7.62 (m, 3H) , 7.70 (m, IH) , 7.97 (m, 2H) ,
8.41 (d, J = 7.9 Hz, 2H) , 8.63 (br. s, IH) , 8.72 (d, J = 7.8 Hz, IH) , 11.35 (br. S, IH) ; EI-MS 371.2 (M+H); HPLC- Method C, Rt 12.64 min. Example 320 (5-Isobutylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-91) : XH NMR (500MHz, DMSO-d6) δ 0.94 (d, J = 6.7 Hz, 6H) , 1.88 (m, IH) , 3.12 (t, J = 6.4 Hz, 2H) , 7.45 (br. s, IH) , 7.58 (t, J = 7.2 Hz, 3H) , 7.64 (t, J = 7.1 Hz, IH) , 7.71 (m, IH) , 7.98 (m, 2H) ,- 8.44 (dd, J = 1.3, 7.9 Hz, 2H) , 8.62 (br. s, IH) , 8.72 (d, J = 8.3 Hz, IH) , 11.33 (br. S, IH) ; EI-MS 387.2 (M+H); HPLC-Method C, Rt 14.70 min.
Example 321 {5- [ (3S) -3-Methoxymethyl-pyrrolidine-l- carbonyl] -2ff-pyrazol-3-yl}- (2-phenyl-quinazolin-4-yl) - amine (111-93) : XH NMR (500MHz, DMSO-d6) δ 2.00 (m, 2H) , 2.12 (m, IH) , 3.29 (s, 3H) , 3.45 (t, J = 8.7 Hz, IH) , 3.57 (dd, J = 3.2, 9.3 Hz, IH) , 3.86 (m, IH) , 3.92 (m, IH) , 4.36 (m, 2H) , 7.45 (br. s, IH) , 7.59 (t, J = 7.2 Hz, 2H) , 7.63 (m, IH) , 7.69 (m, IH) , 7.97 (m, 2H) , 8.40 (d, J = 7.5 Hz, 2H) , 8.74 (d, J = 7.6 Hz, IH) , 11.38 (br. S, IH) ; EI-MS 429.2 (M+H); HPLC-Method C, Rt 13.84 min.
Example 322 (2 -Phenyl-quinazolin-4-yl) - (5-m- tolylcarbamoyl-2ff-pyrazol-3-yl) -amine (111-94) : XH NMR
(500MHz, DMSO-d6) δ 2.33 (s, 3H) , 6.97 (d, J = 7.5 Hz, IH) , 7.27 (t, J = 7.8 Hz, IH) , 7.62 (m, 7H) , 7.72 (m, IH) , 7.98 ( , 2H) , 8.46 (dd, J = 2.0, 7.9 Hz, 2H) , 8.71 (m, IH) , 10.29 (S, IH) , 11.31 (br. s, IH) ; EI-MS 421.2 (M+H); HPLC-Method C, Rt 17.11 min.
Example 323 (2-Phenyl-quinazolin-4-yl) - (5-p- tolylcarbamoyl-2ff-pyrazol-3-yl) -amine (111-95): XH NMR (500MHz, DMS0-d6) δ 2.30 (s, 3H) , 7.20 (d, J = 8.3 Hz, 2H) , 7.62 ( , 5H) , 7.68 (d, J = 8.3 Hz, 2H) , 7.72 (m, IH) , 7.98 (m, 2H) , 8.46 (dd, J = 1.8, 7.0 Hz, 2H) , 8.72 (m, IH) , 10.31 (S, IH) , 11.36 (br. S, IH) ; EI-MS 421.2 (M+H); HPLC-Method C, Rt 16.95 min. Example 324 (5-Methylcarbamoyl-2ff-pyrazol-3-yl) - (2- phenyl-quinazolin-4-yl) -amine (111-96) : XH NMR (500MHz, DMSO-d6) δ 2.82 (d, J = 4.6 Hz, 3H) , 7.31 (br. S, IH) , 7.62 (m, 3H) , 7.69 (m, IH) , 7.97 (m, 2H) , 8.42 (d, J = 7.1 Hz, 2H) , 8.59 (br. S, 1H), 8.71 (d, J = 8.0 Hz, IH) , 11.30 (br. S, IH) ; EI-MS 345.1 (M+H); HPLC-Method C, Rt 11.02 min.
Example 325 [5- (Morpholine-4-carbonyl) -2ff-pyrazol-3-yl] - (2-phenyl-quinazolin-4-yl) -amine (111-97) : XH NMR (500MHz, DMSO-d6) δ 3.33 (m, 4H) , 3.83 (m 4H) , 7.34. (br. S, IH) , 7.53 (m, 4H) , 7.86 (m, 2H) , 8.43 (m, 2H) , 8.67 (d, J = 8.6 Hz, IH) , 10.70 (s, IH) , 13.56 (s, IH) ; EI-MS 401.2 (M+H); HPLC-Method A, Rt 2.68 min.
Example 326 [5- (l-Methylpiperazine-4-carbonyl) -2H- pyrazol-3-yl] - (2-phenyl-quinazolin-4-yl) -amine (111-98) :
XH NMR (500MHz, DMSO-d6) δ 2.25 (s, 3H) , 2.43 (m, 4H) , 3.87 (m 4H) , 7.33 (br. S, IH) , 7.53 (m, 4H) , 7.87 (m, 2H) , 8.45 (m, 2H) , 8.67 (d, J = 7.6 Hz, IH) , 10.70 (s, IH) , 13.30 (S, IH) ; EI-MS 414.2 (M+H); HPLC-Method A, Rt 2.38 min.
Example 327 [5- (2-Hydroxyethylcarbamoyl-2ff-pyrazol-3-yl] - (2-phenyl-quinazolin-4-yl) -amine (111-99) : XH NMR (500MHz, DMSO-d6) δ 3.36 (m, 2H) , 3.52 (m, 2H) , 4.79 (m, IH) , 7.50 (m, 5H) , 7.83 ( , 2H) , 8.50 (m, 4H) , 10.52 (br. s, IH) , 13.25 (s, IH) ; EI-MS 375.1 (M+H); HPLC-Method A, Rt 2.51 min.
Example 328 (5-Carbamoyl-2ff-pyrazol-3-yl) - (2 -phenyl- quinazolin-4-yl) -amine (III-100) : To a solution of 5- (2- phenyl-quinazolin-4-yla ino) -lff-pyrazole-3-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester (270 mg, 0.63 mmol). in DMF (20 ml) was added a solution of ammonia in 1,4- dioxane (0.5 M, 10 ml). The resulting mixture was stirred at room temperature for 24 h. After concentration of the solvents, the residue was added to water (20 ml) . The resulting precipitate was collected to afford III-100 (168 mg, 80%) as a yellow solid. XH NMR (500MHz, DMSO-d6) δ 7.77-7.51 (m, 6H) , 7.86 (br s, 2H) , 8.11 (m, IH) , 8.50 (m, 2H) „ 8.63 (m, IH) , 10.52 (s, IH) , 11.25 (s, IH) ; EI-MS 331.1 (M+H); HPLC-Method A, Rt 2.52 min.
Example 329 (4-Bromo-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (III-101) : Prepared according to Method A to afford a yellow solid, mp 189°C; XH NMR (DMSO- d6) δ 7.44-7.46 (3H, m) , 7.58 (IH, m) , 7.87 (2H, d) , 8.15 (IH, s) , 8.31-8.34 (2H, m) , 8.49 (IH, d) , 10.08 (IH, s) , 13.13 (IH, S) ; IR (solid) 3286, 2969, 1738, 1632; MS 366.2/368.2(M+H)+.
Example 330 (4-Bromo-5-methyl-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (III-102) : mp 183-185°C; XH NMR
(DMSO) δ 2.33 (3H, br s) , 7.44-7.46 (3H, m) , 7.57 (IH, m) , 7.84-7.87 (2H, m) , 8.31-8.34 (2H, m) , 8.48 (IH, d) , 10.05 (IH, S) , 12.91 (IH, br s) ; IR (solid) 3362, 3065, 2831, 1619, 1578; MS 380.2/382.2 (M+H) +.
Example 331 (4-Cyano-2ff-pyrazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (III-103) : mp >250°C; XH NMR (DMSO) δ 7.47-7.49 (3H, m) , 7.64 (IH, m) , 7.91 (2H, m) , 8.40-
8.43 (2H, m) , 8.53 (IH, d) , 8.71 (IH, d) , 10.61 (IH, s) , 13.60 (IH, s) ; IR (solid) 3277, 3069, 2855, 2231, 1625; MS 313.2 (M+H) +. Example 332 (5-Methyl-2ff-pyrazol-3-yl) - (2-morpholin-4-yl- quinazolin-4-yl) -amine (III-104) : mp 223-224°C; XH NMR (DMSO) δ 2.26(3H, s) , 3.65(4H, m) , 3.75(4H, m) , 6.44(lH, s) , 7.12 (IH, d) , 7.33(1H, d), 7.56(1H, t) , 8.37(1H, d) , 10.01(1H, S) , 12.13 (IH, br s) ; IR (solid) 1621, 1578, 1537, 1475, 1434, 1385; MS -311.0 (M+H) + .
Example 333 (5-M thyl-2ff-pyrazol-3-yl) - (2-piperazin-l-yl- quinazolin-4-yl) -amine (III-105) : mp 179-181°C; XH NMR (DMSO) δ 2.26 (3H, s) , 2.74 (4H, br s) , 3.71(4H, br s) , 6.43 (IH, S) , 7.08(1H, t) , 7.30(1H, d) , 7.53(1H, t) , 8.34 (lH' f d) , 9.50 (IH, s) , 12.08 (IH, br s) ; IR (solid) 2853, 1619, 1603, 1566, 1549, 1539; MS 310.0 (M+H)+
Example 334 [2- (4-Methylpiperidin-l-yl) -quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (III-106) : mp l48-150°C; XH NMR (DMSO) δ l.06(3H, d) , 1.03(2H, m) , 1.51-1.70 (3H, m) , 2.26(3H, S) , 2.86(2H, m) , 4.73(2H, d) , 6.44(1H, s) , 7.06(1H, d) , 7.29(1H, d) , 7.52(1H, t) , 8.32(1H, d) , 9.92(1H, S) , 12.09(1H, br s) ; IR (solid) 2917, 2840, 1629, 1593, 1562, 1546, 1486; MS 323.0 (M+H)+.
Example 335 [2- (4-Methylpiperazin-l-yl) -quinazolin-4-yl] - (5-methyl-2ff- yrazol-3-yl) -amine (III-107) : mp 105-107°C; XH NMR (DMSO) δ 2.21(3H, s) , 2.26(3H, s) , 2.34(4H, m) , 3.75(4H, m) , 6.45(1H, s) , 7.09(1H, t) , 7.31(1H, d) , 7.54(1H, t) , 8.34(1H, d) , 9.96(1H, s) , 12.12(1H, br s) ; IR (solid) 2934, 2844, 2804, 1620, 1593, 1572, 1536, 1476; MS 324.0 (M+H)+.
Example 336 ( 5 -Methyl -2ff-pyrazol- 3 -yl) - (2 -piperidin- l-yl - quinazolin-4-yl) -amine (III-108) : mp 294 °C ; XH NMR (DMSO) δ 1 .45 -1 . 58 (4H, m) , 1 . 63 (2H, m) , 2 . 26 (3H, s) , 3 . 79 (4H, m) , 6.45 (IH, br s) , 7.06 (IH, t) , 7.29 (IH, d) , 7.52 (IH, t) , 8.33 (IH, d) , 9.92 (IH, s) , 12.11 (IH, br S) ; IR (solid) 2929, 2847, 1632, 1591, 1500, 1482, 143.7, 1382; MS 309.3 (M+H)+.
Example 337 (2-Azepan-l-yl) -quinazolin-4-yl] - (5-methyl- 2ff-pyrazol-3-yl) -amine (III-109) : mp 269°C; XH NMR (DMSO) δ 1.50 (4H, br s) , 1.76 (4H, br s) , 2.25 (3H, s) , 3.78 (4H, t) , 6.55 (IH, br s) , 7.03 (IH, t) , 7.28 (IH, d) , 7.50 (IH, t) , 8.33 (IH, d) , 9.92 (IH, s) , 12.09 (IH, br S) ; IR (solid) 3427, 2963, 2927, 2909, 2872, 2850, 1623, 1595, 1586, 1568, 1504, 1486, 1468, 1386, 1427; MS 323.3 (M+H) + .
Example 338 [2- (4- (2-Hydroxyethylpiperidin-l-yl) - quinazolin-4 -yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (III- llO) : mp 175°C; XH NMR (DMSO) δ 1.08 (2H, m) , 1.38 (2H, m) , 1.57-1.83 (3H, m) , 2.26 (3H, s) , 2.85 (2H, t)-, 3.47 (2H, m) , 4.38 (IH, t) , 4.75 (2H, d) , 6.45 (IH, br s) , 7.06 (IH, t) , 7.29 (IH, d) , 7.52 (IH, t) , 8.32 (IH, d) , 9.93 (IH, s) , 12.12 (IH, br s) ; IR (solid) 3365, 3073, 2972, 2868, 1622, 1604, 1586, 1568, I486,. 1463, 1440, 1394; MS 353.2 (M+H)+.
Example 339 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (4- methylpiperidin-1-yl) -quinazolin-4-yl] -amine (III-lll) :
To a solution of (5-cyclopropyl-Iff-pyrazol-3 -yl) - (2- chloro-quinazσlin-4-yl) -amine (118 mg, 0.41 mmol) in tert-butanol (3.0 L) was added 4-methylpiperidine (0.49 mL, 4.1 mmol) and. the reaction mixture heated at reflux overnight. The reaction mixture was concentrated in vacuo and the residue dissolved in a mixture EtOH:water (1:3, 4 mL) . Potassium carbonate (57mg, 0.41 mmol) was added and the mixture stirred at room temperature for 2 hours. The resulting suspension was filtered, washed with water (x2) , and rinsed with Et20 (x2) to afford III- lll as a white solid (123mg, 85%) : mp 190°C; XH NMR (DMSO) δ 0.66 (2H, s) , 0.93 (5H, br s) , 1.07 (2H, d) , 1.66 (3H, s) , 1.91 (IH, S) , 2.85 (2H, t) , 4.72 (2H, d) , 6.33 (IH, s) , 7.06 (IH, t) , 7.29 (IH, d) , 7.52 (IH, t) , 8.31 (IH, d) , 9.95 (IH, s), 12.18 (IH, br s) ; IR (solid) 2925, 2852, 1622, 1590, 1581, 1558, 1494, 1481, 1453, 1435, 1394; MS 349.2 (M+H)+.
Example 340 [2- (l,4-Dioxa-8-aza-spiro [4, 5] dec-8-yl) - quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (III-
112): mp 191°C; XH NMR (DMSO) δ 1.65 (4H, s) , 2.26 (3H, s) , 3.90 (4H, s) , 3.93 (4H, s) , 6.43 (IH, br s) , 7.09 (IH, t) , 7.32 (IH, d) , 7.54 (IH, t) , 8.35 (IH, d) , 9.99 (IH, br s) , 12.13 (IH, br s) ; IR (solid) 3069, 2964, 2927, 2868, 1618, 1581, 1568, 1540, 1495, 1481, 1435, 1390; MS 367.3 (M+H)+.
Example 341 [2- (4-Cyclopentylamino-piperidin-l-yl) - quinazolin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (III- 113): mp 191°C; XH NMR (DMSO) δ 1.33 (2H, d) , 1.65 (4H, s) , 1.87 (2H, d) , 2.20 (IH, s) , 2.26 (3H, s) , 2.49 (2H, S) , 3.00 (2H, t) , 3.36 (2H, s) , 4.61 (2H, d) , 6.45 (IH, br s) , 7.07 (IH, s) , 7.31 (IH, d) , 7.52 (IH, s) , 8.33 (IH, d) , 9.94 (IH, br s) , 12.12 (IH, br s) ; IR (solid) 3371, 2943, 1622, 1600, 1581, 1545, 1509, 1463, 1440, 1390; MS 378.2 (M+H) + .
Example 342 [2- (4 -Hydroxypiperidin-1-yl) -quinazolin-4 - yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (III-114) : mp 123°C; XH NMR (DMSO) δ 1.34 (2H, d) , 1.80 (2H, d) , 2.26 (3H, s) , 3.24 ,(2H, t) , 3.72 (IH, br s) , 4.39 (2H, d) , 4.70 (IH, d) , 6.44 (IH, br s) , 7.07 (IH, t) , 7.30 (IH, d) , 7.53 (IH, t) , 8.33 (IH, d) , 9.94 (IH, br s) , 12.11 (IH, br s) ; IR (solid) 3265, 3151, 2927, 2863, 1622, 1600, 1572, 1540, 1504, 1476, 1440, 1390, 1349, 1066, 1098; MS 325.3 (M+H)+.
Example 343 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (4- hydroxy-4-phenylpiperidin-l-yl) -quinazolin-4-yl] -amine (III-115) : mp 131°C; XH NMR (DMSO) δ 0.64 (2H, q) , 0.93 (2H, q) , 1.68 (2H, d) , 1.83-1.97 (3H, m) , 3.20-3.45 (2H, m) , 4.69 (2H, d) , 5.11 (IH, s) , 6.37 (IH, br s) , 7.08
(IH, t) , 7.20 (IH, t) , 7.31 (3H, t) , 7.49 (2H, d) , 7.53 (IH, t) , 8.33 (IH, d) , 9.98 (IH, br s) , 12.18 (IH, br s) ; IR (solid) 3362, 2952, 2934, 2911, 2870, 2825, 1618, 1584, 1570, 1559, 1536, 1481, 1459, 1431, 1372, 1336, 1213, 994; MS 427.6 (M+H)+.
Example 344 (5-Cyclopropyl-2ff- yrazol-3-yl) - [2- (1,3- dihydro-isoindol-2-yl) -quinazolin-4-yl] -amine (III-116) :
Prepared according to Method E-I to afford an off-white solid, mp 237°C; XH NMR (DMSO-d6) δ 0.79 (2H, s) , 1.00 (2H, d) , 1.99 (IH, m) , 4.92 (4H, d) , 6.72 (IH, br s) , 7.13 (IH, t) , 7.33 (2H, s) , 7.30-7.48 (3H, ) , 7.58 (IH, t) , 8.40 (IH, d) , 10.12 (IH, s) , 12.17 (IH, s) ; IR (solid) 3449, 3318, 2850, 1623, 1595, 1577, 1541, 1509, 1482, 1432, 1391, 1359, 1141, 1027, 877, 814; MS 369.4 (M+H) + .
Example 345 (2-Azepan-l-yl) -quinazolin-4-yl] - (5- cyclopropyl-2ff-pyrazol-3-yl) -amine (III-117) : mp 199- 200°C; XH NMR (DMS0-d6) δ 0.60-0.70 (2H, m) , 0.90-1.00
(2H, m) , 1.45-1.57 (4H, m) , 1.70-1.85 (4H, m) , 1.88-1.97 (IH, m) , 3.75-3.87 (4H, m) , 6.42 (IH, s) , 7.02 (IH, t) , 7.27 (IH, d) , 7.49 (IH, t) , 8.29 (IH, d) , 9.91 (IH, s) , 12.19 (IH, br S) ; IR (solid) 2929, 1624, 1595, 1581, 1563, 1542, 1498, 1482, 1440, 1426, 1397, 1356, 1305, 1000, 825, 754; MS'349.2 (M+H)+.
Example 346 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (3,4- dihydro-Iff-isoquinolin-2 -yl) -quinazolin-4-yl] -amine (III- 118): mp 182-184°C; XH NMR (DMSO) δ 0.75 (2H, d) , 1.02 (2H,.d), 1.96 (IH, m) , 2.89 (2H, m) , 4.05 (2H, m) , 4.94 (2H, s), 6.46 (IH, S) , 7.10 (IH, t) , 7.21 (4H, d) , 7.37 (IH, d) , 7.55 (IH, d) , 8.36 (IH, d) , 10.05 (IH, s) , 12.23 (IH, br s) ; IR (solid) 1621, 1581, 1560, 1537, 1479, 1456, 1426, 1396, 1374, 1341, 1222; MS 383.3 (M+H) X
Example 347 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (2,3- dihydro-indol-1-yl) -quinazolin-4-yl] -amine (III-119) : mp 150-153°C; XH NMR (DMSO) δ 0.74 (2H, d) , 0.98 (2H, d) , 1.96 (IH, m) , 3.15 (2H, t) , 4.25 (2H, t) , 6.45 (IH, br s) , 6.88 (IH, t) , 7.09 (IH, t) , 7.20 (2H, m) , 7.53 (IH, d) , 7.65 (IH, t) , 8.43 (2H, br s) , 10.09 (IH, s) , 12.28 (IH, br s) ; IR (solid) 1621, 1588, 1577, 1564,, 1537, 1487, 1455, 1425, 1386, 1259;. MS 369.3 (M+H) + .
Example 348 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (4- hydroxymethylpiperidin-1-yl) -quinazolin-4 -yl] -amine (III- 120): mp 142°C; XH NMR (DMSO) δ 0.67 (2H, d) , 0.96 (2H, d) , 1.10 (2H, q) , 1.55-1.70 (3H, m) , 1.91 (IH, m) , 2.85 (2H, t) , 3.28 (2H, s) , 4.48 (IH, s) , 4.76 (2H, d) , 6.34 (IH, s) , 7.06 (IH, t) , 7.30 (IH, d) , 7.52 (IH, t) , 8.31 (IH, d) , 9.96 (IH, s) , 12.19 (IH, s) ; IR (solid) 3363, 3000, 2927, 2854, 1618, 1604, 1573, 1536, 1509, 1477, 1436, 1395, 1354, 1314, 1241, 1186, 1091, 995, 941, 823; MS 365.8 (M+H)+.
Example 349 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (3,4- dihydro-2ff-quinolin-l-yl) -quinazolin-4-yl] -amine (III- 121): mp 137-145°C; XH NMR (DMSO-d6) δ 0.55 (2H, d) , 0.88 (2H,. d) , 1.78 (IH, m) , 1.92 (2H, t) , 2.75 (2H, t) , 4.04 (2H, t) , 6.20 (IH, br s) , 6.97 (IH, t) , 7.14 (IH, m) , 7.19 (IH, t) , 7.42 (IH, d) , 7.61 (IH, t) , 7.67 (IH, d) , 8.43 (IH, d) , 10.04 (IH, s) , 12.21 (IH, br s) ; IR (solid) 1622, 1572, -1539, 1493, 1454, 1420, 1373, 1249; MS 383.3 (M+H)+.
Example 350 (5-Methoxycarbonyl-2ff-pyrazol-3-yl) - [2- (piperidine-1-yl) -quinazolin-4-yl] -amine (III-122) : XH NMR
(500MHz, CDC13) δl.7-1.8(6H, m) , δ 3.8 (4H, m) , δ 3.9 (3H, s) , δ 5.5 (IH, s) , δ 7.15 (IH, t) , δ 7.4 (IH, d) , δ 7.6 (IH, t) , δ 8.0 (IH, d) . HPLC-Method B, (starting with 95% H20) Rt 7.4 min; MS (ES+) 353.24 (M+H).
Example 351 [5- (Piperidine-1-carbonyl) -2ff-pyrazol-3-yl] [2- (piperidine-1-yl) -quinazolin-4-yl] -amine (III-123) :
HPLC-Method B, (starting with 95% H20:0.1% TFA) Rt 8.0 min; MS (ES+) 406.30, (ES-) 404.30.
Example 352 (5-Hydroxymethyl-2ff-pyrazol-3-yl) - [2- (piperidin-1-yl) -quinazolin-4-yl] -amine (III-124) : To a solution of III-122 (10.0 mg, 0.028 mmol) in THF (6 mL) at ambient temperature was slowly added a IM solution of LiAlH4 in THF (0.05 mL, 0.05 mmol). After 15 minutes the solution was quenched with water and IN HCl . The product was extracted from the aqueous layer with EtOAc. The organic layer was dried over MgS04, filtered, and concentrated in vacuo. The residue was purified by preparatory HPLC to afford III-124 (4.0 mg, 44%). HPLC- Method B, (starting with 95% H2O:0.1% TFA) Rt 6.1 min; MS (ES+) 325.13 (M+H), (ES-) 323.13 (M-H).. Example 353 (5-Carbamoyl-2ff-pyrazol-3-yl) - [2- (piperidin- 1-yl) -quinazolin-4-yl] -amine (III-125) : A solution of III-122 (1.5 g, 4.3 mmol) in 2.0 M NH3/MeOH (100 mL) was heated at 110°C for 2 days. The dark brown reaction mixture was concentrated in vacuo to afford a viscous oil which was purified by column chromatography to yield 0.7 g (50%). of III-125. XH NMR (500MHz, CD30D-d3) δl.6 (4H, m) , δl.7 (2H, m) , δ 3.3 (IH, s) , δ 3.8 (4H, m) , δ 5.5 (IH, s) , δ 7.15 (IH, t) , δ 7.45 (IH, d) , δ 7.55 (IH, t) , δ 8.0 (IH, d) ; HPLC-Method B, (starting with 95% H2O:0.1% TFA) Rt 5.9.min; MS (ES+) 338.13, (ES-) 336.15.
Example 354 (5-Carbamoyl-2ff-pyrazol-3-yl) - [2- (4- methylpiperidin-1-yl) -quinazolin-4-yl] -amine (III-126) : HPLC-Method B,. (starting with 95% H2O:0.1% TFA) Rt 6.4 min; MS (ES+) 352.19, (ES-) 350.20.
Example 355 (5,7-Difluoro-Iff-indazol-3-yl) - (2-phenyl- 5,6,7,8-tetrahydroquinazolin-4-yl) -amine (III-127) : XH NMR (500 MHz, DMS0-d6) δ 13.7 (s, IH) , 10.3 (s, br, IH) , 7.90 (d, 2H) , 7.52 (t, IH) , 7.45 (m, 3H) , 7.26 (d, IH) , 2.99 (m, 2H) , 2.75 (m, 2H) , 1.95 (br, 4H) ppm; MS (ES+) 378.24 (M+H); (ES-) 376.23 (M-H); HPLC-Method A, Rt 3.04 min.
Example 356 (2-Pheny1-5, 6, 7, 8-tetrahydroquinazolin-4-yl) - (5-trifluoromethyl-lff-indazol-3-yl) -amine (III-128) : XH
NMR (500 MHz, DMS0-d6) δl3.4 (s, IH) , 10.2 (s, br, IH) , 8.13 (s, IH) , 7.86 (d, 2H) , 7.78 (d, IH) , 7.69 (d, IH) , 7.50 (t, IH) , 7.35 (dd, 2H) , 2.89 (m, 2H) , 2.72 (m, 2H) , 1.90 (s, br, 4H) ppm; MS (ΞS+) 410.24 (M+H); (ES-) 408.23 (M-H); HPLC-Method A, Rt 3.19 min. Example 357 (7 -Fluoro- Iff- indazol -3-yl) - (2-phenyl - quinazolin-4-yl) -amine (III-129) : XH NMR (500 MHz, DMSO- d6) δl3.6 (S, IH) , 11.1 (s, br, IH) , 8.65 (d, IH) , 8.03 (d, 2H) , 7.95 (s, 2H) , 7.67 (m, IH) , 7.45 (m, 2H) , 7.33 (t, 2H) , 7.22 (dd, IH) , 6.99 (td, IH) ppm. MS (ES+) : m/e= 356.20 (M+H);- HPLC-Method A Rt 3.00 min.
Example 358 (5 -Fluoro- Iff- indazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (III-130) : XH NMR (500 MHz, DMSO- d6) δl3.2 (s, IH) , 11.3 (s, br, IH) , 8.67 (d, IH) , 8.04 (d, 2H) , 7.96 (s, 2H) , 7.70 (m, IH) , 7.58 (dd, IH) , 7.43 (m, 4H) , 7.28 (td, IH) ppm. MS (ES+) 356.20 (M+H) ; HPLC- Method A, Rt 3.00 min.
Example 359 ( 5, 7 -Di f luoro- Iff- indazol -3-yl) - (2 -phenyl - quinazolin- 4-yl) -amine (III-131) : XH NMR (500 MHz, DMSO- d6) δl3.7 (s, IH) , 8/65 (d, IH) , 8.04 (d, 2H) , 7.95 (s, 2H) , 7.68 (m, IH) , 7.45 (m, IH) , 7.35 (m, 4H) ppm. MS (ES+) : m/e= 374.17 (M+H); HPLC-Method A, Rt 3.07 min.
Example 360 (Iff- Indazol -3-yl) - [2- (3-trifluoromethyl- phenyl) -quinazolin-4 -yl] -amine (III-132) : H NMR (500MHz, DMSO-d6) δ 7.06 (t, IH) , 7.42 (t, IH) , 7.59 (d, IH) , 7.63 (t, IH) , 7.66 (d, IH) , 7.71 (m, IH) , 7.80 (d, IH) , 7.98 (m, 2H) , 8.33 (s, IH) , 8.46 (d, IH) , 8.71 (d, IH)., 11.04 (br. s, IH), 12.97 (s, IH) ; EI-MS 406.1 (M+l) ; HPLC- Method A, Rt 3.15 min.
Example 361 (2-Phenyl-quinazolin-4-yl) - (lff-pyrazolo [4,3- b]pyridin- 3-yl) -amine (III-133) : XH NMR (500 MHz, DMSO-d6) δl3.3 (s, br, IH) , 11.4 (s, br, IH) , 8.78 (d, IH) ., 8.58 (dd, IH) , 8.24 (d, IH) , 8.10 ( , 2H) , 7.95 (d, 2H) , 7.86 (t, IH) , 7.56 (m, 2H) , 7.44 (t, 2H) ppm. MS (ES+) 339.11 (M+H); HPLC-Method A, Rt 2.63 min.
Example 362 [5- (3-Methoxy-phenyl) -6-oxo-5, 6-dihydro-lH- pyrazolo [4, 3 -c]pyridazin-3-yl] - (2-phenyl-quinazolin-4- yl)-amine (III-134) : XH NMR (500 MHz, MeOH-d4) δ8.65 (d, IH) , 8.17 (m, 3H) , 8.10 (d, IH) , 7.90 (t, IH) , 7.75 (t, IH) , 7.58 (m, 2H) , 7.25 (t, IH) , 6.95 (m, 2H) , 6.85 (d, IH) , 6.80 (s, IH) , 3.64 (s, 3H) ppm. MS (ES+) : m/e= 462.2 (M+H) .
Example 363 (6-Oxo-5-phenyl-5, 6-dihydro-lH-pyrazolo [4,3- c]pyridazin-3-yl) - (2 -phenyl-quinazolin-4-yl) -amine (III- 135): XH NMR (500 MHz, MeOH-d4) δ8.61 (d, IH) , 8.13 (m, 3H) , 8.05 (d, IH) , 7.85 (t, IH) , 7.70 (t, IH) , 7.58 (m, 2H) , 7.32 (m, 5H) , 6.79 (s, IH) ppm. MS (ES+) : m/e= 432.2 (M+H) .
Example 364 [5- (4-Methox -phenyl) -6-oxo-5, 6-dihydro-lH- pyrazolo [4,3-c]pyridazin-3-yl] - (2-phenyl-quinazolin-4- yl) -amine (III-136) : MS (ES+) 462.2 (M+H).
Example 365 [5- (2,4-Dichloro-phenyl) -6-oxo-5, 6-dihydro- lH-pyrazolo [4,3-c]pyridazin-3-yl] - (2-phenyl-quinazolin-4- yl)-amine (III-137) : XH NMR (500 MHz, MeOH-d4) δ8.63 (d, IH) , 8.17 (m, 4H) , 7.89 (t, IH) , 7.73 (t, IH) , 7.61 (t, 2H) , 7.57 (d, IH) , 7.32 (m, IH) , 7.21 (d, IH) , 6.84 (s, IH) ppm. MS (ES+) : m/e= 500.1(M+H).
Example 366 [6 -Oxo- 5 - (3 - tri fluoromethyl -phenyl) -5, 6- dihydro-lH-pyrazolo [4 , 3 -c] pyridazin-3 -yl] - (2-phenyl - quinazolin-4 -yl) -amine (III-138) : XH NMR (500 MHz , MeOH- d4 ) δ8 . 55 (d, IH) , 8 .19 (d, 2H) , 7 . 92 (m, 2H) , 7 . 65 (m, 3H) , 7 . 45 ( t , 2H) , 7 . 25 ( t , IH) , 7 . 13 (t , IH) , 7 . 05 (t , IH) , 6 . 75 ( S , IH) ppm . MS (ES+ ) : m/e= 500 . 2 (M+H) .
Example 367 [6-Oxo-5- (4-Phenoxy- henyl) -5,6-dihydro-lH- pyrazolo [4, 3 -c]pyridazin-3-yl] - (2 -phenyl-quinazolin-4- yl)-amine. (III-139) : MS (ES+) 524..3(M+H).
Example 368 [5- (4 -Chloro-phenyl) -6-oxo-5,6-dihydro-lH- pyrazolo[4,3-c]pyridazin-3-yl] - (2 -phenyl-quinazolin-4- yl) -amine (III-140) : MS (ES+) 466.2 (M+H).
Example 369 (2-imidazol-l-yl-quinazolin-4-yl) - (lff- indazol-3-yl) -amine (III-141) : XH NMR (500MHz, DMSO-d6) δ 7.10 (t, IH) , 7.44 (t, IH) , 7.50 (br. S, IH) , 7.60 (d, IH) , 7.72 (m, 2H) , 7.77 (m, IH) , 7.88 (d, IH) , 7.98 (t,
IH) , 8.73 (d, IH) , 8.96 (s, IH) , 11.23 (s, IH) , 13.06 (s, IH) ; EI-MS 328.1 (M+l) ; .HPLC-Method A, Rt 2.93 min.
Example 370 (Iff-Indazol-3-yl) - [2- (2-methyl-imidazol-l-yl- quinazolin-4-yl] -amine (III-142) : XH NMR (500MHz, DMSO-d6) δ 2.48 (s, 3H) , 7.10 (t, IH) , 7.43 (t, IH) , 7.57 (d, IH) , 7.60 (d, IH) , 7.67 (d, IH) , 7.76 (td, IH) , 7.86 (d, IH) , 7.91 (d, IH) , 8.01 (td, IH) , 8.72 (d, IH) , 11.15 (s, IH) , 13.10 (S, IH) ; EI-MS 342.1 (M+l); HPLC-Method A, Rt 3.06 min.
Example 371 (Iff-Indazol-3-yl) - (2-piperidin-l-yl- quinazolin-4-yl) -amine (III-143) : XH NMR (500MHz, DMSO-d6) δ 1.48 (m, 6H) , 3.60 (m, 4H) , 7.11 (t, IH) , 7.52 (t, IH) , 7.55 (d, IH), 7.64 (d, IH) , 7.69 (d, IH) , 7.75 (d, IH) , 7.90 (t, IH) , 8.58 (d, IH) , 11.82 (br. S, IH) , 13.25 (s, IH) ; EI-MS 345.1 (M+l); HPLC-Method A, R 3.03 min. Example 372 (Iff-Indazol-3-yl) - [2- (octahydro-quinolin-1- yl) -quinazolin-4-yl] -amine (III-144) : XH NMR (500MHz, DMSO-d6) δ 0.6-1.9 (m, 13 H) , 3.15 (m, IH) , 3.25 (m, IH) , 4.0 (m, IH) , 7.10 (t, 0.5H) , 7.12 (t, 0.5H), 7.55 (m, 2H) , 7.66 (d, 0.5 H) , 7.69 (d, 0.5 H) , 7.77 (d, IH) , 7.91 (t, IH) , 8.55 (d, 0.5 H) , 8.59 (d, 0.5 H) , 11.46 (s, 0.5 H) , 11.54 (s, 0.5 H) , 11.78 (s, 0.5 H) , 11.84 (s, 0.5 H) , 13.10 (S, 0.5 H) , 13.12 (s, 0.5 H) ; EI-MS 399.3 (M+l) ; HPLC-Method A, R 3.37 min.
Example 373 (Iff-Indazol-3-yl) - [2- (2, 6 -dimethyl- orpholin- 4-yl) -quinazolin-4-yl] -amine (III-145) : XH NMR (500MHz,
DMS0-d6) δ 1.0 (m, 6H) , 4.0 (m, 6H) , 7.12 (t, IH) , 7.41 (td, IH) , 7.56 (t, IH) , 7.58 (d, IH) , 7.68 (dd, IH) , 7.77 (t, IH) , 7.93 (t, IH) , 8.60 (d, IH) , 11.69 (s, IH) , 13.16 (s, IH) ; EI-MS 375.3 (M+l); HPLC-Method A, Rt 2.93 min.
Example 374 (5-Methyl-2ff-pyrazol-3-yl) - (2-phenyl- pyrimidin-4-yl) -amine (IV-1) : mp 245-246°C; XH NMR (DMSO) δ 2.26 (3H, s) , 6.32 (IH, br s) , 7.07 (IH, br s) , 7.48-
7.54 (3H, m) , 8.33-8.39 (3H, m) , 9.87 (IH, s) , 12.03 (IH, S) ; IR (solid) 1628, 1589, 1579, 1522, 1479, 1441, 1393, 1336; MS 252.2 (M+H) + .
Example 375 [6- (4-Aσetamidophenylsulfanyl) -2-phenyl- pyrimidin-4-yl] - (5-methyl-2ff-pyrazol—3-yl) -amine (IV-3) :
A suspension of Fenclorim (4, 6-dichloro-2- phenylpyrimidine) (O.lg, 0.44 mmol), 3-amino-5- methylpyrazole (0.045 g, 0.47 mmol), N, N- diisopropylethylamine (0.08 ml, 0.47 mmol) and sodium iodide (0.067 g, 0.44 mmol) in n-butanol (5 ml) were heated at 117 °C for 18 hours. The solvent was removed in vacuo and the crude product purified by flash chromatography (silica gel, 3:2 Petrol :EtOAc) to afford 0.037 g (29 % yield) of (6-Chloro-2-phenyl-pyrimidin-4- yl) - (5-methyl-2ff- yrazol—3-yl) -amine as a off-white solid. A suspension of the above pyrimidine (0.037 g, 0.13 mmol) and thioacetamidothiophenol (0.108 g, 0.64 mmol) in tert-butanol was heated at 85 °C under nitrogen , for 2 days. The reaction mixture was cooled to room temperature and the solvent removed in vacuo . The concentrate was dissolved in EtoAσ, and washed with NaHC03 (sat, aq.). The organic layer is concentrated in vacuo, and the crude product by preperative HPLC. The residual disulfide that still remained in the mixture after HPLC may be removed by precipitation from EtOAc and filtration. The mother liquor was concentrated to afford IV-3 (7mg, 13 % yield) as an off-white solid: mp 235- 236°C; XH NMR (DMSO) δ 2.10 (3H, s) , 2.21 (3H, s) , 6.33 (IH, br s) , 7.50 (3H, m) , 7.7-7.59 (2H, m) , 7.76-7.78 (2H, m) , 8.25 (2H, m) , 9.72, 10.26 and 11.93 (3 H, 3 x br S) ; IR (solid) 1669, 1585, 1551, 1492, 1392, 1372, 1312, 1289, 1259, 1174, 1102, 1089, 1027, 1015, 984; MS 417.3 (M+H) + .
Example 376 [2- (4-Methylpiperidin-l-yl) -pyrimidin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (IV-4) : mp 215-216°C; H NMR (CD3OD) δ 0.96 (3H, d) , 1.16 (2H, m) , 1.66 (3H, m) , 2.27 (3H, s) , 2.86 (2H, t) , 4.58 (2H, m) , 4.78 (2H, exch.protons ) , 6.13 (2H, m) , 7.83 (IH, d) ; IR (solid) 1593, 1550, 1489, 1436, 1331, 1246, 1231; MS 273.1 (M+H)+.
Example 377 [2- (4-Methylpiperidin-l-yl) -5-nitropyrimidin- 4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (IV-5) : mp 185- 187°C; XH NMR (DMSO) δ 0.93 (3H, d) , 1.06-1.18 (2H, m) ,. 1.68-1.80 (3H, m) , 2.26 (3H, s) , 3.01-3.12 (2H, m) , 4.63 (IH, d) , 4.80 (IH, d) , 6.39 (IH, s) , 9.00 (IH, s) , 10.41 (IH, S) , 12.36 (IH, S) ; IR (solid) 1589, 1517, 1479, 1446, 1346, 1317, 1246, 1222, 1055; MS 318.2 (M+H)X
Example 378 [5-Amino-2- (4-Methylpiperidin-l-yl) - pyrimidin-4-yl] - (5-methyl-2ff-pyrazol-3-yl) -amine (IV-6):
To a solution of IV-5. (48 mg, 0.151 mmol) in. ethanol (2.0 mL) was added tin dichloride dihydrate (171 mg, 0.756 mmol) and the resulting mixture heated at reflux for 3 hours . The reaction was cooled to room temperature and poured onto a mixture of IM NaOH: dichloromethane :propanol (18:8:4mL) and stirred for 15 minutes. The layers were separated and the aqueous layer extracted twice with dichloromethane. The combined organic layers were concentrated in vacuo and the residue purified by flash chromatography (silica gel, gradient dichloromethane:MeOH) to afford IV-6 as a grey solid (27mg, 63%): XH NMR (DMSO) δ 0'.88-1.04 (5H, m) , 1.55-1.62 (3H, m) , 2.21 (3H, S) , 2.70 (2H, m) , 3.36 (2H, m) , 4.40 (2H, m) , 6.37 (IH, s), 7.49 (IH, s) , 8.40 (IH, s) , 11.92 (IH, br s) ; MS 288.2 (M+H)+.
Example 379 [5-Amino-6-methyl-2- (4-methylpiperidin-l-yl) - pyrimidin-4-yl] - (5-methyl-2ff- yrazol-3-yl) -amine (IV-7) : mp 172-175°C; XH NMR (DMSO) δ 0.90 (3H, d) , 1.03 (2H, m) , 1.52-1.62 (3H, m) . 2.13 (3H, s) , 2.20 (3H, s) , 2.69 (2H, m) , 3.92 (2H, br s) , 4.44 (2H, d) , 6.35 (IH, s) , 8.41 (IH, s) , 11.85 (IH, br s) ; IR (solid) 1612, 1589, 1489, 1446, 1317; MS 302.5 (M+H)+.
Example 380 [6-Methyl-2- (4-methyl-phenyl) -pyrimidin-4- yl] - (5-phenyl-2ff-pyrazol-3-yl) -amine (IV-10) : MS 342.34 (M+H); HPLC-Method E, Rt 1.334 min. Example 381 [2- (4-Chloro-phenyl) -6-methyl-pyrimidin-4- yl] - (5-furan-2-yl-2ff-pyrazol-3-yl) -amine (IV-11): MS
352.11 (M+H); HPLC Method E, Rt 1.194 min.
Example 382 5-Furan-2-yl-2ff-pyrazol-3-yl) - (6-methyl-2- phenyl-pyrimidin-4-yl) -amine (IV-12) : MS 318.21 (M+H); HPLC-Method E, 1.192 min.
Example 383 [6-Methyl-2- (4- trifluoromethyl-phenyl) - pyrimidin-4-yl] - (5-phenyl-2-yl-2ff-pyrazol-3-yl) -amine (IV-13) : MS 396.24 (M+H); HPLC-Method E, Rt 1.419 min.
Example 384 (5-Furan-2-yl-2ff-pyrazol-3-yl) - [6-methyl-2- (4 -trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (IV-14) MS 386.08 (M+H); HPLC-Method E 1.347 min.
Example 385 [2- (2,3-Dihydro-benzo [1,4] dioxin-2-yl) -6- methyl-pyrimidin-4-yl] - (5-furan-2-yl-2ff-pyrazol-3-yl) - amine (IV-15) : MS 376.18 (M+H); HPLC-Method E, Rt 1.181 min.
Example 386 [2- (2,3-Dihydro-bezo [1, 4] dioxin-2-yl) -6- ethyl-pyrimidin-4-yl] - (5-methyl-2ff-pyrazol—3-yl) -amine (IV-16): MS 338.17 (M+H); HPLC-Method E, Rt 1.082 min.
Example 387 (6-Ethyl-2 -phenyl-pyrimidin-4-yl) - (5-methyl- 2ff-pyrazol-3-yl) -amine (IV-17): MS 280.18 (M+H); HPLC- Method E, Rt 1.024 min.
Example 388 (6-Methyl-2 -phenyl-pyrimidin-4-yl) - (5-phenyl- 2ff-pyrazol-3-yl) -amine (IV-19): MS 328.51 (M+H); HPLC- Method E, Rt 1.192 min. Example 389 [6-Ethyl-2- (4-trifluoromethyl-phenyl) - pyrimidin-4-yl] - (5-me hyl-2ff-pyrazol-3-yl) -amine (IV-20) ι
MS 348.5 (M+H); HPLC-Method E, Rt 1.224 min.
Example 390 (5-Furan-2-yl-2ff-pyrazol-3-yl) - [6-methyl-2- (4-methyl-phenyl) -pyrimidin-4-yl] -amine (IV-21): MS
332.23 (M+H); HPLC-Method E, Rt 1.139 min.
Example 391 (6-Methoxymethyl-2-phenyl-pyrimidin-4-yl) - (5- methyl-2ff-pyrazol-3-yl) -amine (IV-22): MS 296.31 (M+H); HPLC-Method E, Rt 0.971 min.
Example 392 (5, 6-Dimethyl-2-phenyl-pyrimidin-4-yl) - (5- methyl-2ff-pyrazol-3-yl) -amine (IV-23) : MS 280.2 (M+H); HPLC-Method E, Rt 0.927 min.
Example 393 (6-Methyl-2-phenyl-pyrimidin-4-yl) - (5-methyl- 2ff-pyrazol-3-yl) -amine (IV-24) : MS 266.18 (M+H); HPLC- Method E, Rt 0.925 min.
Example 394 [6-Ethyl-2- (4-methyl-phenyl) -pyrimidin-4-yl] ■ (5-methyl-2ff-pyrazol-3-yl) -amine (IV-25) : MS 294.46 (M+H); HPLC-Method E, Rt 1.174 min.
Example 395 [2- (4-Chloro-phenyl) -6-ethyl-pyrimidin-4-yl] ■ (5-methyl-2ff-pyrazol-3-yl) -amine (IV-26) : MS 314.42 (M+H); HPLC-Method E Rt 1.213 min.
Example 396 (5-Methyl-lH-pyrazol-3-yl) - (6-methyl-2-p- tolyl-pyrimidin-4-yl) -amine (IV-27) : MS 280.45 (M+H); . HPLC-Method E, Rt 1.135 min.
Example 397 (Iff-Indazol-3-yl) - (6-methoxymethyl-2-phenyl- pyrimidin-4-yl) -amine (IV-28) : XH NMR (500 MHz, DMSO) δ 3.57 (3H, s) , 4.65 (2H, s) , 7.23 (IH, J=7.5 Hz, t) , 7.52 (IH, J=7.6 Hz, t) , 7.63 (4H, m) , 7.75 (IH, br) , 8.13 (IH, J=5.5 Hz, br d) , 8.44 (IH, J=5.7 Hz, br d) , 10.6 (IH, br) , 12.8 (IH, br s) ppm; HPLC-Method A, Rt 2.944 min; MS (FIA) 332.1 (M+H)+.
Example 398 (5-Methyl-2ff-pyrazol-3-yl) - (2-pyridin-4-yl- thieno[3,2-d]pyrimidin-4-yl)-amine (IV-29) : XH NMR (DMSO) δ 2.34 (3H, s) , 6.66 (IH, s) , 7.53 (IH, d) , 7.84 (IH, d) , 8.32 (2H, d) , '8.70 (2H, d) ; MS 309.6 (M+H) + .
Example 399 (5-Methyl-2ff-pyrazol-3-yl) - (2-phenyl- pyrido[3, 4-d] pyrimidin -4-yl) -amine (IV-30) : mp 225°C; XH NMR (DMSO) δ 2.35 (3H, s) , 6.81 (IH, s) , 7.50-7.63 (3H, m) , 8.45-8.52 (2H, m) , 8.54 (IH, d) , 8.62 (IH, d) , 9.20 (IH, s) , 10.79 (IH, s) , 12.38 (IH, br s) ; IR (solid) 2958, 2917, 2852, 1593, 1565, 1524, 1467, 1450; MS 303.2 (M+H) + .
Example 400 (5-Methyl-22ϊ-pyrazol-3-yl) - (2-phenyl- pyrido [2, 3-d] pyrimidin-4-yl) -amine (IV-31) :
To a solution of 4-chloro-2-phenyl-pyrido [2, 3- d] pyrimidine (J. Pharm. Belg., 29, 1974, 145-148) (109mg,
0.45 mmol) in THF (15 L) was added 3-amino-5-methyl pyrazole (48 mg, 0.5 mmol) and the resulting mixture heated at 65 °C overnight. The mixture was cooled to room temperature and the resulting suspension was filtered and washed with Et20. The solid was dissolved in a mixture EtOH:water and the pH adjusted to pH 7. The aqueous was extracted twice with ethyl acetate and the combined organic layers were dried (MgS04) , filtered, and concentrated in vacuo . The residue was purified by flash chromatography (Si02, DCM-MeOH gradient) to afford IV-31 as an off-white solid (69 mg, 50%) : mp 234 °C; XH NMR (DMSO) δ 2.14 (3H, s) , 5.99 (IH, s) , 7.20-7.40 (3H, m) , 7.40-7.50 (3H, m) , 8.60 (IH, d) , 8.79 (IH, d) , 12.82 (IH, br S) ; IR (solid) 2957, 2921, 2857, 1644, 1560, 1459, 1427; MS 303.2 (M+H)+.
Example 401 (5-Cyclopropyl-2ff-pyrazol-3-yl) - (2-phenyl- pyrido[3,4-d]pyrimidin-4-yl) -amine (IV-32) : off-white solid, mp 232-233°C; XH NMR (DMSO) δ 0.70-0.85 (2H, m) , 0.90-1.05 (2H, m) , 1.05-2.07 (IH, m) , 6.75 (IH, s) , 7.50- 7.75 (3H, m) , 8.40-8.70 (4H, m) , 9.20 (IH, s) , 10.80 (IH, s) , 12.41 (IH) ; IR (solid) 3178, 1601, 1573, 1532, 1484, 1452, 1409, 1367, 1328, 802, 781, 667; MS 329.2 (M+H)+.
Example 402 [2- (4-Methylpiperidin-l-yl) -purin-4-yl] - (5- methyl-2ff-pyrazol-3-yl) -amine (IV-33): To a suspension of 2,4-dichloro-purine (2.0 g, 10.6 mmol) in anhydrous ethanol (10 L) was added 5-methyl-Iff-pyrazol-3-yl amine (2.05 g, 21.2 mmol). The resulting mixture was stirred at room temperature for 48 h. The resulting precipitate was collected by filtration, washed with ethanol, and dried under vacuum to afford 1.524 g (58% yield) of (2- chloro-purin-4-yl) - (5-methyl-lff-pyrazol-3-yl) -amine which was used in the next step without further purification. To a solution of (2-chloro-purin-4-yl) - (5-methyl-lff- pyrazol-3-yl) -amine (200 mg, 0.80 mmol) was added 4- methylpiperidine (4 mL, 8.01 mmol) and the reaction mixture heated at reflux overnight. The solvent was evaporated and the residue dissolved in a mixture EtOH-.water (1:3, 4 L) . Potassium carbonate (57mg, 0.41 mmol) was added and the mixture was stirred at room temperature for 2 hours. The resulting suspension was filtered, washed with water (x2) and rinsed with Et20 (x2) to afford IV-33 as a white solid (225mg, 90%) : mp >300°C; XH NMR (DMSO) δ 0.91 (3H, d) , 1.10 (2H, m) , 1.65 (3H, m) , 2.24 (3H, s) , 2.84 (2H, m) , 4.60 (2H, m) , 6.40 (IH, s) , 7.87 (IH, m) , 9.37-9.59 (IH, m) , 12.03-12.39 (2H, m) ; IR (solid) 1651, 1612, 1574, 1484, 1446, 1327, 1317, 1255, 1203; MS 313.3 (M+H)+.
Example 403 (5-Cyclopropyl-2ff-pyrazol-3-yl) - [2- (4- methylpiperidin-1-yl) -pyrrolo [3,2-d]pyrimidin-4-yl] -amine (IV-34) : white solid; XH NMR (DMSO) δ 0.65 (2H, m) , 0.91- 0.96 (5H, m) , 1.08 (2H, m) , 1.58-1.64 (3H, m) , 1.89 (IH, m) , 2.77 (2H, t) , 4.57 (2H, d) , 6.09 (IH, s) , 6.38 (IH, s) , 7.33 (IH, S) , 9.42 (IH, s) , 10.65 (IH, s) , 12.02 (IH, br s) ; MS 338.3 (M+H)+.
Example 404 [6-Benzyl-2-phenyl-5, 6,7, 8-tetrahydro- pyrido[4,3-d]pyrimidin-4-yl] - (5-fluoro-lff-indazol-3-yl) - amine (IV-35) : XH NMR (500 MHz, DMSO-d6) δ 13.0 (s, IH) , 10.4 (s, br, IH) , 9.73 (s, IH, TFA-OH) , 8.00 (d, 2H) , 7.64 (m, 2H) , 7.59 (dd, IH) , 7.52 (m, 3H) , 7.41 (t, IH) , 7.31 (m, 3H) , 7.14 (dd, IH) , 4.58 (s, 2H) , 4.35 (br, 2H) , 3.74 (m, 2H) , 3.17 (s, 2H) ppm. MS (ES+) : m/e= 451.30 (M+H); HPLC-Method A, Tret 2.96 min.
Example 405 (5-Fluoro-Iff-indazol-3-yl) - (2-phenyl-5, 6,7, 8- tetrahydro-pyrido [4, 3-d] pyrimidin-4-yl) -amine (IV-36) : Prepared from IV-35 (0.13 mmol) by treatment with an equal weight of Pd/C (10%) in 4.4% HCOOH in MeOH at room temperature for 12 h. The mixture was filtered through celite, the filtrate was evaporated, and crude product was purified by HPLC to afford IV-36 as yellow solid in 35% yield. H NMR (500 MHz, DMSO-d6) δ 12.9 (s, IH) , 9.06 (s, IH) , 7.99 (d, 2H) , 7.57 (dd, IH) , 7.34 (m, IH) , 7.28 (m, 3H) , 7.22 (d, IH) , 3.83 (s, 2H) , 3.05 (m, 2H) , 2.72 (m, 2H) ppm. MS (ES+) : m/e= 361.20 (M+H); HPLC-Method A, Tret 2.68 min. Example 406 (5-Methyl-2ff-pyrazol-3-yl) - (3 -phenyl- isoquinolin-1-yl) -amine (V-l) : To a solution of 1-chloro- 3 -phenylisoquinoline (J. Het. Chem., 20, 1983, 121- 128)(0.33g, .1.37 mmol) in DMF (anhydrous, 5 mL) was added 3-amino-5-methylpyrazole (0.27g, 2.74 mmol) and potassium carbonate (0.57g, 4.13 mmol) and the resulting mixture was heated at' reflux for 6 hours . The reaction mixture was then cooled and solvent removed in vacuo . The residue was extracted twice with ethyl acetate and the combined organic layers washed with brine, dried (MgS04) , filtered and concentrated in vacuo. The crude product was purified by flash chromatography (Si0 , gradient DCM-MeOH) to afford V-l as a colourless oil; XH NMR (MeOD) δ 2.23 (3H, s) , 5.61 (IH, s) , 7.41 (IH, m) , 7.52(2H, m) ,
7.62(1H, m) , 7:81 (IH, m) , 8.07(1H, d) , 8.19 (2H, m) , 8.29(1H, s) , 8.54 (IH, d) ; MS 301.2 (M+H) + .
Example 407 (Iff-Indazol-3-yl) - [3- (2-trifluoromethyl- phenyl) -isoquinoline-1-yl] -amine (V-2) : A solution of 1- chloro-3- (2-trifluoromethyl-phenyl) -isoquinoline (100 mg, 0.326 mmol) and Iff-indazol-3-ylamine (86 mg, 0.651 mmol) in ethanol (3 mL) was heated at 160 C and the solvent evaporated with a stream of nitrogen. The remaining oil was then heated at 160 C for 18 hours under nitrogen. The resulting melt was dissolved in 5% methanol : dichloromethane (50 L) , washed with saturated aqueous sodium bicarbonate (1 x 25 mL) then dried over magnesium sulfate. Purification by silica gel chromatography (25% to 50% hexane:ethyl acetate) afforded V-2 as a yellow solid (35 mg, 27%) . XH NMR (500 MHz, d6- DMSO) δ 9.78 (br S, IH) , 8.62 (d, IH) , 7.9-7.85 (m, IH) , 7.78-7.72 (m, IH) , 7.70-7.68 (m, IH) , 7.65-7.62 (πv, IH) , 7.60-7.55 (m, IH) , 7.52-7.45 (m, 3H) , 7.41-7.38 (m, IH) , 7.28-7.25 (m, IH) , 7.18 (s, IH) , 6.95-6.92 (m, IH) , 5.76 (S, IH) ; LC-MS (ES+) m/e= 405.18 (M+H); HPLC-Method D Rt 2.74 min.
Example 408 (5,7-Difluoro-lff-indazoi-3-yl) - [3- (2-. trifluoromethyl-phenyl) -isoquinolin-1-yl] -amine (V-3) :
Prepared from 5, 7-difluoro-Iff-indazol-3 -ylamineto afford compound V-3 as a yellow solid (90 mg, 63%) . XH NMR (500
MHz, d6-DMSO) δ 13.25 (s, IH) , 9.92 (br s, IH) , 8.61 (d, IH) , 7.9 (d, IH) , 7.81-7.49 (m, 6H) , 7.26-7.2 (m, 2H) , 7.12-7.10 (m, IH) ; LC-MS (ES+) m/e= 441.16 (M+H); HPLC- Method D, Rt 3.58 min.
Example 409 (5-Methyl-2ff-pyrazol-3-yl) - (2 -phenyl- quinolin-4-yl) -amine (V-4): To a mixture of 4-chloro-2- phenylquinoline (J. Het. Chem., 20, 1983, 121-128) (0.53g, 2.21 mmol) in diphenylether (5 mL) was added 3-amino-5- methylpyrazole (0.43g, 4.42 mmol) and the resulting mixture heated at 200°C overnight with stirring. The reaction mixture was cooled to ambient temperature then petroleum ether (20 mL) was added and the resulting precipitate was isolated by filtration. The crude solid was purified by flash chromatography (Si02, gradient DCM- MeOH) to afford V-4 as a white solid: mp 242-244°C; XH NMR (DMSO) δ 2.27(3H, s) , 6.02(1H, s) , 7.47(2H, d) , 7.53- 7,40(2H, br m) , 7.67(1H, m) , 7.92(1H, m) , 8.09(2H, d) , 8.48(2H, m) , 9.20(1H, . s) , 12.17(1H, br s) ; IR (solid) 1584, 1559, 1554, 1483, 1447, 1430, 1389; MS 301.2 (M+H)+.
Example 410 (Iff-Indazol-3-yl) - (2-phenyl-quinolin-4-yl) - amine (V-5) : XH NMR (500 MHz, d6-DMS0) δ 12.78 (s, IH) , 9.50 (S, IH) , 8.65 (d, IH) , 8.15 (s, IH) , 8.04-7.98 (m, 3H) , 7.94 (s, IH) , 7.78-7.75 (m, IH) , 7.60-7.40 (m, 6H) , 7.15-7.10 (m, IH) . LC-MS (ES+) m/e= 337.11 (M+H); HPLC- Method D, Rt 2.10 min.
Example 411 (2-Phenyl-quinolin-4-yl) - (lff-pyrazolo [4,3- b]pyridin-3-yl) -amine (V-6) : XH NMR (500 MHz, DMSO-d6) δl3.6 (s, IH) , 11.4 (s, IH)., 8.94 (d, IH) , 8.61 (dd, IH) , 8.23 (d, IH) , 8.16 (dd, IH) , 8.12 (t, IH) , 7.89 (t, IH) , 7.86 (d, IH) , 7.65 (m, 4H) , 7.54 (s, IH) , 7.52 (dd, IH) ppm. MS (ES+) : m/e= 338.11 (M+H); HPLC-Method A, HPLC- Method D, Rt 2.91 min.
Example 412 (Iff-Indazol-3-yl) - [2- (2-trifluoromethyl- phenyl) -quinolin- -yl] -amine (V-7) : XH NMR (500 MHz, d6- DMSO) δ 12.68 (s, IH) , 9.51 (s, IH) , 8.7 (d, IH), 7.95- 7.89 ( , 2H) , 7.83-7.70 (m, 3H) , 7.68-7.62 (m, 2H) , 7.60 (s, IH) , 7.55-7.52 (m, IH) , 7.49-7.45 (m, IH) , 7.40-7.37 (m, IH) , 7.12-7.09 (m, IH) ; LC-MS (ES+) m/e= 405.15 (M+H); HPLC-Method D Rt 2.25 min.
Example 413 (5,7-Difluoro-lff-indazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinolin-4-yl] -amine (V-8) : XH NMR
(500 MHz, d6-DMSO) δ 13.31 (s, IH) , 9.49 (s, IH) , 8.70- 8.67 (m, IH) , 7.96-7.92 (m, IH) , 7.85-7.66 (m, 7H) , 7.63- 7.60 (m, IH) , 7.42-7.40 (m, IH) . LC-MS (ES+) m/e= 441.18 (M+H); HPLC-Method D Rt 2.39 min.
Example 414 [2- (2-trifluoromethyl-phenyl) -quinolin-4-yl] - (lff-pyrazolo [4, 3-b]pyridin-3-yl) -amine (V-9) : XH NMR (500 MHZ, DMSO-d6) δl3.6 (s, IH) , 11.6 (s, br, IH) , 8.98 (d, IH) , 8.57 (dd, IH) , 8.12 (m, 3H) , 7.97 (m, 2H) , 7.86 (m, 3H) , 7.49 (dd, IH) , 7.23 (s, IH) ppm. MS (ES+) : m/e= 406.20 (M+H); HPLC-Method A Rt 2.91 min. Example 415 (2-Phenyl-quinazolin-4-yl) - (2ff- [1,2,4] triazol-3-yl) -amine (IX-154): off-white solid, mp 266-267°C; XH NMR (DMSO) δ 7.50-7.70 (4H, m) , 7.85-8.00 (2H, m) , 8.15-8.25 (2H, m) , 8.37-8.45 (2H, m) , 8.58 (IH, d) , 13.90 (IH, br s) ; IR (solid) 3344, 3059, 1630, 1609, 1570, 1557, 1543, 1501, 1495, 1445, 1411, 1355, 1326, 1267, 1182, 1053, 1038, 760, 676, 667, 654; MS 289.2 (M+H)+.
Example 416 (5-Methyl-2ff- [1,2,4] triazol-3-yl) - (2-phenyl- quinazolin-4-yl) -amine (IX-155): XH NMR (500 MHz, DMSO- d6) δ8.59 (s, IH) , 8.42 (d, J = 6.7 Hz, 2H) , 7.79 ( , 4H) , 8.03 (m, 2H) , 7.74 ( , 4H) , 2.51 (s, 3H) ppm. MS (ES+) : m/e= 303.08 (M+H); HPLC-Method A, Rt 2.64 min.
Example 417 (2ff- [1,2,4] -Triazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4-yl] -amine (IX-47) : Pale yellow solid (52% yield) . XH NMR (500 MHz, DMS0-d6) δ8.54 (S, IH) , 8.15 (s, br, IH) , 7.91 (t, IH) , 7.85 (m, 2H) , 7.76 (m, 3H) , 7.66 (t, IH) ppm. MS (ES+) : m/e=
357.13 (M+H); (ES-): m/e= 355.15 (M-H); HPLC-Method A, Rt 2.81 min.
Example 418 (5-Methyl-2ff- [1,2, 4] triazol-3-yl) - [2- (2- trifluoromethylphenyl) -quinazolin-4 -yl] -amine (IX-38):
Pale yellow solid (54% yield) . XH NMR (500 MHz, DMS0-d6) δ8.44 (s, br, IH) , 7.92 (m, 3H) , 7.84 (m, IH) , 7.77 (m, 2H) , 7.68 (t, IH) , 2.28 (s, 3H) ppm. MS (ES+) : m/e=
371.14 (M+H); (ES-): m/e= 369.18 (M-H); HPLC-Method A, Rt 2.89 min.
Example 419 (5-Methylsulfanyl-2ff- [1,2,4] triazol-3-yl) - [2- (2-trifluoromethylphenyl) -quinazolin-4-yl] -amine (IX- 156) : Pale yellow solid (65% yield) . XH NMR (500 MHz, DMSO-d6) δ8.56 (br, IH) , 7.90 (t, IH) , 7.84 (m, 2H) , 7.78 (m, 2H) , 7.67 ( , 2H) , 2.51 (s, 3H, buried by DMSO) ppm. MS (ES+) : m/e= 403.12 (M+H); (ES-): m/e= 401.16 (M-H) ; HPLC-Method A, Rt 3.20 min.
Example 420 (Iff- [l,2,4]Triazol-3-yl) - [3- (2- trifluoro ethyl-phenyl) -isoquinolin-1-yl] -amine (IX-175) : A solution of l-chloro-3- (2-trifluoromethyl-phenyl) - isoquinoline (0.326 mmol) and Iff- [1, 2,4] triazol-3-ylamine (0.651 mmol) in ethanol (3 L) was heated at 160°C and the solvent evaporated with a stream of nitrogen. The remaining oil was then heated at 160°C for 18 hours under nitrogen. The resulting melt was dissolved in 5% methanol/dichloromethane (50 mL) , washed with saturated aqueous sodium bicarbonate (1 x 25 mL) then dried over magnesium sulfate. Purification by silica gel chromatography afforded IX-175 as a colorless oil (4% yield). XH NMR (500 MHz, CDC13) δ 9.18 (d, IH) , 8.82 (s, IH) , 7.90 (d, IH) , 7.85-7.75 (m, 3H) , 7.71-7.62 (m, 3H) , 7.60-7.55 (m, 2H) , 4.42-4.35 (m, IH) . LC-MS (ES+) 356.16 (M+H); HPLC-Method D, Rt 3.55 min.
Example 421 (2-Phenyl-quinolin-4-yl) - (Iff- [1,2,4] triazol- 3-yl) -amine (IX-176): Pale yellow solid (30% yield). XH NMR (500 MHz, d6-DMS0) δ 13.82 (s, IH) , 9.91 (s, IH) ,
8.80 (s, IH) , 8.70-8.65 (m, IH) , 8.55 (s, IH) , 8.15-8.12 (m, 2H) , 8.03-7.98 (m, IH) , 7.75-7.72 (m, IH) , 7.57-7.49 (m, 3H) . LC-MS (ES+) m/e= 288.11 (M+H); HPLC-Method D, Rt 1.55 min. .
Example 422 (Iff- [1,2,4] triazol-3-yl) - [2- (2- trifluoromethyl-phenyl) -quinolin-4-yl] -amine (IX-177) :
Pale yellow solid (46% yield) . XH NMR (500 MHz, d6-DMS0) δ 13.70 (s, IH) , 9.98 (s, IH) , 8.70 (d, IH) , 8.49 (s, IH) , 8.30 (s, IH) , 7.94-7.88 (m, 2H) , 7.80-7.68 (m, 3H) , 7.64-7.56 (m, 2H) . LC-MS (ES+) m/e= 356.18 (M+H); HPLC- Method D, Rt 1.68 min.
Example 423 (l-H-Indazol-3-yl) - [5-methyl-β-morpholin-4- yl-2- (2-trifluoromethyl-phenyl) -pyrimidin-4-yl] -amine (11-251) : Colorless film; 2 % yield; XH-NMR (500 MHz, CD3OD) δ 7.84 (m, 2H) , 7.71 (m, 3H) , 7.41 (t, 2H) , 7.14 (m, IH) , 3.74 (m, 4H) , 3.69 (m, 4H) , 1.24 (s, 3H) ppm; HPLC-Method A Rt 3.26 min; MS (FIA) 455.1 (M+H) .
BIOLOGICAL TESTING The activity of the compounds as protein kinase inhibitors may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of the activated protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/protein kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with the protein kinase bound to known radioligands.
BIOLOGICAL TESTING EXAMPLE 1 Kj DETERMINATION FOR THE INHIBITION OF GSK-3 Compounds were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al. (1998) Protein Sci . 7, 2249) . Reactions were carried out in a solution containing 100 M HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCI, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, MO) and 300 μM peptide (HSSPHQS(P03H2)EDEEE, American Peptide, Sunnyvale, CA) . Reactions were carried out at 30 °C and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase . An assay stock buffer solution was prepared containing all of the reagents listed above with the . exception of ATP and the test compound of interest. The assay stock buffer solution (175 μl) wa.s incubated in a 96 well plate with 5 μl of the test compound of interest at final concentrations spanning 0.002 μM to 30 μM at 30 °C for 10 min. Typically, a 12 point titration was conducted by preparing serial dilutions (from 10 mM compound stocks) with DMSO of the test compounds in daughter plates . The reaction was initiated by the addition of 20 μl of ATP (final concentration 20 μM) .
Rates of reaction were obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, CA) over 10 min at 30 °C. The Ki values were determined from the rate data as a function of inhibitor concentration. The following compounds were shown to have Ki values less than 0.1 μM for GSK-3: compounds II-l, II- 105, 11-33, 11-34, 11-36, 11-39, 11-38, 11-39, 11-40, II- 41, 11-42, 11-46, 11-57, 11-59, 11-60, 11-61, 11-62, II- 63, 11-64, 11-66, 11-67, 11-69, 11-70, 11-53, 11-71, II- 99, 11-73, 11-74, 11-75, 11-76, 11-77, II-7, II-8, II-9, 11-10, 11-24, 11-19, 11-78, 11-54, 11-79, 11-80, 11-81, 11-82, 11-83, 11-84, 11-56, 11-86, 11-20, 11-25, 11-26, 11-85, 11-21, 11-27, 11-28, 11-87, 11-88, 11-29, 11-11, 11-12, 11-30, 11-31, 11-13, 11-14, 11-15, 11-16, 11-17, 11-18, 11-79, 11-23, II-2, 11-90, 11-91, 11-92, 11-93, II-3, II-4, II-5, II-6, 11-94, 11-95, 11-96, 11-107, II- 108, 11-109, 11-110, 11-124, 11-125, 11-111, 11-112, II- 113, 11-114, 11-115, 11-116, 11-117, 11-118, 11-119, II- 120, 11-121, 11-208, III-8, III-7, III-9, 111-37, 111-38, 111-39, 111-40, I.II-42, 111-45, 111-46, 111-47, 111-48, 111-49, 111-51, 111-52, 111-53, 111-54, 111-55, 111-56, 111-57, 111-58, 111-59, 111-60, 111-61, 111-62, 111-63, 111-30, 111-65, 111-66, 111-67, 111-70, 111-73, 111-31, 111-75, 111-76, 111-77, 111-33, 111-34, III-106, III-108, III-109, III-lll, 111-35, 111-116, 111-117, III-118, III- 119, III-120, III-121, III-127, II.I-128, III-141, III- 130, III-131, IV-15, IV-16, IV-17, IV-20, IV-25, IV-26, IV-30, IV-34, V-3, and IX-47. The following compounds were shown to have Ki values between 0.1 and 1.0 μM for GSK-3: compounds II- 103, 11-104, 11-35, 11-44, 11-45, 11-49, 11-50, 11-97, 11-101, 11-22, 11-32, 111-41, 111-43, 111-44, 111-28, 111-50, 111-29, 111-64, 111-71, 111-74, 111-78, 111-82, 111-88, 111-90, III-102, III-105, III-107, III-110, III- 112, III-114, III-115, III-122, III-124, III-124, IV-1, III-l, III-138, III-140, III-142, III-129, III-132, III- 134, III-135, III-136, IV-1, IV-10, IV-11, IV-12, IV-13, IV-14, IV-19, IV-21, IV-22, IV-23, IV-24, IV-3, IV-4, IV- 6, IV-7, IV-8, IV-29, IV-31, IV-32, IV-33, IV-36, V-2, V- 7, IX-38, IX-154, and IX-177.
The following compounds were shown to have Ki values between 1.0 and 20 μM for GSK-3: compounds 11-43, 11-65, 11-48, 11-47, 11-51, 11-68, 11-52, 11-72, 11-100, 11-98, 11-89, 111-68, 111-81, 111-83, 111-91, 111-94,
111-95, 111-96, 111-97, 111-98, 111-99, III-100, III-101, III-103, III-123, III-137, III-139, III-143, III-145, III-146, V-4, V-8, IX-156, and IX-176. BIOLOGICAL TESTING EXAMPLE 2 Ki DETERMINATION FOR THE INHIBITION OF AURORA-2
Compounds were screened in the following manner for their ability to inhibit Aurora-2 using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249) .
To an assay stock buffer solution containing 0.1M HEPES 7.5, 10 mM MgCl2, 1 mM DTT, 25 mM NaCI, .2.5 mM phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate kinase, 10 mg/ml lactate dehydrogenase, 40 mM ATP, and
800 μM peptide (LRRASLG, American Peptide, Sunnyvale, CA) was added a DMSO solution of a compound of the present invention to a final concentration of 30 μM. The resulting mixture was incubated at 30 °C for 10 min. The reaction was initiated by the addition of 10 μL of
Aurora-2 stock solution to give a final concentration of 70 nM in the assay. The rates of reaction were obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30 °C using a BioRad Ultramark plate reader (Hercules, CA) . The Ki values were determined from the rate data as a function of inhibitor concentration.
The following compounds were shown to have Ki values less than 0.1 μM for Aurora-2: compounds 11-33, 11-34, 11-36, 11-37, 11-40, 11-41, 11-55, III-7, III-9, 111-37, 111-38, 111-39, 111-40, 111-41, 111-42, 111-44, 111-45, 111-46, 111-47, 111-48, 111-49, 111-50, 111-51, 111-52, 111-53, 111-54, 111-55, 111-56, 111-57, 111-59, 111-60, 111-61, 111-63, 111-30, 111-65, 111-66, 111-67, 111-70, 111-31, 111-76, 111-77, 111-78, 111-80, 111-32, 111-33, 111-34, III-106, III-108, III-109, III-110, III- lll, III-112, III-114, 111-35, III-115, III-116, III-117, III-118, III-119, III-120, III-121, IV-7, IV-30, IV-32, and IV-34. The following compounds were shown to have Ki values between 0.1 and 1.0 μM for Aurora-2: compounds II- 1, 11-105, 11-35, 11-38, 11-39, 11-42, 11-64, 11-70, II- 53, 11-99, 11-77, 11-79, 11-86, 11-20, 11-93, 11-94, III- 28, 111-58, 111-64, 111-71, 111-73, 111-74, 111-75, III- 102, III-105, III-107, III-113, III-124, III-l, III-130, IV-1, IV-3, IV-4, IV-6, IV-29, IV-33, and V-4.
The following compounds were shown to have Ki values between 1.0 and 20 μM for Aurora-2: compounds II- 103, 11-104, 11-57, 11-59, 11-61, 11-63, 11-67, 11-69, 11-75, 11-76, 11-10, 11-19, 11-78, 11-54, 11-80, 11-82, 11-21, 11-90, 11-91, 11-96, 11-107, 111-68, 111-79, III- 82, III-101, III-103, III-127, III-141, III-129, III-132, IV-31, V-2, IX-47, IX-154, and IX-177.
BIOLOGICAL TESTING EXAMPLE 3 CDK-2 INHIBITION ASSAY Compounds were screened in the following manner for their ability to inhibit CDK-2 using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249) .
To an assay stock buffer solution containing 0.1M HEPES 7.5, 10 mM MgCl2, 1 mM DTT, 25 mM NaCI, 2.5 mM phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate kinase, 10 mg/ml lactate dehydrogenase, 100 mM ATP, and 100 μM peptide (MAHHHRSPRKRAKKK, American Peptide, Sunnyvale, CA) was added a DMSO solution of a compound of the present invention to a final concentration of 30 μM. The resulting mixture was incubated at 30 °C for 10 min. The reaction was initiated by the addition of
10 μL of CDK-2/Cyclin A stock solution to give a final concentration of 25 nM in the assay. The rates of reaction were obtained by monitoring absorbance at 340 nm over a 5-minute read time at 30 °C using a BioRad Ultramark plate reader (Hercules, CA) . The Ki values were determined from the rate data as a function of inhibitor concentration.
BIOLOGICAL TESTING EXAMPLE 4
ERK INHIBITION ASSAY Compounds were assayed for the inhibition of ERK2 by a spectrophotometric coupled-enzyme' assay (Fox et al (1998) Protein Sci 1 , 2249) . In this assay, a fixed concentration of activated ERK2 (10 nM) was incubated with various concentrations of the compound in DMSO (2.5 %) for 10 min. at 30°C in 0.1 M HEPES buffer, pH 7.5, containing- 10 mM MgC^, 2.5 mM phosphoenolpyruvate, 200 μM NADH, 150 μg/mL pyruvate kinase, 50 μg/mL lactate dehydrogenase, and 200 μM erktide peptide. The reaction was initiated by the addition of 65 μM ATP. The rate of decrease of absorbance at 340 nM was monitored. The IC5o was evaluated from the rate data as a function of inhibitor concentration. The following compounds were shown to have a Ki value of <lμM for ERK-2: III-109, III-lll, III-115, III-
117, III-118, III-120, and IV-4.
The following compounds were shown to have a Ki value of between lμM and 12UM for ERK-2: III-63, III-40, and III-108.
BIOLOGICAL TESTING EXAMPLE 5 AKT INHIBITION ASSAY Compounds were screened for their ability to inhibit AKT using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249). Assays were carried out in a mixture of 100 mM HEPES 7.5, 10 mM MgC12, 25 mM NaCI , 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 170 μM ATP (Sigma Chemicals) and 200 μM peptide (RPRAATF, American Peptide, Sunnyvale, CA) . Assays were carried out at 30 °C and 45 nM AKT. Final concentrations of the components of the coupled enzyme system were 2.5 M phpsphoenolpyruvate, 300 μM NADH, 30 μg/ML pyruvate kinase and 10 μg/ml lactate dehydrogenase.
An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of AKT, DTT, and the test compound of interest. 56 μl of the stock solution was placed in a 384 well plate followed by addition of 1 μl of 2 mM DMSO' stock containing the test compound (final compound concentration 30 uM) . The plate was preincubated for about 10 minutes at 30°C and the reaction initiated by addition of 10 μl of enzyme (final concentration 45 nM) and 1 mM DTT. Rates of reaction were obtained using a BioRad Ultramark plate reader (Hercules, CA) over a 5 minute read time at 30 °C. Compounds showing greater than 50% inhibition versus standard wells containing the assay mixture and DMSO without test compound were titrated to determine IC50 values.
BIOLOGICAL TESTING EXAMPLE 6 SRC INHIBITION ASSAY The compounds were evaluated as inhibitors of human Src kinase using either a radioactivity-based assay or spectrophotometric assay.
Src Inhibition Assay A: Radioactivity-based Assay The compounds were assayed as inhibitors of full length recombinant human Src kinase (from Upstate Biotechnology, cat. no. 14-117) expressed and purified from baculo viral cells. Src kinase activity was monitored by following the incorporation of 33P from ATP into the tyrosine of a random poly Glu-Tyr polymer substrate of composition, Glu:Tyr = 4:1 (Sigma, cat. no. P-0275) . The following were the final concentrations of the assay components: 0.05 M HEPES, pH 7.6, 10 mM MgCl2, 2 mM DTT, 0.25 mg/ml BSA, 10 μM ATP (1-2 μCi 33P-ATP per reaction) , 5 mg/ml poly Glu-Tyr, and 1-2 units of recombinant human Src kinase. In a typical assay, all the reaction components with the exception of ATP were pre-mixed and aliquoted into assay plate wells. Inhibitors dissolved in DMSO were added to the wells to give a final DMSO concentration of 2.5%. The assay plate was incubated at 30 °C for 10 min before initiating the reaction with 33P-ATP. After 20 min of reaction, the reactions were quenched with 150 μl of 10% trichloroacetic acid (TCA) containing 20 mM Na3P04. The quenched samples were then transferred to a 96-well filter plate (Whatman, UNI-Filter GF/F Glass Fiber
Filter, cat no. 7700-3310) installed on a filter plate vacuum manifold. Filter plates were washed four times with 10% TCA containing 20 mM Na3P04 and then 4 times with methanol. 200μl of scintillation fluid was then added to each well. The plates were sealed and the amount of radioactivity associated with the filters was quantified on a TopCount scintillation counter. The radioactivity incorporated was plotted as a function of the inhibitor concentration. The data was fitted to a competitive inhibition kinetics model to get the Ki for the compound.
Src Inhibition Assay B: Spectrophotometric Assay The ADP produced from ATP by the human recombinant Src kinase-catalyzed phosphorylation of poly Glu-Tyr substrate was quanitified using a coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249) . In this assay one molecule of NADH is oxidised to NAD for every molecule of ADP produced in the kinase reaction. The disappearance of NADH can be conveniently followed at 340 nm.
The following were the final concentrations of the assay components: 0.025 M HEPES, pH 7.6, 10 mM MgCl2, 2 mM DTT, 0.25 mg/ml poly Glu-Tyr, and 25 nM of recombinant human Src kinase. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 200 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase. In a typical assay, all the reaction components with the exception of ATP were pre-mixed and aliquoted into assay plate wells. Inhibitors dissolved in DMSO were added to the wells to give a final DMSO concentration of 2.5%. The assay plate was incubated at 30 °C for 10 min before initiating the reaction with 100 μM ATP. The absorbance change at 340 nm with time, the rate of the reaction, was monitored on a molecular devices plate reader. The data of rate as a function of the inhibitor concentration was fitted to cσmpettive inhibition kinetics model to get the K for the compound.
The following compounds were shown to have a Ki value of <100nM on SRC: 111-31, 111-32, 111-33, 111-34, 111-35, 111-47, 111-65, 111-66, 111-37, 111-38, 111-39, 111-40, 111-42, 111-44, 111-48, 111-49, 111-70, 111-45, 111-78, 111-76, and IV- 32.
The following compounds were shown to have a Ki value of between lOOnM and lμM for SRC: 111-63, 111-71, 111-75, 111-73, 111-72, 111-74, 111-80, 111-50, IV-30.
The following compounds were shown to have a Ki value of between lμM and 6μM for SRC: III-79, IV-1, and
IV-31.
While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments which have been represented by way of example.

Claims (25)

We claim:
1. A compound of formula VII:
VII
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
G is Ring C or Ring D;
Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2 , 4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1, any non-ortho carbon position on Ring C is optionally and independently substituted by -R5, and two adjacent substituents on Ring C are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted by halo, oxo, or -R8;
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo or -R5, and at any substitutable ring nitrogen by -R4, provided that when Ring D is a six-membered aryl or heteroaryl ring, -R5 is hydrogen at each ortho carbon position of Ring D;
R1 is selected from -halo, -CN, -N0 , T-V-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or Cι_6 aliphatic group, said phenyl, heteroaryl, and heterocyclyl rings each optionally substituted by up to three groups independently selected from halo, oxo, or -R8, said Cι-6 aliphatic group optionally substituted with halo, cyano, nitro, or oxygen, or Rx and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
Ry is hydrogen or T-R3";
T is a valence bond or a Cι-4 alkylidene chain;
R2 and R2' are independently selected from -R, -T-W-R6, or R2 and R2' are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable carbon on said fused ring formed by R2 and R2' is substituted by halo, oxo, -CN, -N02, -R7, or -V-R6, and any substitutable nitrogen on said ring formed by R2 and R2' is substituted by R4;
R3" is selected from an optionally substituted group selected from C3-ι0 carbocyclyl, C6-ιo aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; each R is independently selected from hydrogen or an optionally substituted group selected from Cχ.6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms ; each R4 is independently selected from -R7, -COR7,
-C02 (optionally substituted Cχ-6 aliphatic) , -C0N(R7)2, or -S02R7, or two R4 on the same nitrogen are taken together to form a 5-8 membered heterocyclyl or heteroaryl ring; each R5 is independently selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N0 , -CN, -S(0)R, -S02R, -SR, -N(R4)2, -C0N(R4)2, -S02N(R4)2, -OC(=0)R, -N(R4)COR, -N(R4) C02 (optionally substituted Cι_6 aliphatic) , -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N (R4) CON (R4) 2, -N(R4)S02N(R4)2, -N(R4)S02R, or -OC (=0) N (R4) 2, or R5 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring C;
V is -0-, -S-, -SO-, -S02-, -N(R6)S02-, -S02N(R6)-, -N(R6)-, -CO-, -CO2-, -N(R6)CO-, -N(R6)C(0)0-, -N(R6)CON(R6) -, -N(R6)S02N(R6) -, -N (R6) N (R6) - , -C(0)N(R6)-, -0C(0)N(R6)-, -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6)-, -C (R6) 2N (R6) - , -C(R6)2N(R6)C(0) -, -C(R6)2N(R6)C(0)0-, -C (R6) =NN (R6) - , -C(R6)=N-0-, -C(Rδ)2N(R6)N(R6) -, -C (R6) 2N (R6) S02N (R6) - , or -C(R6)2N(R6)C0N(R6) -;
W is -C(R6)20-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2S02-, -C(R6)2S02N(R6) -, -C(R6)2N(R6) -, -CO-, -C02-, -C(R6)OC(0) -, -C(R6)0C(0)N(R6) -, -C (R6) 2N (R6) CO- , -C(R6)2N(R6)C(0)0-, -C(R6)=NN(R6) -, -C(R6)=N-0-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)S02N(R6) -, -C(R6)2N(R6)CON(R6) -, or -CON(R6)-; each R6 is independently selected from hydrogen, an optionally substituted Cι_4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; each R7 is independently selected from hydrogen or an optionally substituted Cι_6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; each R8 is independently selected from an optionally substituted Cι_4 aliphatic group, -OR6, -SR6, -COR6, -S02R6, -N(R6)2, -N(R6)N(R6)2, -CN, -N02, -CON(R6)2, or -C02R6; and
R9 is selected from -R, halo, -OR, -C(=0)R, -C02R, -COCOR, -N02, -CN, -S(0)R, -S02R, -SR, -N(R4)2, -CON(R4)2, -S02N(R)2, -OC(=0)R, -N(R )COR, -N (R4) C02 (optionally substituted Cι-6 aliphatic) , -N(R4)N(R4) 2, -C=NN(R )2, -C=N-OR, -N(R4)CON(R4)2, -N (R4) S02N (R4) 2, -N(R4)S02R, or -OC(=0)N(R4)2.
2. The compound according to claim 1, wherein said compound has one or more features selected from the group consisting of:
(a) Ring C is an optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and R1 is -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2 - -C02R6, -CONH2, -NHCOR6, -OC(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2, 3 , -tetrahydroquinolinyl,
2, 3 -dihydro-Iff-isoindolyl, 2, 3 -dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Ry is T-R3", wherein T is a valence bond or a methylene; and
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cx-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
3. The compound according to claim 2, wherein: )
(a) Ring C is an optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is selected from a naphthyl, quinolinyl or isoquinolinyl ring, and Rx is -halo, an optionally substituted Cι-6 aliphatic group, phenyl, -COR6, -OR6, -CN, -S02R6, -S02NH2, -N(R6)2, -C02R6, -C0NH2, -NHCOR6, -OC(0)NH2, or -NHS02R6; or Ring D is an optionally substituted ring selected from a phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4- tetrahydroisoquinolinyl, 1,2,3, -tetrahydroquinolinyl,
2 , 3 -dihydro-Iff-isoindolyl , 2,3 -dihydro-Iff-indolyl , isoquinolinyl, quinolinyl, or naphthyl ring;
(b) Ry is T-R3", wherein T is a valence bond or a methylene; and
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a Cχ,6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring.
4. The compound according to claim 2 , wherein said compound has one or more features selected from the group consisting of:
(a) Ring C is an optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and Rx is -halo, a Cι_6 haloaliphatic group, a Cι-6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2, 3 , 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2 , 3 -dihydro-Iff- isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from C3-6 carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Cι-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6 -membered carbocyclo ring; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02, -N(R4)2, optionally substituted Cχ.6 aliphatic group, -OR, -C(0)R, -C02R, -CONH(R4), -N(R4)C0R, -S02N(R4)2, or -N(R4)S02R.
5. The compound according to claim 4, wherein:
(a) Ring C is a n optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and Rx is -halo, a Cχ-6 haloaliphatic group, a Cι_6 aliphatic group, phenyl, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1,2, 3, 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, 2, 3 -dihydro-Iff-isoindolyl, 2,3- dihydro-Iff-indolyl, isoquinolinyl, quinolinyl, or naphthyl ;
(b) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from C3_6 carbocyclyl, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(c) R2' is hydrogen and R2 is hydrogen or a substituted or unsubstituted group selected from aryl, or a Cι-6 aliphatic group, or R2 and R2' are taken together with their intervening atoms to form a substituted or unsubstituted benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -halo, -CN, -N02, -N(R)2, optionally substituted Cχ.6 aliphatic group, -OR, -C(0)R, -C02R, -C0NH(R4), -N(R4)COR, -S02N(R4)2, or -N(R4)S02R.
6. The compound according to claim 4 , wherein said compound has one or more of the features selected from the group consisting of:
(a) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(b) Ring C is an optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and R1 is -halo, a Cι-4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1 , 2 , 3 , 4 -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ;
(c) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cι-4 alkyl, -Ci-4 haloalkyl, -N02, -0 (Ci-4 alkyl) , -C02 (Cι- alkyl) , -CN, -S02 (Ci-4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02 (Ci_4 alkyl) , -NHC(O) (d-4 alkyl) , -C(0)NH2/ or -CO (Cι-4 alkyl) , wherein the (Ci_4 alkyl) is a straight, branched, or cyclic alkyl group; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Cι-4 aliphatic), -N(Cι-4 aliphatic)2, -0(Cι- aliphatic), Cι_4 aliphatic, and -C02 (Cι_4 aliphatic).
7. The compound according to claim 6, wherein:
(a) Ry is T-R3", wherein T is a valence bond or a methylene and R3" is an optionally substituted group selected from phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring;
(b) Ring C is an optionally substituted ring selected from phenyl or pyridinyl, wherein when Ring C and two adjacent substituents thereon form a bicyclic ring system, the bicyclic ring system is a naphthyl ring, and Rx is -halo, a Cι_4 aliphatic group optionally substituted with halogen, or -CN; or Ring D is an optionally substituted ring selected from phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 1, 2 , 3 , -tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl, isoquinolinyl, quinolinyl, or naphthyl ; , (c) R2 and R2' are taken together with their intervening atoms to form a benzo, pyrido, pyrimido or partially unsaturated 6-membered carbocyclo ring optionally substituted with -halo, -N(R4)2, -Cι_4 alkyl, -Ci-4 haloalkyl, -N02, -0 (Cι_4 alkyl) , -C02 (Cι-4 alkyl) , -CN, -S02(Ci_4 alkyl) , -S02NH2, -0C(0)NH2, -NH2S02 (Cι-4 alkyl) , -NHC(O) (Ci-4 alkyl) , -C(0)NH2, or -CO (Cι-4 alkyl) , wherein the (Ci-4 alkyl) is a straight, branched, or cyclic alkyl group; and
(d) Ring D is substituted by oxo or R5, wherein each R5 is independently selected from -Cl, -F, -CN, -CF3, -NH2, -NH(Cι_4 aliphatic), -N(Cι_ aliphatic)2, -0(Cι-4 aliphatic), Cι_4 aliphatic, and -C02(Cι_4 aliphatic).
8. The compound according to claim 7, wherein said compound is selected from Table 6.
9. A composition comprising a compound according to any of claims 1-8 and a pharmaceutically acceptable carrier.
10. The composition according to claim 9 further comprising a second therapeutic agent.
11. A method of inhibiting GSK-3 or Aurora activity in a patient comprising the step of administering to said patient a therapeutically effective amount of the composition according to claim 9.
12. The method according to claim 11, wherein said method inhibits GSK-3 activity in a patient.
13. A method of inhibiting GSK-3 or Aurora activity in a biological sample comprising contacting said biological sample with the compound according to claim 1.
14. A method of treating a disease that is alleviated by treatment with an GSK-3 inhibitor, said method comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of the composition according to claim 9.
15. The method according to claim 14 further comprising the step of administering to said patient a second therapeutic agent.
16. The method according to claim 14, wherein said disease is diabetes.
17. The method according to claim 14, wherein said disease is Alzheimer's disease.
18. The method according to claim 14, wherein said disease is schizophrenia.
19. A method of enhancing glycogen synthesis in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 9.
20. A method of lowering blood levels of glucose in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 9.
21. A method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 9.
22. A method of inhibiting the phosphorylation of β-catenin in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 9.
23. A method of treating a disease that is alleviated by treatment with an aurora inhibitor, which method comprises the step of administering to a patient in need of such a treatment a therapeutically effective amount of the composition according to claim 9.
24. The method according to claim 23, further comprising the step of administering to said patient a second therapeutic agent.
25. The method according to claim 23 wherein said disease is cancer.
AU2001296871A 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors Abandoned AU2001296871A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006201265A AU2006201265B2 (en) 2000-09-15 2006-03-21 Pyrazole Compounds Useful As Protein Kinase Inhibitors

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23279500P 2000-09-15 2000-09-15
US60232795 2000-09-15
US25788700P 2000-12-21 2000-12-21
US60257887 2000-12-21
US28694901P 2001-04-27 2001-04-27
US60286949 2001-04-27
PCT/US2001/042152 WO2002022608A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001296871A1 true AU2001296871A1 (en) 2002-03-26

Family

ID=27398347

Family Applications (9)

Application Number Title Priority Date Filing Date
AU2001294558A Abandoned AU2001294558A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A Abandoned AU2001296871A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001292670A Abandoned AU2001292670A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A Abandoned AU2001290912A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290914A Abandoned AU2001290914A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001296875A Abandoned AU2001296875A1 (en) 2000-09-15 2001-09-14 Triazole compounds useful as protein kinase inhibitors
AU2001291013A Abandoned AU2001291013A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290944A Abandoned AU2001290944A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2008252044A Abandoned AU2008252044A1 (en) 2000-09-15 2008-12-03 Compounds Useful as Protein Kinase Inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001294558A Abandoned AU2001294558A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors

Family Applications After (7)

Application Number Title Priority Date Filing Date
AU2001292670A Abandoned AU2001292670A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A Abandoned AU2001290912A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290914A Abandoned AU2001290914A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001296875A Abandoned AU2001296875A1 (en) 2000-09-15 2001-09-14 Triazole compounds useful as protein kinase inhibitors
AU2001291013A Abandoned AU2001291013A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2001290944A Abandoned AU2001290944A1 (en) 2000-09-15 2001-09-14 Pyrazole compounds useful as protein kinase inhibitors
AU2008252044A Abandoned AU2008252044A1 (en) 2000-09-15 2008-12-03 Compounds Useful as Protein Kinase Inhibitors

Country Status (23)

Country Link
US (7) US7098330B2 (en)
EP (8) EP1318814B1 (en)
JP (9) JP4105949B2 (en)
KR (4) KR20030032035A (en)
CN (3) CN1469875A (en)
AP (1) AP2003002762A0 (en)
AT (8) ATE326459T1 (en)
AU (9) AU2001294558A1 (en)
BR (1) BR0114088A (en)
CA (8) CA2422299C (en)
DE (8) DE60120194T2 (en)
DK (1) DK1318997T3 (en)
ES (3) ES2266258T3 (en)
HU (4) HUP0302173A2 (en)
IL (6) IL154786A0 (en)
MX (8) MXPA03002299A (en)
NO (4) NO20031188L (en)
NZ (4) NZ525014A (en)
PE (1) PE20020451A1 (en)
PL (1) PL361676A1 (en)
PT (2) PT1317448E (en)
TW (1) TWI303636B (en)
WO (8) WO2002022603A1 (en)

Families Citing this family (407)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638073D1 (en) * 1996-09-04 2009-12-24 Intertrust Tech Corp Reliable infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, trade-timing and automation, distributed processing and rights management
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
NZ519121A (en) 1999-12-24 2004-05-28 Aventis Pharma Ltd Azaindoles useful as Syk kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR20030032035A (en) * 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002050073A1 (en) * 2000-12-19 2002-06-27 Smithkline Beecham P.L.C. Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
MXPA03005610A (en) * 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
KR100847169B1 (en) 2000-12-21 2008-07-17 글락소 그룹 리미티드 Pyrimidinamine as an angiogenesis regulator
US7276523B2 (en) 2001-03-30 2007-10-02 Smithkline Beecham Corporation Aminopyridine derivatives as estrogen receptor modulators
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003018563A1 (en) 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
BR0212841A (en) 2001-09-26 2004-08-03 Pharmacia Italia Spa Active aminoindazole derivative as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
TWI330183B (en) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
SE0104140D0 (en) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002357164A1 (en) 2001-12-17 2003-06-30 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2003062209A2 (en) 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RU2004126671A (en) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS
DE60332433D1 (en) * 2002-03-15 2010-06-17 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003224025A1 (en) * 2002-04-05 2003-10-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg p38 kinase inhibitors for treating mucus hypersecretion
ES2340475T3 (en) 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated CRYSTALLIZED STRUCTURE OF AURORA-2 PROTEIN AND ITS UNION POCKETS.
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
EP1527070B1 (en) 2002-06-14 2013-01-09 Merck Serono SA Azole methylidene cyanide derivatives and their use as protein kinase modulators
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004007504A1 (en) * 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
CA2494367A1 (en) * 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
DK1534286T3 (en) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
KR20050032105A (en) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compositions useful as inhibitors of gsk-3
SI1532145T1 (en) * 2002-08-02 2007-02-28 Vertex Pharma Pyrazole compositions useful as inhibitors of gsk-3
JP2006507237A (en) * 2002-08-13 2006-03-02 メルク シャープ エンド ドーム リミテッド Phenylpyridazine derivatives as ligands for GABA receptors
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
FR2844267B1 (en) * 2002-09-05 2008-02-15 Aventis Pharma Sa NOVEL DERIVATIVES OF AMINOINDAZOLES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
PL374946A1 (en) * 2002-09-05 2005-11-14 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004024159A1 (en) * 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
JP2006512314A (en) 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Use of the compositions as JAK inhibitors and other protein kinase inhibitors
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
MXPA05005477A (en) * 2002-11-21 2005-07-25 Chiron Corp 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer.
CN1735607B (en) * 2002-11-21 2010-06-09 诺华疫苗和诊断公司 2,4,6-Trisubstituted pyrimidines as phosphatidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co Nitrogen-containing heterocyclic compounds and medicinal use thereof
MXPA05005554A (en) 2002-12-12 2005-07-26 Aventis Pharma Sa Aminoindazole derivatives and use thereof as kinase inhibitors.
FR2848554A1 (en) * 2002-12-12 2004-06-18 Aventis Pharma Sa New aminoindazole derivatives are kinase inhibitors, useful in the treatment of neurodegenerative diseases, obesity, metabolic disorders, diabetes, hypertension, polycystic ovarian syndrome, cancers and other disorders
US20040156869A1 (en) 2002-12-13 2004-08-12 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
JP2006521398A (en) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド Bicyclic pyrimidine inhibitors of TGFβ
AU2004230928B2 (en) * 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
CA2522430A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
WO2004096808A1 (en) * 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
US20070032537A1 (en) * 2003-06-13 2007-02-08 Arena Pharmaceuticals, Inc. 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
KR20060016817A (en) * 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 Small molecule toll-like receptor (TLL) antagonists
TW200510373A (en) 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
BRPI0412259B1 (en) 2003-07-22 2019-08-20 Astex Therapeutics Limited 3,4-Disubstituted 1H-pyrazole compounds as cyclin-dependent kinase (CDK) modulators, their uses, process for their preparation and pharmaceutical composition
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN1894222A (en) * 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 Fused pyrimidine compounds as voltage-gated ion channel inhibitors
AU2004263148B2 (en) * 2003-08-06 2008-08-21 Vertex Pharmaceuticals, Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
EP1668013B1 (en) * 2003-09-23 2012-02-22 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
GB0323137D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
US7579349B2 (en) * 2003-10-17 2009-08-25 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
US8455489B2 (en) * 2003-11-10 2013-06-04 Exelixis, Inc. Substituted pyrimidine compositions and methods of use
CA2545258A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
ES2360703T3 (en) * 2003-12-03 2011-06-08 Ym Biosciences Australia Pty Ltd INHIBITORS OF THE TUBULINA.
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
CN1914204A (en) * 2003-12-09 2007-02-14 弗特克斯药品有限公司 Naphthyridine derivatives and their use as modulators of muscarinic receptors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
UA86614C2 (en) 2004-01-23 2009-05-12 Амген Инк Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
US7459457B2 (en) 2004-04-13 2008-12-02 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
MY139355A (en) * 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP1598348A1 (en) * 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2006012624A2 (en) * 2004-07-21 2006-02-02 The Regents Of The University Of California Mechanism-based crosslinkers
JP2008510734A (en) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
DE602005027081D1 (en) 2004-08-19 2011-05-05 Dsm Ip Assets Bv METHOD FOR THE RECTIFICATION OF VITAMIN E ACETATE
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
EP1789413A1 (en) 2004-09-13 2007-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (en) 2004-09-24 2006-12-06 Hoffmann La Roche DERIVATIVES OF FTALAZINONA; ITS OBTAINING AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
BRPI0516751A (en) 2004-09-30 2008-09-16 Tibotec Pharm Ltd bicyclic pyrimidines that inhibit hcv
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
ATE479687T1 (en) 2004-10-15 2010-09-15 Takeda Pharmaceutical KINASE INHIBITORS
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
JP2008518955A (en) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ Pyridazine compounds and methods
CN101087766B (en) 2004-11-02 2011-09-07 西北大学 Pyridazine compounds, compositions and methods
MX2007005857A (en) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Kinase inhibitors.
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2008525422A (en) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク Heteroaromatic derivatives useful as anticancer agents
JP5208516B2 (en) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド Pyrimidine derivatives as kinase modulators and methods of use
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
MX2007009017A (en) * 2005-01-26 2007-09-19 Schering Corp 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer.
PT2383268E (en) * 2005-02-04 2015-12-21 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
US20080161278A1 (en) * 2005-03-23 2008-07-03 Astrazeneca Ab 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
KR20070122194A (en) 2005-03-25 2007-12-28 티보텍 파마슈티칼즈 리미티드 Heterobicyclic Inhibitors of HCl
CA2602372A1 (en) * 2005-04-05 2006-10-12 Astrazeneca Ab Pyrimidine derivatives for use as anticancer agents
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
AU2006241825A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
US8232278B2 (en) 2005-06-24 2012-07-31 Gilead Sciences, Inc. Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
AU2006279376B2 (en) * 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
KR20140025610A (en) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. Substituted pyrazole compounds
CN101316587B (en) * 2005-09-30 2013-04-03 迈卡纳治疗股份有限公司 Substituted pyrazole compounds
ES2274712B1 (en) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. NEW IMIDAZOPIRIDINE DERIVATIVES.
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
HRP20120824T1 (en) 2005-10-28 2012-11-30 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
PL1951684T3 (en) 2005-11-01 2017-03-31 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BRPI0619706A2 (en) * 2005-11-03 2011-10-11 Vertex Pharma compound, composition, method for inhibiting aurora kinase activity in a biological sample, method for treating a proliferative disorder in a patient, method for treating cancer in an individual
NZ567892A (en) 2005-11-08 2010-12-24 Vertex Pharma Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CA2633584A1 (en) * 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
TWI424999B (en) 2006-01-17 2014-02-01 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
KR20080103996A (en) 2006-02-16 2008-11-28 쉐링 코포레이션 Pyrrolidine Derivatives as ERP inhibitors
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080145A1 (en) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
AU2007235237B2 (en) * 2006-04-11 2011-08-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
MY154798A (en) 2006-06-27 2015-07-31 Takeda Pharmaceutical Fused cyclic compounds
WO2008001070A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
SI2049500T1 (en) * 2006-07-06 2012-01-31 Array Biopharma Inc CYCLOPENTA ?áD?å PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITORS
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
KR20090064418A (en) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 Combination with 4-acylaminopyridine derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2009119181A (en) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS Glycogen synthase-kinase-3 inhibitors
DE602007004750D1 (en) * 2006-11-02 2010-03-25 Vertex Pharma AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINOPYRIDINES AND AMINOPYRIMIDINES
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008077650A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
MX2009008341A (en) 2007-02-06 2009-08-12 Novartis Ag Pi 3-kinase inhibitors and methods of their use.
AU2008215948A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2008100412A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Pharmaceutical composition
JP5520057B2 (en) * 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) * 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
AU2008226466B2 (en) * 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
AU2008247592A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2008137621A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2688584A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101687863B (en) * 2007-05-04 2012-09-12 阿斯利康(瑞典)有限公司 Amino-thiazolyl-pyrimidine derivatives and their use in the treatment of cancer
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA2687966A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2166849A4 (en) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc Substituted pyrazole compounds
EP2166854A4 (en) * 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES
CN101687840A (en) 2007-06-25 2010-03-31 霍夫曼-拉罗奇有限公司 Benzimidazole amido derivatives as kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
MX2009014013A (en) * 2007-07-05 2010-01-28 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors.
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5282091B2 (en) 2007-07-25 2013-09-04 ブリストル−マイヤーズ スクイブ カンパニー Triazine kinase inhibitor
CN101790532B (en) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 Preparation method of 5-fluoro-1H-pyrazolo [3,4-b ] pyridine-3-amine and derivatives thereof
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
AU2008326784B2 (en) * 2007-11-20 2014-04-24 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
PL2225230T3 (en) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
DK2639224T3 (en) * 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
JP2011032169A (en) * 2007-12-11 2011-02-17 Genecare Research Institute Co Ltd 4-aminopyrimidine derivative and medicinal composition containing the compound
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
ES2426092T3 (en) * 2008-01-09 2013-10-21 Array Biopharma, Inc. 5H-Cyclopenta [d] pyrimidines as AKT protein kinase inhibitors
ES2403284T3 (en) 2008-01-09 2013-05-17 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN102015693B (en) 2008-02-21 2014-10-29 默沙东公司 Compounds as ERK inhibitors
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
JP2011513483A (en) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrimidines and pyridines useful as inhibitors of protein kinases
CL2009000904A1 (en) * 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
BRPI0908637B8 (en) 2008-05-21 2021-05-25 Ariad Pharma Inc compound and pharmaceutical composition thereof
WO2009150462A1 (en) * 2008-06-11 2009-12-17 Astrazeneca Ab Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
JP2011526912A (en) * 2008-07-03 2011-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Naphthyridinone as a protein kinase inhibitor
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
MX2011001196A (en) 2008-07-31 2011-05-30 Genentech Inc Pyrimidine compounds, compositions and methods of use.
EP2312945A4 (en) * 2008-08-13 2012-05-09 Merck Sharp & Dohme PURINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2010031056A2 (en) * 2008-09-15 2010-03-18 The Regents Of The University Of California Methods and compositions for modulating ire1, src, and abl activity
MX2011003447A (en) * 2008-09-30 2011-07-29 Astrazeneca Ab Heterocyclic jak kinase inhibitors.
US20110257208A1 (en) * 2008-11-19 2011-10-20 Matthew Duncton Compounds useful as faah modulators and uses thereof
KR101048448B1 (en) 2008-11-21 2011-07-11 한국화학연구원 Novel pyrazolo [4,3-ｂ] pyridine derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof and pharmaceutical compositions containing the same as active ingredients
PL2393360T3 (en) 2009-02-05 2016-04-29 Takeda Pharmaceuticals Co Pyridazinone compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2401267B1 (en) * 2009-02-27 2014-01-15 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and their use in methods
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
CN102548558B (en) 2009-03-23 2014-04-30 Msdk.K.公司 Novel aminopyridine derivatives having Aurora A selective inhibitory action
CA2755810A1 (en) * 2009-03-24 2010-09-30 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
EP2411011A4 (en) * 2009-03-24 2012-08-15 Msd Kk NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE INHIBITORY ACTION OF AURORA A
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (en) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
US9078902B2 (en) 2009-06-09 2015-07-14 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
CN102573481A (en) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 Ureidophenyl substituted triazine derivatives and their therapeutical applications
CA2766151A1 (en) * 2009-06-24 2010-12-29 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (en) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
US20110053916A1 (en) * 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
CN102020657A (en) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 Condensed heteroaryl derivative, and preparation method and application thereof
US8288381B2 (en) * 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
RU2515541C2 (en) 2009-11-12 2014-05-10 Ф.Хоффманн-Ля Рош Аг N-7 substituted purines and pyrazolopyrimidines, compositions thereof and methods for use
AU2011215638B2 (en) 2010-02-11 2016-04-28 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
DK3150198T3 (en) 2010-04-07 2021-11-01 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) -CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIODIN-2-YL) BENZOIC ACID AND ADMINISTRATION
EP2571867B1 (en) 2010-05-21 2015-11-04 Noviga Research AB Novel pyrimidine derivatives
CN105837519A (en) 2010-06-04 2016-08-10 霍夫曼-拉罗奇有限公司 Aminopyrimidine derivatives as lrrk2 modulators
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
JP5998142B2 (en) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103313978B (en) 2010-11-10 2015-04-15 霍夫曼-拉罗奇有限公司 Pyrazole aminopyrimidine derivatives as LRRK2 modulators
ES2650744T3 (en) 2010-12-14 2018-01-22 Electrophoretics Limited Casein kinase 1 delta inhibitors (CK1delta)
CA2822565A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
WO2012135779A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
RU2477723C2 (en) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Protein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical composition
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
HK1197232A1 (en) 2011-08-25 2015-01-09 霍夫曼-拉罗奇有限公司 Serine/threonine pak1 inhibitors
PT2755483T (en) 2011-09-14 2019-02-18 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
MX2014003501A (en) 2011-09-22 2014-07-22 Pfizer Pyrrolopyrimidine and purine derivatives.
UA111503C2 (en) 2011-09-27 2016-05-10 Новартіс Аг 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-ONE AS INHIBITORS OF THE MUTANT IDH
CA2854248A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag 2,4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
HK1207072A1 (en) * 2012-03-16 2016-01-22 埃克希金医药品有限公司 3,5-diaminopyrazole kinase inhibitors
AU2013237226A1 (en) * 2012-03-19 2014-10-09 Emory University Quinazoline compounds and their use in therapy
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
SI3459942T1 (en) 2012-04-24 2021-05-31 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
KR102091895B1 (en) * 2012-05-03 2020-04-14 제넨테크, 인크. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
JP6218808B2 (en) * 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Pyrazole aminopyrimidine derivatives as LRRK2 modulators
BR112014032346A2 (en) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals methods for treating tyrosine kinase inhibitor resistant malignancies in patients with genetic polymorphisms or ahi1 mutation dysregulations employing dianhydrogalactitol, diacetyl anhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
KR102215272B1 (en) 2012-09-28 2021-02-15 이그니타, 인코포레이티드 Azaquinazoline inhibitors of atypical protein kinase c
JO3470B1 (en) 2012-10-08 2020-07-05 Merck Sharp & Dohme 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
RU2015118647A (en) * 2012-11-20 2017-01-10 Дженентек, Инк. AMINOPYRIMIDINE COMPOUNDS AS T790M MUTANT EGFR INHIBITORS
MX385385B (en) 2012-11-21 2025-03-18 Ptc Therapeutics Inc SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS.
CN103012428A (en) 2013-01-08 2013-04-03 中国药科大学 4-(five-membered heterocycle pyrimidin/substituted pyridine) amino-1H-3-pyrazolecarboxamide CDK (cyclin dependent kinase)/Aurora dual inhibitor and application thereof
CN105120862A (en) 2013-01-08 2015-12-02 萨穆梅德有限公司 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
EP2951170B1 (en) * 2013-02-04 2018-10-24 Janssen Pharmaceutica NV Flap modulators
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
EP2769722A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
JO3377B1 (en) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
ME03336B (en) 2013-03-12 2019-10-20 Vertex Pharma DNA-PK INHIBITORS
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN105764501A (en) 2013-07-26 2016-07-13 现代化制药公司 Compositions for improving the therapeutic benefit of bisantrene
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
WO2015028848A1 (en) * 2013-09-02 2015-03-05 Piramal Enterprises Limited Bicyclic heterocyclic compounds as multi-kinase inhibitors
JP6427197B2 (en) 2013-10-03 2018-11-21 クラ オンコロジー， インコーポレイテッド Inhibitors of ERK and methods of use
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
RU2675270C2 (en) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Co-crystals and pharmaceutical compositions containing same
PL3068392T3 (en) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
WO2015076801A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted triazine bmi-1 inhibitors
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
EP3071553A4 (en) * 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104672250B (en) * 2013-11-29 2017-11-07 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
CN109045032A (en) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 Aminopyridines and application method
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
CN104926795B (en) * 2014-03-17 2017-11-10 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
TWI675836B (en) * 2014-03-25 2019-11-01 美商伊格尼塔公司 Azaquinazoline inhibitors of atypical protein kinase c
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (en) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
CN107110831B (en) 2014-11-18 2020-02-21 弗特克斯药品有限公司 Methods for conducting high-throughput experiments with high-performance liquid chromatography
TWI704151B (en) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk inhibitors
CN107074874B (en) * 2014-12-22 2019-04-23 伊莱利利公司 ERK inhibitor
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3070084A1 (en) * 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
US10752612B2 (en) 2015-04-17 2020-08-25 Ludwig Institute For Cancer Research Ltd PLK4 inhibitors
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024015A1 (en) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
KR20180080262A (en) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 Treatment of osteoarthritis
GB201604647D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP7010851B2 (en) 2016-06-01 2022-02-10 バイオスプライス セラピューティクス インコーポレイテッド N- (5- (3- (7- (3-Fluorophenyl) -3H-imidazole [4,5-c] pyridin-2-yl) -1H-indazole-5-yl) pyridin-3-yl)- Method for preparing 3-methylbutaneamide
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
KR102593742B1 (en) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 Methods of using indazole-3-carboxamide and their use as WNT/B-catenin signaling pathway inhibitors
CA3041332A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
IT201700047189A1 (en) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia COMPOUNDS AND COMPOSITIONS FOR CANCER TREATMENT, RETINAL DISORDERS AND CARDIOMYOPATHIES
AR112027A1 (en) * 2017-06-15 2019-09-11 Biocryst Pharm Inc ALK 2 KINASE INHIBITORS CONTAINING IMIDAZOLE
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
CN110582489B (en) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
CN110582491B (en) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
CN109384774B (en) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 Polysubstituted pyrazine/triazine amide compounds and preparation method and application thereof
MX2020004255A (en) 2017-10-27 2020-07-29 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor.
GB201801226D0 (en) * 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2020005935A1 (en) * 2018-06-25 2020-01-02 Kadmon Corporation, Llc Glucose uptake inhibitors
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
WO2020039093A1 (en) 2018-08-24 2020-02-27 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as ahr modulators
KR102328682B1 (en) * 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same
WO2020045941A1 (en) * 2018-08-27 2020-03-05 주식회사 대웅제약 Novel heterocyclic amine derivative and pharmaceutical composition comprising same
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
SI3902803T1 (en) 2018-12-27 2023-06-30 Les Laboratoires Servier Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020142748A1 (en) 2019-01-03 2020-07-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing transcription factor eb polypeptide levels
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
MX2021011289A (en) 2019-03-22 2021-11-03 Sumitomo Pharma Oncology Inc Compositions comprising pkm2 modulators and methods of treatment using the same.
EP3950693A4 (en) 2019-03-28 2022-09-07 Jiangsu Hengrui Medicine Co., Ltd. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CA3135070A1 (en) 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
CN109826608A (en) * 2019-04-08 2019-05-31 中国科学院地质与地球物理研究所 A staged fracturing device
JP2022530383A (en) * 2019-04-22 2022-06-29 貝達薬業股▲ふん▼有限公司 Quinazoline compounds and their pharmaceutical uses
US11155549B2 (en) 2019-04-24 2021-10-26 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
EP3959213B1 (en) 2019-04-24 2024-06-05 Theravance Biopharma R&D IP, LLC Pyrimidine jak inhibitors for the treatment of skin diseases
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3978498A1 (en) 2019-05-24 2022-04-06 Jiangsu Hengrui Medicine Co., Ltd. Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
JP2022535743A (en) * 2019-05-29 2022-08-10 アイエフエム デュー インコーポレイテッド Compounds and compositions for treating conditions associated with STING activity
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN114302876A (en) * 2019-09-06 2022-04-08 英夫拉索姆有限公司 NLRP3 inhibitor
CA3153456A1 (en) * 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
CR20220170A (en) 2019-10-11 2022-10-10 Incyte Corp Bicyclic amines as cdk2 inhibitors
EP4110778A1 (en) * 2020-02-26 2023-01-04 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CA3176957A1 (en) * 2020-03-27 2021-09-30 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
CA3184076A1 (en) 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
CA3184990A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2022032484A1 (en) * 2020-08-11 2022-02-17 北京诺诚健华医药科技有限公司 Pyridazine-3-formamide compound, and preparation method therefor and medical use thereof
CN114149410B (en) * 2020-09-07 2025-02-25 四川科伦博泰生物医药股份有限公司 Pyridocyclic compounds and preparation methods and uses thereof
US20230331731A1 (en) 2020-09-29 2023-10-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
WO2022107919A1 (en) * 2020-11-19 2022-05-27 주식회사 보로노이 N-containing heteroaryl derivative, and pharmaceutical composition for preventing or treating protein kinase-related diseases comprising same as active ingredient
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CR20230598A (en) 2021-06-28 2024-04-25 Blueprint Medicines Corp CDK2 INHIBITORS
CA3232178A1 (en) 2021-09-21 2023-03-30 Daniela PIZZIRANI Pyridazinyl amino derivatives as alk5 inhibitors
CN116023380B (en) * 2021-10-26 2024-01-23 沈阳药科大学 Pyrazolopyrimidine derivative, and preparation method and application thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20250100997A1 (en) 2022-01-11 2025-03-27 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2024206628A1 (en) * 2023-03-30 2024-10-03 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133081A (en) 1964-05-12 J-aminoindazole derivatives
US665330A (en) * 1899-12-18 1901-01-01 Antoine J Langelier Machine for making blanks for sewing-machine needles or similar articles.
US3935183A (en) * 1970-01-26 1976-01-27 Imperial Chemical Industries Limited Indazole-azo phenyl compounds
BE754242A (en) * 1970-07-15 1971-02-01 Geigy Ag J R DIAMINO-S-TRIAZINES AND DINITRO-S-TRIAZINES
US3998951A (en) * 1974-03-13 1976-12-21 Fmc Corporation Substituted 2-arylquinazolines as fungicides
DE2458965C3 (en) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazole-N-carboxylic acid derivatives, process for their preparation and pharmaceuticals containing them
MA18829A1 (en) 1979-05-18 1980-12-31 Ciba Geigy Ag PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR THERAPEUTIC USE
DOP1981004033A (en) 1980-12-23 1990-12-29 Ciba Geigy Ag PROCEDURE TO PROTECT CROP PLANTS FROM PHYTOTOXIC ACTION OF HERBICIDES.
SE8102193L (en) * 1981-04-06 1982-10-07 Pharmacia Ab THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND ITS USE
SE8102194L (en) * 1981-04-06 1982-10-07 Pharmacia Ab THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND PHARMACEUTICAL PREPARATION INCLUDING THIS
JPS58124773A (en) * 1982-01-20 1983-07-25 Mitsui Toatsu Chem Inc 5-Methylthiopyrimidine derivatives, their production methods, and agricultural and horticultural fungicides
EP0136976A3 (en) * 1983-08-23 1985-05-15 Ciba-Geigy Ag Use of phenyl pyrimidines as plant regulators
DE3725638A1 (en) 1987-08-03 1989-02-16 Bayer Ag NEW ARYLOXY (OR THIO) AMINOPYRIMIDINE
JPH0532662A (en) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd Substituted pyrazole derivative and agricultural and horticultural fungicide
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en) 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JP2657760B2 (en) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
EP0672042B1 (en) 1993-10-01 2006-05-03 Novartis AG Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
DE69532817T2 (en) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge USE OF PYRAZOLE COMPOUNDS FOR THE TREATMENT OF GLOMERULONEPHRITIS, CANCER, ATHEROSCLEROSIS OR RESTENOSIS
US5658902A (en) * 1994-12-22 1997-08-19 Warner-Lambert Company Quinazolines as inhibitors of endothelin converting enzyme
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
AU726058B2 (en) 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE227283T1 (en) 1996-07-13 2002-11-15 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
JPH10130150A (en) * 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd Pharmaceuticals consisting of acetic acid amide derivatives
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
EP0929553B1 (en) * 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
EP0932598A1 (en) 1996-10-11 1999-08-04 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
EA200000409A1 (en) 1997-10-10 2000-10-30 Сайтовиэ, Инк. Compounds, pharmaceutical compositions, methods for inhibiting cell death in a cell or tissue, methods of treating or REDUCE cell death, treatment or prophylaxis of polycystic kidney or anemia / erythropoiesis in an animal way to protect an organ or tissue of mammals from extinction CELLS, METHOD FOR REDUCTION OR PREVENTION CELL DEFENSE IN ORGAN OR TREATMENT OF DONOR AFTER THEIR TRANSPLANTATION, THE WAY TO REDUCE OR PREVENT THE DESTRUCTION OF SPERM OR EGGS
DE19756388A1 (en) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2000026421A (en) * 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd Diaryl sulfide derivative and pest controlling agent
KR20010041015A (en) * 1998-02-17 2001-05-15 윌리엄 제이. 리플린 Anti-viral pyrimidine derivatives
KR20010041905A (en) 1998-03-16 2001-05-25 시토비아 인크. Dipeptide caspase inhibitors and the use thereof
BR9911612A (en) 1998-06-02 2001-02-06 Osi Pharm Inc Pyrrole [2,3d] pyrimidine compositions and their uses
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000011003A1 (en) * 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000021955A1 (en) 1998-10-08 2000-04-20 Astrazeneca Ab Quinazoline derivatives
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
IL144215A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
AU3441400A (en) 1999-03-29 2000-10-16 Uutech Limited Peptide
JP4673977B2 (en) 1999-03-30 2011-04-20 ノバルティス アーゲー Phthalazine derivatives for the treatment of inflammatory diseases
AU781849C (en) 1999-06-17 2006-03-02 Synta Pharmaceuticals Corp. Inhibitors of IL-12 production
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP2001042764A (en) 1999-08-04 2001-02-16 Sony Corp Map display device
HUP0300340A3 (en) 1999-08-13 2005-04-28 Vertex Pharmaceuticals Inc Cam Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases, pharmaceutical compositions containing them and their use
MXPA02003436A (en) 1999-10-07 2002-08-20 Amgen Inc Triazine kinase inhibitors.
CA2392971C (en) 1999-11-30 2008-10-07 Pfizer Products Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
ATE335489T1 (en) * 1999-12-02 2006-09-15 Osi Pharm Inc ADENOSINE A3, A2A AND A3 RECEPTORS SPECIFIC COMPOUNDS AND THEIR USES
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
WO2001047897A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
SK14082001A3 (en) * 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Pyrazole derivatives as inhibitors of erk and pharmaceutical composition containing same
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PT1268519E (en) 2000-04-03 2005-08-31 Vertex Pharma PROTEASE SERINE INHIBITORS, PARTICULARLY PROTEASE NS3 HEPATITIS C VIRUS
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
DE60133897D1 (en) * 2000-06-28 2008-06-19 Astrazeneca Ab SUBSTITUTED CHINAZOLIN DERIVATIVES AND THEIR USE AS AURORA-2-KINASE INHIBITORS
NZ523782A (en) 2000-07-21 2005-10-28 Dendreon Corp Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20030027093A (en) 2000-08-31 2003-04-03 화이자 프로덕츠 인크. Pyrazole Derivatives and Their Use as Protein Kinase Inhibitors
AU2001290940A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR20030032035A (en) 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compounds useful as protein kinase inhibitors
HUP0302221A3 (en) 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines
DE10061863A1 (en) * 2000-12-12 2002-06-13 Basf Ag Preparation of triethylenediamine, useful for making pharmaceuticals and polymers, by reacting ethylenediamine over specific zeolite catalyst
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND THEIR ANALOGS AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS, AND THEIR USE
MXPA03005610A (en) * 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
DE60223790T4 (en) 2001-03-29 2009-05-07 Vertex Pharmaceuticals Inc., Cambridge HEMMER OF C-JUN TERMINAL KINASE (JNK) AND OTHER PROTEIN KINASE
CA2443487A1 (en) * 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
US6762179B2 (en) * 2001-05-31 2004-07-13 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
WO2003004492A1 (en) * 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
RU2004126671A (en) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS
US7179826B2 (en) * 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
DE60332433D1 (en) * 2002-03-15 2010-06-17 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
ES2289279T3 (en) * 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated USEFUL COMPOSITIONS AS PROTEINQUINASE INHIBITORS.
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US7863282B2 (en) 2003-03-14 2011-01-04 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
KR20050032105A (en) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compositions useful as inhibitors of gsk-3
WO2004041814A1 (en) * 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as jak inhibitors
US7407962B2 (en) * 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
ATE396731T1 (en) * 2003-03-25 2008-06-15 Vertex Pharma THIAZOLES FOR USE AS INHIBITORS OF PROTEIN KINASES
JP2006524688A (en) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド Thiazoles useful as protein kinase inhibitors
US7579349B2 (en) 2003-10-17 2009-08-25 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
JP4329649B2 (en) 2004-08-30 2009-09-09 ソニー株式会社 Imaging apparatus and optical system driving method
AU2006279376B2 (en) 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
KR20140025610A (en) 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. Substituted pyrazole compounds
BRPI0619706A2 (en) 2005-11-03 2011-10-11 Vertex Pharma compound, composition, method for inhibiting aurora kinase activity in a biological sample, method for treating a proliferative disorder in a patient, method for treating cancer in an individual
DE602006021776D1 (en) 2005-11-16 2011-06-16 Vertex Pharma AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
DE602007004750D1 (en) 2006-11-02 2010-03-25 Vertex Pharma AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINOPYRIDINES AND AMINOPYRIMIDINES
WO2008077086A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
AU2008226466B2 (en) 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
JP5520057B2 (en) 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as inhibitors of protein kinases
EP2142537A2 (en) 2007-03-20 2010-01-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP2010524962A (en) 2007-04-17 2010-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Drug discovery for aurora kinase inhibitors
WO2008137621A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2688584A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CA2687966A1 (en) 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors

Also Published As

Publication number Publication date
JP2004509114A (en) 2004-03-25
DE60119748D1 (en) 2006-06-22
EP1317448A1 (en) 2003-06-11
KR100896664B1 (en) 2009-05-14
AU2001290944A1 (en) 2002-03-26
ATE346064T1 (en) 2006-12-15
NO326850B1 (en) 2009-03-02
NZ525014A (en) 2005-09-30
EP1317448B1 (en) 2005-05-04
ATE326458T1 (en) 2006-06-15
CA2422299A1 (en) 2002-03-21
PT1317448E (en) 2005-08-31
DE60120194T2 (en) 2007-03-29
DE60110616T2 (en) 2006-02-23
AU2001296875A1 (en) 2002-03-26
WO2002022608A1 (en) 2002-03-21
HK1057890A1 (en) 2004-04-23
NO20031188D0 (en) 2003-03-14
AU2008252044A1 (en) 2009-01-22
JP2004509116A (en) 2004-03-25
IL154747A (en) 2010-05-17
EP1317452B1 (en) 2006-05-17
PE20020451A1 (en) 2002-06-06
US7098330B2 (en) 2006-08-29
ES2242771T3 (en) 2005-11-16
US6696452B2 (en) 2004-02-24
PL361676A1 (en) 2004-10-04
DE60110616D1 (en) 2005-06-09
WO2002022607A1 (en) 2002-03-21
HUP0302173A2 (en) 2003-09-29
NO20031190L (en) 2003-05-13
NO327708B1 (en) 2009-09-14
WO2002022606A1 (en) 2002-03-21
US20030078166A1 (en) 2003-04-24
AU2001290912A1 (en) 2002-03-26
CA2422367A1 (en) 2002-03-21
ATE327990T1 (en) 2006-06-15
NO20031188L (en) 2003-05-13
MXPA03002294A (en) 2005-09-08
EP1317447B1 (en) 2006-05-17
HUP0401819A2 (en) 2004-12-28
JP4105949B2 (en) 2008-06-25
JP2004509115A (en) 2004-03-25
ES2266259T3 (en) 2007-03-01
ES2266258T3 (en) 2007-03-01
EP1318814A2 (en) 2003-06-18
MXPA03002299A (en) 2003-06-06
JP2004512277A (en) 2004-04-22
DK1318997T3 (en) 2006-09-25
DE60110616T3 (en) 2012-07-05
NO20031190D0 (en) 2003-03-14
WO2002022605A1 (en) 2002-03-21
IL154784A0 (en) 2003-10-31
KR20030032035A (en) 2003-04-23
HUP0401819A3 (en) 2009-06-29
AU2008252044A8 (en) 2009-01-29
MXPA03002291A (en) 2003-06-06
KR100876069B1 (en) 2008-12-26
US20120071657A1 (en) 2012-03-22
IL154817A0 (en) 2003-10-31
JP4111824B2 (en) 2008-07-02
EP1317449B1 (en) 2006-05-31
AU2001290914A1 (en) 2002-03-26
CA2422378A1 (en) 2002-03-21
KR20030030004A (en) 2003-04-16
HK1057747A1 (en) 2004-04-16
CA2422367C (en) 2010-05-18
CA2422354A1 (en) 2002-03-21
NO20031191L (en) 2003-05-13
CA2422354C (en) 2009-12-08
US8633210B2 (en) 2014-01-21
ATE327992T1 (en) 2006-06-15
HK1058356A1 (en) 2004-05-14
HK1057702A1 (en) 2004-04-16
US20040116454A1 (en) 2004-06-17
CA2422377A1 (en) 2002-03-21
JP2004509118A (en) 2004-03-25
HK1057887A1 (en) 2004-04-23
EP1317444B1 (en) 2006-05-31
EP1317444A1 (en) 2003-06-11
ES2242771T5 (en) 2011-10-14
EP1317452A1 (en) 2003-06-11
HUP0302411A2 (en) 2003-11-28
HUP0302172A2 (en) 2003-09-29
US20050004110A1 (en) 2005-01-06
JP2008115195A (en) 2008-05-22
AU2001292670A1 (en) 2002-03-26
NZ545284A (en) 2007-06-29
JP4922539B2 (en) 2012-04-25
WO2002022602A3 (en) 2002-06-27
MXPA03002297A (en) 2003-06-06
EP1317447A1 (en) 2003-06-11
JP2004509117A (en) 2004-03-25
CA2422379C (en) 2008-11-18
AP2003002762A0 (en) 2003-03-31
ATE294797T1 (en) 2005-05-15
DE60120198D1 (en) 2006-07-06
CN1469875A (en) 2004-01-21
PT1318997E (en) 2006-10-31
CA2422380C (en) 2009-03-24
JP2004525075A (en) 2004-08-19
CA2422377C (en) 2010-04-13
JP4170752B2 (en) 2008-10-22
NZ525008A (en) 2004-12-24
DE60120193D1 (en) 2006-07-06
TWI303636B (en) 2008-12-01
DE60119749D1 (en) 2006-06-22
US20030055044A1 (en) 2003-03-20
HK1057888A1 (en) 2004-04-23
EP1317448B2 (en) 2011-05-04
DE60124744T2 (en) 2007-10-04
US20060258658A1 (en) 2006-11-16
CA2422299C (en) 2010-05-11
DE60128709T2 (en) 2007-12-27
CA2422379A1 (en) 2002-03-21
WO2002022604A1 (en) 2002-03-21
AU2001291013A1 (en) 2002-03-26
US20040097501A1 (en) 2004-05-20
US7115739B2 (en) 2006-10-03
CN1473161A (en) 2004-02-04
JP2004509113A (en) 2004-03-25
EP1318997A1 (en) 2003-06-18
JP4105948B2 (en) 2008-06-25
MXPA03002293A (en) 2003-06-06
CA2422380A1 (en) 2002-03-21
EP1317450B1 (en) 2006-11-22
CN100355750C (en) 2007-12-19
DE60120194D1 (en) 2006-07-06
EP1318997B1 (en) 2006-05-31
MXPA03002292A (en) 2003-06-06
HK1057748A1 (en) 2004-04-16
WO2002022602A2 (en) 2002-03-21
MXPA03002289A (en) 2003-06-06
NO20031189L (en) 2003-05-13
CA2422371A1 (en) 2002-03-21
DE60119748T2 (en) 2007-04-26
KR20030030006A (en) 2003-04-16
DE60120198T2 (en) 2007-05-10
WO2002022603A1 (en) 2002-03-21
IL154784A (en) 2010-04-29
CA2422378C (en) 2010-04-27
US7951820B2 (en) 2011-05-31
HK1057543A1 (en) 2004-04-08
NZ525009A (en) 2005-05-27
US7390815B2 (en) 2008-06-24
JP4105947B2 (en) 2008-06-25
DE60124744D1 (en) 2007-01-04
CN1469874A (en) 2004-01-21
IL154747A0 (en) 2003-10-31
DE60119749T2 (en) 2007-05-10
EP1317449A1 (en) 2003-06-11
BR0114088A (en) 2003-06-17
IL154786A0 (en) 2003-10-31
DE60120193T2 (en) 2007-03-29
MXPA03002295A (en) 2003-06-06
EP1317450A1 (en) 2003-06-11
CA2422371C (en) 2010-05-18
ATE363284T1 (en) 2007-06-15
EP1318814B1 (en) 2007-05-30
AU2001294558A1 (en) 2002-03-26
ATE327991T1 (en) 2006-06-15
KR20030030005A (en) 2003-04-16
US6638926B2 (en) 2003-10-28
DE60128709D1 (en) 2007-07-12
NO20031189D0 (en) 2003-03-14
NO20031191D0 (en) 2003-03-14
ATE326459T1 (en) 2006-06-15
WO2002022601A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2006201391C1 (en) Pyrazole Compounds Useful As Protein Kinase Inhibitors
CA2422380C (en) Pyrazole compounds useful as protein kinase inhibitors
HK1057890B (en) Pyrazole compounds useful as protein kinase inhibitors
HK1057888B (en) Pyrazole compounds useful as protein kinase inhibitors
HK1057747B (en) Pyrazole compounds useful as protein kinase inhibitors
HK1057543B (en) Pyrazole compounds useful as protein kinase inhibitors